ANNUAL REPORT

FY 2021 — Form 10-K

FY 2021PDF · 180 pages1.1 MB
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒	☒ 	Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021 	or
☐ 	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission file number 1-8002
THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its charter)
Delaware 	04-2209186
(State of incorporation) 	(I.R.S. Employer Identification No.)
168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 622-1000
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $1.00 par value 	TMO 	New York Stock Exchange
0.750% Notes due 2024 	TMO 24A 	New York Stock Exchange
0.125% Notes due 2025 	TMO 25B 	New York Stock Exchange
2.000% Notes due 2025 	TMO 25 	New York Stock Exchange
1.400% Notes due 2026 	TMO 26A 	New York Stock Exchange
1.450% Notes due 2027 	TMO 27 	New York Stock Exchange
1.750% Notes due 2027 	TMO 27B 	New York Stock Exchange
0.500% Notes due 2028 	TMO 28A 	New York Stock Exchange
1.375% Notes due 2028 	TMO 28 	New York Stock Exchange
1.950% Notes due 2029 	TMO 29 	New York Stock Exchange
0.875% Notes due 2031 	TMO 31 	New York Stock Exchange
2.375% Notes due 2032 	TMO 32 	New York Stock Exchange
2.875% Notes due 2037 	TMO 37 	New York Stock Exchange
1.500% Notes due 2039 	TMO 39 	New York Stock Exchange
1.875% Notes due 2049 	TMO 49 	New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes 	☒	☒ 	No 	☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes 	☐ 	No 	☒	☒
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months and (2) has been subject to such filing requirements for the past 90 days. 	Yes 	☒	☒ 	No 	☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during
the preceding 12 months. Yes 	☒	☒ 	No 	☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange
Act. 	Large accelerated filer 	☒	☒ 	Accelerated filer 	☐ 	Non-accelerated filer 	☐ 	Smaller reporting company 	☐ 	Emerging growth company 	☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. 	☒	☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes 	☐ 	No 	☒	☒
As of July 2, 2021, the aggregate market value of the voting stock held by nonaffiliates of the Registrant was approximately $201,672,052,000 (based on the last reported sale of
common stock on the New York Stock Exchange Composite Tape reporting system on July 2, 2021).
As of February 5, 2022, the Registrant had 	391,191,770 	shares of Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Sections of Thermo Fisher’s definitive Proxy Statement for the 2022 Annual Meeting of Shareholders are incorporated by reference into Parts II and III of this report.

-- 1 of 180 --

THERMO FISHER SCIENTIFIC INC.
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021
TABLE OF CONTENTS
Page
PART I
Item 1. 	Business 	3
Item 1A. 	Risk Factors 	17
Item 1B. 	Unresolved Staff Comments 	25
Item 2. 	Properties 	25
Item 3. 	Legal Proceedings 	25
Item 4. 	Mine Safety Disclosures 	25
PART II
Item 5. 	Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 	25
Item 6. 	Reserved 	25
Item 7. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations 	26
Item 7A. 	Quantitative and Qualitative Disclosures About Market Risk 	35
Item 8. 	Financial Statements and Supplementary Data 	36
Item 9. 	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 	36
Item 9A. 	Controls and Procedures 	36
Item 9B. 	Other Information 	37
Item 9C. 	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 	37
PART III
Item 10. 	Directors, Executive Officers and Corporate Governance 	38
Item 11. 	Executive Compensation 	38
Item 12. 	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 	38
Item 13. 	Certain Relationships and Related Transactions, and Director Independence 	38
Item 14. 	Principal Accountant Fees and Services 	38
PART IV
Item 15. 	Exhibits and Financial Statement Schedules 	39
Item 16. 	Form 10-K Summary 	39
2

-- 2 of 180 --

THERMO FISHER SCIENTIFIC INC.
PART I
Item 1. 	Business
General Development of Business
Thermo Fisher Scientific Inc. (also referred to in this document as “Thermo Fisher,” “we,” the “company,” or the “registrant”) is the world leader in serving
science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We serve customers working in pharmaceutical and biotech
companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and
process control settings. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services
through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
We continuously increase our depth of capabilities in technologies, software and services, and leverage our extensive global channels to address our
customers’ emerging needs. We do this through organic investments in research and development and through acquisitions. Our goal is to make our customers
more productive in an increasingly competitive business environment, and enable them to solve their challenges, from complex research to improved patient care,
environmental, industrial quality and process monitoring, and consumer safety.
On December 8, 2021, the company acquired PPD, Inc., a leading global provider of clinical research services to the pharma and biotech industry. The
addition of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their
productivity within the drug development process. PPD is now part of our Laboratory Products and Biopharma Services segment.
Forward-looking Statements
Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), are made throughout this Annual
Report on Form 10-K. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including
without limitation statements regarding: projections of revenues, expenses, earnings, margins, tax rates, tax provisions, cash flows, pension and benefit obligations
and funding requirements, and our liquidity position; cost reductions, restructuring activities, new product and service developments, competitive strengths or
market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting
pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and
fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; the
expected impact of the COVID-19 pandemic on the company’s business; and any other statements that address events or developments that Thermo Fisher intends
or believes will or may occur in the future. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and
similar expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the
company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change,
and readers should not rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this
report. A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements,
including those detailed under the heading, “Risk Factors” in Part I, Item 1A.
Business Segments and Products
We report our business in four segments – Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma
Services.
During 2021, the Life Sciences Solutions and Specialty Diagnostics segments as well as the laboratory products business continued to support COVID-19
diagnostic testing, scaling and evolving their molecular diagnostics solutions and plastic consumables businesses to respond to the on-going COVID-19 pandemic.
The biosciences and bioproduction businesses also expanded their capacity to meet the needs of pharma and biotech customers as they rapidly expanded their own
production volumes to meet global vaccine manufacturing requirements. Additionally, through our pharma services business, we provided our pharma and biotech
customers with the services they needed to develop and produce vaccines and therapies globally.
Life Sciences Solutions Segment
Through our Life Sciences Solutions segment, we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical
research, discovery and production of new drugs and vaccines as well as diagnosis of infection
3

-- 3 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government
markets. Life Sciences Solutions includes four primary businesses – Biosciences, Genetic Sciences, Clinical Next-Generation Sequencing, and BioProduction.
Biosciences
Our biosciences business includes reagents, instruments and consumables that help our customers conduct biological and medical research, discover new
drugs and vaccines, and diagnose infection and disease, such as COVID-19.
Our biosciences offerings include:
• 	Reagents, instruments, and consumables used for protein biology, molecular biology, sample preparation and cell imaging and analysis. The portfolio
includes antibodies and products for protein purification, detection, modification, and analysis; and sequencing, detection and purification products used
for high-content analysis of nucleic acids. Many of these products are also used in applied markets, including agriculture, forensics, diagnostics product
development, toxicology research and diagnostic testing.
• 	Tools used for genetic engineering, amplification, quantification and analysis as well as RNA isolation, including stem cell reprogramming kits,
transfection reagents, RNA interference reagents, along with gene editing tools and gene synthesis products.
• 	Cell culture media, reagents, and plastics for preserving and growing mammalian cells which are used in many life science research applications.
• 	Fluorescence-based technologies, which facilitate the labeling of molecules for biological research and drug discovery. These technologies include a wide
range of cell analysis instruments, including flow cytometers and imaging platforms that enable fluorescence microscopy.
• 	Protein analysis products, including precast electrophoresis gels for separating nucleic acids and proteins, and western blotting and staining tools.
Genetic Sciences
Our genetic sciences business combines a wide variety of instruments and related reagents used to provide high-value genomic solutions to assist customer
decisions in the research, clinical, healthcare and applied markets.
Our offerings include real-time polymerase chain reaction (PCR) technology used to identify changes in gene expression, genotyping or proteins on an
individual gene-by-gene basis and for diagnostic testing to identify infection and disease such as COVID-19; capillary electrophoresis (CE) sequencing, a core
technology used in DNA sequencing and fragment analysis and forensic analysis applications; and microarray technology, used in gene expression, genotyping and
reproductive health.
Our genetic analyzers served as the foundational platform used to sequence the first human genome. These systems are used in a variety of basic, commercial
and clinical research applications.
Clinical Next-Generation Sequencing
Our clinical next-generation sequencing (NGS) business focuses on delivering simple, fast and cost-effective NGS technology for a range of applications. The
business is focused on targeted sequencing solutions for research use, the application of NGS in oncology and companion diagnostics.
BioProduction
Our bioproduction business supports developers and manufacturers of biological-based therapeutics and vaccines with a portfolio of premium solutions and
services focused on upstream cell culture, downstream purification, analytics for detection and quantitation of process/product impurities, and a suite of single-use
solutions spanning the biologics workflow.
Our bioproduction offerings include:
• 	Single-use bioproduction solutions that provide our customers with faster turnaround and set-up times, minimal validation requirements, reduced
investment and running costs, and increased flexibility of manufacturing capacity.
• 	Production cell culture media solutions, which are used by leading biotechnology and pharmaceutical companies to grow cells in controlled conditions
and enable large scale cGMP (Current Good Manufacturing Practices) manufacturing of drugs and vaccines, including the COVID-19 vaccine. We also
provide our customers with the associated services to optimize the productivity of these production platforms.
4

-- 4 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
• 	Chromatography products, which deliver superior capacity and resolution for process-scale bioseparations, and offer a broad set of scalable options for the
purification of antibodies, antibody fragments and proteins.
• 	Rapid molecular products that deliver accurate results in less than four hours for contaminant detection, identification and quantitation.
• 	Scalable solutions for the manufacture of cell therapy-based drugs.
Our Doe & Ingalls offerings include chemical distribution and supply chain services that provide primarily life science manufacturers with reliable, secure
supply chains for their chemical raw materials.
Analytical Instruments Segment
Through our Analytical Instruments segment, we provide a broad offering of instruments, consumables, software and services that are used for a range of
applications in the laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology,
academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. This segment includes three primary businesses
– Chromatography and Mass Spectrometry, Chemical Analysis, and Materials and Structural Analysis.
Chromatography and Mass Spectrometry
Our chromatography and mass spectrometry (MS) business provides analytical instrumentation for organic and inorganic sample analysis across both applied
technologies and life science research. These products are complemented by laboratory information management systems (LIMS); chromatography data systems
(CDS); database analytical tools; automation systems; a range of consumables, such as a line of chromatography columns; and a range of sample preparation and
separation products including auto-samplers and multiplexing systems.
Chromatography is a technique for separating, identifying and quantifying individual chemical components of substances based on their specific physical and
chemical characteristics. Our chromatography product line includes high-performance liquid chromatography, ion chromatography and gas chromatography
systems, all of which are supported by our Chromeleon chromatography data system software.
• 	Liquid Chromatography (LC) Systems 	analyze complex sample matrices in liquids. Our high-pressure liquid chromatography (HPLC) and ultrahigh-
pressure liquid chromatography (UHPLC) systems offer high throughput and sensitivity and are sold either as stand-alone systems or integrated with our
mass spectrometers (LC/MS and LC/MS/MS). These systems are used for a range of applications, from complex proteomic analyses to routine industrial
quality assurance and quality control (QA/QC).
• 	Ion Chromatography (IC) Systems 	separate ionic (charged) or highly polar molecules (e.g., sugars and carbohydrates), usually found in water-based
solutions, and typically detect them based on their electrical conductivity. Our IC products are used in a wide range of applications, including scientific
research, and environmental testing, as well as quality control in pharmaceutical, food and beverage, and other industrial processes.
• 	Gas Chromatography (GC) Systems 	analyze complex sample matrices in gases, comprising both separation and detection technology. Separation
technology is common to all gas chromatography analyzers and is paired with either a conventional detector (GC) or with different types of mass
spectrometers (GC/MS). Our GC/MS offering includes a triple-stage quadrupole, a single-stage quadrupole, an Orbitrap, and an ion trap for a range of
applications, including food safety testing, quantitative screening of environmental samples, and complex molecular analyses.
• 	Elemental Analysis Spectrometers 	use atomic spectroscopy techniques to identify trace concentrations of elements in liquid and solid samples primarily in
environmental, petrochemical, food safety, metallurgical, geochemical and clinical/toxicology research applications. These products are widely used in
growth markets such as China, India and Latin America to support compliance with increasingly stringent international environmental and consumer
safety regulations.
Mass spectrometry is a technique for analyzing chemical compounds, individually or in complex mixtures, by forming charged ions that are then analyzed
according to their mass-to-charge ratios. In addition to molecular information, each discrete chemical compound generates a pattern that provides structurally
identifiable information. Our comprehensive offering includes life sciences mass spectrometry systems; and inorganic mass spectrometry systems; as well as a
range of sample preparation and separation products, including auto-samplers and multiplexing systems.
• 	Life Sciences Mass Spectrometers 	include triple quadrupole and Orbitrap technologies. Our triple quadrupole systems provide high-performance
quantitative analysis of chemicals in biological fluids, environmental samples and food
5

-- 5 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
matrices. They are also used by the pharmaceutical industry for targeted quantitation during drug discovery. Our Orbitrap technologies provide high-
resolution and accurate mass capabilities for both research and applied markets and are well suited for drug metabolism, proteomics, environmental
analysis, food safety, toxicology and clinical research applications. We also offer a comprehensive portfolio of instrument control and data analysis
software to help customers simplify their workflows and obtain knowledge from often complex data.
• 	Inorganic Mass Spectrometers 	include four product lines: isotope ratio mass spectrometry (IRMS); multi-collector isotope ratio mass spectrometry
(MC/IRMS); inductively coupled plasma mass spectrometry (ICP/MS); and high-resolution trace mass spectrometry (HR Trace/MS). These products are
primarily used for qualitative and quantitative analysis of inorganic matter in a range of applications, including environmental analysis, materials science
and earth sciences.
Chemical Analysis
Our chemical analysis products fall into three main categories: production, process and analytics; field safety instruments; and environmental and process
instruments. Customers use these products to quickly and accurately analyze the composition of materials to optimize workflows primarily in industrial
applications or to help them comply with governmental regulations and industry safety standards. Our product lines range from those used on production lines to
improve quality and efficiency, to portable systems for rapid and real-time chemical identification in the field or to analyze, measure or respond to hazardous
situations.
• 	Production, Process and Analytics 	includes production line process monitoring and control systems for a range of industrial applications. For example,
we offer on-line instruments that analyze bulk materials non-invasively and in real time to improve quality control and ensure safe operation in a mine or
cement manufacturing plant, as well as systems that enable high-speed weighing during bulk materials handling. We also offer gauging systems that
employ ionizing and non-ionizing technologies to measure the total thickness, basis weight and coating thickness of flat-sheet materials, such as steel,
plastics, foil, rubber and glass. We also offer on-line analyzers based on a variety of technologies, such as X-ray imaging and ultra-trace chemical
detection, to inspect packaged goods for physical contaminants, validate fill quantities, or check for missing or broken parts on-line and at high speeds in
the food and beverage, pharmaceutical production and packaging industries, to maintain safety and quality standards.
• 	Field Safety Instruments 	are rugged handheld products that provide rapid, precise, real-time analysis at the point of need. Our main product categories are
elemental analyzers, optical analyzers and radiation detection instruments. Our portable elemental analyzers use X-ray fluorescence (XRF) or Laser-
induced breakdown spectroscopy technologies in QA/QC applications to identify metal alloys in scrap metal recycling; in precious metals analysis; in
environmental analysis; and for lead screening in a range of consumer products. Our portable optical analyzers utilize Raman, Fourier transform infrared
(FTIR) and near-infrared (NIR) technologies for use in the field by first responders and law enforcement and military personnel who need to quickly and
accurately identify chemicals and explosives in critical safety and security situations. Other applications include QA/QC in pharmaceutical production and
identification of counterfeit drugs. Our radiation measurement products are used to monitor, detect and identify specific forms of radiation in nuclear
power, environmental, industrial, medical, and security applications. Our primary customers include national, regional, and local government agencies
responsible for monitoring cargo, vehicles and people traveling across borders. These products are also used by first-responders in safety and security
situations, and for worker safety in the nuclear power and other industrial markets.
• 	Environmental and Process Instruments 	include fixed and portable instrumentation that help our customers protect people and the environment as well as
comply with government regulations and industry safety standards. Our products are used by environmental regulatory agencies and power plant
operators to measure ambient air, and stack gas emissions for compliance with regulated emissions standards for criteria pollutant gases. Our products are
also used in ambient particulate monitoring applications by customers in mining environments to provide continuous measurements and logging of real-
time concentrations and median particle sizes of airborne dust, smoke, mist and fumes to improve efficiency and increase worker safety.
In addition to our broad product offerings, we offer a variety of specialized services to our customers, including equipment servicing, instrument calibration
services, asset management and training.
Electron Microscopy
Our electron microscopy business (formerly known as materials and structural analysis business) includes electron microscopy, molecular spectroscopy and
bulk elemental analysis instruments that are used by customers in life sciences, materials sciences, semiconductor and industrial markets to accelerate breakthrough
discoveries.
6

-- 6 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
• 	Electron Microscopy Instruments 	include transmission electron microscopes which provide imaging and characterization at the atomic scale, with
applications in semiconductor development, materials science research and the characterization of protein structure and function. We also offer scanning
electron microscopes which resolve features from the optical regime down to the nanometer length scale and are used for a wide variety of applications
from materials characterization in science and engineering to applications in natural resources, manufacturing, and biological systems. Our DualBeam
focused ion beam-scanning electron microscope systems are used for sample preparation, 3D characterization, nanoprototyping, and industrial failure
analysis. Our focused ion beam microscopes are used in a range of process control, failure analysis, and materials research applications. We also offer
electrical failure analysis instruments which are used in root cause failure analysis and quality control; microCT instruments which are micro-computed
tomography solutions for quantitative analysis of a broad range of materials, providing 3D visualization of large volumes non-destructively; and a range
of surface analysis instruments commonly used in the semiconductor, metals, coatings, and polymer industries as a product development and failure
analysis tool. We also provide 3D visualization software that turns the data and images generated by a broad range of instruments into 3D visualizations
of the microscopic sample, allowing for quantitative analysis of material properties.
• 	Molecular Spectroscopy Instruments 	are divided into four primary techniques: FTIR, Raman, NIR and ultraviolet/visible (UV/Vis) spectroscopy. These
technologies are typically used in the laboratory to provide information on the structure of molecules to identify, verify and quantify organic materials in
pharmaceutical, biotechnology, polymer, chemical, and forensic sciences. Our material characterization instruments include rheometers and extruders that
measure viscosity, elasticity, processability, and temperature-related mechanical changes of various materials.
• 	Bulk Elemental Analysis Instruments 	and analyzers use XRF, X-ray diffraction (XRD), and arc spark optical emission (OES) techniques for accurate and
precise analysis of bulk materials in the metals, cement, minerals, and petrochemicals industries.
Specialty Diagnostics Segment
Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products in order to serve
customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of
diagnoses, which improves patient care in a more cost-efficient manner. This segment has five primary businesses – Clinical Diagnostics, ImmunoDiagnostics,
Microbiology, Transplant Diagnostics and our Healthcare Market Channel.
Clinical Diagnostics
Our clinical diagnostics products include a broad offering of liquid, ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls and
calibration verification fluids. In particular, we provide products used for COVID-19 testing; drugs-of-abuse testing; therapeutic drug monitoring, including
immunosuppressant drug testing; thyroid hormone testing; serum toxicology; clinical chemistry; immunology; hematology; coagulation; glucose tolerance testing;
first trimester screening; tumor markers testing; and biomarkers testing for sepsis, acute myocardial infarction and congestive heart failure. We also private-label
many of our reagents and controls for major 	in vitro 	diagnostics companies through OEM arrangements. In many instances, we will work with customers or
partners to develop new products and applications for their instrument platforms.
We have developed one of the broadest menus for drugs-of-abuse immunoassays. We also provide a broad offering of immunosuppressant drug
immunoassays that can be used on a variety of clinical chemistry analyzers.
Our clinical chemistry systems include analyzers and reagents to analyze and measure routine blood and urine chemistry, such as glucose and cholesterol; and
advanced testing for specific proteins, therapeutic drug monitoring and drugs-of-abuse. Our diagnostic test range currently covers approximately 80 different
validated methods. We also provide pre- and post-analytical automation for preparation of blood specimens before and after analysis, and specialty diagnostic tests
based on patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening.
ImmunoDiagnostics
Our immunodiagnostics offerings include developing, manufacturing and marketing complete blood-test systems to support the clinical diagnosis and
monitoring of allergy, asthma and autoimmune diseases. We offer antibody tests for approximately 20 indications to help diagnose autoimmune diseases such as
rheumatoid arthritis, celiac disease, lupus and scleroderma. Our products include ImmunoCAP for allergy and asthma tests and EliA for autoimmunity tests.
7

-- 7 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
Microbiology
Our microbiology offerings include dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect
pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products and associated products for the microbiology laboratory. Our products help
customers worldwide to diagnose infectious disease; determine appropriate antimicrobial therapy; implement effective infection control programs; and detect
microbial contamination of their products or manufacturing facilities.
Within the food and pharmaceutical industries, our products are used to assure the safety and quality of consumer products by monitoring production
environments; raw materials and end products for bacterial contamination; and animal health in the dairy industry.
Transplant Diagnostics
Our transplant diagnostics products include human leukocyte antigen (HLA) typing and testing for the organ transplant market. Our diagnostic tests are used
by transplant centers for tissue typing, primarily to determine the compatibility of donors and recipients pre-transplant, and to detect the presence of antibodies
post-transplant that can lead to transplant rejection. These transplant diagnostic tests are widely used across the transplant-testing workflow to improve patient
outcomes. Our transplant diagnostic offerings include several lines of HLA typing and antibody detection assays utilizing serological, molecular, enzyme-linked
immunosorbent assays (ELISA), flow, and multiplexing technologies.
Healthcare Market Channel
Our healthcare market channel offerings include a broad array of consumables, diagnostic kits and reagents, equipment, instruments, solutions and services for
hospitals, clinical laboratories, reference laboratories, physicians’ offices and other clinical testing facilities. These products are manufactured by Thermo Fisher
and third parties and are primarily used in clinical diagnosis. We go to market through our expert sales force, segment-relevant printed collateral and digital
content, and a state-of-the-art website, www.fishersci.com/healthcare, containing full product content for more than 1.5 million products.
Laboratory Products and Biopharma Services Segment
Our Laboratory Products and Biopharma Services segment (formerly known as Laboratory Products and Services) offers virtually everything needed for the
laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core
activities and helps them to be more efficient, productive and cost-effective. The segment also includes a comprehensive offering of outsourced services used by
the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. We serve the
pharmaceutical, biotechnology, academic, medical device, government and other research and industrial markets, as well as the clinical laboratory market through
five key businesses: Laboratory Products, Laboratory Chemicals, Research and Safety Market Channel, Pharma Services and Clinical Research.
Laboratory Products
Our laboratory products are used primarily by pharmaceutical companies for drug discovery and development and by biotechnology companies and
universities for life science research to advance the prevention and cure of diseases and enhance quality of life. This offering consists of equipment, accessories,
and services for sample preparation, storage and protection, and analysis:
• 	Laboratory Equipment Technologies 	includes our leading laboratory refrigerators and freezers, ultralow-temperature freezers and cryopreservation
storage tanks for maintaining samples in a cold environment to protect them from degradation. 	We also offer temperature control products such as heated
bath circulators, immersion coolers, recirculating chillers, water baths, and dry baths in a range of sizes, temperatures and configurations for life science,
analytical chemistry, manufacturing and quality-control applications. In addition, we offer sample preparation and preservation equipment, which protects
our customers’ chemical and biological samples and supports the growth of cells and organisms in optimal conditions such as temperature, carbon dioxide
and humidity, as well as incubators and related products. We also offer centrifugation products, which are used to separate biological matrices and
inorganic materials, including microcentrifuges, general use bench-top centrifuges and floor models. Additionally, we offer biological safety cabinets,
which enable technicians to handle samples without risk to themselves or their environment and without risk of cross-contamination of samples.
• 	Water and Laboratory Products 	include water analysis instruments such as meters, electrodes and solutions for the measurement of pH, ions,
conductivity, dissolved oxygen, turbidity and other key parameters in the lab and production
8

-- 8 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
line. We also offer other laboratory equipment such as water purification systems, shakers, vacuum concentrators, microbiological incubators, ovens,
furnaces, hotplates, stirrers, stirring hotplates, and other related products.
• 	Laboratory Plastics Essentials 	include a leading offering of laboratory pipette tips and a complementary range of handheld and automated pipetting
systems, supporting low- through high-throughput activity. These products optimize productivity and ergonomics and ensure accurate results. We also
offer sample preparation and storage products such as centrifugation consumables as well as vials and organization systems for ultralow temperature and
cryogenic storage, with specific products designed for low protein binding and low DNA binding and containers for packaging life science and diagnostic
reagents as well for the storage and transport of bulk intermediates and active pharmaceutical ingredients. Additionally, our offerings include a complete
selection of clinical specimen collection products, drug-of-abuse collection kits and environmental and food-safety glass and plastic vials, bottles and
containers, plastic transfer pipettes, general purpose clinical laboratory consumables and containers for breast milk collection, storage and feeding
primarily used in neo-natal units and by lactation specialists. We also provide OEM and custom kit assembly services for clinical and drugs-of-abuse test
kits.
Laboratory Chemicals
Our laboratory chemicals offering comprises a broad range of chemicals, solvents and reagents supporting virtually every laboratory application – from
research and drug discovery to development and manufacturing. This portfolio includes organic chemicals used to synthesize new materials; essential laboratory
chemicals used by scientists to purify, extract, separate, identify and manufacture products; high-purity analytical reagents; bioreagents used in many different
applications, from cell growth to detailed protein analysis; novel chemical building blocks, reactive intermediates and screening libraries used to accelerate drug
discovery; and precious metals, salts and solutions used in a broad range of applications where highly specific reactions are desired. 	We provide bulk volumes of
many products for scale-up from research to development and customized services for chemical procurement, processing, production, testing, and packaging.
Research and Safety Market Channel
Our research and safety market channel serves academic, pharmaceutical, biotechnology, government and industrial customers. We go to market through our
expert sales force, segment-relevant printed collateral and digital content in four languages, a state-of-the-art website, www.fishersci.com, containing full product
content for more than 1.5 million products, and our global network of resellers and distributors.
We have an international network of warehouses in our primary markets through which we maintain inventory and coordinate product delivery. With
specialized product vaults and warehouse management systems, we are able to handle the complete range of products we offer to our customers. Our transportation
capabilities include our dedicated fleet of delivery vehicles as well as parcel shipping capabilities that are closely integrated with our third-party parcel carriers.
Throughout the product delivery process, we provide our customers with convenient access to comprehensive electronic systems that offer automated catalog
search, product order and invoicing, and payment capabilities.
Our channel offers a mix of products that are manufactured by Thermo Fisher, by third parties for us on a private-label basis, and by third parties under their
brand but offered for sale exclusively through us. We also offer a broad range of third-party products representing leading industry brand names on a non-exclusive
basis.
Our research products include a complete offering of laboratory products, ranging from capital equipment and instruments to chemicals to consumable
products. Our safety products include clean-room and controlled-environment supplies, personal protective equipment, firefighting, military, and first responder
equipment and supplies, and environmental monitoring and sampling equipment. Our education products include science-related and laboratory products for the K-
12 and secondary education markets.
In addition to our broad product offerings, we offer a variety of specialized services to our customers through our Unity Lab Services team, including training,
equipment servicing and asset management, and dedicated supply management personnel. We also offer scientific support services including desktop delivery,
coordination of instrument calibration and service, and on-site customer service.
Pharma Services
We provide the entire spectrum of development, manufacturing and clinical trials services for both small-molecule and large-molecule pharmaceuticals. This
includes i) development of a suitable formulation and manufacturing process for the active pharmaceutical ingredient (API) or biologic; ii) technology transfer to
scale up the manufacturing; iii) labeling, packaging, distribution and logistics for clinical trials; and iv) commercial scale manufacturing and packaging.
9

-- 9 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
• 	Drug Substance Services 	- Our service offerings address small molecules, produced through chemical synthesis, and large molecules such as antibodies
and proteins produced through mammalian cell culture. We provide development and manufacturing services for small molecule APIs and the
biologically active component of pharmaceutical products under current good manufacturing practice (cGMP) conditions from early development through
commercial production. We also provide a full range of viral vector development and manufacturing services for customers developing and
commercializing gene and cell therapies, including process development, optimization, scale-up, analytical development and qualification of viral vectors
for commercial manufacturing. Our breadth of vector platform includes the five most widely used virus types, providing extensive coverage across the
gene and cell therapy landscape.
• 	Drug Product Services 	- We manufacture both small-molecule and large-molecule products for customers in conventional and specialized dosage forms.
We differentiate ourselves by our breadth of dosage forms and specialized capabilities in both oral solid and sterile dosage forms. We provide a wide
spectrum of advanced formulation, production and technical services and scientific expertise and solutions, from the early stages of a product’s
development to regulatory approval and commercial scale production.
• 	Clinical Trials Services - 	We provide a comprehensive global supply chain offering for pharmaceutical and biotechnology companies engaged in clinical
trials, including comparator sourcing; specialized packaging; over-encapsulation; multi-lingual and specialized labeling and distribution for phase I
through phase IV clinical trials; biological-specimen management and biobanking services; specialty pharmaceutical logistics; clinical supply-chain
planning and management; and a global distribution logistics network.
• 	Advanced Therapy Services - 	We provide a global network of cell and gene therapy development, manufacturing and supply chain services for Plasmid,
mRNA drug substance and cell therapy manufacturing.
Clinical Research
We offer comprehensive, integrated clinical development and analytical services to our biopharmaceutical, biotechnology, government and academic
customers. Our clinical development services include all phases of development (i.e., Phases I-IV), peri- and post-approval and site and patient access services. Our
analytical services include a range of high-value, advanced testing services, including bioanalytical, biomarker, vaccine, cGMP and central laboratory services.
• 	Clinical Development Services 	- Within our clinical development services business, we provide early development and clinical research management
services, site and patient access services, and peri- and post-approval services.
Through our early development and clinical research management services offering, we provide comprehensive support to early clinical development
programs, including Phase I trials. We conduct early-phase studies at our dedicated in-patient clinical facilities and complement these Phase I clinical
research units with a global network of affiliated clinical trial sites. We also provide full-service protocol management for Phases II-IV clinical research
studies for investigational new drugs, biologics and medical devices. Our suite of services for Phases II-IV clinical trials includes protocol design; clinical
trial strategic feasibility and investigator site selection; project management; site study startup activities; patient recruitment; clinical monitoring and data
capture; data management; biostatistics; safety medical monitoring/pharmacovigilance; regulatory affairs; medical writing; global clinical supplies;
eClinical services; quality assurance; and virtual and digitally enabled trial solutions.
Through our site and patient access services offering we combine our unique-in-industry patient recruitment capability with a large independent network
of dedicated clinical research investigator sites to offer services to complement the traditional site selection model, speeding study enrollment through
efficient and predictive centralized recruitment while leveraging our network sites exclusively or in conjunction with independent investigators.
Through our peri- and post-approval services offering, we provide real-world research and evidence-based solutions to demonstrate the real-world
effectiveness, safety, and value of biopharmaceutical and biotechnology products. We also provide industry inbound and outbound peri- and post-
approval contact center solutions focused on medical and clinical support to the biopharmaceutical industry.
• 	Analytical Services 	- We own and operate an integrated and scaled suite of laboratory services. Our bioanalytical laboratories analyze drug and metabolite
concentrations from biological fluid and tissue samples within preclinical and human clinical studies. Our biomarker laboratory is closely aligned with
both the central laboratories and bioanalytical laboratories to provide customized solutions for biomarker projects, including ligand binding, flow
cytometry and molecular genomics. We also perform testing for vaccines, such as immunogenicity testing to evaluate the efficacy of vaccines in inducing
cellular and humoral immune responses, and employ molecular detection methods, such as
10

-- 10 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
polymerase chain reaction testing to detect the absence of pathogens or to characterize attenuated vaccine strains following administration of a vaccine.
We provide early preclinical development through post-approval testing services and product analysis laboratory services that are designed to be
compliant with cGMPs, and our central laboratories provide highly standardized safety and biomarker testing services with customized results databases
for our customers.
Sales and Marketing
We market and sell our products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors and
various catalogs.
We offer our products and services through leading brands including:
• 	The Thermo Scientific brand offers customers in research, diagnostics, industrial, and applied markets a complete range of high-end analytical
instruments as well as laboratory equipment, software, services, consumables and reagents. Our portfolio of products includes innovative technologies for
mass spectrometry, chromatography, elemental analysis, electron microscopy, molecular spectroscopy, sample preparation, informatics, chemical
research and analysis, cell culture, bioprocess production, cellular, protein and molecular biology research, allergy testing, drugs-of-abuse testing,
therapeutic drug monitoring testing, microbiology, as well as environmental monitoring and process control.
• 	The Applied Biosystems brand offers customers in research, clinical and applied markets integrated instrument systems, reagents, and software for genetic
analysis. Our portfolio includes innovative technologies for genetic sequencing and real-time, digital and end point PCR, that are used to determine
meaningful genetic information in applications such as COVID-19 testing, cancer diagnostics, human identification testing, and animal health, as well as
inherited and infectious disease.
• 	The Invitrogen brand offers life science customers a broad range of consumables and instruments that accelerate research and ensure consistency of
results. Our portfolio of products includes innovative solutions for cellular analysis and biology, flow cytometry, cell culture, protein expression, synthetic
biology, molecular biology and protein biology.
• 	Fisher Scientific is our channels brand, offering customers a complete portfolio of laboratory equipment and consumables, chemicals, supplies and
services used in scientific research, healthcare, safety, and education markets. These products are offered through an extensive network of direct sales
professionals, segment-relevant printed collateral and digital content, a state-of-the-art website, and supply-chain management services.
• 	Unity Lab Services is our instrument and equipment services brand, offering a complete portfolio of services from enterprise-level engagements to
individual instruments and laboratory equipment, regardless of the original manufacturer. Through our network of world-class service and support
personnel, we provide services that are designed to help our customers improve productivity, reduce costs, and drive decisions with better data.
• 	Patheon is our contract development and manufacturing brand, representing the comprehensive offering of services that we provide to customers ranging
from small biotech to large pharmaceutical companies. We support our customers’ development of innovative medicines, including biologics, gene
therapies and vaccines. By leveraging our expanding global network of facilities, we deliver high-quality services at all stages of the drug lifecycle, from
discovery to development through clinical trials services and commercial manufacturing.
• 	PPD is our clinical research services brand, helping customers in the biopharmaceutical industry bring their medicines and other treatments to patients
around the world. Our clinical development services include all phases of development (i.e., Phases I-IV), peri- and post-approval and site and patient
access services. Our analytical services offer a range of high-value, advanced testing services, including bioanalytical, biomarker, vaccine, cGMP and
central laboratory services.
We have approximately 15,000 sales personnel including highly trained technical specialists who enable us to better meet the needs of our more technical end-
users. We also provide customers with product standardization and other supply-chain-management services to reduce procurement costs.
New Products and Research and Development
Our business includes the development and introduction of new products and may include entry into new business segments. We anticipate that we will
continue to make significant expenditures for research and development as we seek to provide a continuing flow of innovative products to maintain and improve
our competitive position.
11

-- 11 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
Resources
Raw Materials
Our management team believes that we have a readily available supply of raw materials for all of our significant products from various sources. No single
supplier is material, although for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design, certain materials
components may be sourced from a single supplier or a limited number of suppliers that can readily provide such materials or components.
Raw material and fuel prices are subject to fluctuations due to market conditions. We employ many strategies, including the use of alternative materials, to
mitigate the effect of these fluctuations on our results.
For a discussion of risks related to our supply chain and raw material and fuel prices, refer to “Risk Factors” in Part I, Item 1A.
Patents, Licenses and Trademarks
Patents are important in many aspects of our business. No particular patent, or related group of patents, is so important, however, that its loss would
significantly affect our operations as a whole. Where appropriate, we seek patent protection for inventions and developments made by our personnel that are
incorporated into our products or otherwise fall within our fields of interest. Patent rights resulting from work sponsored by outside parties do not always accrue
exclusively to the company and may be limited by agreements or contracts.
We protect some of our technology as trade secrets and, where appropriate, we use trademarks or register trademarks used in connection with products. We
also enter into license agreements with others to grant and/or receive rights to intellectual property rights.
All trademarks, trade names, product names, graphics and logos of Thermo Fisher contained herein are trademarks or registered trademarks of Thermo Fisher
or its subsidiaries, as applicable, in the United States and/or other countries. Solely for convenience, we may refer to trademarks in this Annual Report on Form 10-
K without the ™ and ® symbols. Such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted by law, our rights
to our trademarks. To the extent other trademarks appear in this Annual Report on Form 10-K, they are the property of their respective owners.
Seasonal Influences
Revenues in the fourth quarter are historically stronger than in other quarters due to the capital spending patterns of industrial, pharmaceutical and government
customers. Sales of flu tests and related diagnostic products vary quarter to quarter and year to year based on the severity and duration of each period’s flu season.
Sales of allergy tests vary quarter to quarter and year to year based on the severity and duration of each period’s airborne pollen allergens.
Government Contracts
Although the company transacts business with various government agencies, no government contract is of such magnitude that a renegotiation of profits or
termination of the contract at the election of the government agency would have a material adverse effect on the company’s financial results.
Competition
The company encounters aggressive and able competition in virtually all of the markets we serve. Because of the diversity of our products and services, we
face many different types of competitors and competition. Our competitors include a broad range of manufacturers, third-party distributors and service providers.
Competitive climates in many of the markets we serve are characterized by changing technology and customer demands that require continuing research and
development. Our success primarily depends on the following factors:
• 	technical performance and advances in technology that result in new products and improved price/performance ratios;
• 	product differentiation, availability and reliability;
• 	the depth of our capabilities;
• 	our reputation among customers as a quality provider of products and services;
• 	customer service and support;
• 	active research and application-development programs; and
• 	relative prices of our products and services.
12

-- 12 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
Government Regulation
Environmental Regulations
We are subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and other
countries. U.S. federal environmental legislation that affects us includes the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the
Clean Air Act, the Clean Water Act, the Safe Drinking Water Act, and the Comprehensive Environmental Response Compensation and Liability Act (CERCLA).
We are also subject to regulation by the Occupational Safety and Health Administration (OSHA) concerning employee safety and health matters. The United States
Environmental Protection Agency (USEPA), OSHA, and other federal agencies have the authority to promulgate regulations that have an effect on our operations.
In addition to these federal laws and regulations, various states have been delegated certain authority under the aforementioned federal statutes and have
authority over these matters under state laws. Many state and local governments have adopted environmental and employee safety and health laws and regulations,
some of which are similar to federal requirements.
A number of our operations involve the handling, manufacturing, use or sale of substances that are or could be classified as toxic or hazardous materials within
the meaning of applicable laws. Consequently, some risk of environmental harm is inherent in our operations and products, as it is with other companies engaged
in similar businesses.
Our expenses for environmental requirements are incurred generally for ongoing compliance and historical remediation matters. Based on current information,
we believe that these compliance costs are not material. For historical remediation obligations, our expenditures relate primarily to the cost of permitting,
installing, and operating and maintaining groundwater-treatment systems and other remedial measures.
Our Fair Lawn and Somerville, New Jersey facilities entered into administrative consent orders with the New Jersey Department of Environmental Protection
in 1984 to maintain groundwater-remediation activities at these sites, and are currently under the State’s Licensed Site Remediation Professional Program. As the
owner of the Fair Lawn facility, we are listed as a potentially responsible party for remediation within an area called the Fair Lawn Wellfields Superfund Site, and,
in 2008, the company and certain other parties entered into a consent order with the USEPA to complete a Remedial Investigation/Feasibility Study. In 2018, the
USEPA issued a Record of Decision, setting forth the scope of required remediation work at the site, which includes upgrading a water treatment plant to address
constituents such as chlorinated organic compounds, 1,4-dioxane, and perfluorooctanoic acid/perfluorooctane sulfonate (PFOA/PFOS). In 2020, the court approved
a consent decree that requires the company and another responsible party to finance and perform the required remediation work with USEPA oversight.
In 2011, our Life Technologies subsidiary entered into a consent decree with the USEPA and other responsible parties to implement a groundwater remedy at
the former Davis Landfill Superfund site in Smithfield, Rhode Island. After years of additional study, in September, 2020, USEPA revised its cleanup plan by
selecting an interim remedial approach that includes groundwater treatment followed by additional monitoring of site conditions. Depending on the results of these
treatment and monitoring activities over the next several years, USEPA anticipates selecting a final groundwater remedy for the site. In November 2021, the 2011
consent decree was amended to reflect the parties’ obligations to implement USEPA’s interim remedy.
We record accruals for environmental liabilities based on current interpretations of environmental laws and regulations when it is probable that a liability has
been incurred and the amount of such liability can be reasonably estimated. We calculate estimates based upon several factors, including reports prepared by
environmental specialists and management’s knowledge and experience with these environmental matters. We include in these estimates potential costs for
investigation, remediation and operation and maintenance of cleanup sites. Accrued liabilities for environmental matters totaled $65 million at December 31, 2021.
These environmental liabilities do not include third-party recoveries to which we may be entitled. We believe that our accrual is adequate for the
environmental liabilities we currently expect to incur. As a result we believe that our ultimate liability with respect to environmental matters will not have a
material adverse effect on our financial position, results of operations or cash flows. However, we may be subject to remedial or compliance costs due to future
events, such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies, changes
in the conduct of our operations, and the effect of changes in accounting rules, which could have a material adverse effect on our financial position, results of
operations or cash flows. For a discussion of the environmental laws and regulations that the Company’s operations, products and services are subject to and other
environmental contingencies, refer to Note 12 to our Consolidated Financial Statements – Commitments and Contingencies.
13

-- 13 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
Other Laws and Regulations
Our operations, and some of the products and services we offer, are subject to a number of complex and stringent laws and regulations governing the
development, testing, approval, production, handling, transportation and distribution of chemicals, drugs and other similar products, including the operating and
security standards of the Food and Drug Administration, the Drug Enforcement Administration, the Bureau of Alcohol, Tobacco, Firearms and Explosives, and
various state boards of pharmacy as well as comparable state and foreign agencies. As Thermo Fisher’s businesses also include export and import activities, we are
subject to pertinent laws enforced by the U.S. Departments of Commerce, State and Treasury. In addition, our logistics activities must comply with the rules and
regulations of the Department of Transportation, the Federal Aviation Administration and similar foreign agencies. While we believe we are in compliance in all
material respects with such laws and regulations, any noncompliance could result in substantial fines or otherwise restrict our ability to provide competitive
distribution services and thereby have an adverse effect on our financial condition. To date, no such laws or regulations have had a material impact on our
operations.
We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government
contracts could harm our business by leading to a reduction in revenues associated with these customers. We have agreements relating to the sale of our products to
government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. We are also
subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could also result in
suspension of these contracts, criminal, civil and administrative penalties or debarment.
For a discussion of risks related to changes in governmental regulations, refer to “Risk Factors” in Part I, Item 1A.
Human Capital
The success of Thermo Fisher is fueled by colleagues who are highly engaged and feel empowered to achieve their goals. Everything we do starts with our
Mission – to enable our customers to make the world healthier, cleaner and safer. Our colleagues understand the role they play in fulfilling that Mission and that
inspires them to bring their best to work each day. Our Mission is not only a differentiator for us externally, but a motivator for us internally.
Our culture is rooted in our 4i Values of Integrity, Intensity, Innovation and Involvement. Within this framework, we strive to create a safe, fair and positive
working environment for our colleagues around the world. We want our teams to feel they have a stake in our success, a voice in our direction and to be
empowered to make a difference for the key stakeholders we serve.
Every year, we conduct an Employee Involvement Survey to solicit direct feedback from our colleagues on what we’re doing well and where we need to
improve. We then compile the feedback to measure our progress using three key indices: Leadership, Involvement and Inclusion. In 2021, 86 percent of our
workforce completed the survey, and we saw marked improvement in each index and across nearly every survey question, despite the challenges of a sustained
pandemic environment. Our continued focus on enhancing our culture helps position our company to be an even better place to work.
We are committed to maintaining the strongest team in our industry, focusing on developing and retaining our colleagues, while leveraging our leadership to
attract new colleagues to our company. As of December 31, 2021, we employed approximately 130,000 colleagues globally, with an approximate regional
distribution as follows: 67,000 based in the Americas, 20,000 in the Asia Pacific region, and nearly 42,000 in Europe, the Middle East and Africa (EMEA).
Diversity and Inclusion
We recognize that the future aspirations outlined in our Vision for 2030, which serves as our long-term roadmap, will only be achievable if we have a culture
that values diversity and inclusion. While diversity of gender and ethnicity are important – and we’re focused on continuously improving– for us, diversity of
backgrounds, experiences and viewpoints is equally vital to our long-term success. When those differences are welcomed and supported, we create an inclusive
workplace that unlocks the true benefits of diversity.
Diversity and Inclusion (D&I) is not an initiative at Thermo Fisher. It’s woven into the fabric of our culture, and our colleagues are encouraged to openly
share the wide range of perspectives they represent. We work together to create an inclusive culture where our colleagues feel they belong and are empowered to
contribute, collaborate and innovate. Embracing individual differences is critical to our success. For example, Thermo Fisher was named as a Top 100 Female
Friendly Employer by Forbes in 2021 as well as a Best Place to Work for LGBTQ Equality for the seventh consecutive year. Establishing this kind of environment
is critical in empowering our colleagues so they can contribute their best ideas and bring their true selves to work each day.
14

-- 14 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
Our D&I focus is embedded in every stage of our colleague lifecycle – from recruiting to onboarding, training, development and longer-term career planning.
We track our progress on our D&I strategic objectives through a core set of metrics that are reviewed during routine business operating mechanisms, including
Quarterly Business Reviews, Human Resource Reviews, Board Reviews and through team dashboards that are shared each month with leaders across the company.
This enables frequent, meaningful, data-driven discussions across our businesses and functions on a range of D&I factors, including gender and ethnic
representation. This approach also ensures we consistently prioritize our opportunities to improve. We understand the critical role diversity plays in sustained
business success, and our teams are empowered to ensure our workforce represents the customers we serve. Further, to provide additional transparency to our U.S.
workforce demographics, in 2021, following our report submission to the U.S. Equal Employment Opportunity Commission, we disclosed our EEO-1 report on our
website and we plan to continue to do so on an annual basis.
We are committed to ensuring our colleagues have access to resources, awareness training and internal networks that offer support and guidance. Our D&I
strategy is greatly enabled by our Employee Resource Groups (ERGs), which bring together individuals with similar interests to share experiences, learn from each
other and collaborate to identify solutions to business challenges. Our ERGs reinforce that all colleagues can make a difference for our customers, for each other
and for our company. As of December 31, 2021, we had 10 ERGs globally, with more than 220 local ERG chapters.
Talent Development
Our overarching goal from a talent perspective is to create opportunities for our colleagues to achieve their full potential and career aspirations here at Thermo
Fisher. We are committed to creating an exceptional colleague experience from their first day throughout their career with us. We focus on the entire lifecycle of a
colleague’s career, from their initial recruitment, to onboarding, through ongoing development and training to enhance their skills so they are in the best position to
deliver on their goals and achieve their career aspirations.
In today’s environment, we know talent is a key competitive advantage, and that building the strongest team in the industry is critical to our future. From our
colleague referral program, summer internships, university relations, to our Graduate Leadership Development Program, we continue to build strong internal and
external sourcing channels.
Once on board, talent development at Thermo Fisher is a key organizational capability. We continue to make significant investments to support our colleagues
along every step of their career journey to help support their success. Our talent development framework incorporates a multi-faceted approach, including formal
and self-paced training, networking opportunities, on-the-job stretch learning, coaching, mentoring and manager training utilizing contemporary technology
solutions to support the broad needs of our workforce.
We provide multiple programs at all career levels, from online learning for all colleagues through Thermo Fisher University, to focused trainings for managers
at various experience levels, to our Global Leadership Program for executives. We also support our colleagues’ career advancement through our tuition
reimbursement program.
In a company our size, we can also actively manage our talent through rotational opportunities across our businesses, functions and geographies that help our
colleagues gain new experiences, share knowledge and broaden their skills. Our executives and leaders participate in frequent talent discussions as well as formal
reviews, leveraging workforce data and predictive analytics to better anticipate the talent requirements of our business based on our growth opportunities and
market demand.
Thermo Fisher is dedicated to talent development to meet our evolving business needs and to provide our colleagues with opportunities for long and fulfilling
careers. Our colleagues are passionate about our company, and their role in our success, and it’s our responsibility to help them reach their full potential.
Total Rewards
We offer a comprehensive total rewards package that we regularly evaluate and measure against established benchmarks to ensure its effectiveness in
recruiting and retention, and to position Thermo Fisher as an employer of choice. In 2021, we reinvested an incremental $1 billion back into our global workforce
in the form of pay, benefits, and workplace enhancements.
Our health and wellness programs provide competitive, flexible programs that our global colleagues and their families can count on. For example, for U.S.
colleagues, we offer a choice of comprehensive national medical, dental and vision plans; a wellness program, including valuable health incentive opportunities
and tax-advantaged savings and spending accounts; as well as commuter benefits, employee assistance programs, optional group legal coverage, and company-paid
disability, accident and life insurance. We also offer a company-paid proprietary program for cancer care called the Impact Program, which gives our colleagues
and their families access to personalized support and direct lines of communication to experts in cancer genetics and genomics. Similar benefits are available in all
countries around the world where we operate.
15

-- 15 of 180 --

THERMO FISHER SCIENTIFIC INC.
Business (continued)
We also invest in our colleagues’ financial health, helping them to grow and protect their savings, plan for the future and share in the success of the company
they are helping to build. We deliver comprehensive rewards, including competitive base pay, and also provide a variety of incentive and equity programs that, by
design, directly link the impact of colleague contributions to the company’s overall success.
Disclosure Pursuant to Section 13(r) of the Exchange Act
In March 2021, the Russian Federal Security Service (the FSB) was designated as a blocked party under Executive Order 13382. During the quarter ended
December 31, 2021, one of our Russian affiliates responded to an official inquiry from FSB in connection with the validity of certain product warranties on certain
instruments sold by a reseller of the Russian affiliate to a health center based in Russia. This interaction did not result in any revenue or otherwise contribute to our
net income for the quarter and all such dealings were legal and authorized by General License 1B issued by the U.S. Department of the Treasury’s Office of
Foreign Assets Control. We expect our Russian affiliate to respond to similar regulatory inquiries in the future, as necessary and to the extent permitted by
applicable U.S. sanctions laws and regulations.
Available Information
The company files annual, quarterly and current reports, proxy statements and other documents with the Securities and Exchange Commission (SEC) under
the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information that issuers, including the company,
file electronically with the SEC. The public can obtain any documents that we file with the SEC at www.sec.gov. We also make available free of charge on or
through our own website at www.thermofisher.com our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and, if
applicable, amendments to those reports filed or furnished pursuant to Section 13(a) of the Exchange Act as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the SEC. In addition, paper copies of these documents may be obtained free of charge by writing to the company care of its
Investor Relations Department at our principal executive office located at 168 Third Avenue, Waltham, Massachusetts 02451.
Information about Our Executive Officers
As of February 24, 2022, our executive officers were:
Name 	Age Present Title
(Fiscal Year First Became Executive Officer) 	Other Positions Held
Marc N. Casper 	53 	Chairman, President and Chief Executive Officer (2001) 	President and Chief Executive Officer (2009-2020)
Chief Operating Officer (2008-2009)
Executive Vice President (2006-2009)
Mark P. Stevenson 	59 	Retiring Executive Vice President and Chief Operating
Officer (2014)
Executive Vice President and Chief Operating Officer (2017-2021)
Executive Vice President and President, Life Sciences Solutions
(2014-2017)
President and Chief Operating Officer, Life Technologies
Corporation (2008-2014)
Michel Lagarde 	48 	Executive Vice President and Chief Operating Officer (2017) 	Executive Vice President (2019-2021)
Senior Vice President and President, Pharma Services (2017-2019)
President and Chief Operating Officer, Patheon N.V. (2016-2017)
Managing Director, JLL Partners* (2008-2016)
Gianluca Pettiti 	43 	Executive Vice President (2021) 	Senior Vice President and President, Specialty Diagnostics (2019-
2021)
President, Biosciences (2018-2019)
President, China (2015-2017)
Michael A. Boxer 	60 	Senior Vice President, General Counsel and Secretary**
(2018) Executive Vice President and Group General Counsel, Luxottica
Group S.p.A. (2011-2017)
Stephen Williamson 	55 	Senior Vice President and Chief Financial Officer (2015) 	Vice President, Financial Operations (2008-2015)
Joseph R. Holmes 	43 	Vice President and Chief Accounting Officer (2021) 	Senior Director, Technical Accounting (2017-2021)
*JLL Partners is a private equity firm focused on healthcare.
**Assumed additional role of Secretary effective November 5, 2021.
16

-- 16 of 180 --

THERMO FISHER SCIENTIFIC INC.
Item 1A. 	Risk Factors
Set forth below are the risks that we believe are material to our investors. This section contains forward-looking statements. You should refer to the
explanation of the qualifications and limitations on forward-looking statements in 	Item 1. Business 	under the caption “Forward-looking Statements”.
Industry and Economic Risks
Our growth would suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality. 	Our
growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets would diminish demand for
our products and services, which would adversely affect our financial statements. Certain of our businesses operate in industries that may experience periodic,
cyclical downturns.
Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate. 	Our business is affected by
general economic conditions, both inside and outside the U.S. If the global economy and financial markets, or economic conditions in Europe, the U.S. or other key
markets, continue to be unstable (including as a result of the COVID-19 pandemic), it could adversely affect the business, results of operations and financial
condition of the company and its customers, distributors, and suppliers, having the effect of:
• 	reducing demand for some of our products;
• 	increasing the rate of order cancellations or delays;
• 	increasing the risk of excess and obsolete inventories;
• 	increasing pressure on the prices for our products and services;
• 	causing supply interruptions, which could disrupt our ability to produce our products; and
• 	creating longer sales cycles and greater difficulty in collecting sales proceeds.
Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of
operations. 	International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The
exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange
rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also
adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in
currencies other than the one in which they primarily do business (the “functional currency”). Movements in the invoiced currency relative to the functional
currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates
could have a larger effect on our financial results. In 2021, currency translation had a favorable effect of $619 million on revenues due to the weakening of the U.S.
dollar relative to other currencies in which the company sells products and services.
Some emerging market countries may be particularly vulnerable to periods of global and local political, legal, regulatory and financial instability, including
issues of geopolitical relations, the imposition of international sanctions in response to certain state actions and/or sovereign debt issues, and may have a higher
incidence of corruption and fraudulent business practices. As a result of these and other factors, our strategy to grow in emerging markets may not be successful,
and growth rates in these markets may not be sustainable.
In addition, many of our employees, contract manufacturers, suppliers, job functions, outsourcing activities and manufacturing facilities are located outside the
U.S. Accordingly, our future results could be harmed by a variety of factors, including:
• 	interruption to transportation flows for delivery of parts to us and finished goods to our customers;
• 	changes in a specific country's or region's political, economic or other conditions;
• 	changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes
and sanctions and other trade barriers;
• 	tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs adopted by the U.S.
government on various imports from China and by the Chinese government on certain U.S. goods;
17

-- 17 of 180 --

THERMO FISHER SCIENTIFIC INC.
Risk Factors (continued)
• 	the impact of public health epidemics/pandemics on the global economy, such as the COVID-19 pandemic;
• 	uncertainties regarding the collectability of accounts receivable;
• 	the imposition of governmental controls;
• 	diverse data privacy and protection requirements;
• 	supply interruptions, which could disrupt our ability to produce our products;
• 	negative consequences from changes in tax laws;
• 	difficulty in staffing and managing widespread operations;
• 	differing labor regulations;
• 	differing protection of intellectual property;
• 	unexpected changes in regulatory requirements;
• 	the effects of the U.K.'s departure from the E.U., known as Brexit; and
• 	geopolitical uncertainty or turmoil, including terrorism and war.
Demand for some of our products depends on capital spending policies of our customers and on government funding policies. 	Our customers include
pharmaceutical and chemical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Many
factors, including public policy spending priorities, available resources and product and economic cycles, have a significant effect on the capital spending policies
of these entities.
Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget. An impasse in federal
government budget decisions could lead to substantial delays or reductions in federal spending.
We are subject to risks associated with public health crises and epidemics/pandemics, such as the COVID-19 pandemic. 	Our global operations expose
us to risks associated with public health crises and epidemics/pandemics, such as COVID-19. The global spread of COVID-19 has created significant volatility,
uncertainty and worldwide economic disruption, resulting in an economic slowdown of potentially extended duration.
COVID-19 has had an adverse impact on certain of our operations, supply chains and distribution systems, including as a result of impacts associated with
preventive and precautionary measures that we, other businesses and governments are taking. National, state and local governments have implemented and may
continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and
shutdowns and other measures. These measures may disrupt normal business operations and may have significant negative impacts on businesses and financial
markets worldwide.
The company has mobilized to support the COVID-19 response with products and services that help diagnose the virus as well as assisting customers to
develop therapeutics and vaccines used to protect from the virus. Our ability to continue to manufacture products is highly dependent on our ability to maintain the
safety and health of our factory employees. The ability of our employees to work may be significantly impacted by individuals contracting or being exposed to
COVID-19. While we are following the requirements of governmental authorities and taking preventative and protective measures to prioritize the safety of our
employees, these measures may not be successful, and we may be required to temporarily close facilities or take other measures. While we are staying in close
communication with our sites, employees, customers and suppliers and acting to mitigate the impact of this dynamic and evolving situation, the duration and extent
of the effect of COVID-19 on the company is not determinable.
In addition, several of the company’s businesses have had an increase in revenues due to sales of products addressing diagnosis and treatment of COVID-19.
While these positive impacts are expected to continue into 2022, the duration and extent of future revenues from such sales are uncertain and dependent primarily
on customer testing demand.
Business Risks
We must develop new products, adapt to rapid and significant technological change and respond to introductions of new products by competitors to
remain competitive. 	Our growth strategy includes significant investment in and expenditures for product development. We sell our products in several industries
that are characterized by rapid and significant technological changes, frequent new product and service introductions and enhancements and evolving industry
standards. Competitive factors include technological innovation, price, service and delivery, breadth of product line, customer support, e-business
18

-- 18 of 180 --

THERMO FISHER SCIENTIFIC INC.
Risk Factors (continued)
capabilities and the ability to meet the special requirements of customers. Our competitors may adapt more quickly to new technologies and changes in customers’
requirements than we can. Without the timely introduction of new products, services and enhancements, our products and services will likely become
technologically obsolete over time, in which case our revenues and operating results would suffer.
Many of our existing products and those under development are technologically innovative and require significant planning, design, development and testing
at the technological, product and manufacturing-process levels. Our customers use many of our products to develop, test and manufacture their own products. As a
result, we must anticipate industry trends and develop products in advance of the commercialization of our customers’ products. If we fail to adequately predict our
customers’ needs and future activities, we may invest heavily in research and development of products and services that do not lead to significant revenues.
It may be difficult for us to implement our strategies for improving internal growth. 	Our growth depends in part on the growth of the markets which we
serve. Any decline or lower than expected growth in our served markets could diminish demand for our products and services, which would adversely affect our
results of operations and financial condition. To address this issue, we are pursuing a number of strategies to improve our internal growth, including:
• 	strengthening our presence in selected geographic markets;
• 	allocating research and development funding to products with higher growth prospects;
• 	developing new applications for our technologies;
• 	expanding our service offerings;
• 	continuing key customer initiatives;
• 	combining sales and marketing operations in appropriate markets to compete more effectively;
• 	finding new markets for our products; and
• 	continuing the development of commercial tools and infrastructure to increase and support cross-selling opportunities of products and services to take
advantage of our depth in product offerings.
We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.
Because we compete directly with certain of our larger customers and product suppliers, our results of operations could be adversely affected in the
short term if these customers or suppliers abruptly discontinue or significantly modify their relationship with us. 	Our largest customer in the laboratory
products business is also a significant competitor. Our business may be harmed in the short term if our competitive relationship in the marketplace with certain of
our large customers results in a discontinuation of their purchases from us. In addition, we manufacture products that compete directly with products that we source
from third-party suppliers. We also source competitive products from multiple suppliers. Our business could be adversely affected in the short term if any of our
large third-party suppliers abruptly discontinues selling products to us.
Integrating PPD into our business may be more difficult, costly or time consuming than expected and the anticipated benefits and cost savings of the
transaction may not be fully realized. 	The success of the PPD acquisition, including the realization of anticipated benefits and cost savings, depends, in part, on
our ability to successfully integrate PPD into our business. The integration is a difficult, costly and time-consuming process. It is possible that the integration
process could result in the loss of key employees or the disruption of our ongoing business or that the alignment of standards, controls, procedures and policies may
adversely affect our ability to maintain relationships with clients, customers, suppliers and employees or to fully achieve the anticipated benefits and cost savings
of the transaction. The loss of key employees could adversely affect our ability to successfully conduct our business in the markets in which PPD now operates,
which could have an adverse effect on our financial results.
If we experience difficulties with the integration process, the anticipated benefits and cost savings of the PPD acquisition may not be realized fully or at all, or
may take longer to realize than expected, and our business may be unable to grow as planned, which could materially impact our business, cash flow, financial
condition or results of operations as well as adversely impact our share price. The integration process may also result in significant expenses and charges, both cash
and noncash.
Our inability to complete any pending acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect
on our business. 	Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services.
Certain acquisitions may be difficult to complete for a number of reasons, including the need for antitrust and/or other regulatory approvals, as well as disputes or
litigation. Any
19

-- 19 of 180 --

THERMO FISHER SCIENTIFIC INC.
Risk Factors (continued)
acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets of the acquired company. Further, we may not
be able to integrate acquired businesses successfully into our existing businesses, make such businesses profitable, or realize anticipated cost savings or synergies,
if any, from these acquisitions, which could adversely affect our business.
Moreover, we have acquired many companies and businesses. As a result of these acquisitions, we recorded significant goodwill and indefinite-lived
intangible assets (primarily tradenames) on our balance sheet, which amount to approximately $41.92 billion and $1.24 billion, respectively, as of December 31,
2021. In addition, we have definite-lived intangible assets totaling $18.88 billion as of December 31, 2021. We assess the realizability of goodwill and indefinite-
lived intangible assets annually as well as whenever events or changes in circumstances indicate that these assets may be impaired. We assess the realizability of
definite-lived intangible assets whenever events or changes in circumstances indicate that these assets may be impaired. These events or circumstances would
generally include operating losses or a significant decline in earnings associated with the acquired business or asset. Our ability to realize the value of the goodwill
and intangible assets will depend on the future cash flows of these businesses. These cash flows in turn depend in part on how well we have integrated these
businesses. If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of
those assets.
Operational Risks
Our reliance upon sole or limited sources of supply for certain materials or components could cause production interruptions, delays and
inefficiencies. 	Some of our businesses purchase certain materials from sole or limited source suppliers for reasons of quality assurance, regulatory requirements,
cost effectiveness, availability or uniqueness of design. If these or other suppliers encounter financial, operating or other difficulties or if our relationship with them
changes, we might not be able to quickly establish or qualify replacement sources of supply. The supply chains for our businesses could also be disrupted by
supplier capacity constraints, bankruptcy or exiting of the business for other reasons, decreased availability of key raw materials or commodities and external
events such as natural disasters, pandemic health issues such as COVID-19, war, terrorist actions, governmental actions and legislative or regulatory changes. Any
of these factors could result in production interruptions, delays, extended lead times and inefficiencies.
A significant disruption in, or breach in security of, our information technology systems or violation of data privacy laws could adversely affect our
business. 	As a part of our ongoing effort to upgrade our current information systems, we periodically implement new enterprise resource planning software and
other software applications to manage certain of our business operations. As we implement and add functionality, problems could arise that we have not foreseen.
Such problems could disrupt our ability to provide quotes, take customer orders and otherwise run our business in a timely manner. When we upgrade or change
systems, we may suffer interruptions in service, loss of data or reduced functionality. In addition, if our new systems fail to provide accurate pricing and cost data
our results of operations and cash flows could be adversely affected.
We also rely on our information technology systems to process, transmit and store electronic information (including sensitive data such as confidential
business information and personally identifiable data relating to employees, customers and other business partners) and to manage or support a variety of critical
business processes and activities (such as interacting with suppliers, selling our products and services, fulfilling orders and billing, collecting and making
payments, shipping products, providing services and support to customers, tracking customer activity, fulfilling contractual obligations and otherwise conducting
business). Our systems may be vulnerable to damage or interruption from natural disasters, power loss, telecommunication failures, terrorist attacks, computer
hackers, computer viruses, ransomware, phishing, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets,
and other attempts to harm our systems. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite
any precautions we may take, such problems could result in, among other consequences, interruptions in our services, which could harm our reputation and
financial results. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. Any of the cyber-
attacks, breaches or other disruptions or damage described above, if significant, could materially interrupt our operations, delay production and shipments, result in
theft of our and our customers’ intellectual property and trade secrets, damage customer, business partner and employee relationships and our reputation or result in
defective products or services, legal claims and proceedings, liability and penalties under privacy laws and increased cost for security and remediation, each of
which could adversely affect our business and financial results. Our liability insurance may not be sufficient in type or amount to cover us against claims related to
security breaches, cyber-attacks and other related breaches.
If we are unable to maintain reliable information technology systems and appropriate controls with respect to global data privacy and security requirements
and prevent data breaches, we may suffer regulatory consequences in addition to business consequences. As a global organization, we are subject to data privacy
and security laws, regulations, and customer-imposed
20

-- 20 of 180 --

THERMO FISHER SCIENTIFIC INC.
Risk Factors (continued)
controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business. For
example, in the U.S., individual states regulate data breach and security requirements and multiple governmental bodies assert authority over aspects of the
protection of personal privacy. European laws require us to have an approved legal mechanism to transfer personal data out of Europe, and the EU General Data
Protection Regulation imposes significantly stricter requirements in how we collect and process personal data. Several countries, such as China and Russia, have
passed laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions. Government
enforcement actions can be costly and interrupt the regular operation of our business, and data breaches or violations of data privacy laws can result in fines,
reputational damage and civil lawsuits, any of which may adversely affect our business, reputation and financial statements.
We may have difficulty attracting and retaining a highly qualified workforce. 	Our success is largely dependent upon our ability to attract and retain
highly qualified scientific, technical, clinical and management workforce in a highly competitive environment. Qualified individuals are in high demand, and we
may incur significant costs to attract them. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes or
recruitment by competitors. Our ability to attract and retain key talent also depends in part on how well we maintain a strong workplace culture that is attractive to
employees. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a
material impact on our financial condition and results of operations.
We may incur unexpected costs from increases in fuel and raw material prices, which could reduce our earnings and cash flows. 	Our primary
commodity exposures are for fuel, petroleum-based resins and steel. While we may seek to minimize the impact of price increases through higher prices to
customers and various cost-saving measures, our earnings and cash flows could be adversely affected in the event these measures are insufficient to cover our
costs.
Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may
disrupt our ability to ship products, increase our costs and lower our profitability. 	We ship a significant portion of our products to our customers through
independent package delivery companies, such as Federal Express in the U.S. and DHL in Europe. We also maintain a small fleet of vehicles dedicated to the
delivery of our products and ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S. Postal
Service. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in
a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain
of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not
able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.
Natural disasters, public health crises, political crises, and other catastrophic events or other events outside of our control may disrupt our facilities
or the facilities of third parties on which we depend, and could impact customer spending. 	We have significant operations in California, near major
earthquake faults, which make us susceptible to earthquake risk. An earthquake or other natural disaster such as a fire or hurricane or power shortages or outages
could disrupt our operations or impair our critical systems. Any of these disruptions or other events outside of our control, such as strikes or other labor unrest,
could have an adverse effect on our results of operations. In addition, if any of our facilities, including our manufacturing or warehouse facilities, or the facilities of
our suppliers, third-party service providers, or customers, is affected by natural disasters, such as earthquakes, tsunamis, power shortages or outages, floods or
monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict, or other events
outside of our control, such as trade protectionism, strikes or other labor unrest, our results of operations could be adversely affected. Moreover, these types of
events could negatively impact customer spending in the impacted regions or depending upon the severity, globally, which could also adversely impact our
operating results.
Increasing attention to environmental, social and governance matters may impact our business, financial results or stock price. 	Companies across all
industries are facing increasing scrutiny from stakeholders related to their environmental, social and governance (ESG) practices and disclosures, including
practices and disclosures related to climate change, diversity and inclusion and governance standards. Investor advocacy groups, certain institutional investors,
lenders, investment funds and other influential investors are also increasingly focused on ESG practices and disclosures and in recent years have placed increasing
importance on the implications and social cost of their investments. In addition, government organizations are enhancing or advancing legal and regulatory
requirements specific to ESG matters. The heightened stakeholder focus on ESG issues related to our business requires the continuous monitoring of various and
evolving laws, regulations, standards and expectations and the associated reporting requirements. A failure to adequately meet stakeholder expectations may result
in noncompliance, the loss of business, reputational impacts, diluted market valuation, an inability to attract customers and an
21

-- 21 of 180 --

THERMO FISHER SCIENTIFIC INC.
Risk Factors (continued)
inability to attract and retain top talent. In addition, our adoption of certain standards or mandated compliance to certain requirements could necessitate additional
investments that could impact our profitability.
Legal, Quality and Regulatory Risks
Changes in governmental regulations may reduce demand for our products or increase our expenses. 	We compete in many markets in which we and our
customers must comply with federal, state, local and international regulations, such as environmental, health and safety and food and drug regulations. We develop,
configure and market our products to meet customer needs created by those regulations. Any significant change in regulations could reduce demand for our
products or increase our expenses. For example, we manufacture pharmaceuticals and many of our instruments are marketed to the pharmaceutical industry for use
in discovering and developing drugs. Changes in the U.S. Food and Drug Administration’s (the FDA) regulation of the drug discovery and development process
could have an adverse effect on the demand for these products.
We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with
government contracts could harm our business by leading to a reduction in revenues associated with these customers. 	We have agreements relating to the
sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the
government. The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and
conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A
failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.
Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could
suffer. 	Our pharma services offerings are highly exacting and complex, due in part to strict quality and regulatory requirements. Our operating results in this
business depend on our ability to execute and, when necessary, improve our quality management strategy and systems, and our ability to effectively train and
maintain our employee base with respect to quality management. A failure of our quality control systems could result in problems with facility operations or
preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow specific
protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations. Such problems could affect
production of a particular batch or series of batches of products, requiring the destruction of such products or a halt of facility production altogether.
In addition, our failure to meet required quality standards may result in our failure to timely deliver products to our customers, which in turn could damage our
reputation for quality and service. Any such failure could, among other things, lead to increased costs, lost revenues, reimbursement to customers for lost drug
product, registered intermediates, registered starting materials, and active pharmaceutical ingredients, other customer claims, damage to and possibly termination
of existing customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or
products. Production problems in our drug and biologic manufacturing operations could be particularly significant because the cost of raw materials for such
manufacturing is often high. If problems in preparation or manufacture of a product or failures to meet required quality standards for that product are not
discovered before such product is released to the market, we may be subject to adverse regulatory actions, including product recalls, product seizures, injunctions
to halt manufacture and distribution, restrictions on our operations, civil sanctions, including monetary sanctions, and criminal actions. In addition, such problems
or failures could subject us to litigation claims, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical
ingredients, the cost of which could be significant.
We are subject to product and other liability risks for which we may not have adequate insurance coverage. 	We may be named as a defendant in
product liability lawsuits, which may allege that products or services we have provided from our pharma services offerings have resulted or could result in an
unsafe condition or injury to consumers. Additionally, products currently or previously sold by our environmental and process instruments and radiation
measurement and security instruments businesses include fixed and portable instruments used for chemical, radiation and trace explosives detection. These
products are used in airports, embassies, cargo facilities, border crossings and other high-threat facilities for the detection and prevention of terrorist acts. If any of
these products were to malfunction, it is possible that explosive or radioactive material could fail to be detected by our product, which could lead to product
liability claims. In addition, patients involved in our clinical services trials conducted by our clinical development services business or taking drugs approved on
the basis of those trials may also bring personal injury claims against us. There are also many other factors beyond our control that could lead to liability claims,
such as the reliability and competence of the customers’ operators and the training of such operators.
Any such product liability claims brought against us could be significant and any adverse determination may result in liabilities in excess of our insurance
coverage. Although we carry product liability insurance, we cannot be certain that our current insurance will be sufficient to cover these claims or that it can be
maintained on acceptable terms, if at all.
22

-- 22 of 180 --

THERMO FISHER SCIENTIFIC INC.
Risk Factors (continued)
We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies.
We are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the FDA, the
U.S. Drug Enforcement Agency (the DEA), various state boards of pharmacy, state health departments, the U.S. Department of Health and Human Services (the
DHHS), the European Medicines Agency (the EMA), the EU member states and other comparable agencies and, in the future, any changes to such laws and
regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices and drug safety. Our
subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of the DEA, the FDA, the
DHHS, foreign agencies including the EMA, and other various state boards of pharmacy, state health departments and/or comparable state agencies as well as
certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale.
The manufacture, distribution and marketing of many of our products and services, including medical devices, and our pharma and clinical development
services, are subject to extensive ongoing regulation by the FDA, the DEA, the EMA, and other equivalent local, state, federal and non-U.S. regulatory authorities.
In addition, we are subject to inspections by these regulatory authorities. Failure by us or by our customers to comply with the requirements of these regulatory
authorities, including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could result in warning letters,
product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or
withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could expose us to contractual or
product liability claims, contractual claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients or
personal injury, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are the sole manufacturer of a number
of pharmaceuticals for many of our customers and a negative regulatory event could impact our customers' ability to provide products to their customers.
We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the handling, transportation and
manufacture of substances that could be classified as hazardous, and we are required to comply with various import laws and export control and economic
sanctions laws, which may affect our transactions with certain customers. In certain circumstances, export control and economic sanctions regulations may prohibit
the export of certain products, services and technologies. In other circumstances, we may be required to obtain an export license before exporting the controlled
item. Compliance with the various import laws that apply to our businesses can restrict our access to, and increase the cost of obtaining, certain products and at
times can interrupt our supply of imported inventory. Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain
necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of operations.
Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents or business
partners. 	We have internal controls and compliance systems to protect the company against acts committed by employees, agents or businesses that we acquire
that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing,
sales and marketing practices, conflicts of interest, competition, employment practices and workplace behavior, export and import compliance, money laundering
and data privacy, but these controls and systems may not be sufficient to prevent every such wrongful act. In particular, the U.S. Foreign Corrupt Practices Act, the
U.K. Bribery Act 2010 and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments
to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental
corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in
the U.S. and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and nonmonetary penalties and could
cause us to incur significant legal and investigatory fees. In addition, the government may seek to hold us liable for violations committed by companies which we
acquire. We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations of such standards of conduct could occur that could
have a material effect on our business, reputation and financial statements.
Our inability to protect our intellectual property could have a material adverse effect on our business. In addition, third parties may claim that we
infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result. 	We place considerable emphasis on obtaining
patent and trade secret protection for significant new technologies, products and processes because of the length of time and expense associated with bringing new
products through the development process and into the marketplace. Our success depends in part on our ability to develop patentable products and obtain and
enforce patent protection for our products both in the U.S. and in other countries. We own numerous U.S. and foreign patents, and we intend to file additional
applications, as appropriate, for patents covering our products. Patents may not
23

-- 23 of 180 --

THERMO FISHER SCIENTIFIC INC.
Risk Factors (continued)
be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to
protect our technology. Any issued patents owned by or licensed to us may be challenged, invalidated or circumvented, and the rights under these patents may not
provide us with competitive advantages. In addition, competitors may design around our technology or develop competing technologies. Intellectual property rights
may also be unavailable or limited in some foreign countries, which could make it easier for competitors to capture increased market position. We could incur
substantial costs to defend ourselves in suits brought against us or in suits in which we may assert our patent rights against others. An unfavorable outcome of any
such litigation could materially adversely affect our business and results of operations.
We also rely on trade secrets and proprietary know-how with which we seek to protect our products, in part, by confidentiality agreements with our
collaborators, employees and consultants. These agreements may not adequately protect our trade secrets and other proprietary rights. These agreements may be
breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently developed by
our competitors.
Third parties may assert claims against us to the effect that we are infringing on their intellectual property rights. In the event that a claim relating to
intellectual property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may
seek licenses to such intellectual property or challenge those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at
all, and our challenge of the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture, or
distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.
Risks Relating to Financial Profile
Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows. 	As a global company, we are subject to taxation in
numerous countries, states and other jurisdictions. In preparing our financial statements, we record the amount of tax that is payable in each of the countries, states
and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors,
including a change in the mix of our profitability from country to country, changes in accounting for income taxes, the results of examinations and audits of our tax
filings and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax
rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash
flows.
Our existing and future indebtedness may restrict our investment opportunities or limit our activities and negatively impact our credit ratings. 	As of
December 31, 2021, we had approximately $34.87 billion in outstanding indebtedness. In addition, we have availability to borrow under a revolving credit facility
that provides for up to $5.00 billion (as of January 7. 2022) of unsecured multi-currency revolving credit (the Facility). We may also obtain additional long-term
debt and lines of credit to meet future financing needs, which would have the effect of increasing our total leverage.
Our leverage could have negative consequences, including increasing our vulnerability to adverse economic and industry conditions, limiting our ability to
obtain additional financing and limiting our ability to acquire new products and technologies through strategic acquisitions.
Our ability to make scheduled payments, refinance our obligations or obtain additional financing will depend on our future operating performance and on
economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flow to meet our obligations. If we are unable
to service our debt, refinance our existing debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures or research and
development expenditures.
Additionally, the agreements governing our debt require that we maintain a financial ratio, and contain affirmative and negative covenants that restrict our
activities by, among other limitations, limiting our ability to incur additional indebtedness, merge or consolidate with other entities and create liens. The covenants
in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the
Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the
Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.5:1.0 as of the last
day of any fiscal quarter.
Our ability to comply with these financial restrictions and covenants is dependent on our future performance, which is subject to prevailing economic
conditions and other factors, including factors that are beyond our control such as the impact of foreign exchange rates and interest rates. Our failure to comply
with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under
that instrument and
24

-- 24 of 180 --

THERMO FISHER SCIENTIFIC INC.
Risk Factors (continued)
require us to prepay that debt before its scheduled due date. Also, an acceleration of the debt under certain of our debt instruments would trigger an event of default
under other of our debt instruments.
Item 1B. 	Unresolved Staff Comments
None.
Item 2. 	Properties
The company owns and leases office, engineering, laboratory, production and warehouse space throughout the world.
Item 3. 	Legal Proceedings
There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See “Note 12
to our Consolidated Financial Statements – 	Commitments and Contingencies.”
Item 4. 	Mine Safety Disclosures
Not applicable.
PART II
Item 5. 	Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Price of Common Stock
Our common stock is traded on the New York Stock Exchange under the symbol TMO.
Holders of Common Stock
As of February 5, 2022, the company had 2,619 holders of record of its common stock. This does not include holdings in street or nominee names.
Issuer Purchases of Equity Securities
There was no share repurchase activity for the company’s fourth quarter of 2021. On September 23, 2021, the Board of Directors authorized the repurchase of
up to $3.00 billion of the company’s common stock. Early in the first quarter of 2022, the company repurchased $2.00 billion of the company's common stock. At
February 24, 2022, $1.00 billion was available for future repurchases of the company’s common stock under this authorization.
Item 6. 	Reserved
Not applicable.
25

-- 25 of 180 --

THERMO FISHER SCIENTIFIC INC.
Item 7. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations
Reference is made throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations to Notes to the 	Consolidated
Financial Statements, which begin on page F-1 of this report. Management's discussion and analysis of financial condition and results of operations for 2019 is
included in Item 7 of the company’s 2020 	Annual Report on Form 10-K 	filed with the Securities and Exchange Commission.
The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These
non-GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “Non-GAAP 	Measures” later in
this “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
Overview
Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve
complex analytical challenges, improve patient diagnostics and therapies, and increase laboratory productivity. Markets served include pharmaceutical and biotech,
academic and government, industrial and applied, as well as healthcare and diagnostics. The company’s operations fall into four segments (Note 4): Life Sciences
Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.
Financial Highlights - 2021 Compared With 2020
(Dollars in millions except per share amounts) 	2021 	2020 	Change
Revenues 	$ 	39,211 	$ 	32,218 	22 	%
GAAP operating income 	$ 	10,028 	$ 	7,794 	29 	%
GAAP operating income margin 	25.6 	% 	24.2 	% 	1.4 	pt
Adjusted operating income 	(non-GAAP measure) 	$ 	12,138 	$ 	9,556 	27 	%
Adjusted operating income margin 	(non-GAAP measure) 	31.0 	% 	29.7 	% 	1.3 	pt
GAAP diluted earnings per share attributable to Thermo Fisher Scientific Inc. 	$ 	19.46 	$ 	15.96 	22 	%
Adjusted earnings per share 	(non-GAAP measure) 	$ 	25.13 	$ 	19.56 	28 	%
Organic Revenue Growth
Revenue growth 	22 	%
Impact of acquisitions 	3 	%
Impact of currency translation 	2 	%
Organic revenue growth* 	(non-GAAP measure) 	17 	%
* 	Results may not sum due to rounding.
The company mobilized in early 2020 to support the COVID-19 pandemic response with products and services that help analyze, diagnose and protect from
the virus. However, as a result of the pandemic’s impact on various markets, the company saw a significant reduction in customer activity in several businesses by
late March 2020 that materially adversely affected primarily the 2020 results of the Analytical Instruments segment and, to a lesser extent, some businesses within
the company’s other three segments. The negative impact significantly lessened in 2021, but could worsen in 2022 dependent on the success of global efforts to
control and unwind from the pandemic and economic activity ramping up. During 2021, the Life Sciences Solutions and Specialty Diagnostics segments as well as
the laboratory products business continued to support COVID-19 diagnostic testing, scaling and evolving their molecular diagnostics solutions and plastic
consumables businesses to respond to the on-going COVID-19 pandemic. The biosciences and bioproduction businesses also expanded their capacity to meet the
needs of pharma and biotech customers as they rapidly expanded their own production volumes to meet global vaccine manufacturing requirements. Additionally,
through our pharma services business, we provided our pharma and biotech customers with the services they needed to develop and produce vaccines and therapies
globally. While these positive impacts are expected to continue through 2022, the duration and extent of future revenues from such sales are uncertain and
dependent primarily on customer testing as well as therapy and vaccine demand. Sales of products related to COVID-19 response were $9.23 billion and $6.63
billion in 2021 and 2020, respectively.
Conditions were strong in each of the company’s end markets during 2021. Revenues were particularly strong in pharma and biotech driven by strong market
dynamics and the company’s role in supporting customers across a wide range of therapeutic areas, including our role in supporting COVID-19 vaccines and
therapies. Customers in the academic and
26

-- 26 of 180 --

THERMO FISHER SCIENTIFIC INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Overview (continued)
government market increased demand as a result of positive funding trends around the globe and a return to pre-pandemic levels of activity. Customer activity in
the industrial and applied market returned to pre-pandemic levels in 2021. Revenues from customers in the diagnostics and healthcare market were driven by
growth in COVID-19 testing-related products as the company continued to support the societal response to the pandemic. Sales growth was strong across all
geographic regions during 2021. The company continues to execute its proven growth strategy which consists of three pillars:
• 	Developing high-impact, innovative new products,
• 	Leveraging our scale in high-growth and emerging markets, and
• 	Delivering a unique value proposition to our customers.
GAAP operating income margin and adjusted operating income margin increased in 2021 due primarily to profit on higher sales and sales mix, offset in part
by strategic growth investments to support the company’s near and long-term growth.
The company’s references to strategic growth investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of
geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and
other expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company’s references throughout
this discussion to productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business system including
reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure following restructuring
actions, including headcount reductions and consolidation of facilities, and low cost region manufacturing. Productivity improvements are calculated net of
inflationary cost increases.
Notable Recent Acquisitions
On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector
manufacturing business of Groupe Novasep SAS for $830 million in net cash consideration. The European viral vector manufacturing business provides
manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities
for cell and gene vaccines and therapies.
On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company,
for $407 million in net cash consideration and contingent consideration with an initial fair value of $65 million due upon the completion of certain milestones.
Mesa Biotech has developed and commercialized a PCR based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19.
The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care.
On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-
the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as
well. The company expects to make fixed lease payments aggregating to $555 million (excluding renewals) from 2021 to 2041, with additional amounts dependent
on the extent of revenues from customers of the facility other than CSL.
On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of
clinical research services to the pharma and biotech industry, for $15.99 billion in net cash consideration and $43 million of equity awards exchanged. The addition
of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their
productivity within the drug development process. In 2020, PPD generated revenues of $4.68 billion.
On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S. based developer and manufacturer of
recombinant proteins, for $1.86 billion in net cash consideration. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and
growth factors. The acquisition expands the segment’s bioscience offerings.
Results of Operations
The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 4.
Accordingly, the following segment data are reported on this basis.
27

-- 27 of 180 --

THERMO FISHER SCIENTIFIC INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Results of Operations (continued)
(Dollars in millions) 	2021 	2020
Revenues
Life Sciences Solutions 	$ 	15,631 	$ 	12,168
Analytical Instruments 	6,069 	5,124
Specialty Diagnostics 	5,659 	5,343
Laboratory Products and Biopharma Services 	14,862 	12,245
Eliminations 	(3,010) 	(2,662)
Consolidated revenues 	$ 	39,211 	$ 	32,218
Life Sciences Solutions
Organic* 	(non-
GAAP measure)
(Dollars in millions)
2021 	2020 Total
Change Currency
Translation Acquisitions/
Divestitures
Revenues 	$ 	15,631 	$ 	12,168 	28 	% 	2 	% 	3 	% 	23 	%
Segment income 	$ 	7,817 	$ 	6,109 	28 	%
Segment income margin 	50.0 	% 	50.2 	% 	-0.2 pt
* 	Results may not sum due to rounding
The increase in segment revenues at existing businesses in 2021 was driven by a combination of increased demand for testing to diagnose COVID-19 with
higher sales of biosciences products and strong demand in each of the segment’s businesses. The decrease in segment income margin resulted primarily from
strategic growth investments, offset in part by profit on higher sales.
Analytical Instruments
Organic* 	(non-
GAAP measure)
(Dollars in millions)
2021 	2020
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues 	$ 	6,069 	$ 	5,124 	18 	% 	2 	% 	— 	% 	17 	%
Segment income 	1,197 	808 	48 	%
Segment income margin 	19.7 	% 	15.8 	% 	3.9 pt
* 	Results may not sum due to rounding
The increase in segment revenues at existing businesses in 2021 was due to increased demand for products sold by each of the segment’s primary businesses
with particular strength in electron microscopy instruments as well as chromatography and mass spectrometry instruments. The increase in segment income margin
was primarily due to profit on higher sales and, to a lesser extent, a $108 million charge in 2020 related to a long-term supply contract (discussed in Note 12),
offset in part by strategic growth investments.
Specialty Diagnostics
Organic* 	(non-
GAAP measure)
(Dollars in millions)
2021 	2020
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues 	$ 	5,659 	$ 	5,343 	6 	% 	1 	% 	— 	% 	5 	%
Segment income 	1,280 	1,368 	(6) 	%
Segment income margin 	22.6 	% 	25.6 	% 	-3.0 pt
* 	Results may not sum due to rounding
The increase in segment revenues at existing businesses in 2021 was due to higher demand primarily driven by products addressing treatment of COVID-19,
with particular strength in sales of products sold through the segment's healthcare market channel, immunodiagnostics and clinical diagnostics products. The
decrease in segment income margin was primarily due to sales mix and strategic investments, offset in part by profit on higher sales and, to a lesser extent, a
$13 million credit to cost of product revenue as a result of changing the method of accounting for inventories (discussed in Note 1).
28

-- 28 of 180 --

THERMO FISHER SCIENTIFIC INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Results of Operations (continued)
Laboratory Products and Biopharma Services
Organic* 	(non-
GAAP measure)
(Dollars in millions)
2021 	2020
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues 	$ 	14,862 	$ 	12,245 	21 	% 	2 	% 	5 	% 	15 	%
Segment income 	1,844 	1,271 	45 	%
Segment income margin 	12.4 	% 	10.4 	% 	2.0 pt
* 	Results may not sum due to rounding
The increase in segment revenues at existing businesses in 2021 was primarily due to increased demand in each of the segment’s principal businesses with
particular strength in products sold through its pharma services business and research and safety market channel and, to a lesser extent, laboratory products
businesses. The increase in segment income margin was primarily due to profit on higher sales and sales mix, and, to a lesser extent, acquisitions and a $20 million
credit to cost of product revenue as a result of changing the method of accounting for inventories (discussed in Note 1), offset in part by strategic growth
investments.
Non-operating Items
(Dollars in millions) 	2021 	2020
Net interest expense 	$ 	493 	$ 	488
GAAP other income/(expense) 	(694) 	(76)
Adjusted other income/(expense) 	(non-GAAP measure) 	38 	45
GAAP tax rate 	12.5 	% 	11.8 	%
Adjusted tax rate 	(non-GAAP measure) 	14.6 	% 	14.3 	%
Net interest expense (interest expense less interest income) increased due primarily to the increase in debt to finance the acquisition of PPD and for general
corporate purposes, offset in part by lower average interest rates. See additional discussion under the caption “Liquidity and Capital Resources” below.
GAAP other income/(expense) and adjusted other income/(expense) includes currency transaction gains and losses on non-operating monetary assets and
liabilities and net periodic pension benefit cost/income, excluding the service cost component. GAAP other income/(expense) in 2021 also includes $767 million of
losses on the early extinguishment of debt (Note 10) and $36 million of financing costs associated with obtaining bridge financing commitments in connection with
the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments. GAAP other income/(expense) in 2020 includes $81 million of
financing costs for a terminated acquisition, primarily for loan commitment fees and entering into hedging contracts and $42 million of expense reclassified from
accumulated other comprehensive items related to a hedge arrangement (Note 14), offset in part by $10 million of net gains on investments.
The company’s GAAP and adjusted tax rates increased in 2021 compared to 2020, primarily due to higher profits at different marginal rates, offset in part by
the benefits of our tax planning initiatives. The company’s 2021 GAAP and adjusted tax rates were also impacted by income tax benefits on intra-entity
transactions totaling $284 million. In 2020, the company’s GAAP and adjusted tax rates were impacted by foreign tax credit planning in Sweden which resulted in
$96 million of foreign tax credits, with no related incremental U.S. income tax expense; a net income tax benefit of $51 million from a domestication transaction
involving the transfer of non-U.S. subsidiaries to the U.S.; and a $47 million income tax benefit related to a foreign exchange loss for tax purposes on certain
intercompany financing arrangements. Additionally, the 2020 GAAP tax rate included a $27 million tax benefit from tax audit settlements.
The effective tax rate in both 2021 and 2020 was also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-
deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes were higher than its income tax expense for financial
reporting purposes and totaled $2.18 billion and $1.32 billion in 2021 and 2020, respectively.
The company expects its GAAP effective tax rate in 2022 will be between 9% and 11% based on currently forecasted rates of profitability in the countries in
which the company conducts business and expected generation of foreign tax credits. The effective tax rate can vary significantly from period to period as a result
of discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 13% in 2022.
29

-- 29 of 180 --

THERMO FISHER SCIENTIFIC INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Results of Operations (continued)
The company has operations and a taxable presence in approximately 50 countries outside the U.S. Some of these countries have lower tax rates than the U.S.
The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the
statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a
change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income, aside from any
resulting one-time adjustment to the company’s deferred tax balances to reflect a new rate.
Liquidity and Capital Resources
The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital
primarily via mergers and acquisitions and secondarily via share buybacks and dividends.
December 31, 	December 31,
(In millions) 	2021 	2020
Cash and cash equivalents 	$ 	4,477 	$ 	10,325
Total debt 	34,870 	21,735
Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs
outside of the U.S. including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also
transfers cash to the U.S. using non-taxable returns of capital as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals
any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity
effects from its significant non-U.S. cash balances for the foreseeable future.
The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its
revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24
months.
As of December 31, 2021, the company’s short-term debt totaled $2.54 billion. On January 7, 2022, the company replaced its prior credit facility with a new
revolving credit facility with a bank group that provides up to $5.00 billion of unsecured multi-currency revolving credit (Note 10). If the company borrows under
this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper
markets are not available. As of December 31, 2021, no borrowings were outstanding under the company’s revolving credit facility, although available capacity
was reduced by approximately $4 million as a result of outstanding letters of credit.
(In millions) 	2021 	2020
Net cash provided by operating activities 	$ 	9,312 	$ 	8,289
Net cash used in investing activities 	(21,932) 	(1,510)
Net cash provided by financing activities 	6,581 	959
Free cash flow 	(non-GAAP measure) 	6,809 	6,823
During 2021, cash provided by income was offset in part by investments in working capital. Increases in accounts receivable and inventories used cash of
$204 million and $1.07 billion, respectively, primarily to support growth in sales. An increase in accounts payable provided cash of $479 million. Changes in other
assets and other liabilities used cash of $724 million primarily due to the timing of tax and incentive compensation payments. Cash payments for income taxes
were $2.18 billion during 2021.
During 2020, cash provided by income was offset in part by investments in working capital. Increases in accounts receivable and inventories used cash of
$1.30 billion and $508 million, respectively, primarily to support growth in sales. Changes in other assets and other liabilities provided cash of $1.45 billion
primarily due to the timing of incentive compensation payments and, to a lesser extent, customer billings. Cash payments for income taxes were $1.32 billion
during 2020.
During 2021, acquisitions used cash of $19.40 billion. The company's investing activities also included the purchase of $2.52 billion of property, plant and
equipment for capacity and capability investments. During 2020, the company’s investing activities were principally for the purchase of property, plant and
equipment.
30

-- 30 of 180 --

THERMO FISHER SCIENTIFIC INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Liquidity and Capital Resources (continued)
During 2021, issuance of senior notes provided $18.14 billion of cash. A net increase in commercial paper obligations provided cash of $2.51 billion.
Repayment of debt used cash of $11.74 billion, including $4.30 billion to repay the debt assumed in the acquisition of PPD. The company’s financing activities
also included the repurchase of $2.00 billion of the company's common stock (4.1 million shares) and the payment of $395 million in cash dividends. On
September 23, 2021, the Board of Directors authorized the repurchase of up to $3.00 billion of the company’s common stock. Early in the first quarter of 2022, the
company repurchased $2.00 billion of the company's common stock (3.3 million shares). At February 24, 2022, authorization remained for $1.00 billion of future
repurchases of the company’s common stock. As discussed in Note 10, in the first quarter of 2022 the company redeemed its 3.650% Senior Notes due 2025 for a
total cash outlay of $375 million.
During 2020, issuance of senior notes provided cash of $3.46 billion. Repayment of senior notes used cash of $710 million. The company’s financing
activities also included the repurchase of $1.50 billion of the company’s common stock (4.5 million shares) and the payment of $337 million in cash dividends.
The company expects that for all of 2022, expenditures for property, plant and equipment, net of disposals, will be between $2.5 and $2.7 billion.
In addition to the obligations on the balance sheet at December 31, 2021, which include, but are not limited to, debt (Note 10), unrecognized tax benefits (Note
8), operating leases (Note 11) pension obligations (Note 7) and contingent consideration (Note 14), the company has entered into unconditional purchase
obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties (Note 12).
The company is contingently liable with respect to certain legal proceedings and related matters. An unfavorable outcome that differs materially from current
accrual estimates, if any, for one or more of the matters described under the heading “Product Liability, Workers Compensation and Other Personal Injury
Matters,” in Note 12 could have a material adverse effect on the company’s financial position as well as its results of operations and cash flows.
Non-GAAP Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial
measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects
of currency translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-term and
long-term financial trends, investors may wish to consider the impact of acquisitions and foreign currency translation on revenues. Thermo Fisher management
uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior
periods.
We report adjusted operating income, adjusted operating income margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe
that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating
results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such
results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating
decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:
• 	Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related
costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing
commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
• 	Costs/income associated with restructuring activities, such as reducing overhead and consolidating facilities. We exclude these costs because we believe
that the costs related to restructuring activities are not indicative of our normal operating costs.
• 	Equity in earnings of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be
expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant
litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of
our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
• 	The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions
may be allocated to intangible assets that have lives of up to 20 years. Exclusion of
31

-- 31 of 180 --

THERMO FISHER SCIENTIFIC INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Non-GAAP Measures (continued)
the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and
with both acquisitive and non-acquisitive peer companies.
• 	The tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate changes), the
latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.
We report free cash flow, which is operating cash flow, excluding net capital expenditures to provide a view of the continuing operations’ ability to generate
cash for use in acquisitions and other investing and financing activities. The company uses this measure as an indication of the strength of the company and its
ability to generate cash for use in acquisitions and other investing and financing activities. Free cash flow is not a measure of cash available for discretionary
expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.
The non-GAAP financial measures of Thermo Fisher Scientific’s results of operations and cash flows included in this Form 10-K are not meant to be
considered superior to or a substitute for Thermo Fisher Scientific’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP
financial measures to the most directly comparable GAAP financial measures are set forth within the “Overview” and “Results of Operations” sections and below.
(Dollars in millions except per share amounts) 	2021 	2020
Reconciliation of adjusted operating income and adjusted operating income margin
GAAP operating income 	$ 	10,028 	25.6 	% 	$ 	7,794 	24.2 	%
Cost of revenues charges (a) 	8 	0.0 	% 	6 	0.0 	%
Selling, general and administrative charges (credits) (b) 	144 	0.4 	% 	(10) 	0.0 	%
Restructuring and other costs (c) 	197 	0.5 	% 	99 	0.3 	%
Amortization of acquisition-related intangible assets 	1,761 	4.5 	% 	1,667 	5.2 	%
Adjusted operating income 	(non-GAAP measure) 	$ 	12,138 	31.0 	% 	$ 	9,556 	29.7 	%
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense) 	$ 	(694) 	$ 	(76)
Adjustments (d) 	732 	121
Adjusted other income/(expense) 	(non-GAAP measure) 	$ 	38 	$ 	45
Reconciliation of adjusted tax rate
GAAP tax rate 	12.5 	% 	11.8 	%
Adjustments (e) 	2.1 	% 	2.5 	%
Adjusted tax rate 	(non-GAAP measure) 	14.6 	% 	14.3 	%
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc. 	$ 	19.46 	$ 	15.96
Cost of revenues charges (a) 	0.02 	0.01
Selling, general and administrative charges (credits) (b) 	0.36 	(0.02)
Restructuring and other costs (c) 	0.50 	0.25
Amortization of acquisition-related intangible assets 	4.43 	4.17
Other income/expense adjustments (d) 	1.84 	0.30
Benefit from income taxes (e) 	(1.49) 	(1.12)
Equity in losses of unconsolidated entities 	0.01 	0.01
Adjusted EPS 	(non-GAAP measure) 	$ 	25.13 	$ 	19.56
32

-- 32 of 180 --

THERMO FISHER SCIENTIFIC INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Non-GAAP Measures (continued)
(Dollars in millions except per share amounts) 	2021 	2020
Reconciliation of free cash flow
GAAP net cash provided by operating activities 	$ 	9,312 	$ 	8,289
Purchases of property, plant and equipment 	(2,523) 	(1,474)
Proceeds from sale of property, plant and equipment 	20 	8
Free cash flow 	(non-GAAP measure) 	$ 	6,809 	$ 	6,823
(a) 	Adjusted results in 2021 exclude charges for the sale of inventories revalued at the date of acquisition. Adjusted results in 2020 exclude $4 million of accelerated depreciation
on manufacturing assets to be abandoned due to facility consolidations and $2 million of charges to conform the accounting policies of recently acquired businesses with
the company’s accounting policies.
(b) 	Adjusted results in 2021 and 2020 exclude certain third-party expenses (credits), principally transaction/integration costs (including reimbursement thereof) related to
recent/terminated acquisitions; credits from changes in estimates of contingent acquisition consideration; and charges associated with product liability litigation.
(c) 	Adjusted results in 2021 and 2020 exclude restructuring and other costs consisting principally of severance, abandoned facility and other expenses of headcount reductions
within several businesses and real estate consolidations, and charges for impairment of acquired technology. Adjusted results in 2021 exclude $35 million of charges for
compensation due to employees of recently acquired businesses at the date of acquisition.
(d) 	Adjusted results in 2021 and 2020 exclude net gains on investments and charges for amortization of bridge loan commitment fees and entering hedging contracts for
recent/terminated acquisitions. Adjusted results in 2021 exclude $767 million of losses on the early extinguishment of debt. Adjusted results in 2020 exclude $42 million of
charges related to terminated interest rate swaps and $8 million of net charges for the settlement/curtailment of pension plans.
(e) 	Adjusted provision for income taxes in 2021 and 2020 excludes the incremental tax benefit for the pre-tax reconciling items between GAAP and adjusted net income,
incremental tax impacts from audit settlements and incremental tax impacts from adjusting the company's non-U.S. deferred tax balances as a result of tax rate changes.
Critical Accounting Policies and Estimates
The company’s discussion and analysis of its financial condition and results of operations is based upon its financial statements, which have been prepared in
accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to
make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent liabilities. On an
on-going basis, management evaluates its estimates, including those related to acquisition-related measurements and income taxes. Management believes the most
complex and sensitive judgments, because of their significance to the consolidated financial statements, result primarily from the need to make estimates about the
effects of matters that are inherently uncertain. Management bases its estimates on historical experience, current market and economic conditions and other
assumptions that management believes are reasonable. The results of these estimates form the basis for judgments about the carrying value of assets and liabilities
where the values are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
The company believes the following represent its critical accounting policies and estimates used in the preparation of its financial statements:
Acquisition-related Measurements
Business Combinations
The company uses assumptions and estimates in determining the fair value of assets acquired and liabilities assumed in a business combination. The
determination of the fair value of intangible assets, which represent a significant portion of the purchase price in many of the company’s acquisitions, requires the
use of significant judgment with regard to (i) the fair value and (ii) whether such intangibles are amortizable or non-amortizable and, if the former, the period and
the method by which the intangible asset will be amortized. The company estimates the fair value of acquisition-related intangible assets principally based on
projections of cash flows that will arise from identifiable intangible assets of acquired businesses, which include estimates of customer attrition and technology
obsolesce rates. The projected cash flows are discounted to determine the present value of the assets at the dates of acquisition. See Note 2 for additional
information about our recent business combinations.
33

-- 33 of 180 --

THERMO FISHER SCIENTIFIC INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Critical Accounting Policies and Estimates (continued)
Goodwill and Indefinite-lived Intangible Assets
The company evaluates goodwill and indefinite-lived intangible assets for impairment annually and when events occur or circumstances change that would
more likely than not reduce the fair value of the asset below its carrying amount. Events or circumstances that might require an interim evaluation include
unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by
governments and courts. Goodwill and indefinite-lived intangible assets totaled $41.92 billion and $1.24 billion, respectively, at December 31, 2021 (see Note 1 for
additional information). Estimates of discounted future cash flows require assumptions related to revenue and operating income growth rates, discount rates and
other factors. For the goodwill impairment tests, the company considers (i) peer revenues and earnings trading multiples from companies that have operational and
financial characteristics that are similar to the respective reporting units and (ii) estimated weighted average costs of capital. Different assumptions from those
made in the company’s analysis could materially affect projected cash flows and the company’s evaluation of goodwill and indefinite-lived intangible assets for
impairment.
The company performed the quantitative goodwill impairment test for all of its reporting units and indefinite-lived intangible assets. Indications of fair value
based on projections of cash flows, which increased over the prior year projections at higher rates than the increases in carrying values, and on peer revenues,
earnings trading multiples and discount rates, which were relatively consistent with the prior year, were sufficient to conclude that no impairment of goodwill or
indefinite-lived intangible assets existed at the end of the tenth fiscal month of 2021, the date of the company’s annual impairment testing. There were no interim
impairments of goodwill or indefinite-lived intangible assets in 2021. There can be no assurance, however, that an economic downturn will not materially
adversely affect peer trading multiples and the company’s businesses such that they do not achieve their forecasted profitability and these assets become impaired.
Should the fair value of the company’s goodwill or indefinite-lived intangible assets decline because of reduced operating performance, market declines, or other
indicators of impairment, or as a result of changes in the discount rate, charges for impairment may be necessary.
Definite-lived Intangible Assets
Definite-lived intangible assets totaled $18.88 billion at December 31, 2021 (see Note 1 for additional information). The company reviews definite-lived
intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. Actual cash
flows arising from a particular intangible asset could vary from projected cash flows which could imply different carrying values from those established at the
dates of acquisition and which could result in impairment of such asset. The company recorded impairments of $0.12 billion in 2021 (see Note 16 for additional
information).
Contingent Consideration
The fair value of contingent consideration liabilities, which were initially exchanged for control of businesses or assumed from acquired businesses, was $0.32
billion at December 31, 2021. At each reporting period, the fair value of contingent consideration is determined using either discounted cash flow analyses, Monte
Carlo simulations, or fair values of an underlying recapitalization investment portfolio. Changes in the fair value of contingent consideration liabilities can result
from changes in estimates of revenue or operating results or in the timing or likelihood of achieving milestones, as well as changes in the fair values of the
investments underlying the recapitalization investment portfolio. These changes resulted in (benefits)/charges of $(0.05) billion during 2021 (see Note 14 for
additional information).
Income Taxes
Unrecognized Tax Benefits
In the ordinary course of business there is inherent uncertainty in quantifying the company’s income tax positions. The company assesses income tax positions
and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available at the
reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the company has recorded the largest amount of tax
benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant
information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the
financial statements. Should tax return positions that the company expects are sustainable not be sustained upon audit, the company could be required to record an
incremental tax provision for such taxes. The company’s liability for these unrecognized tax benefits totaled $1.12 billion at December 31, 2021 (see Note 8 for
additional information).
34

-- 34 of 180 --

THERMO FISHER SCIENTIFIC INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Critical Accounting Policies and Estimates (continued)
The company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and non-U.S. tax
authorities, as well as to tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires the company to
interpret the related tax laws and regulations and the use of estimates and assumptions regarding significant future events, such as the amount, timing and character
of deductions, permissible revenue recognition methods under the tax law and the sources and character of income and tax credits. Changes in tax laws,
regulations, agreements and treaties, currency exchange restrictions or the company’s level of operations or profitability in each taxing jurisdiction could have an
impact upon the amount of current and deferred tax balances and hence the company’s net income.
Valuation Allowances
The company estimates the degree to which tax assets will result in a benefit, after consideration of all positive and negative evidence, and provides a
valuation allowance for tax assets that it believes will more likely than not go unused. In situations in which the company has been able to determine that its
deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it
becomes more likely than not that a tax asset will be used, the company reverses the related valuation allowance. Any such reversals are recorded as a reduction of
the company’s tax provision. The company’s tax valuation allowance totaled $0.97 billion at December 31, 2021 (see Note 8 for additional information). Should
the company’s actual future taxable income by tax jurisdiction vary from estimates, additional allowances or reversals thereof may be necessary.
Undistributed Earnings
The company has not provided U.S. state income taxes or additional non-U.S. taxes on certain of its non-U.S. subsidiaries’ undistributed earnings, as such
amounts are intended to be reinvested outside the United States indefinitely in the respective jurisdictions based on specific business plans and tax strategies (see
Note 8 for additional information). These business plans and tax strategies consider: short-term and long-term forecasts and budgets of the U.S. parent and non-
U.S. subsidiaries; working capital and other needs in locations where earnings are generated; the company’s past practices regarding non-U.S. subsidiary
dividends; sources of financing by the U.S. parent, such as issuing debt or equity; and uses of cash by the U.S. parent that are more discretionary in nature, such as
business combinations and share repurchase programs. However, should the company change its business plans and tax strategies in the future and decide to
repatriate a portion of these earnings to one of its U.S. subsidiaries, including cash maintained by these non-U.S. subsidiaries, the company would recognize
additional tax liabilities. It is not practicable to estimate the amount of additional U.S. state income tax and non-U.S. tax liabilities that the company would incur.
The company’s intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax costs.
Recent Accounting Pronouncements
A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.
Item 7A. 	Quantitative and Qualitative Disclosures About Market Risk
The company is exposed to market risk from changes in interest rates and currency exchange rates, which could affect its future results of operations and
financial condition. The company manages its exposure to these risks through its regular operating and financing activities. The company has periodically hedged
interest rate risks of fixed-rate instruments with offsetting interest rate swaps. Additionally, the company uses short-term forward and option contracts primarily to
hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates. Such exposures result from purchases, sales, cash and
intercompany loans that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts
principally hedge transactions denominated in euro, Swiss franc, British pounds sterling, Canadian dollars, Czech koruna, Japanese yen and Hong Kong dollars.
Income and losses arising from these derivative contracts are recognized as offsets to losses and income resulting from the underlying exposure being hedged. The
company does not enter into speculative derivative agreements.
Interest Rates
The company is exposed to changes in interest rates while conducting normal business operations as a result of ongoing investing and financing activities,
which affect the company’s debt as well as cash and cash equivalents. As of December 31, 2021, the company’s debt portfolio was comprised primarily of fixed
rate borrowings. The fair market value of the company’s
35

-- 35 of 180 --

THERMO FISHER SCIENTIFIC INC.
Quantitative and Qualitative Disclosures About Market Risk (continued)
fixed interest rate debt is subject to interest rate risk. Generally, the fair market value of fixed interest rate debt will increase as interest rates fall and decrease as
interest rates rise. The total estimated fair value of the company’s debt at December 31, 2021 was $36.05 billion (Note 14). Fair values were determined from
available market prices using current interest rates and terms to maturity. If interest rates were to decrease by 100 basis points, the fair value of the company’s debt
at December 31, 2021 would increase by approximately $2.51 billion. If interest rates were to increase by 100 basis points, the fair value of the company’s debt at
December 31, 2021 would decrease by approximately $2.52 billion.
In addition, interest rate changes would result in a change in the company’s interest expense due to variable-rate debt instruments including swap
arrangements. In 2021, a 100 basis point increase in interest rates on the swap arrangements and variable-rate debt would have increased the company’s annual pre-
tax interest expense by approximately $6 million.
Currency Exchange Rates
The company views its investment in international subsidiaries with a functional currency other than the U.S. dollar as permanent. The company’s investment
in international subsidiaries is sensitive to fluctuations in currency exchange rates. The functional currencies of the company’s international subsidiaries are
principally denominated in euro, British pounds sterling, Swedish kronor, Canadian dollars, Norwegian kroner and Danish kroner. The effect of a change in the
period ending currency exchange rates on the company’s net investment in international subsidiaries is reflected in the “accumulated other comprehensive items”
component of shareholders’ equity. The company also uses foreign currency-denominated debt to partially hedge its net investments in foreign operations against
adverse movements in exchange rates. A 10% depreciation in year-end 2021 functional currencies, relative to the U.S. dollar, would result in a reduction of
shareholders’ equity of approximately $1.23 billion.
The fair value of forward currency-exchange contracts is sensitive to changes in currency exchange rates. The fair value of forward currency-exchange
contracts is the estimated amount that the company would pay or receive upon termination of the contract, taking into account the change in currency exchange
rates. A 10% depreciation in year-end 2021 non-functional currency exchange rates related to the company’s contracts would result in an additional unrealized loss
on forward currency-exchange contracts of $71 million. A 10% appreciation in year-end 2021 non-functional currency exchange rates related to the company’s
contracts would result in an unrealized gain on forward currency-exchange contracts of $71 million. The unrealized gains or losses on forward currency-exchange
contracts resulting from changes in currency exchange rates are expected to approximately offset losses or gains on the exposures being hedged.
Certain of the company’s cash and cash equivalents are denominated in currencies other than the functional currency of the depositor and are sensitive to
changes in currency exchange rates. A 10% depreciation in the related year-end 2021 non-functional currency exchange rates applied to such cash balances would
result in a negative impact of $27 million on the company’s net income.
Item 8. 	Financial Statements and Supplementary Data
This data is submitted as a separate section to this report. See 	Item 15 “Exhibits and Financial Statement Schedules.”
Item 9. 	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A. 	Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the
company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period
covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and
procedures. Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the company’s
disclosure controls and procedures were effective at the reasonable assurance level.
36

-- 36 of 180 --

THERMO FISHER SCIENTIFIC INC.
Changes in Internal Control over Financial Reporting
There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the
fiscal quarter ended December 31, 2021, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial
reporting.
Management’s Annual Report on Internal Control Over Financial Reporting
The company’s management, including the company’s chief executive officer and chief financial officer, is responsible for establishing and maintaining
adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company. Internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles. The company’s management conducted an assessment of the effectiveness of the
company’s internal control over financial reporting as of December 31, 2021 based on criteria established in “Internal Control - Integrated Framework” (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, the company’s management concluded
that, as of December 31, 2021, the company’s internal control over financial reporting was effective. Management’s assessment of the effectiveness of the
company’s internal control over financial reporting as of December 31, 2021, excluded PPD, Inc., Mesa Biotech, Inc. and PeproTech, Inc., which were acquired by
the company in 2021 in separate purchase business combinations. These entities, whose total assets and total revenues were excluded from the company’s
assessment, represented approximately 5% and 2%, respectively, of the related consolidated amounts as of and for the year ended December 31, 2021. Based upon
Securities and Exchange Commission staff guidance, companies are allowed to exclude certain acquisitions from their assessments of internal control over
financial reporting during the first year of an acquisition while integrating the acquired companies.
The company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the company’s internal control
over financial reporting as of December 31, 2021, as stated in their report that appears on page F-2 of this Annual Report on Form 10-K.
Item 9B. 	Other Information
On February 24, 2022, the company and Mark P. Stevenson entered into a consulting agreement relating to ongoing services that Mr. Stevenson will provide
to the company following his last day as an employee on March 18, 2022. Under the consulting agreement, which has a term ending March 1, 2023, Mr. Stevenson
will serve on the company’s Scientific Advisory Board and will also provide ongoing advice and services relating to COVID-19 research and products. During the
term of the consulting agreement, Mr. Stevenson’s outstanding and unvested equity awards granted in fiscal year 2021 will continue to vest in accordance with
their original terms based on his continued service to the company and, if he provides consulting services through March 1, 2023, his outstanding and unvested
equity awards granted in fiscal year 2021 will vest to the same extent as if he had retired as an employee on March 1, 2023 and the post-termination exercise period
of all of Mr. Stevenson’s stock options, to the extent vested and exercisable on March 1, 2023, will be extended until the original maximum term of such stock
options. The agreement also contains provisions that restrict Mr. Stevenson’s ability during the term of the consulting agreement, and (i) for a period of twelve
months thereafter, to work for or provide consulting services to, any competitor of the company, and (ii) for a period of eighteen months thereafter, to solicit for
hire employees or consultants of the company or to solicit customers or clients of the company.
The foregoing summary of the consulting agreement is subject to, and qualified in its entirety by, the full text of such agreement, which is filed as an exhibit to
this Annual Report on Form 10-K.
Item 9C. 	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
37

-- 37 of 180 --

THERMO FISHER SCIENTIFIC INC.
PART III
Item 10. 	Directors, Executive Officers and Corporate Governance
The information with respect to directors required by this Item will be contained in our definitive proxy statement to be filed with the SEC not later than 120
days after the close of business of the fiscal year (2022 Definitive Proxy Statement) including under “Corporate governance—Board of directors—selection, skills
and experience—Director nominee skills, experience, and background,” and “Corporate governance—Board of directors—selection, skills and experience—
Nominees and incumbent directors,” and is incorporated in this report by reference.
The information with respect to executive officers required by this Item is included in 	Item 1 of Part I 	of this report.
The other information required by this Item will be contained in our 2022 Definitive Proxy Statement including under “Corporate governance—Board
practices, policies and processes —Corporate Governance Guidelines” and “Corporate Governance—Board leadership structure—Board committees,” and is
incorporated in this report by reference.
Item 11. 	Executive Compensation
The information required by this Item will be contained in our 2022 Definitive Proxy Statement including under “Corporate governance—Compensation of
directors,” and “Executive compensation,” and is incorporated in this report by reference.
Item 12. 	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item will be contained in our 2022 Definitive Proxy Statement including under “Information about stock ownership—Equity
compensation plan information” and “Information about stock ownership—Security ownership of certain beneficial owners and management,” and is incorporated
in this report by reference.
Item 13. 	Certain Relationships and Related Transactions, and Director Independence
The information required by this Item will be contained in our 2022 Definitive Proxy Statement including under “Corporate governance—Board practices,
policies and processes—Related person transactions,” and “Corporate governance—Board leadership structure—How we assess director independence,” and is
incorporated in this report by reference.
Item 14. 	Principal Accountant Fees and Services
The information required by this Item will be contained in our 2022 Definitive Proxy Statement including under “Audit matters—Independent auditor fees”
and “Audit matters—Audit Committee’s pre-approval policies and procedures,” and is incorporated in this report by reference.
38

-- 38 of 180 --

THERMO FISHER SCIENTIFIC INC.
PART IV
Item 15. 	Exhibits and Financial Statement Schedules
(a) 	The following documents are filed as part of this report:
(1) 	Consolidated Financial Statements (see Index on page F-1 of this report)
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheet
Consolidated Statement of Income
Consolidated Statement of Comprehensive Income
Consolidated Statement of Cash Flows
Consolidated Statement of 	Redeemable 	Noncontrolling Interest and 	Equity
Notes to Consolidated Financial Statements
(2) 	All schedules are omitted because they are not applicable or not required, or because the required information is included either in the consolidated
financial statements or in the notes thereto.
(b) 	Exhibits
See the Exhibit Index on page 	41.
Item 16. 	Form 10-K Summary
None.
39

-- 39 of 180 --

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its
behalf by the undersigned, thereunto duly authorized.
Date: 	February 24, 2022 	THERMO FISHER SCIENTIFIC INC.
By: 	/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant
and in the capacities indicated, as of February 24, 2022.
By: 	/s/ Marc N. Casper 	By: 	/s/ Thomas J. Lynch
Marc N. Casper 	Thomas J. Lynch
Chairman, President and Chief Executive Officer 	Lead Director
(Principal Executive Officer)
By: 	/s/ Stephen Williamson 	By: 	/s/ Jim P. Manzi
Stephen Williamson 	Jim P. Manzi
Senior Vice President and Chief Financial Officer 	Director
(Principal Financial Officer)
By: 	/s/ Joseph R. Holmes 	By: 	/s/ James C. Mullen
Joseph R. Holmes 	James C. Mullen
Vice President and Chief Accounting Officer 	Director
(Principal Accounting Officer)
By: 	/s/ Nelson J. Chai 	By: 	/s/ Lars R. Sørensen
Nelson J. Chai 	Lars R. Sørensen
Director 	Director
By: 	/s/ C. Martin Harris 	By: 	/s/ Debora L. Spar
C. Martin Harris 	Debora L. Spar
Director 	Director
By: 	/s/ Tyler E. Jacks 	By: 	/s/ Scott M. Sperling
Tyler E. Jacks 	Scott M. Sperling
Director 	Director
By: 	/s/ R. Alexandra Keith 	By: 	/s/ Dion J. Weisler
R. Alexandra Keith 	Dion J. Weisler
Director 	Director
40

-- 40 of 180 --

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX
Exhibit Number 	Description of Exhibit
2.1 	Agreement and Plan of Merger, dated as of April 15, 2021, by and among Thermo Fisher Scientific Inc., Powder Acquisition Corp. and PPD, Inc. 	(filed as
Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed April 16, 2021 [File No. 1-8002] and incorporated in this document by reference).
3.1 	Amended and Restated Certificate of Incorporation of the Registrant 	(filed as Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K for the year
ended December 31, 2005 [File No. 1-8002] and incorporated in this document by reference).
3.2 	Amendment to Thermo Fisher Scientific Inc.’s Third Amended and Restated Certificate of Incorporation 	(filed as Exhibit 3.1 to the Registrant’s Current
Report on Form 8-K filed November 14, 2006 [File No. 1-8002] and incorporated in this document by reference).
3.3 	Certificate of Elimination of the Series B Junior Participating Preferred Stock of the Company, dated November 13, 2015 	(filed as Exhibit 3.1 to the
Registrant’s Current Report on Form 8-K filed November 16, 2015 [File No. 1-8002] and incorporated in this document by reference).
3.4 	Amended and Restated By-Laws of the Registrant, as amended and effective as of July 8, 2021 	(filed as Exhibit 3.1 to the Registrant’s Current Report on
Form 8-K filed July 9, 2021 [File No. 1-8002] and incorporated in this document by reference).
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with
respect to long-term debt of the Registrant or its consolidated subsidiaries.
4.1 	Indenture dated as of November 20, 2009 between the Company and The Bank of New York Mellon Trust Company, N.A. 	(filed as Exhibit 99.1 to the
Registrant’s Current Report on Form 8-K filed November 20, 2009 [File No. 1-8002] and incorporated in this document by reference).
4.2 	Sixth Supplemental Indenture, dated as of December 11, 2013, between the Company and The Bank of New York Mellon Trust Company, N.A. 	(filed as
Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed December 11, 2013 [File No. 1-8002] and incorporated in this document by reference).
4.3 	Eighth Supplemental Indenture, dated as of November 24, 2014, among the Company, The Bank of New York Mellon Trust Company, N.A., as trustee, and
The Bank of New York Mellon, London Branch, as paying agent 	(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 24,
2014 [File No. 1-8002] and incorporated in this document by reference).
4.4 	Eleventh Supplemental Indenture, dated as of December 9, 2015, between the Company and The Bank of New York Mellon Trust Company, N.A. 	(filed as
Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed December 9, 2015 [File No. 1-8002] and incorporated in this document by reference).
4.5 	Thirteenth Supplemental Indenture, dated as of September 12, 2016, between the Company and The Bank of New York Mellon Trust Company, N.A., as
trustee 	(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed September 12, 2016 [File No. 1-8002] and incorporated in this document
by reference).
4.6 	Fifteenth Supplemental Indenture, dated as of March 16, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee
(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed March 16, 2017 [File No. 1-8002] and incorporated in this document by
reference).
4.7 	Sixteenth Supplemental Indenture, dated as of July 24, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee
(filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed July 24, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.8 	Seventeenth Supplemental Indenture, dated as of August 14, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as
trustee 	(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 14, 2017 [File No. 1-8002] and incorporated in this document by
reference).
4.9 	Eighteenth Supplemental Indenture, dated as of September 30, 2019, between the Company, and The Bank of New York Mellon Trust Company, N.A., as
trustee 	(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed September 30, 2019 [File No. 1-8002] and incorporated in this document
by reference).
4.10 	Nineteenth Supplemental Indenture, dated as of October 8, 2019, between the Company, and the Bank of New York Mellon Trust Company, N.A., as
trustee 	(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 8, 2019 [File No. 1-8002] and incorporated in this document by
reference).
4.11 	Twenty-First Supplemental Indenture, dated as of April 2, 2020, between the Company, and The Bank of New York Mellon Trust Company, N.A., as
trustee 	(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed April 2, 2020 [File No. 1-8002] and incorporated in this document by
reference).
4.12 	Twenty-Second Supplemental Indenture, dated as of August 23, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as
trustee 	(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 23, 2021 [File No. 1-8002] and incorporated in this document by
reference).
4.13 	Third Supplemental Indenture, dated as of October 18, 2021, among 	Thermo Fisher Scientific (Finance 	I) B.V. (Thermo Fisher International), as issuer, the
Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee 	(filed as Exhibit 4.2 to the Registrant’s Current Report on
Form 8-K filed October 18, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.14 	Twenty-Third Supplemental Indenture, dated as of October 22, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as
trustee 	(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 22, 2021 [File No. 1-8002] and incorporated in this document by
reference).
4.15 	Indenture, dated as of August 9, 2016, among Thermo Fisher International, as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust
Company, N.A., as trustee 	(filed as Exhibit 4.1 to the Registrant’s Current Report on Form 	8-K filed August 9, 2016 [File No. 1-8002] and incorporated in
this document by reference).
41

-- 41 of 180 --

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX
Exhibit Number 	Description of Exhibit
4.16 	Fourth Supplemental Indenture, dated as of November 18, 2021, among Thermo Fisher 	Scientific (Finance 	I) B.V. (Thermo Fisher 	International), as issuer,
the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee 	(filed as Exhibit 4.2 to the Registrant’s Current Report on
Form 8-K filed August 9, 2016 [File No. 1-8002] and incorporated in this document by reference).
4.17 	Description of the Registrant’s Securities
10.1 	Thermo Fisher Scientific Inc. Deferred Compensation Plan for Directors of the Registrant, as amended and restated 	effective November 10, 2006 	(filed as
Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 29, 2007 [File No. 1‑8002] and incorporated in this
document by reference).*
10.2 	Thermo Electron Corporation Deferred Compensation Plan, effective November 1, 2001 	(filed as Exhibit 10.13 to the Registrant’s Annual Report on
Form 10-K for the fiscal year ended December 29, 2001 [File No. 1-8002] and incorporated in this document by reference).*
10.3 	Form of Amended and Restated Indemnification Agreement between the Registrant and its directors and officers (filed as Exhibit 10.2 to the 	Registrant’s
Registration Statement on Form S-4 	[Reg. No. 333-90661] and incorporated in this document by reference).*
10.4 	Summary of Thermo Fisher Scientific Inc. Annual 	Non-Management 	Director Compensation 	(filed as Exhibit 10.1 to the Registrant’s Current Report on
Form 8-K filed February 24, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.5 	Summary of 2021 	Annual Cash Incentive Plan*
10.6 	Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers, effective as of January 1, 2009 	(filed as
Exhibit 10.25 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2009 [File No. 1-8002] and incorporated in this document
by reference).*
10.7 	Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. (filed as Exhibit 10.12 to Fisher Scientific International Inc.’s Annual
Report on Form 10-K for the year ended December 31, 1992 [File No. 1-10920] and incorporated in this document by reference).*
10.8 	First Amendment to the Fisher Scientific International Inc. Retirement Plan for Non-Employee Directors 	(filed as Exhibit 10.04 to Fisher Scientific
International Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 [File No. 1-10920] and incorporated in this document by
reference).*
10.9 	Amendment to Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. 	(filed as Exhibit 10.02 to Fisher Scientific International
Inc.’s Current Report on Form 8-K filed March 7, 2006 [File No. 1-10920] and incorporated in this document by reference).*
10.10 	Thermo Fisher Scientific Inc. Amended and Restated 2005 Deferred Compensation Plan, effective January 1, 2020 	(filed as Exhibit 10.1 to the Registrant’s
Quarterly Report on Form 10-Q for the quarter ended June 27, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.11 	2009 Restatement of Executive Severance Agreement, between Marc 	N. 	Casper and the Registrant, dated November 21, 2009 	(filed as Exhibit 10.5 to the
Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.12 	Executive Change In Control Retention Agreement, between Marc 	N. 	Casper and the Registrant, dated November 21, 2009 	(filed as Exhibit 10.6 to the
Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.13 	Noncompetition Agreement, between Marc 	N. 	Casper and the Registrant, dated November 21, 2009 	(filed as Exhibit 10.7 to the Registrant’s Current Report
on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.14 	Amendment No. 1 to 2009 Restatement of Executive Severance Agreement, dated February 25, 2010, between the Registrant and Marc N. Casper 	(filed as
Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed February 25, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.15 	Amendment No. 2 to 2009 Restatement of Executive Severance Agreement, dated November 30, 2010, between the Registrant and Marc N. Casper 	(filed as
Exhibit 10.55 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document
by reference).*
10.16 	Amendment No. 1 to Executive Change In Control Retention Agreement, dated November 30, 2010, between Marc N. Casper and the Registrant 	(filed as
Exhibit 10.56 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document
by reference).*
10.17 	Amendment No. 2 to Executive Change in Control Retention Agreement, dated March 16, 2018, between Marc N. Casper and the Registrant 	(filed as
Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 [File No. 1-8002] and incorporated in this document
by reference).*
10.18 	Form of Executive Change in Control Retention Agreement for Officers (other than Marc 	N. 	Casper) 	(filed as Exhibit 10.2 to the Registrant's Quarterly
Report on Form 10-Q for the quarter ended March 31, 2018 [File No. 1-8002] and incorporated in this document by reference).*
10.19 	Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement for Directors 	(filed as Exhibit 10.1 to the Registrant’s Quarterly Report on
Form 10-Q for the quarter ended April 2, 2011 [File No. 1-8002] and incorporated in this document by reference).*
42

-- 42 of 180 --

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX
Exhibit Number 	Description of Exhibit
10.20 	Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement effective February 	26, 2013 	(filed as Exhibit 10.4 to the Registrant’s
Current Report on Form 8-K filed February 27, 2013 [File No. 1-8002] and incorporated in this document by reference).*
10.21 	Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc 	N. 	Casper 	effective February 	26, 2013 	(filed as
Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed February 27, 2013 [File No. 1-8002] and incorporated in this document by reference).*
10.22 	Form of 	Nonstatutory 	Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc 	N. 	Casper 	effective February 	26, 2013 	(filed as
Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed February 27, 2013 [File No. 1-8002] and incorporated in this document by reference).*
10.23 	Thermo Fisher Scientific Inc. 2013 Stock Incentive Plan 	(filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed May 23, 2013 [File
No. 1-8002] and incorporated in this document by reference).*
10.24 	Supplemental Executive Retirement Plan effective as of December 31, 2005, as amended and restated as of August 28, 2006 	(filed as Exhibit 10.3 to
Applera Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 [File No. 1-04389] and incorporated in this document by
reference).*
10.25 	Amendment to Supplemental Executive Retirement Plan, effective as of January 1, 2010 	(filed as Exhibit 10.1 to Life Technologies Corporation’s Current
Report on Form 8-K filed December 18, 2009 [File No. 000-25317] and incorporated in this document by reference).*
10.26 	Noncompetition Agreement between the Registrant and Mark 	P. 	Stevenson, dated September 10, 2015 	(filed as Exhibit 10.1 to the Registrant’s Quarterly
Report on Form 10-Q for the quarter ended September 26, 2015 [File No. 1-8002] and incorporated in this document by reference).*
10.27 	Form of Thermo Fisher Scientific Inc.’s 	Nonstatutory 	Stock Option Agreement for Officers 	(filed as Exhibit 10.44 to the Registrant's Annual Report on
Form 10-K for the year ended December 31, 2016 [File No. 1-8002] and incorporated in this document by reference).*
10.28 	Patheon N.V. 2016 Omnibus Incentive Plan 	(filed as Exhibit 10.2 to the Current Report on Form 8-K filed by Patheon N.V. on July 26, 2016 [File No. 001-
37837] and incorporated in this document by reference).*
10.29 	Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated March 7, 2017 	(filed as Exhibit 4.5 to the Registrant's Registration Statement on Form S-
8 filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.30 	Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated August 23, 2017 	(filed as Exhibit 4.6 to the Registrant's Registration Statement on Form
S-8 filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.31 	Credit Agreement, dated 	January 	7, 2022, among Thermo Fisher Scientific Inc., certain Subsidiaries of Thermo Fisher Scientific Inc. from time to time
party thereto, Bank of America, N.A., as Administrative Agent and each lender from time to time party thereto 	(filed as Exhibit 10.1 to the Registrant’s
Current Report on Form 8-K filed January 7, 2022 [File No. 1-8002] and incorporated in this document by reference).
10.32 	Form of Performance Restricted Stock Unit Agreement effective February 26, 2019 	(filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-
Q for the quarter ended March 30, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.33 	Form of Performance Restricted Stock Unit Agreement for Marc 	N. 	Casper effective February 26, 2019 	(filed as Exhibit 10.2 to the Registrant’s Quarterly
Report on Form 10-Q for the quarter ended March 30, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.34 	Letter Agreement between the Registrant and Michel Lagarde dated August 28, 2017 	(filed as Exhibit 10.39 to the Registrant’s Annual Report on Form 10-
K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.35 	Option Agreement Under the Patheon N.V. 2016 Omnibus Incentive Plan between Patheon N.V. and Michel Lagarde dated July 20, 2016 	(filed as Exhibit
10.40 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by
reference).*
10.36 	Option Agreement Under the Patheon N.V. 2016 Omnibus Incentive Plan between Patheon N.V. and Michel Lagarde dated March 23, 2017 	(filed as
Exhibit 10.42 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document
by reference).*
10.37 	Thermo Fisher Scientific Inc. Executive Severance Policy 	(filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended
June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.38 	Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers 	(filed as Exhibit 10.2 to the Registrant’s
Quarterly Report on Form 10-Q for the quarter ended June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.39 	Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement effective as of February 25, 2020 	(filed as Exhibit 10.45 to the
Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.40 	Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement 	effective as of February 25, 2020 	(filed as Exhibit 10.46 to the Registrant’s
Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
43

-- 43 of 180 --

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX
Exhibit Number 	Description of Exhibit
10.41 	Form of Thermo Fisher Scientific Inc.’s 	Nonstatutory 	Stock Option Agreement for Officers 	effective as of February 25, 2020 	(filed as Exhibit 10.47 to the
Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.42 	Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc 	N. 	Casper 	effective as of February 25, 2020 	(filed
as Exhibit 10.48 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this
document by reference).*
10.43 	Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc 	N. 	Casper 	effective as of February 	25, 2020 	(filed as Exhibit
10.49 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by
reference).*
10.44 	Form of 	Nonstatutory 	Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc 	N. 	Casper 	effective as of February 25, 2020 	(filed as
Exhibit 10.50 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document
by reference).*
10.45 	Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc 	N. 	Casper 	(filed as Exhibit 10.47 to the Registrant’s Annual
Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.46 	Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper 	(filed as Exhibit 10.48 to the
Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.47 	Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement 	(filed as Exhibit 10.49 to the Registrant’s Annual Report on Form
10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.48 	PPD, Inc. 2020 Omnibus Incentive Plan 	(filed as Exhibit 10.38 to PPD Inc.’s Form S-1/A filed January 27, 2020 [File No. 333-235860] and incorporated in
this document by reference).*
10.49 	Consulting Agreement between the Registrant and Mark P. Stevenson, dated February 24, 2022*
21 	Subsidiaries of the Registrant.
22 	Subsidiary Issuer of Guaranteed Securities.
23.1 	Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm.
31.1 	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-
Oxley Act of 2002.
31.2 	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-
Oxley Act of 2002.
32.1 	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002.**
32.2 	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002.**
101.INS 	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline
XBRL document.
101.SCH 	XBRL Taxonomy Extension Schema Document.
101.CAL 	XBRL Taxonomy Calculation Linkbase Document.
101.DEF 	XBRL Taxonomy Definition Linkbase Document.
101.LAB 	XBRL Taxonomy Label Linkbase Document.
101.PRE 	XBRL Taxonomy Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
_______________________
*Indicates management contract or compensatory plan, contract or arrangement.
** Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be
incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.
44

-- 44 of 180 --

THERMO FISHER SCIENTIFIC INC.
INDEX OF CONSOLIDATED FINANCIAL STATEMENTS
The following Consolidated Financial Statements of the Registrant and its subsidiaries are required to be included in Item 15:
Page
Report of Independent Registered Public Accounting Firm (PCAOB ID 238) 	F-2
Consolidated Balance Sheet as of December 31, 2021 and 2020 	F-6
Consolidated Statement of Income for the years ended December 31, 2021, 2020 and 2019 	F-7
Consolidated Statement of Comprehensive Income for the years ended December 31, 2021, 2020 and 2019 	F-8
Consolidated Statement of Cash Flows for the years ended December 31, 2021, 2020 and 2019 	F-9
Consolidated Statement of Redeemable Noncontrolling Interest and Equity for the years ended December 31, 2021, 2020 and 2019 	F-10
Notes to Consolidated Financial Statements 	F-11
F-1

-- 45 of 180 --

Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of Thermo Fisher Scientific Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheet of Thermo Fisher Scientific Inc. and its subsidiaries (the “Company”) as of December
31, 2021 and 2020, and the related consolidated statements of income, of comprehensive income, of redeemable noncontrolling interest and equity
and of cash flows for each of the three years in the period ended December 31, 2021, including the related notes (collectively referred to as the
“consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2021, based
on criteria established in 	Internal Control - Integrated Framework 	(2013) issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company
as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31,
2021 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in
all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in 	Internal Control -
Integrated Framework 	(2013) issued by the COSO.
Change in Accounting Principle
As discussed in Note 1 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial
reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on
Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated
financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and
whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on
a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and
F-2

-- 46 of 180 --

significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of
internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a
material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits
also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable
basis for our opinions.
As described in Management’s Annual Report on Internal Control Over Financial Reporting, management has excluded PPD, Inc., Mesa Biotech,
Inc. and PeproTech, Inc. from its assessment of internal control over financial reporting as of December 31, 2021 because they were acquired by the
Company in purchase business combinations during 2021. We have also excluded PPD, Inc., Mesa Biotech, Inc. and PeproTech, Inc. from our audit
of internal control over financial reporting. PPD, Inc., Mesa Biotech, Inc. and PeproTech, Inc. are wholly-owned subsidiaries whose total assets and
total revenues excluded from management’s assessment and our audit of internal control over financial reporting collectively represent
approximately 5% and 2%, respectively, of the related consolidated financial statement amounts as of and for the year ended December 31, 2021.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A
company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in
reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles,
and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the
company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the
company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the
degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were
communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the
consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit
matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the
critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Income taxes
As described in Note 8 to the consolidated financial statements, the Company’s provision for income taxes for the year ended December 31, 2021 was
$1,109 million. The Company has
F-3

-- 47 of 180 --

deferred tax liabilities, net, of $2,829 million (including a valuation allowance of $968 million) and unrecognized tax benefits of $1,124 million as of
December 31, 2021. As disclosed by management, the Company operates in numerous countries under many legal forms and, as a result, is subject to
the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments.
Determination of taxable income in any jurisdiction requires management to interpret the related tax laws and regulations and to use estimates and
assumptions regarding significant future events, such as the amount, timing and character of deductions, permissible revenue recognition methods
under the tax law and the sources and character of income and tax credits. Management assesses income tax positions and records tax benefits for all
years subject to examination based upon management’s evaluation of the facts, circumstances and information available at the reporting date. For
those tax positions where it is more likely than not that a tax benefit will be sustained, management has recorded the largest amount of tax benefit
with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant
information. 	For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been
recognized in the financial statements. Management estimates the degree to which tax assets will result in a benefit, after consideration of all positive
and negative evidence, and provides a valuation allowance for tax assets that it believes will more likely than not go unused. In situations in which
management has been able to determine that the Company’s deferred tax assets will be realized, that determination generally relies on future
reversals of taxable temporary differences and expected future taxable income. If it becomes more likely than not that a tax asset will be used,
management reverses the related valuation allowance.
The principal considerations for our determination that performing procedures relating to income taxes is a critical audit matter are (i) the
significant judgment by management when interpreting the numerous and complex tax laws and regulations as it relates to determining the
provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, (ii) a
high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to the provision for income
taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, and (iii) the audit effort
involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the
consolidated financial statements. These procedures included testing the effectiveness of controls relating to the provision for income taxes, deferred
tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits. These procedures also included, among
others (i) testing the accuracy of the provision for income taxes, including the rate reconciliation and permanent and temporary differences, (ii)
evaluating whether the data utilized in the calculations of the provision for income taxes, deferred tax assets and liabilities, and liabilities for
unrecognized tax benefits were appropriate and consistent with evidence obtained in other areas of the audit, (iii) evaluating management’s
assessment of the realizability of deferred tax assets on a jurisdictional basis, (iv) evaluating the identification of liabilities for unrecognized tax
benefits and the reasonableness of the more likely than not determination in consideration of court decisions, legislative actions, statutes of
limitations, and developments in tax examinations by jurisdiction, (v) testing the calculation of the liability for unrecognized tax benefits by
jurisdiction, including estimates of the amount of income tax benefit expected to be sustained, and (vi) evaluating the adequacy of the Company’s
disclosures. Professionals with specialized skill and knowledge were used to assist in evaluating the reasonableness of management’s judgments and
estimates related to the application of foreign and domestic tax laws and regulations.
F-4

-- 48 of 180 --

Acquisition of PPD, Inc. - Valuation of Customer Relationships Intangible Assets
As described in Note 2 to the consolidated financial statements, on December 8, 2021, the Company acquired PPD, Inc. for $15.99 billion in net cash
consideration and $43 million of equity awards exchanged, which resulted in $6,264 million of customer relationships intangible assets being
recorded. As disclosed by management, assumptions and estimates are used in determining the fair value of the customer relationships intangible
assets acquired in a business combination. Management estimates the fair value of acquisition-related customer relationships intangible assets
principally based on projections of cash flows that will arise from the customer relationships of PPD, Inc., which include estimates of customer
attrition rates. The projected cash flows are discounted to determine the present value of the assets at the date of the acquisition.
The principal considerations for our determination that performing procedures relating to the valuation of the acquired customer relationships
intangible assets from the acquisition of PPD, Inc. is a critical audit matter are (i) the significant judgment by management when determining the
fair value of the acquired customer relationships intangible assets, (ii) a high degree of auditor judgment, subjectivity, and effort in performing
procedures and evaluating management’s significant assumptions related to projections of cash flows and discount rates, and (iii) the audit effort
involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the
consolidated financial statements. These procedures included testing the effectiveness of controls relating to the acquisition accounting, including
controls over management’s valuation of the customer relationships intangible assets. These procedures also included, among others (i) reading the
purchase agreement, (ii) testing management’s process for determining the fair values of the acquired customer relationships intangible assets, (iii)
evaluating the appropriateness of the valuation methodology utilizing discounted projected cash flows, (iv) testing the completeness and accuracy of
the underlying data used in the discounted projected cash flows, and (v) evaluating the reasonableness of the significant assumptions used by
management related to projections of cash flows and discount rates. Evaluating management’s significant assumption related to projections of cash
flows involved evaluating whether the significant assumption used by management was reasonable considering (i) the current and past performance
of PPD, Inc., (ii) the consistency with external market and industry data, and (iii) whether the significant assumption was consistent with evidence
obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the
valuation methodology utilizing discounted projected cash flows and (ii) the reasonableness of the discount rate significant assumption.
/s/PricewaterhouseCoopers LLP
Boston, Massachusetts
February 24, 2022
We have served as the Company’s auditor since 2002.
F-5

-- 49 of 180 --

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED BALANCE SHEET
December 31, 	December 31,
(In millions except share and per share amounts) 	2021 	2020
Assets
Current assets:
Cash and cash equivalents 	$ 	4,477 	$ 	10,325
Accounts receivable, less allowances of $150 and $135 	7,977 	5,741
Inventories 	5,051 	4,029
Contract assets, net 	968 	731
Other current assets 	1,640 	1,131
Total current assets 	20,113 	21,957
Property, plant and equipment, net 	8,333 	5,912
Acquisition-related intangible assets, net 	20,113 	12,685
Other assets 	4,640 	2,457
Goodwill 	41,924 	26,041
Total assets 	$ 	95,123 	$ 	69,052
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations 	$ 	2,537 	$ 	2,628
Accounts payable 	2,867 	2,175
Accrued payroll and employee benefits 	2,427 	1,916
Contract liabilities 	2,655 	1,271
Other accrued expenses 	2,950 	2,314
Total current liabilities 	13,436 	10,304
Deferred income taxes 	3,837 	1,794
Other long-term liabilities 	4,540 	3,330
Long-term obligations 	32,333 	19,107
Commitments and contingencies (Note 12)
Redeemable noncontrolling interest 	122 	—
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 439,154,741 and 437,088,297 shares issued 	439 	437
Capital in excess of par value 	16,174 	15,579
Retained earnings 	35,431 	28,116
Treasury stock at cost, 44,720,112 and 40,417,789 shares 	(8,922) 	(6,818)
Accumulated other comprehensive items 	(2,329) 	(2,807)
Total Thermo Fisher Scientific Inc. shareholders’ equity 	40,793 	34,507
Noncontrolling interests 	62 	10
Total equity 	40,855 	34,517
Total liabilities, redeemable noncontrolling interest and equity 	$ 	95,123 	$ 	69,052
The accompanying notes are an integral part of these consolidated financial statements.
F-6

-- 50 of 180 --

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENT OF INCOME
Year Ended
December 31, 	December 31, 	December 31,
(In millions except per share amounts) 	2021 	2020 	2019
Revenues
Product revenues 	$ 	30,361 	$ 	25,306 	$ 	19,496
Service revenues 	8,850 	6,912 	6,046
Total revenues 	39,211 	32,218 	25,542
Costs and operating expenses:
Cost of product revenues 	13,594 	11,407 	10,037
Cost of service revenues 	5,979 	4,807 	4,177
Selling, general and administrative expenses 	8,007 	6,930 	6,144
Research and development expenses 	1,406 	1,181 	1,003
Restructuring and other costs (income) 	197 	99 	(413)
Total costs and operating expenses 	29,183 	24,424 	20,948
Operating income 	10,028 	7,794 	4,594
Interest income 	43 	65 	224
Interest expense 	(536) 	(553) 	(676)
Other income/(expense) 	(694) 	(76) 	(70)
Income before income taxes 	8,841 	7,230 	4,072
Provision for income taxes 	(1,109) 	(850) 	(374)
Equity in (losses) earnings of unconsolidated entities 	(4) 	(3) 	—
Net income 	7,728 	6,377 	3,698
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest 	3 	2 	2
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	7,725 	$ 	6,375 	$ 	3,696
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic 	$ 	19.62 	$ 	16.09 	$ 	9.24
Diluted 	$ 	19.46 	$ 	15.96 	$ 	9.17
Weighted average shares
Basic 	394 	396 	400
Diluted 	397 	399 	403
The accompanying notes are an integral part of these consolidated financial statements.
F-7

-- 51 of 180 --

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
Year Ended
December 31, 	December 31, 	December 31,
(In millions) 	2021 	2020 	2019
Comprehensive income
Net income 	$ 	7,728 	$ 	6,377 	$ 	3,698
Other comprehensive items:
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $231, $(221) and $25) 	373 	(118) 	(106)
Reclassification adjustment for losses included in net income 	— 	— 	30
Unrealized gains and losses on hedging instruments:
Unrealized losses on hedging instruments (net of tax benefit of $0, $20 and $12) 	— 	(65) 	(38)
Reclassification adjustment for losses included in net income (net of tax benefit of $17, $14 and
$6) 	56 	45 	19
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of
tax provision (benefit) of $11, $(1) and $(31)) 	36 	(8) 	(93)
Amortization of net loss and prior service benefit included in net periodic pension cost (net of
tax benefit of $6, $4 and $2) 	13 	18 	8
Total other comprehensive items 	478 	(128) 	(180)
Comprehensive income 	8,206 	6,249 	3,518
Less: comprehensive income attributable to noncontrolling interests and redeemable noncontrolling
interest 	2 	2 	3
Comprehensive income attributable to Thermo Fisher Scientific Inc. 	$ 	8,204 	$ 	6,247 	$ 	3,515
The accompanying notes are an integral part of these consolidated financial statements.
F-8

-- 52 of 180 --

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
Year Ended
December 31, 	December 31, 	December 31,
(In millions) 	2021 	2020 	2019
Operating activities
Net income 	$ 	7,728 	$ 	6,377 	$ 	3,698
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment 	831 	658 	564
Amortization of acquisition-related intangible assets 	1,761 	1,667 	1,713
Change in deferred income taxes 	(647) 	(552) 	(302)
Gain on sales of businesses 	— 	— 	(482)
Stock-based compensation 	230 	196 	181
Loss on early extinguishment of debt 	767 	— 	184
Other non-cash expenses 	190 	338 	82
Changes in assets and liabilities, excluding the effects of acquisitions and disposition:
Accounts receivable 	(204) 	(1,302) 	(225)
Inventories 	(1,065) 	(508) 	(458)
Accounts payable 	479 	59 	266
Contributions to retirement plans 	(34) 	(96) 	(50)
Other 	(724) 	1,452 	(198)
Net cash provided by operating activities 	9,312 	8,289 	4,973
Investing activities
Acquisitions, net of cash acquired 	(19,395) 	(38) 	(1,843)
Proceeds from sale of business, net of cash divested 	— 	— 	1,128
Purchase of property, plant and equipment 	(2,523) 	(1,474) 	(926)
Proceeds from sale of property, plant and equipment 	20 	8 	36
Other investing activities, net 	(34) 	(6) 	118
Net cash used in investing activities 	(21,932) 	(1,510) 	(1,487)
Financing activities
Net proceeds from issuance of debt 	18,137 	3,464 	5,638
Repayment of debt 	(11,738) 	(710) 	(6,355)
Proceeds from issuance of commercial paper 	2,512 	383 	2,781
Repayments of commercial paper 	— 	(387) 	(3,464)
Purchases of company common stock 	(2,000) 	(1,500) 	(1,500)
Dividends paid 	(395) 	(337) 	(297)
Net proceeds from issuance of company common stock under employee stock plans 	156 	196 	153
Other financing activities, net 	(91) 	(150) 	(74)
Net cash provided by (used in) financing activities 	6,581 	959 	(3,118)
Exchange rate effect on cash 	194 	176 	(63)
(Decrease) increase in cash, cash equivalents and restricted cash 	(5,845) 	7,914 	305
Cash, cash equivalents and restricted cash at beginning of year 	10,336 	2,422 	2,117
Cash, cash equivalents and restricted cash at end of year 	$ 	4,491 	$ 	10,336 	$ 	2,422
The accompanying notes are an integral part of these consolidated financial statements.
F-9

-- 53 of 180 --

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENT OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY
Redeemable
Noncontrolling
Interest
Common Stock 	Capital in
Excess of
Par Value
Retained
Earnings
Treasury Stock
Accumulated
Other
Comprehensive
Items
Total
Thermo Fisher
Scientific Inc.
Shareholders’
Equity
Noncontrolling
Interests
Total
Equity	(In millions) 	Shares 	Amount 	Shares 	Amount
Balance at December 31, 2018 	$ 	— 	432 	$ 	432 	$ 	14,621 	$ 	18,696 	29 	$ 	(3,665) 	$ 	(2,498) 	$ 	27,586 	$ 	8 	$ 	27,594
Cumulative effect of accounting
changes 	— 	— 	— 	— 	4 	— 	— 	— 	4 	— 	4
Issuance of shares under
employees' and directors'
stock plans 	— 	2 	2 	262 	— 	1 	(71) 	— 	193 	— 	193
Stock-based compensation 	— 	— 	— 	181 	— 	— 	— 	— 	181 	— 	181
Purchases of company common
stock 	— 	— 	— 	— 	— 	6 	(1,500) 	— 	(1,500) 	— 	(1,500)
Dividends declared ($0.76 per
share) 	— 	— 	— 	— 	(304) 	— 	— 	— 	(304) 	— 	(304)
Net income 	— 	— 	— 	— 	3,696 	— 	— 	— 	3,696 	2 	3,698
Other comprehensive items 	— 	— 	— 	— 	— 	— 	— 	(181) 	(181) 	1 	(180)
Contributions from (distributions
to) noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	— 	— 	(2) 	(2)
Balance at December 31, 2019 	— 	434 	434 	15,064 	22,092 	36 	(5,236) 	(2,679) 	29,675 	9 	29,684
Cumulative effect of accounting
changes 	— 	— 	— 	— 	(1) 	— 	— 	— 	(1) 	— 	(1)
Issuance of shares under
employees' and directors'
stock plans 	— 	3 	3 	319 	— 	— 	(82) 	— 	240 	— 	240
Stock-based compensation 	— 	— 	— 	196 	— 	— 	— 	— 	196 	— 	196
Purchases of company common
stock 	— 	— 	— 	— 	— 	4 	(1,500) 	— 	(1,500) 	— 	(1,500)
Dividends declared ($0.88 per
share) 	— 	— 	— 	— 	(350) 	— 	— 	— 	(350) 	— 	(350)
Net income 	— 	— 	— 	— 	6,375 	— 	— 	— 	6,375 	2 	6,377
Other comprehensive items 	— 	— 	— 	— 	— 	— 	— 	(128) 	(128) 	— 	(128)
Contributions from (distributions
to) noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	— 	— 	(1) 	(1)
Balance at December 31, 2020 	— 	437 	437 	15,579 	28,116 	40 	(6,818) 	(2,807) 	34,507 	10 	34,517
Issuance of shares under
employees' and directors'
stock plans 	— 	2 	2 	324 	— 	1 	(104) 	— 	222 	— 	222
Stock-based compensation 	— 	— 	— 	230 	— 	— 	— 	— 	230 	— 	230
Purchases of company common
stock 	— 	— 	— 	— 	— 	4 	(2,000) 	— 	(2,000) 	— 	(2,000)
Dividends declared ($1.04 per
share) 	— 	— 	— 	— 	(410) 	— 	— 	— 	(410) 	— 	(410)
Recognition upon acquisition 	122 	— 	— 	— 	— 	— 	— 	— 	— 	— 	—
Net income 	1 	— 	— 	— 	7,725 	— 	— 	— 	7,725 	2 	7,727
Other comprehensive items 	(1) 	— 	— 	— 	— 	— 	— 	478 	478 	— 	478
Contributions from (distributions
to) noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	— 	— 	50 	50
Other 	— 	— 	— 	41 	— 	— 	— 	— 	41 	— 	41
Balance at December 31, 2021 	$ 	122 	439 	$ 	439 	$ 	16,174 	$ 	35,431 	45 	$ 	(8,922) 	$ 	(2,329) 	$ 	40,793 	$ 	62 	$ 	40,855
The accompanying notes are an integral part of these consolidated financial statements.
F-10

-- 54 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1. 	Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate
life sciences research, solve complex analytical challenges, improve patient diagnostics and therapies, and increase laboratory productivity. Markets served include
pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.
Principles of Consolidation
The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany
accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to exercise
significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. At
December 31, 2021 and 2020, the company had such investments with carrying amounts of $576 million and $32 million, respectively. The company has elected
the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity
method. At December 31, 2021, the fair value of such investments was $217 million.
Redeemable Noncontrolling Interest
The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable
noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining
ownership interest at its pre-acquisition fair value.
Presentation
Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Revenue Recognition
Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer,
which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a
point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are
recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs
accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain
multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance
obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is
transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the
customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs
that would otherwise be capitalized and amortized over a period of less than one year.
Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from
existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date.
Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service
arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g.,
pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and
practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company
records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.
Contract-related Balances
Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company
maintains allowances for doubtful accounts for estimates of expected losses resulting from
F-11

-- 55 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in
existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons
for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are
available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized
commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it
is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such
amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s
performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration
becomes unconditional.
Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on
service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be
transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance
obligations in the same contract.
Warranty Obligations
The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time
product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty
agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred.
Leases
Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet.
Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in
the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the
company’s obligations.
Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation
to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease
payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes
operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over
the expected life of the leased asset, and an immaterial amount of interest expense.
Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information
available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease
terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense
is recognized on a straight-line basis over the lease term.
As a lessee, the company accounts for the lease and non-lease components as a single lease component.
Research and Development
The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and
development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and
development costs are expensed as incurred.
Restructuring Costs
Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a
substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such
benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time
benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual
elements that are subject to different accounting models.
F-12

-- 56 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs,
that are not associated with or will not be incurred to generate revenues. These include costs that represent amounts under contractual obligations that exist prior to
the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to
cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to
abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.
Income Taxes
The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax
basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A
valuation allowance is provided for tax assets that will more likely than not go unused.
The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return
presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.
Earnings per Share
Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares
outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share
has been computed using the treasury stock method for outstanding stock options and restricted units.
Cash and Cash Equivalents
Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three
months or less. These investments are carried at cost, which approximates market value.
Inventories
Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to
the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of
inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject
to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable
value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are
included in cost of revenues in the accompanying statement of income. The components of inventories are as follows:
December 31, 	December 31,
(In millions) 	2021 	2020
Raw materials 	$ 	1,922 	$ 	1,305
Work in process 	676 	540
Finished goods 	2,453 	2,184
Inventories 	$ 	5,051 	$ 	4,029
Prior to the third quarter of 2021, certain of the company’s businesses utilized the LIFO method of accounting for inventories. During the third quarter of
2021, these businesses, which comprised approximately 5% of consolidated inventories, changed from the LIFO method to the FIFO method. The company
believes this change is preferable as it will provide a consistent, uniform costing method for all inventories across the company, better reflect the current value of
inventories, and improve comparability with peers. Prior financial statements have not been retrospectively adjusted due to immateriality. The cumulative pre-tax
effect of this change in accounting principle of $33 million was recorded as an increase to inventories and a decrease to cost of product revenues in the third quarter
of 2021. This change was recorded in the Laboratory Products and Biopharma Services ($20 million) and Specialty Diagnostics ($13 million) segments.
The value of inventories maintained using the LIFO method was $274 million at December 31, 2020, which was below estimated replacement cost by $49
million. Reductions to cost of revenues as a result of the liquidation of LIFO inventories were nominal during 2019, 2020 and the first half of 2021.
F-13

-- 57 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Property, Plant and Equipment
Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to
expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the
property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the
shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are
eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. Property, plant and equipment consists of the
following:
December 31, 	December 31,
(In millions) 	2021 	2020
Land 	$ 	431 	$ 	410
Buildings and improvements 	2,575 	2,192
Machinery, equipment and leasehold improvements 	9,587 	6,975
Property, plant and equipment, at cost 	12,593 	9,577
Less: Accumulated depreciation and amortization 	4,260 	3,665
Property, plant and equipment, net 	$ 	8,333 	$ 	5,912
Acquisition-related Intangible Assets
Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically
identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company
reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the
assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows.
In these situations, the carrying value is written down to fair value.
In addition, the company has tradenames and in-process research and development that have indefinite lives and which are not amortized. Intangible assets
with indefinite lives are reviewed for impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may
perform an optional qualitative assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than
its carrying amount, no additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to
the fair value, if applicable.
Acquisition-related intangible assets are as follows:
Balance at December 31, 2021 	Balance at December 31, 2020
(In millions) 	Gross Accumulated
Amortization 	Net 	Gross Accumulated
Amortization 	Net
Definite lived:
Customer relationships 	$ 	22,802 	$ 	(7,792) 	$ 	15,010 	$ 	16,593 	$ 	(7,450) 	$ 	9,143
Product technology 	6,041 	(3,977) 	2,064 	5,523 	(3,532) 	1,991
Tradenames 	1,722 	(919) 	803 	1,213 	(897) 	316
Backlog 	1,060 	(59) 	1,001 	— 	— 	—
31,625 	(12,747) 	18,878 	23,329 	(11,879) 	11,450
Indefinite lived:
Tradenames 	1,235 	N/A 	1,235 	1,235 	N/A 	1,235
Acquisition-related intangible assets 	$ 	32,860 	$ 	(12,747) 	$ 	20,113 	$ 	24,564 	$ 	(11,879) 	$ 	12,685
F-14

-- 58 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The estimated future amortization expense of acquisition-related intangible assets with definite lives is as follows:
(In millions)
2022 	$ 	2,489
2023 	2,358
2024 	1,992
2025 	1,669
2026 	1,392
2027 and thereafter 	8,978
Estimated future amortization expense of definite-lived intangible assets 	$ 	18,878
Other Assets
Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, cash surrender
value of life insurance, insurance recovery receivables related to product liability matters, certain intangible assets and other assets.
At December 31, 2021 and 2020, the company had $33 million and $43 million, respectively, of intangible assets not derived from acquisitions, net of
accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years.
Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost
minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the
same issuer. The company performs qualitative assessments to identify impairments of these investments. At December 31, 2021 and 2020, the company had such
investments with carrying amounts of $22 million and $28 million, respectively, and investments measured at NAV of $16 million and $0 million, respectively,
which are included in other assets.
Goodwill
The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely
than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a
significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to
determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting
unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative
assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its reporting units by
using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting
unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2021, 2020 or 2019.
The changes in the carrying amount of goodwill by segment are as follows:
(In millions) Life Sciences
Solutions Analytical
Instruments Specialty
Diagnostics
Laboratory
Products and
Biopharma Services 	Total
Balance at December 31, 2019 	$ 	8,544 	$ 	4,928 	$ 	3,184 	$ 	9,058 	$ 	25,714
Acquisition 	35 	— 	— 	— 	35
Currency translation 	11 	151 	186 	(56) 	292
Balance at December 31, 2020 	8,590 	5,079 	3,370 	9,002 	26,041
Acquisitions 	1,560 	56 	8 	14,400 	16,024
Currency translation 	(7) 	(92) 	(101) 	59 	(141)
Balance at December 31, 2021 	$ 	10,143 	$ 	5,043 	$ 	3,277 	$ 	23,461 	$ 	41,924
F-15

-- 59 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Loss Contingencies
Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities,
self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the
probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the
company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities acquired
in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.
Currency Translation
All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation
adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average
exchange rates for the period. Currency transaction gains are included in the accompanying statement of income and in aggregate were $25 million, $24 million
and $52 million in 2021, 2020 and 2019, respectively.
Derivative Contracts
The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The
company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either
assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the
derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is
recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting
from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional
currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, Swiss franc, British pounds sterling,
Canadian dollars, Czech koruna, Japanese yen and Hong Kong dollars. The company does not hold or engage in transactions involving derivative instruments for
purposes other than risk management.
Cash flow hedges. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component
of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is
presented in the same income statement line item as the earnings effect of the hedged item.
Fair value hedges. 	For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting
loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings.
Net investment hedges. 	The company uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in
foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes and its cross-currency interest
rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency
transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency
interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and
businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely
affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other
three segments. The negative impacts significantly lessened in 2021. The extent and duration of negative impacts in the future, which
F-16

-- 60 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
may include inflationary pressures and supply chain disruptions, are uncertain and may require changes to estimates. Actual results could differ from those
estimates.
Recent Accounting Pronouncements
In November 2021, the FASB issued new guidance to require entities to disclose information about certain types of government assistance they receive,
including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics
of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted
for under a contribution model. The company will adopt this guidance in 2022 using a prospective method. The adoption of this guidance is not expected to have a
material impact on the company’s disclosures; however, the impact will be dependent on the extent of transactions of this nature entered into by the company in
periods subsequent to the date of adoption.
In October 2021, the FASB amended guidance to recognize and measure contract assets and contract liabilities acquired in a business combination. Generally,
this new guidance will result in the company recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The company
adopted this guidance in the fourth quarter of 2021 retrospectively to all business combinations completed in the first three quarters of 2021 and prospectively to all
future business combinations. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements for acquisitions
that closed in 2021; however, the impact in future periods will be dependent on the contract assets and contract liabilities acquired in future business combinations.
In July 2021, the FASB amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and
would have selling losses if they were classified as sales-type or direct financing leases. The company adopted the guidance in the third quarter of 2021 using a
prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements.
In January 2020, the FASB issued new guidance to clarify the interaction of the accounting for certain equity securities, equity method investments, and
certain forward contracts and purchased options. Among other things, the new guidance clarifies that an entity should consider observable transactions that require
it to either apply or discontinue the equity method of accounting for the purposes of applying measurement principles for certain equity securities immediately
before applying or discontinuing the equity method. The company adopted this guidance in 2020 using a prospective method. The adoption of this guidance did not
have a material impact on the company’s consolidated financial statements.
In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of
enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company
adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial
statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in
tax laws or rates.
In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other
postretirement plans. The company adopted the guidance in 2020 using a retrospective method. The adoption of this guidance did not have a material impact on the
company’s disclosures.
In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company adopted the guidance in
2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance did not have a material impact on
the company’s disclosures.
In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the
net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and
supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The
company adopted the guidance in 2020 using a modified retrospective method. The adoption of this guidance reduced accounts receivable and retained earnings by
$1 million on January 1, 2020.
In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at
the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to
leases. During 2017 - 2019, the FASB issued additional guidance and clarification. The company adopted this guidance in January 2019. The company elected to
adopt the guidance using a modified retrospective method, by applying the transition approach as of the beginning of the period of adoption. Comparative periods
have not been restated. As permitted upon transition, the company did not reassess whether any expired or
F-17

-- 61 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
existing contracts were or contained embedded leases, the lease classification for any expired or existing leases, initial direct costs for any leases, or whether land
easements met the definition of a lease if they were not accounted for as leases under the prior guidance. The adoption of this guidance increased retained earnings
by $4 million on January 1, 2019.
Note 2. 	Acquisitions and Disposition
The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill,
primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforce.
These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of
the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the
accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative
expenses as incurred.
2021
On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector
manufacturing business of Groupe Novasep SAS for $830 million in net cash consideration. The European viral vector manufacturing business provides
manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities
for cell and gene vaccines and therapies. The goodwill recorded as a result of this business combination is not tax deductible.
On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company,
for $407 million in net cash consideration and contingent consideration with an initial fair value of $65 million due upon the completion of certain milestones.
Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting infectious
diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the
point of care. The goodwill recorded as a result of this business combination is not tax deductible.
On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-
the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as
well. The company expects to make fixed lease payments aggregating to $555 million (excluding renewals) from 2021 to 2041, with additional amounts dependent
on the extent of revenues from customers of the facility other than CSL. The goodwill recorded as a result of this business combination is not tax deductible.
On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of
clinical research services to the pharma and biotech industry, for $15.99 billion in net cash consideration and $43 million of equity awards exchanged. The addition
of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their
productivity within the drug development process. The goodwill recorded as a result of this business combination is not tax deductible.
On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S. based developer and manufacturer of
recombinant proteins, for $1.86 billion in net cash consideration. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and
growth factors. The acquisition expands the segment’s bioscience offerings. The goodwill recorded as a result of this business combination is not tax deductible.
In addition, in 2021, the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets, an Ireland-based life sciences
distributor and a developer of a digital PCR platform; within the Analytical Instruments segment, a Belgium-based developer of micro-chip based technology for
liquid chromatography columns; and within the Specialty Diagnostics segment, a transplant diagnostics information system provider.
F-18

-- 62 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:
(In millions) 	PPD 	PeproTech
European Viral
Vector Business 	Mesa Biotech
Lengnau biologics
manufacturing
facility 	Other
Purchase price
Cash paid 	$ 	17,237 	$ 	1,947 	$ 	848 	$ 	421 	$ 	17 	$ 	298
Fair value of equity awards exchanged 	43 	— 	— 	— 	— 	—
Fair value of contingent consideration 	— 	— 	— 	65 	1 	117
Cash acquired 	(1,244) 	(83) 	(18) 	(14) 	— 	(13)
$ 	16,036 	$ 	1,864 	$ 	830 	$ 	472 	$ 	18 	$ 	402
Net assets acquired
Current assets 	$ 	2,510 	$ 	63 	$ 	39 	$ 	54 	$ 	— 	$ 	12
Property, plant and equipment 	562 	18 	59 	2 	92 	2
Definite-lived intangible assets:
Customer relationships 	6,264 	514 	302 	— 	— 	2
Product technology 	— 	282 	25 	279 	— 	224
Tradenames 	603 	— 	— 	2 	— 	2
Backlog 	1,060 	— 	— 	— 	— 	—
Goodwill 	13,781 	1,190 	600 	237 	18 	198
Other assets 	1,108 	11 	3 	3 	376 	2
Contract liabilities 	(1,570) 	— 	(59) 	— 	— 	(1)
Deferred tax assets (liabilities) 	(1,803) 	(193) 	(80) 	(72) 	— 	(28)
Finance lease liabilities 	(86) 	— 	(24) 	— 	(82) 	—
Debt assumed 	(4,299) 	— 	— 	— 	— 	—
Other liabilities assumed 	(1,972) 	(21) 	(35) 	(33) 	(386) 	(11)
Redeemable noncontrolling interest 	(122) 	— 	— 	— 	— 	—
$ 	16,036 	$ 	1,864 	$ 	830 	$ 	472 	$ 	18 	$ 	402
The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 17 years for customer relationships, 11 years for product
technology, 7 years for tradenames and 3 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2021 is 14
years.
The preliminary allocations of the purchase price for the acquisitions of the Lengnau biologics manufacturing facility, PPD and PeproTech were based on
estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization, largely with respect to acquired intangible assets, lease assets
and liabilities, and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions.
F-19

-- 63 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Unaudited Pro Forma Information
The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1,
2020:
Year Ended
December 31, 	December 31,
(In millions) 	2021 	2020
Revenues 	$ 	44,886 	$ 	36,887
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	7,369 	$ 	5,361
The historical consolidated financial information of the company and PPD has been adjusted in the pro forma information to give effect to pro forma events
that are directly attributable to the acquisitions and related financing arrangements and are factually supportable.
To reflect the acquisition of PPD as if it had occurred on January 1, 2020, the unaudited pro forma results include adjustments to reflect, among other things,
the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset and the interest expense from debt
financings obtained to partially fund the cash consideration transferred. Pro forma adjustments were tax effected at the company's historical statutory rates in effect
for the respective periods. The unaudited pro forma amounts are not necessarily indicative of the combined results of operations that would have been realized had
the acquisitions and related financings occurred on the aforementioned dates, nor are they meant to be indicative of any anticipated combined results of operations
that the company will experience after the transaction. In addition, the amounts do not include any adjustments for actions that may be taken following the
completion of the transaction, such as expected cost savings, operating synergies, or revenue enhancements that may be realized subsequent to the transaction.
Pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2021, excludes $312 million of transaction costs, initial
restructuring costs, and debt extinguishment costs directly attributable to the PPD acquisition that were included in the determination of net income attributable to
Thermo Fisher Scientific Inc. for that period. These items have reduced pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended
December 31, 2020, by $197 million.
The company’s results would not have been materially different from its pro forma results had the company’s other 2021 acquisitions occurred at the
beginning of 2020.
PPD’s revenues and losses attributable to Thermo Fisher Scientific Inc. in 2021, subsequent to the acquisition date, were $378 million and $(60) million,
respectively. The loss includes non-recurring transaction and compensation costs.
2020
In 2020, the company acquired, within the Life Sciences Solutions segment, a U.S.-based provider of a spectral dye platform for high-resolution biology
applications which will extend the company’s existing tools for protein and cell analysis applications, for a total purchase price of $63 million including the fair
value of contingent consideration.
2019
On April 30, 2019, the company acquired, within the Laboratory Products and Biopharma Services segment, Brammer Bio for approximately $1.67 billion in
cash. Brammer Bio is a leading viral vector contract development and manufacturing organization for gene and cell therapies. The acquisition expanded the
segment’s contract manufacturing capabilities. The purchase price exceeded the fair value of the identifiable net assets and, accordingly, $938 million was
allocated to goodwill, $405 million of which is tax deductible.
In addition, in 2019 the company acquired, within the Analytical Instruments segment, a Slovakia-based provider of mass spectrometry software used for
identification of compounds, and, within the Laboratory Products and Biopharma Services segment, an active pharmaceutical ingredient manufacturing facility in
Cork, Ireland, for an aggregate purchase price of $169 million.
F-20

-- 64 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The components of the purchase price and net assets acquired for 2019 acquisitions are as follows:
(In millions) 	Brammer Bio 	Other
Purchase price
Cash paid 	$ 	1,710 	$ 	169
Cash acquired 	(36) 	—
$ 	1,674 	$ 	169
Net assets acquired
Current assets 	$ 	52 	$ 	58
Property, plant and equipment 	147 	102
Definite-lived intangible assets:
Customer relationships 	744 	—
Product technology 	65 	7
Tradenames 	7 	—
Goodwill 	938 	9
Other assets 	49 	—
Contract liabilities 	(110) 	—
Deferred tax liabilities 	(110) 	(6)
Other liabilities assumed 	(108) 	(1)
$ 	1,674 	$ 	169
The weighted-average amortization periods for definite-lived intangible assets acquired in 2019 are 14 years for customer relationships, 13 years for product
technology and 2 years for tradenames. The weighted average amortization period for all definite-lived intangible assets acquired in 2019 is 14 years.
Disposition
On June 28, 2019, the company sold its Anatomical Pathology business to PHC Holdings Corporation for $1.13 billion, net of cash divested. The business was
part of the Specialty Diagnostics segment. The sale of this business resulted in a pre-tax gain of approximately $478 million, included in restructuring and other
(income) costs, net. Revenues in 2019, through the date of sale, of the business sold were approximately $115 million, net of retained sales through the company's
healthcare market and research and safety market channels.
Note 3. 	Revenues and Contract-related Balances
Disaggregated Revenues
Revenues by type are as follows:
(In millions) 	2021 	2020 	2019
Revenues
Consumables 	$ 	22,608 	$ 	18,527 	$ 	13,109
Instruments 	7,753 	6,779 	6,387
Services 	8,850 	6,912 	6,046
Consolidated revenues 	$ 	39,211 	$ 	32,218 	$ 	25,542
F-21

-- 65 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Revenues by geographic region based on customer location are as follows:
(In millions) 	2021 	2020 	2019
Revenues
North America 	$ 	19,659 	$ 	17,081 	$ 	12,896
Europe 	11,134 	8,284 	6,358
Asia-Pacific 	7,218 	5,822 	5,524
Other regions 	1,200 	1,031 	764
Consolidated revenues 	$ 	39,211 	$ 	32,218 	$ 	25,542
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for
revenues by reportable segment and other geographic data.
Remaining Performance Obligations
The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2021
was $28.30 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 59% of which is expected to occur
within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service
agreements, which typically have durations of three to five years.
Contract-related Balances
Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-
term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows:
December 31, 	December 31,
(In millions) 	2021 	2020
Current contract assets, net 	$ 	968 	$ 	731
Noncurrent contract assets, net 	9 	11
Current contract liabilities 	2,655 	1,271
Noncurrent contract liabilities 	1,238 	763
Substantially all of the current contract liabilities balance at December 31, 2020 and 2019 was recognized in revenues during 2021 and 2020, respectively.
Note 4. 	Business Segment and Geographical Information
The company’s financial performance is reported in four segments. A description of each segment follows.
Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and
production of new drugs and vaccines as well as diagnosis of disease (including COVID-19 through its polymerase chain reaction (PCR) testing and sample
preparation capabilities). These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, academic, and government
markets.
Analytical Instruments: provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the
laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government,
environmental and other research and industrial markets, as well as the clinical laboratory.
Specialty Diagnostics: provides a wide range of diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed
and accuracy of diagnoses. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories.
Laboratory Products and Biopharma Services (formerly known as Laboratory Products and Services): provides virtually everything needed for the laboratory,
including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial and healthcare settings. The
segment also includes a comprehensive offering of
F-22

-- 66 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
outsourced services used by the pharmaceutical and biotech industries for drug development, clinical trials logistics, clinical research services and commercial drug
manufacturing.
The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and
selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from
facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant
litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and
evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.
Business Segment Information
(In millions) 	2021 	2020 	2019
Revenues
Life Sciences Solutions 	$ 	15,631 	$ 	12,168 	$ 	6,856
Analytical Instruments 	6,069 	5,124 	5,522
Specialty Diagnostics 	5,659 	5,343 	3,718
Laboratory Products and Biopharma Services 	14,862 	12,245 	10,599
Eliminations 	(3,010) 	(2,662) 	(1,153)
Consolidated revenues 	39,211 	32,218 	25,542
Segment Income
Life Sciences Solutions 	7,817 	6,109 	2,446
Analytical Instruments 	1,197 	808 	1,273
Specialty Diagnostics 	1,280 	1,368 	930
Laboratory Products and Biopharma Services 	1,844 	1,271 	1,324
Subtotal reportable segments 	12,138 	9,556 	5,973
Cost of revenues charges 	(8) 	(6) 	(17)
Selling, general and administrative (charges) credits 	(144) 	10 	(62)
Restructuring and other (costs) income 	(197) 	(99) 	413
Amortization of acquisition-related intangible assets 	(1,761) 	(1,667) 	(1,713)
Consolidated operating income 	10,028 	7,794 	4,594
Interest income 	43 	65 	224
Interest expense 	(536) 	(553) 	(676)
Other income/(expense) 	(694) 	(76) 	(70)
Income before income taxes 	$ 	8,841 	$ 	7,230 	$ 	4,072
Depreciation
Life Sciences Solutions 	$ 	197 	$ 	140 	$ 	130
Analytical Instruments 	83 	76 	75
Specialty Diagnostics 	128 	100 	67
Laboratory Products and Biopharma Services 	423 	342 	292
Consolidated depreciation 	$ 	831 	$ 	658 	$ 	564
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition and accelerated
depreciation on fixed assets to estimated disposal value in connection with the consolidation of operations. Selling, general and administrative charges/credits
included in the above table consist of third-party transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions,
charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation.
F-23

-- 67 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In millions) 	2021 	2020 	2019
Total assets
Life Sciences Solutions 	$ 	22,751 	$ 	20,209 	$ 	18,306
Analytical Instruments 	9,692 	9,773 	9,896
Specialty Diagnostics 	6,010 	6,534 	5,867
Laboratory Products and Biopharma Services 	52,639 	22,711 	21,761
Corporate/other (a) 	4,031 	9,825 	2,551
Consolidated total assets 	$ 	95,123 	$ 	69,052 	$ 	58,381
Capital expenditures
Life Sciences Solutions 	$ 	810 	$ 	392 	$ 	151
Analytical Instruments 	79 	74 	64
Specialty Diagnostics 	167 	175 	83
Laboratory Products and Biopharma Services 	1,327 	772 	554
Corporate/other 	140 	61 	74
Consolidated capital expenditures 	$ 	2,523 	$ 	1,474 	$ 	926
(a) 	Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Geographical Information
(In millions) 	2021 	2020 	2019
Revenues 	(b)
United States 	$ 	18,907 	$ 	16,435 	$ 	12,366
China 	3,444 	2,797 	2,752
Other 	16,860 	12,986 	10,424
Consolidated revenues 	$ 	39,211 	$ 	32,218 	$ 	25,542
Long-lived Assets 	(c)
United States 	$ 	5,578 	$ 	3,686 	$ 	3,099
Other 	4,286 	3,001 	2,349
Consolidated long-lived assets 	$ 	9,864 	$ 	6,687 	$ 	5,448
(b) 	Revenues are attributed to countries based on customer location.
(c) 	Includes property, plant and equipment, net, and operating lease ROU assets.
Note 5. 	Other Income/(Expense)
In all periods, other income/(expense) includes currency transaction gains and losses on non-operating monetary assets and liabilities and net periodic pension
benefit cost/income, excluding the service cost component which is included in operating expenses on the accompanying statement of income. In 2021, other
income/(expense) includes $767 million of losses on the early extinguishment of debt (Note 10), $36 million of financing costs associated with obtaining bridge
financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments. The company had a
cash outlay of $36 million in 2021 associated with obtaining the bridge financing commitments, included in other financing activities, net, in the accompanying
statement of cash flows.
In 2020, other income/(expense) includes $81 million of financing costs for a terminated acquisition, primarily for loan commitment fees and entering into
hedging contracts and $42 million reclassified from accumulated other comprehensive items related to a hedge arrangement (Note 14), offset in part by $10 million
of net gains on investments. The company had a cash outlay of $51 million in 2020 associated with obtaining the loan commitments included in other financing
activities, net, in the accompanying statement of cash flows.
F-24

-- 68 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
In 2019, other income/(expense) includes $184 million of losses on the early extinguishment of debt (Note 10), offset in part by $44 million of net gains on
investments. The investment gains include a $28 million gain on the sale of a joint venture for net proceeds of $42 million.
Note 6. 	Stock-based Compensation Expense
The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-
based awards, including restricted stock units, stock options or performance-based shares, as determined by the compensation committee of the company’s Board
of Directors or, for certain non-officer grants, by the company’s employee equity committee, which consists of its chief executive officer. The company generally
issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally provide that in
the event of both a change in control of the company and a qualifying termination of an option or unit holder’s employment, all options and service-based restricted
unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides for different treatment).
Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement
eligibility, if earlier, and is primarily included in selling, general and administrative expenses.
Stock Options
The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment
with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using
the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate
fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a
valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical
volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on
U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate was
calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The
compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option
forfeitures.
The weighted average assumptions used in the Black-Scholes option pricing model are as follows:
2021 	2020 	2019
Expected stock price volatility 	26 	% 	22 	% 	21 	%
Risk free interest rate 	0.8 	% 	1.1 	% 	2.4 	%
Expected life of options (years) 	4.3 	4.3 	4.3
Expected annual dividend 	0.2 	% 	0.3 	% 	0.3 	%
The weighted average per share grant-date fair values of options granted during 2021, 2020 and 2019 were $123.97, $61.19 and $53.37, respectively. The total
intrinsic value of options exercised during the same periods was $501 million, $457 million and $320 million, respectively. The intrinsic value is the difference
between the market value of the shares on the exercise date and the exercise price of the option.
F-25

-- 69 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
A summary of the company’s option activity for the year ended December 31, 2021 is presented below:
Shares
(in millions)
Weighted average
exercise price
Weighted average
remaining contractual
term
(in years)
Aggregate
intrinsic
value
(in millions)
Outstanding at December 31, 2020 	5.9 	$ 	221.22
Granted 	1.5 	552.26
Issued in connection with an acquisition 	0.2 	492.35
Exercised 	(1.4) 	183.63
Canceled/expired 	(0.2) 	341.83
Outstanding at December 31, 2021 	6.0 	$ 	319.95 	4.5 	$ 	2,094
Vested and unvested expected to vest at December 31, 2021 	5.7 	$ 	306.64 	4.3 	$ 	2,035
Exercisable at December 31, 2021 	2.8 	$ 	193.39 	2.9 	$ 	1,307
As of December 31, 2021, there was $243 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to
be recognized through 2025 with a weighted average amortization period of 2.9 years.
Restricted Share/Unit Awards
Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued
employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain
performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the
award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of
service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the
grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.
A summary of the company’s restricted unit activity for the year ended December 31, 2021 is presented below:
Units
(in millions)
Weighted
average
grant-date
fair value
Unvested at December 31, 2020 	0.8 	$ 	276.74
Granted 	0.4 	444.61
Issued in connection with an acquisition 	0.2 	628.71
Vested 	(0.5) 	295.70
Forfeited 	(0.1) 	326.90
Unvested at December 31, 2021 	0.8 	$ 	425.39
The total fair value of shares vested during 2021, 2020 and 2019 was $151 million, $126 million and $118 million, respectively.
As of December 31, 2021, there was $250 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is
expected to be recognized through 2025 with a weighted average amortization period of 2.1 years.
Employee Stock Purchase Plans
Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program
at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through payroll
deductions of up to 10% of each participating employee’s qualifying gross wages. The company issued 0.1 million, 0.1 million and 0.2 million shares, respectively,
of its common stock in 2021, 2020 and 2019 under the employee stock purchase plan.
F-26

-- 70 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 7. 	Pension and Other Postretirement Benefit Plans
401(k) Savings Plan and Other Defined Contribution Plans
The company’s 401(k) savings and other defined contribution plans cover the majority of the company’s eligible U.S. and certain non-U.S. employees.
Contributions to the plans are made by both the employee and the company. Company contributions are based on the level of employee contributions. Company
contributions to these plans are based on formulas determined by the company. In 2021, 2020 and 2019, the company charged to expense $299 million, $254
million and $232 million, respectively, related to its defined contribution plans.
Defined Benefit Pension Plans
Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-
time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains
postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the
company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented.
The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as
the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items,
net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic
benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of
plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a)
previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.
The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. During 2021, 2020 and 2019, the company
made cash contributions of approximately $34 million, $96 million and $50 million, respectively. Contributions to the plans included in the following table are
estimated at between $40 and $60 million for 2022.
F-27

-- 71 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:
Domestic pension
benefits
Non-U.S. pension
benefits
(In millions) 	2021 	2020 	2021 	2020
Change in projected benefit obligations
Benefit obligation at beginning of year 	$ 	1,302 	$ 	1,302 	$ 	1,486 	$ 	1,303
Acquisitions 	— 	— 	170 	—
Service costs 	— 	— 	27 	24
Interest costs 	23 	35 	11 	18
Settlements 	— 	— 	(7) 	(38)
Plan participants' contributions 	— 	— 	6 	5
Actuarial (gains) losses 	20 	44 	(57) 	119
Benefits paid 	(85) 	(79) 	(30) 	(26)
Currency translation and other 	— 	— 	(54) 	81
Benefit obligation at end of year 	$ 	1,260 	$ 	1,302 	$ 	1,552 	$ 	1,486
Change in fair value of plan assets
Fair value of plan assets at beginning of year 	$ 	1,267 	$ 	1,201 	$ 	1,160 	$ 	986
Acquisitions 	— 	— 	158 	—
Actual return on plan assets 	37 	138 	14 	92
Employer contribution 	7 	7 	27 	87
Settlements 	— 	— 	(7) 	(38)
Plan participants' contributions 	— 	— 	6 	5
Benefits paid 	(85) 	(79) 	(30) 	(26)
Currency translation and other 	— 	— 	(26) 	54
Fair value of plan assets at end of year 	$ 	1,226 	$ 	1,267 	$ 	1,302 	$ 	1,160
Funded status 	$ 	(34) 	$ 	(35) 	$ 	(250) 	$ 	(326)
Accumulated benefit obligation 	$ 	1,260 	$ 	1,302 	$ 	1,475 	$ 	1,417
Amounts recognized in balance sheet
Noncurrent assets 	$ 	32 	$ 	38 	$ 	205 	$ 	157
Current liability 	(7) 	(8) 	(10) 	(9)
Noncurrent liabilities 	(59) 	(65) 	(445) 	(474)
Net amount recognized 	$ 	(34) 	$ 	(35) 	$ 	(250) 	$ 	(326)
Amounts recognized in accumulated other comprehensive items
Net actuarial loss 	$ 	157 	$ 	142 	$ 	167 	$ 	242
Prior service credits 	— 	— 	(3) 	(2)
Net amount recognized 	$ 	157 	$ 	142 	$ 	164 	$ 	240
For domestic pension plans, actuarial losses experienced in 2021 were driven by differences between actual and expected returns on plan assets for certain
portions of plan benefits indexed to asset returns, which were partially offset by actuarial gains due to increases in the weighted average discount rates used to
determine the projected benefit obligation differences. For non-U.S. pension plans, actuarial gains experienced in 2021 were principally driven by increases in the
weighted average discount rates used to determine the projected benefit obligation.
F-28

-- 72 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
For both domestic and non-U.S. pension plans, actuarial losses experienced in 2020 were principally driven by decreases in the weighted average discount
rates used to determine the projected benefit obligation. For domestic pension plans, the 2020 actuarial losses were partially offset by gains recognized due to the
adoption of an updated mortality assumption.
The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2021 and 2020 and are as
follows:
Domestic pension
benefits
Non-U.S. pension
benefits
2021 	2020 	2021 	2020
Weighted average assumptions used to determine projected benefit
obligations
Discount rate for determining benefit obligation 	2.70 	% 	2.33 	% 	1.45 	% 	0.95 	%
Interest crediting rate for cash balance plans 	2.58 	% 	2.16 	% 	1.25 	% 	1.25 	%
Average rate of increase in employee compensation 	N/A 	N/A 	2.73 	% 	2.30 	%
The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year,
as presented in the following table:
Domestic pension benefits 	Non-U.S. pension benefits
2021 	2020 	2019 	2021 	2020 	2019
Weighted average assumptions used to determine net benefit cost
(income)
Discount rate - service cost 	N/A 	N/A 	N/A 	0.65 	% 	1.21 	% 	1.97 	%
Discount rate - interest cost 	2.33 	% 	3.13 	% 	4.22 	% 	0.80 	% 	1.44 	% 	2.06 	%
Average rate of increase in employee compensation 	N/A 	N/A 	N/A 	2.30 	% 	2.27 	% 	2.47 	%
Expected long-term rate of return on assets 	4.25 	% 	5.00 	% 	5.76 	% 	2.02 	% 	2.33 	% 	3.25 	%
The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current
pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and
the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities
that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.
The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the
determination of the benefit obligation to the relevant projected cash flows.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the
benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative
weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In
addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.
Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity
to meet immediate and future benefit payment requirements.
The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and
management’s expectations of future salary increases.
The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in
excess of plan assets are as follows:
Pension plans
(In millions) 	2021 	2020
Pension plans with projected benefit obligations in excess of plan assets
Projected benefit obligation 	$ 	2,010 	$ 	2,047
Fair value of plan assets 	1,521 	1,529
F-29

-- 73 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit
obligations in excess of plan assets are as follows:
Pension plans
(In millions) 	2021 	2020
Pension plans with accumulated benefit obligations in excess of plan assets
Accumulated benefit obligation 	$ 	1,937 	$ 	1,976
Fair value of plan assets 	1,521 	1,526
The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations.
The net periodic pension benefit cost (income) includes the following components:
Domestic pension benefits 	Non-U.S. pension benefits
(In millions) 	2021 	2020 	2019 	2021 	2020 	2019
Components of net benefit cost (income)
Service cost 	$ 	— 	$ 	— 	$ 	— 	$ 	27 	$ 	24 	$ 	23
Interest cost on benefit obligation 	23 	35 	45 	11 	18 	24
Expected return on plan assets 	(40) 	(47) 	(55) 	(19) 	(19) 	(30)
Amortization of actuarial net loss 	7 	6 	2 	12 	10 	6
Amortization of prior service benefit 	— 	— 	— 	— 	(1) 	(1)
Settlement/curtailment loss 	— 	— 	— 	— 	8 	4
Net periodic benefit cost (income) 	$ 	(10) 	$ 	(6) 	$ 	(8) 	$ 	31 	$ 	40 	$ 	26
Expected benefit payments are estimated using the same assumptions used in determining the company’s benefit obligation at December 31, 2021. Benefit
payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of
these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate
for the five fiscal years thereafter, are as follows:
(In millions)
Domestic
pension
benefits
Non-U.S.
pension
benefits
Expected benefit payments
2022 	$ 	93 	$ 	45
2023 	89 	45
2024 	88 	49
2025 	86 	52
2026 	84 	56
2027-2031 	368 	307
Domestic Pension Plan Assets
The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in
fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets,
primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic
asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are
approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in
fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.
Non-U.S. Pension Plan Assets
The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely
established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the
market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a
portfolio of
F-30

-- 74 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, multi-asset funds, alternative
investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 40% - 90% for fixed income funds, 0% -
35% for multi-asset funds, and 0% - 30% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the
movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.
The fair values of the company’s plan assets at December 31, 2021 and 2020, by asset category are as follows:
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs 	Not subject to
leveling (a)	(In millions) 	2021 	(Level 1) 	(Level 2) 	(Level 3)
Domestic pension plan assets
U.S. equity funds 	$ 	124 	$ 	— 	$ 	— 	$ 	— 	$ 	124
International equity funds 	117 	— 	— 	— 	117
Fixed income funds 	966 	— 	— 	— 	966
Money market funds 	19 	— 	— 	— 	19
Total domestic pension plans 	$ 	1,226 	$ 	— 	$ 	— 	$ 	— 	$ 	1,226
Non-U.S. pension plan assets
Equity funds 	$ 	17 	$ 	— 	$ 	— 	$ 	— 	$ 	17
Fixed income funds 	651 	— 	— 	— 	651
Hedge funds 	3 	— 	— 	— 	3
Multi-asset funds 	73 	— 	— 	— 	73
Derivative funds 	253 	— 	— 	— 	253
Alternative investments 	1 	— 	— 	— 	1
Insurance contracts 	295 	— 	295 	— 	—
Cash / money market funds 	9 	5 	— 	— 	4
Total non-U.S. pension plans 	$ 	1,302 	$ 	5 	$ 	295 	$ 	— 	$ 	1,002
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
F-31

-- 75 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs 	Not subject to
leveling (a)	(In millions) 	2020 	(Level 1) 	(Level 2) 	(Level 3)
Domestic pension plan assets
U.S. equity funds 	$ 	125 	$ 	— 	$ 	— 	$ 	— 	$ 	125
International equity funds 	126 	— 	— 	— 	126
Fixed income funds 	1,001 	— 	— 	— 	1,001
Money market funds 	15 	— 	— 	— 	15
Total domestic pension plans 	$ 	1,267 	$ 	— 	$ 	— 	$ 	— 	$ 	1,267
Non-U.S. pension plan assets
Equity funds 	$ 	74 	$ 	— 	$ 	— 	$ 	— 	$ 	74
Fixed income funds 	510 	— 	— 	— 	510
Hedge funds 	59 	— 	— 	— 	59
Multi-asset funds 	45 	— 	— 	— 	45
Derivative funds 	149 	— 	— 	— 	149
Alternative investments 	6 	— 	— 	— 	6
Insurance contracts 	262 	— 	262 	— 	—
Cash / money market funds 	55 	7 	— 	— 	48
Total non-U.S. pension plans 	$ 	1,160 	$ 	7 	$ 	262 	$ 	— 	$ 	891
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
The tables above present the fair value of the company’s plan assets in accordance with the fair value hierarchy (Note 14). Certain investments that are
measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of these
investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension plan assets.
These investments were also redeemable at the balance sheet date or within limited time restrictions.
Note 8. 	Income Taxes
The components of income before provision for income taxes are as follows:
(In millions) 	2021 	2020 	2019
U.S. 	$ 	3,340 	$ 	4,762 	$ 	2,280
Non-U.S. 	5,501 	2,468 	1,792
Income before income taxes 	$ 	8,841 	$ 	7,230 	$ 	4,072
F-32

-- 76 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The components of the provision for income taxes are as follows:
(In millions) 	2021 	2020 	2019
Current income tax provision
Federal 	$ 	446 	$ 	521 	$ 	267
Non-U.S. 	1,148 	423 	544
State 	160 	175 	62
1,754 	1,119 	873
Deferred income tax provision (benefit)
Federal 	$ 	(227) 	$ 	(237) 	$ 	(222)
Non-U.S. 	(399) 	(18) 	(252)
State 	(19) 	(14) 	(25)
(645) 	(269) 	(499)
Provision for income taxes 	$ 	1,109 	$ 	850 	$ 	374
The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax
rate to income before income taxes due to the following:
(In millions) 	2021 	2020 	2019
Statutory federal income tax rate 	21 	% 	21 	% 	21 	%
Provision for income taxes at statutory rate 	$ 	1,857 	$ 	1,518 	$ 	855
Increases (decreases) resulting from:
Foreign rate differential 	(255) 	(223) 	(204)
Income tax credits 	(315) 	(335) 	(213)
Global intangible low-taxed income 	76 	86 	92
Foreign-derived intangible income 	(119) 	(156) 	(111)
Excess tax benefits from stock options and restricted stock units 	(124) 	(114) 	(80)
Provision for (reversal of) tax reserves, net 	(17) 	(26) 	62
Intra-entity transfers 	(284) 	— 	(79)
Foreign exchange loss on inter-company debt refinancing 	— 	(47) 	(62)
Domestication transaction 	— 	(263) 	—
Valuation allowance 	36 	379 	(4)
Withholding taxes 	164 	115 	38
Basis difference on disposal of business 	— 	— 	73
Tax return reassessments and settlements 	1 	(196) 	(6)
State income taxes, net of federal tax 	82 	147 	22
Other, net 	7 	(35) 	(9)
Provision for income taxes 	$ 	1,109 	$ 	850 	$ 	374
The company has operations and a taxable presence in approximately 50 countries outside the U.S. The company's effective income tax rate differs from the
U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the
U.S. federal statutory rate.
During 2021, the company recorded a $188 million income tax benefit related to the deferred tax implications of an intra-entity transfer of assets. Also in
2021, the company recorded a $96 million income tax benefit related to a capital loss resulting from certain intra-entity transactions.
During 2020, the company settled an IRS audit relating to the 2014, 2015, and 2016 tax years. The company recorded a $25 million net tax benefit primarily
from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $378 million, of which $144 million was
reclassified to income taxes payable. The company recorded $53 million of charges for expired tax credits and other related components of the settlement. The
company recorded a charge of $156 million to establish a valuation allowance against certain U.S. foreign tax credits which the company believes will more likely
than not expire unutilized.
F-33

-- 77 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
In 2020, the company recorded a $263 million income tax benefit related to a domestication transaction involving the transfer of certain non-U.S. subsidiaries
to the U.S., including interest expense of those subsidiaries. The company also recorded a valuation allowance of $212 million against the amount of interest
expense that the company believes will more likely than not go unused. Also in 2020, the company recorded a $47 million income tax benefit, including both U.S.
federal and state taxes, related to a foreign exchange loss for tax purposes on certain intercompany financing arrangements.
In 2019, the company recorded a $62 million income tax benefit, including both U.S. federal and state taxes, related to a foreign exchange loss for tax
purposes on certain intercompany financing arrangements as well as a tax provision of $191 million related to the gain on the sale of the Anatomical Pathology
business. Also in 2019, the company recorded a $79 million benefit related to the deferred tax implications of intra-entity transactions which included a tax benefit
to release a valuation allowance against net operating losses previously determined to be unrealizable.
The foreign tax credits discussed below are the result of foreign earnings and profits remitted or deemed remitted to the U.S. during the reporting year and the
U.S. treatment of taxes paid in the foreign jurisdictions in the years those profits were originally earned.
In 2020, the company implemented foreign tax credit planning in Sweden which resulted in $96 million of foreign tax credits, with no related incremental U.S.
income tax expense.
In 2019, the company implemented foreign tax credit planning in Sweden which resulted in $75 million of foreign tax credits, with no related incremental U.S.
income tax expense.
The company generally receives a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock units held by
employees, for the difference between the exercise price and the market price of the underlying common stock on the date of exercise. The company uses the
incremental tax benefit approach for utilization of tax attributes. These excess tax benefits reduce the tax provision. In 2021, 2020 and 2019, the company's tax
provision was reduced by $124 million, $114 million and $80 million, respectively, of such benefits.
Net deferred tax asset (liability) in the accompanying balance sheet consists of the following:
(In millions) 	2021 	2020
Deferred tax asset (liability)
Depreciation and amortization 	$ 	(4,687) 	$ 	(2,962)
Net operating loss and credit carryforwards 	1,652 	1,668
Reserves and accruals 	162 	164
Accrued compensation 	318 	253
Inventory basis difference 	181 	112
Deferred interest 	295 	227
Unrealized (gains) losses on hedging instruments 	(33) 	242
Other, net 	251 	124
Deferred tax liabilities, net before valuation allowance 	(1,861) 	(172)
Less: Valuation allowance 	968 	933
Deferred tax liabilities, net 	$ 	(2,829) 	$ 	(1,105)
The company estimates the degree to which tax assets and loss and credit carryforwards will result in a benefit based on expected profitability by tax
jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At
December 31, 2021, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense
carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.
F-34

-- 78 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The changes in the valuation allowance are as follows:
Year Ended December 31,
(In millions) 	2021 	2020 	2019
Beginning balance 	$ 	933 	$ 	408 	$ 	471
Additions (reductions) charged to income tax provision, net 	24 	514 	(27)
Additions due to acquisitions 	30 	— 	—
Reduction due to a divestiture 	— 	— 	(33)
Currency translation and other 	(19) 	11 	(3)
Ending balance 	$ 	968 	$ 	933 	$ 	408
At December 31, 2021, the company had net federal, state and non-U.S. net operating loss carryforwards of $72 million, $88 million and $1.18 billion,
respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. The federal and state net operating loss carryforwards expire in
the years 2022 through 2041. Of the net non-U.S. net operating loss carryforwards, $419 million expire in the years 2025 through 2041, and the remainder do not
expire.
At December 31, 2021, the company had foreign tax credit carryforwards of $610 million and deferred interest carryforwards of $295 million. The foreign tax
credit carryforwards will expire in the years 2022 through 2030 while deferred interest carryforwards do not expire.
U.S. federal taxes have been recorded on $24 billion of undistributed foreign earnings as of December 31, 2021. A provision has not been made for certain
U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company’s undistributed foreign earnings are
intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed
foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company’s intent is to only make
distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost.
Unrecognized Tax Benefits
As of December 31, 2021, the company had $1.12 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax
rate.
A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions) 	2021 	2020 	2019
Beginning balance 	$ 	1,091 	$ 	1,552 	$ 	1,442
Additions due to acquisitions 	26 	— 	—
Additions for tax positions of current year 	32 	8 	53
Additions for tax positions of prior years 	60 	— 	69
Reductions for tax positions of prior years 	(5) 	(296) 	(7)
Closure of tax years 	(27) 	— 	—
Settlements 	(53) 	(173) 	(5)
Ending balance 	$ 	1,124 	$ 	1,091 	$ 	1,552
Substantially all of the unrecognized tax benefits are classified as long-term liabilities. The company does not expect its unrecognized tax benefits to change
significantly over the next twelve months.
During 2021, the company’s unrecognized tax benefits increased by $80 million as a result of uncertain tax positions relating to foreign tax positions and
decreased $75 million relating to U.S. federal and state tax positions. The company also assumed $26 million of uncertain tax benefits as part of the acquisition of
PPD.
During 2020, the company’s unrecognized tax benefits decreased $51 million as a result of uncertain tax positions relating to foreign tax positions and $410
million relating to U.S. federal and state tax positions which included $378 million from the settlement of the IRS audit of the 2014, 2015 and 2016 tax years.
During 2019, the company’s unrecognized tax benefits increased $70 million as a result of uncertain tax positions relating to foreign tax positions and
$45 million relating to U.S. federal and state tax positions.
F-35

-- 79 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to
uncertain tax positions and recognized in the balance sheet as of December 31, 2021 and 2020 was $59 million and $78 million, respectively.
The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal
jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout the
world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United Kingdom and
the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years before 2012 and no
longer subject to U.S. federal income tax examinations for years before 2017.
Note 9. 	Earnings per Share
(In millions except per share amounts) 	2021 	2020 	2019
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	7,725 	$ 	6,375 	$ 	3,696
Basic weighted average shares 	394 	396 	400
Plus effect of: stock options and restricted stock units 	3 	3 	3
Diluted weighted average shares 	397 	399 	403
Basic earnings per share 	$ 	19.62 	$ 	16.09 	$ 	9.24
Diluted earnings per share 	$ 	19.46 	$ 	15.96 	$ 	9.17
Antidilutive stock options excluded from diluted weighted average shares 	1 	1 	1
Note 10. 	Debt and Other Financing Arrangements
Effective interest rate at
December 31, 	December 31, 	December 31,
(Dollars in millions) 	2021 	2021 	2020
Commercial Paper 	0.01 	% 	$ 	2,522 	$ 	—
2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 	— 	611
3.00% 7-Year Senior Notes, Due 4/15/2023 	— 	1,000
Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023 	1,000 	—
Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023 	500 	—
0.797% 2-Year Senior Notes, Due 10/18/2023 	1.03 	% 	1,350 	—
Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated) 	0.00 	% 	1,933 	—
0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated) 	0.06 	% 	625 	—
4.15% 10-Year Senior Notes, Due 2/1/2024 	— 	1,000
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 	0.94 	% 	1,137 	1,222
1.215% 3-Year Senior Notes, Due 10/18/2024 	1.42 	% 	2,500 	—
Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024 	500 	—
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 	0.41 	% 	910 	977
4.133% 5-Year Senior Notes, Due 3/25/2025 	— 	1,100
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 	2.10 	% 	728 	782
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) 	0.16 	% 	625 	—
3.65% 10-Year Senior Notes, Due 12/15/2025 	3.77 	% 	350 	350
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 	1.53 	% 	796 	855
2.95% 10-Year Senior Notes, Due 9/19/2026 	— 	1,200
F-36

-- 80 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Effective interest rate at
December 31, 	December 31, 	December 31,
(Dollars in millions) 	2021 	2021 	2020
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 	1.66 	% 	568 	611
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 	1.97 	% 	682 	733
3.20% 10-Year Senior Notes, Due 8/15/2027 	— 	750
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 	0.77 	% 	910 	977
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 	1.46 	% 	682 	733
1.750% 7-Year Senior Notes, Due 10/15/2028 	1.89 	% 	700 	—
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 	2.08 	% 	796 	855
2.60% 10-Year Senior Notes, Due 10/1/2029 	2.74 	% 	900 	900
4.497% 10-Year Senior Notes, Due 3/25/2030 	— 	1,100
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 	0.89 	% 	1,990 	—
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 	1.13 	% 	1,023 	1,099
2.00% 10-Year Senior Notes, Due 10/15/2031 	2.23 	% 	1,200 	—
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 	2.55 	% 	682 	733
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 	1.21 	% 	1,706 	—
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 	2.94 	% 	796 	855
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 	1.73 	% 	1,023 	1,099
2.80% 20-Year Senior Notes, Due 10/15/2041 	2.90 	% 	1,200 	—
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 	1.78 	% 	1,421 	—
5.30% 30-Year Senior Notes, Due 2/1/2044 	5.37 	% 	400 	400
4.10% 30-Year Senior Notes, Due 8/15/2047 	4.23 	% 	750 	750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 	1.98 	% 	1,137 	1,222
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 	2.07 	% 	853 	—
Other 	76 	5
Total borrowings at par value 	34,971 	21,919
Fair value hedge accounting adjustments 	— 	25
Unamortized discount 	(117) 	(102)
Unamortized debt issuance costs 	(184) 	(114)
Total borrowings at carrying value 	34,670 	21,728
Finance lease liabilities 	200 	7
Less: Short-term obligations and current maturities 	2,537 	2,628
Long-term obligations 	$ 	32,333 	$ 	19,107
SOFR - Secured Overnight Financing Rate
EURIBOR - Euro Interbank Offered Rate
The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount and the amortization of any debt
issuance costs.
See Note 14 for fair value information pertaining to the company’s long-term borrowings.
F-37

-- 81 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of December 31, 2021, the annual repayment requirements for debt obligations are as follows:
(In millions) 	Borrowings
Finance Lease
Liabilities
2022 	$ 	2,522 	$ 	15
2023 	5,396 	12
2024 	4,138 	12
2025 	2,610 	12
2026 	797 	12
2027 and thereafter 	19,508 	137
$ 	34,971 	$ 	200
In addition to available borrowings under the company’s revolving credit agreements, discussed below, the company had unused lines of credit of $78 million
as of December 31, 2021. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates.
Credit Facilities
On January 7, 2022, the company entered into a new revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured
multi-currency revolving credit The Facility replaces the company’s $3.00 billion credit facility which was in place at December 31, 2021 (the prior credit facility).
The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term SOFR, a EURIBOR-based rate (for funds drawn in euro)
or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and
events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to
Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment
under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum
Consolidated Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2021, no borrowings were outstanding under the prior
credit facility, although available capacity was reduced by approximately $4 million as a result of outstanding letters of credit.
Commercial Paper Programs
The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S.
program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the
commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183
days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs,
the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest
rates on a fixed or floating basis. As of December 31, 2021, there were $2.52 billion outstanding borrowings under these programs.
Senior Notes
Interest is payable quarterly on the floating rate senior notes, annually on the euro-denominated fixed rate senior notes and semi-annually on all other senior
notes. Each of the fixed rate senior notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and
accrued interest. Except for the euro-denominated floating rate senior notes, which may not be redeemed early, the floating rate senior notes may be redeemed in
whole or in part on or after their applicable call dates at a redemption price of 100% of the principal amount plus accrued interest. The company is subject to
certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge
principal properties as security under borrowing arrangements. The company was in compliance with all covenants at December 31, 2021.
The company intends to allocate an amount equal to the net proceeds from the 0.000% senior notes due 2025 to finance or refinance, in whole or in part,
certain green or social eligible projects. Pending allocation to green or social eligible projects, such net proceeds may be temporarily invested in cash, cash
equivalents, short-term investments, or used to repay other borrowings.
In 2021, the company redeemed some of its existing senior notes. In connection with these redemptions, the company incurred $767 million of losses on the
early extinguishment of debt included in other income/(expense) on the accompanying
F-38

-- 82 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate swap arrangements and received
$22 million, included in other financing activities, net, in the accompanying statement of cash flows.
In 2019, the company refinanced certain of its debt by issuing new senior notes and using the proceeds to redeem some of its existing senior notes. In
connection with these redemptions, the company incurred $184 million of losses on the early extinguishment of debt included in other income/(expense) on the
accompanying statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate swap arrangements
and paid $17 million, included in other financing activities, net, in the accompanying statement of cash flows. The company also terminated related cross-currency
interest rate swap arrangements and received $44 million, included in other investing activities, net, in the accompanying statement of cash flows.
In February 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption the company incurred approximately
$26 million of losses on the early extinguishment of debt in the first quarter of 2022.
Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the Floating Rate
Senior Notes due 2023, the 0.00% Senior Notes due 2023, the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due
2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051 included in the table above (collectively, the “Euronotes”) in registered public
offerings. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher
International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary”
as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the
Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of
Thermo Fisher International are consolidated in the financial statements of the company.
Note 11. 	Leases
As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases
generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate
the arrangement within 1 year.
The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2023, 2024 and 2025. The company has agreed
with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 10). The aggregate maximum guarantee under these
three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance
sheet as of December 31, 2021, but exclude any amounts for residual value guarantees.
F-39

-- 83 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As a lessee, the consolidated financial statements include the following relating to operating leases:
(In millions) 	2021 	2020 	2019
Balance sheet
ROU assets 	$ 	1,531 	$ 	775
Operating lease liabilities - current 	266 	184
Operating lease liabilities - noncurrent 	1,203 	626
Statement of income
Operating lease costs 	$ 	254 	$ 	224 	$ 	208
Variable lease costs 	66 	49 	41
Statement of cash flows
Cash used in operating activities for payments of amounts included in the measurement of
operating lease liabilities 	$ 	288 	$ 	222 	$ 	208
Operating lease ROU assets obtained in exchange for new operating lease liabilities 	293 	202 	205
Weighted average at end of year
Remaining operating lease term 	9.9 years 	6.3 years 	6.2 years
Discount rate 	2.6 	% 	3.4 	% 	4.0 	%
ROU assets are classified in 	other assets 	in the consolidated balance sheet. Operating lease liabilities are classified in 	other accrued expenses 	and 	other long-
term liabilities, respectively, in the consolidated balance sheet.
Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 10 for additional information relating to finance
leases.
As of December 31, 2021, future payments of operating lease liabilities are as follows:
(In millions)
2022 	$ 	303
2023 	248
2024 	193
2025 	144
2026 	120
2027 and thereafter 	650
Total lease payments 	1,658
Less: imputed interest 	189
Total operating lease liability 	$ 	1,469
As a lessor, operating leases, sales-type leases and direct financing leases are not material.
Note 12. 	Commitments and Contingencies
Purchase Obligations
The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or
fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be
purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are
cancelable at any time without penalty. The aggregate amount of the company’s unconditional purchase obligations totaled $2.51 billion at December 31, 2021
and the majority of these obligations are expected to be settled during 2022.
F-40

-- 84 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The Analytical Instruments segment recorded a charge to cost of product revenues for $108 million in 2020 related to an existing supply contract for
components of electron microscopy instruments. The agreement requires the company to make future minimum purchases through 2025. The company developed
and launched an alternative product beginning in 2020 and based on the expected demand for the internally developed product vs. the third-party product, the
company does not expect to use all of the product it will be required to buy, resulting in a loss on the purchase commitment.
Letters of Credit, Guarantees and Other Commitments
Outstanding letters of credit and bank guarantees totaled $266 million at December 31, 2021. Substantially all of these letters of credit and guarantees expire
before 2039.
Outstanding surety bonds and other guarantees totaled $95 million at December 31, 2021. The expiration of these bonds and guarantees ranges through 2023.
The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of
the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required.
The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension
benefits, however the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at
December 31, 2021 was $36 million.
In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to
indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of obligations or
a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in such event, the
company would be entitled to seek indemnification from the buyer.
Indemnifications
In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related
to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The scope
and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a liability.
Generally, a maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the company
has not made significant payments for these indemnifications.
In connection with the company’s efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet
them to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the
facility. As a result, if a third-party vacates the sublet facility, the company would be obligated to make lease or other payments under the master lease agreement.
The company believes that the financial risk of default by sublessors is individually and in the aggregate not material to the company’s financial position or results
of operations.
In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its
products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The
company has not been required to make material payments under such provisions.
Environmental Matters
The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all
potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the
required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the
company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment
systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in
any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and
regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates
based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The
company includes in these estimates potential costs for investigation, remediation and operation and
F-41

-- 85 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
maintenance of cleanup sites. At December 31, 2021, the company’s total environmental liability was approximately $65 million. While management believes the
accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or
compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in
remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position,
results of operations or cash flows.
Litigation and Related Contingencies
The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that
arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and
commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in
the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company
establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely
amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s
judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted
as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties
associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has
been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no
material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses deemed probable for such matters. It is
reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described
below could have a material adverse effect on the company’s results of operations, financial position and cash flows.
Product Liability, Workers Compensation and Other Personal Injury Matters
The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and
other personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company’s continuing
operations at December 31, 2021, was approximately $216 million to $375 million on an undiscounted basis. The portion of these liabilities assumed in the 2006
merger with Fisher was recorded at its fair (present) value at the date of merger. The company’s accrual for all such matters in total, including the discounted
liabilities, was $216 million at December 31, 2021 (or $223 million undiscounted). The accrual includes estimated defense costs and is gross of estimated amounts
due from insurers of $100 million at December 31, 2021 (or $106 million undiscounted) that are included in other assets in the accompanying balance sheet. The
portion of these insurance assets assumed in the merger with Fisher was also recorded at its fair value at the date of merger. In addition to the above accrual, as of
December 31, 2021, the company had a product liability accrual of $11 million (undiscounted) relating to divested businesses.
Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including
actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the
ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance
contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to
the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the
financial condition and ratings of its insurers on an ongoing basis.
F-42

-- 86 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 13. 	Comprehensive Income and Shareholders' Equity
Comprehensive Income (Loss)
Comprehensive income combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as
components of shareholders’ equity in the accompanying balance sheet.
Changes in each component of accumulated other comprehensive items, net of tax are as follows:
(In millions)
Currency
translation
adjustment
Unrealized
losses on
hedging
instruments
Pension and
other
postretirement
benefit
liability
adjustment 	Total
Balance at December 31, 2020 	$ 	(2,438) 	$ 	(91) 	$ 	(278) 	$ 	(2,807)
Other comprehensive items before reclassifications 	373 	— 	36 	409
Amounts reclassified from accumulated other comprehensive items 	— 	56 	13 	69
Net other comprehensive items 	373 	56 	49 	478
Balance at December 31, 2021 	$ 	(2,065) 	$ 	(35) 	$ 	(229) 	$ 	(2,329)
Shareholders’ Equity
At December 31, 2021, the company had reserved 23 million unissued shares of its common stock for possible issuance under stock-based compensation
plans.
Early in the first quarter of 2022, the company repurchased $2.00 billion of the company's common stock (3.3 million shares).
Note 14. 	Fair Value Measurements and Fair Value of Financial Instruments
Fair Value Measurements
The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2021. The
company’s financial assets and liabilities carried at fair value are primarily comprised of investments in publicly traded securities, insurance contracts, investments
in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred
compensation and retirement liabilities; and acquisition-related contingent consideration.
Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.
Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.
Level 3: Inputs are unobservable data points that are not corroborated by market data.
F-43

-- 87 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31,
2021 and December 31, 2020:
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 	2021 	(Level 1) 	(Level 2) 	(Level 3)
Assets
Cash equivalents 	$ 	2,210 	$ 	2,210 	$ 	— 	$ 	—
Investments 	298 	298 	— 	—
Warrants 	15 	— 	15 	—
Insurance contracts 	181 	— 	181 	—
Derivative contracts 	36 	— 	36 	—
Total assets 	$ 	2,740 	$ 	2,508 	$ 	232 	$ 	—
Liabilities
Derivative contracts 	$ 	1 	$ 	— 	$ 	1 	$ 	—
Contingent consideration 	317 	— 	— 	317
Total liabilities 	$ 	318 	$ 	— 	$ 	1 	$ 	317
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 	2020 	(Level 1) 	(Level 2) 	(Level 3)
Assets
Cash equivalents 	$ 	8,971 	$ 	8,971 	$ 	— 	$ 	—
Investments 	21 	21 	— 	—
Warrants 	7 	— 	7 	—
Insurance contracts 	157 	— 	157 	—
Derivative contracts 	28 	— 	28 	—
Total assets 	$ 	9,184 	$ 	8,992 	$ 	192 	$ 	—
Liabilities
Derivative contracts 	$ 	132 	$ 	— 	$ 	132 	$ 	—
Contingent consideration 	70 	— 	— 	70
Total liabilities 	$ 	202 	$ 	— 	$ 	132 	$ 	70
The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash
surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation
of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related
contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent
consideration are recorded in selling, general and administrative expense.
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones,
as well as changes in the fair values of the investments underlying a
F-44

-- 88 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
recapitalization investment portfolio), of the contingent consideration.
(In millions) 	2021 	2020
Contingent consideration
Beginning balance 	$ 	70 	$ 	55
Acquisitions (including assumed balances) 	403 	28
Payments 	(109) 	(4)
Changes in fair value included in earnings 	(47) 	(9)
Ending balance 	$ 	317 	$ 	70
Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
December 31, 	December 31,
(In millions) 	2021 	2020
Notional amount
Interest rate swaps - fair value hedges 	$ 	— 	$ 	1,000
Cross-currency interest rate swaps - designated as net investment hedges 	900 	900
Currency exchange contracts 	2,149 	5,206
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the
balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheet and statement of income.
Fair value – assets 	Fair value – liabilities
December 31, 	December 31, 	December 31, 	December 31,
(In millions) 	2021 	2020 	2021 	2020
Derivatives designated as hedging instruments
Interest rate swaps (a) 	$ 	— 	$ 	25 	$ 	— 	$ 	—
Cross-currency interest rate swaps (a) 	25 	— 	— 	46
Derivatives not designated as hedging instruments
Currency exchange contracts (b) 	11 	3 	1 	86
Total derivatives 	$ 	36 	$ 	28 	$ 	1 	$ 	132
(a) 	The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the accompanying balance sheet under the caption other assets or other long-
term liabilities.
(b) 	The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
The following amounts related to cumulative basis adjustments for fair value hedges were included in the accompanying balance sheet under the caption long-
term obligations:
Carrying amount of the hedged liability
Cumulative amount of fair value hedging
adjustment - increase (decrease) included in
carrying amount of liability
December 31, 	December 31, 	December 31, 	December 31,
(In millions) 	2021 	2020 	2021 	2020
Long-term obligations 	$ 	— 	$ 	1,020 	$ 	— 	$ 	25
F-45

-- 89 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Gain (loss) recognized
(In millions) 	2021 	2020
Fair value hedging relationships
Interest rate swaps
Hedged long-term obligations - included in other income/(expense) 	$ 	25 	$ 	(38)
Derivatives designated as hedging instruments - included in other income/(expense) 	(3) 	38
Derivatives designated as cash flow hedges
Interest rate swaps
Included in unrealized losses on hedging instruments within other comprehensive items 	— 	(85)
Amount reclassified from accumulated other comprehensive items to other income/(expense) 	(73) 	(59)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt
Included in currency translation adjustment within other comprehensive items 	922 	(873)
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items 	71 	(79)
Included in other income/(expense) 	8 	11
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues 	12 	(17)
Included in other income/(expense) 	162 	(81)
Cross-currency interest rate swaps
Included in other income/(expense) 	— 	(9)
Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying
statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.
The company uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations
against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes and its cross-currency interest rate swaps have been
designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses
due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest
accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
See Note 1 and Note 10 for additional information on the company's risk management objectives and strategies.
Cash Flow Hedge Arrangements
In 2020 and 2019, the company entered into interest rate swap arrangements to mitigate the risk of interest rates rising prior to completion of debt offerings.
Based on the company's conclusion that the debt offerings were probable, the swaps hedged the cash flow risk for each of the interest payments on the planned
fixed-rate debt issues. The aggregate fair value of the terminated hedges, net of tax, has been classified as a reduction to accumulated other comprehensive items
and will be amortized to interest expense over the term of the related debt issuances. The company had cash outlays aggregating $85 million and $50 million in
2020 and 2019, respectively, associated with termination of the arrangements, included in other financing activities, net, in the accompanying statement of cash
flows.
In late 2020, the company determined that the previously anticipated debt offerings were probable of not occurring and reclassified $42 million from
accumulated other comprehensive items to other income/(expense). During 2021, in connection with the extinguishment of debt (Note 10), the company
reclassified $65 million from accumulated other comprehensive items to other income/(expense).
F-46

-- 90 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
December 31, 2021 	December 31, 2020
Carrying 	Fair 	Carrying 	Fair
(In millions) 	value 	value 	value 	value
Senior notes 	$ 	32,072 	$ 	33,449 	$ 	21,723 	$ 	24,653
Commercial paper 	2,522 	2,522 	— 	—
Other 	76 	76 	5 	5
$ 	34,670 	$ 	36,047 	$ 	21,728 	$ 	24,658
The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period
ends which represent level 2 measurements.
Note 15. 	Supplemental Cash Flow Information
(In millions) 	2021 	2020 	2019
Cash paid for:
Interest 	$ 	555 	$ 	471 	$ 	790
Income taxes 	2,182 	1,324 	896
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment 	379 	347 	150
Fair value of equity awards exchanged 	43 	— 	—
Fair value of acquisition contingent consideration 	183 	— 	—
Finance lease ROU assets obtained in exchange for new finance lease liabilities 	15 	5 	1
Declared but unpaid dividends 	104 	89 	77
Issuance of stock upon vesting of restricted stock units 	265 	217 	182
Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:
December 31, 	December 31,
(In millions) 	2021 	2020
Cash and cash equivalents 	$ 	4,477 	$ 	10,325
Restricted cash included in other current assets 	13 	10
Restricted cash included in other assets 	1 	1
Cash, cash equivalents and restricted cash 	$ 	4,491 	$ 	10,336
Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative
clearance.
F-47

-- 91 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 16. 	Restructuring and Other Costs (Income)
Restructuring and other costs in 2021 primarily included charges for impairments of an acquired technology asset and a tradename asset, and, to a lesser
extent, compensation due to employees at acquired businesses on the date of acquisition. In 2021, severance actions associated with facility consolidations and cost
reduction measures affected less than 1% of the company’s workforce.
Restructuring and other costs in 2020 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline
operations, including the closure and consolidation of operations within several facilities in the U.S. and Europe, and charges for the write-off of acquired
technology. In 2020, severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce.
Restructuring and other costs (income) in 2019 primarily included the gain on the sale of the company’s Anatomical Pathology business, and, to a lesser
extent, continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of
operations within several facilities in the U.S. and Europe. In 2019, severance actions associated with facility consolidations and cost reduction measures affected
approximately 1% of the company’s workforce.
As of February 24, 2022, the company has identified restructuring actions that will result in additional charges of approximately $20 million, primarily in
2022, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit
arrangements or when the costs have been incurred.
Restructuring and other costs (income) by segment are as follows:
(In millions) 	2021 	2020 	2019
Life Sciences Solutions 	$ 	129 	$ 	34 	$ 	24
Analytical Instruments 	6 	26 	14
Specialty Diagnostics 	18 	9 	(471)
Laboratory Products and Biopharma Services 	35 	23 	17
Corporate 	9 	7 	3
$ 	197 	$ 	99 	$ 	(413)
The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the
accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the
accompanying balance sheet.
(In millions) 	Total (a)
Balance at December 31, 2018 	$ 	80
Cumulative effect of accounting change (b) 	(28)
Net restructuring charges incurred in 2019 (c) 	52
Payments 	(69)
Currency translation 	(1)
Balance at December 31, 2019 	34
Net restructuring charges incurred in 2020 (d) 	51
Payments 	(57)
Currency translation 	(7)
Balance at December 31, 2020 	21
Net restructuring charges incurred in 2021 (e) 	37
Payments 	(40)
Currency translation 	(1)
Balance at December 31, 2021 	$ 	17
(a) 	The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations,
as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
(b) 	Impact of adopting new lease accounting guidance on January 1, 2019.
F-48

-- 92 of 180 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(c) 	Excludes $465 million of net charges, principally $482 million of 	net gain on the sale of businesses 	recorded in the Specialty Diagnostics segment, partially offset by
$17 million of other restructuring charges, net, across the company’s segments primarily for the write-off of acquired technology, pre-acquisition litigation-related matters,
and compensation due to employees at businesses at the date of acquisition.
(d) 	Excludes $48 million of charges, principally $32 million for impairment of acquired technology in the Life Sciences Solutions segment resulting from a reduction in
expected cash flows and, to a lesser extent, charges across the company’s segments for fixed asset writedowns and costs associated with environmental remediation at
abandoned/previously owned facilities.
(e) 	Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and
Laboratory Products and Biopharma Services segment, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation
contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
The company expects to pay accrued restructuring costs primarily through 2022.
F-49

-- 93 of 180 --

Exhibit 4.17
Description of Registrant’s Securities
The following description of registered securities of Thermo Fisher Scientific Inc. is intended as a summary only and therefore is not
a complete description. As used in this “Description of Registrant’s Securities,” the terms “Thermo Fisher,” “Company,” “we,”
“our” and “us” refer to Thermo Fisher Scientific Inc. and do not, unless the context otherwise indicates, include our subsidiaries.
Our authorized capital stock consists of 1.2 billion shares of common stock, $1.00 par value per share, and 50,000 shares of
preferred stock, $100 par value per share. Our common stock is registered under Section 12(b) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”). We also have several classes of debt securities registered under Section 12(b) of the
Exchange Act.
COMMON STOCK
This description of our common stock is based upon, and qualified by reference to, our Third Amended and Restated Certificate of
Incorporation, as amended (our “certificate of incorporation”), our amended and restated by-laws (our “bylaws”) and applicable
provisions of Delaware corporate law (the “DGCL”). You should read our certificate of incorporation and bylaws, which are
incorporated by reference as Exhibits 3.1 to 3.3 and Exhibit 3.4, respectively, to the Annual Report on Form 10-K for the year ended
December 31, 2021, of which this Exhibit 4.17 is a part, for the provisions that are important to you.
General
Annual Meeting. 	Annual meetings of our stockholders are held on the date designated in accordance with our bylaws. Written notice
must be given to each stockholder entitled to vote not less than ten nor more than 60 days before the date of the meeting. The
presence in person or by proxy of the holders of record of a majority of our issued and outstanding shares entitled to vote at such
meeting constitutes a quorum for the transaction of business at meetings of the stockholders, unless or except to the extent that the
presence of a larger number may be required by our certificate of incorporation or the DGCL. Special meetings of the stockholders
may only be called by our board of directors, the chairman of the board of directors or the chief executive officer or, solely to the
extent required by our bylaws, by our secretary at the written request in proper form of one or more stockholders who have
continuously held as stockholders of record not less than 15% of the outstanding shares of our common stock for at least one year
prior to the date such request is delivered to our secretary. Except as may be otherwise provided by applicable law, our certificate of
incorporation or our bylaws, all matters shall be decided by a majority of the votes cast by stockholders entitled to vote thereon at a
duly held meeting of stockholders at which a quorum is present. Except as may be otherwise provided by our certificate of
incorporation, a nominee shall be elected to our board of directors if the votes cast for such nominee’s election exceed the votes cast
against, 	provided 	that if, on the 10 	business day before we mail our notice of meeting to the stockholders, the number of nominees
exceeds the number of directors to be elected, the election shall be decided by a plurality.
Voting Rights. 	Each holder of common stock is entitled to one vote for each share held on all matters to be voted upon by
stockholders.
Dividends. 	The holders of common stock, after any preferences of holders of any preferred stock are entitled to receive dividends
when and if declared by our board of directors out of legally available funds.
th
1

-- 94 of 180 --

Exhibit 4.17
Liquidation, Dissolution and Winding Up. 	In the event of our liquidation, dissolution or winding up, the holders of the common
stock will be entitled to share in our assets available for distribution to stockholders in proportion to the amount of common stock
they own. The amount available for common stockholders is calculated after payment of liabilities. Holders of any preferred stock
will receive a preferential share of our assets before the holders of the common stock receive any assets.
Other Rights. 	Holders of the common stock have no right to:
• 	convert the stock into any other security;
• 	have the stock redeemed; or
• 	purchase additional stock or to maintain their proportionate ownership interest.
The common stock does not have cumulative voting rights. Holders of shares of the common stock are not required to make
additional capital contributions.
Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May Have Anti-Takeover Effects
Certain provisions of our certificate of incorporation and bylaws may have the effect of making it more difficult for a third party to
acquire, or of discouraging a third party from attempting to acquire, control of us. Such provisions could limit the price that certain
investors might be willing to pay in the future for shares of our common stock and may limit the ability of stockholders to remove
current management or directors or approve transactions that stockholders may deem to be in their best interest and, therefore, could
adversely affect the price of our common stock.
Removal of Directors by Stockholders. 	Our bylaws provide that, except as otherwise provided by our certificate of incorporation or
the DGCL, any one or more or all of the members of our board of directors may be removed, with or without cause, by the holders
of a majority of the voting power of the shares entitled to vote thereon.
Board Vacancies Filled Only by Majority of Directors Then in Office. 	Our bylaws provide that, except as otherwise provided by our
certificate of incorporation or the DGCL, vacancies and newly created seats on our board may be filled only by our board of
directors. Further, only our board of directors may determine the number of directors on our board. The inability of stockholders to
determine the number of directors or to fill vacancies or newly created seats on the board makes it more difficult to change the
composition of our board of directors.
Stockholder Nomination of Directors and Proposals. 	Our bylaws provide that a stockholder must notify us in writing of any
stockholder nomination of a director or proposal for other business not less than 60 days and not more than 75 days prior to the first
anniversary of the date on which we first mailed our proxy materials for the preceding year’s annual meeting; 	provided, that if the
date of the annual meeting is advanced or delayed by more than 30 days from such anniversary date, notice by the stockholder to be
timely must be so delivered not later than the close of business on the later of (x) the 90 	day prior to the date of such meeting or (y)
the 10 	day following the day on which public announcement of the date of such annual meeting is first made by us.
th
th
2

-- 95 of 180 --

Exhibit 4.17
Proxy Access. 	Our bylaws provide for proxy access, which permits a stockholder, or a group of up to 20 stockholders, owning 3% or
more of our outstanding common stock continuously for at least three years, to nominate and include in our proxy materials
qualifying director nominees constituting up to the greater of (i) 20% of our board of directors or (ii) two directors. To be timely, any
proxy access notice must be delivered in writing to our secretary not less than 120 days and not more than 150 days prior to the first
anniversary of the preceding year’s annual meeting; 	provided 	that in the event that the date of the annual meeting is advanced by
more than 30 days or delayed (other than as a result of adjournment) by more than 60 days from the first anniversary of the
preceding year’s annual meeting, or if no annual meeting was held in the preceding year, a stockholder’s notice must be received not
earlier than 150 days prior to such annual meeting and not later than the close of business on the later of (a) the 120 	day prior to
such annual meeting and (b) the 10 	day following the day on which notice of the date of such annual meeting was mailed or
publicly announced. The complete proxy access provisions for director nominations are set forth in our bylaws.
“Blank Check” Preferred Stock. 	Our board of directors is authorized, without further action by our stockholders, to issue up to
50,000 shares of “blank check” preferred stock of the par value of $100 per share in one or more series possessing such specific
terms, including dividend rates, conversion prices, voting rights, redemption prices, maturity dates and other special rights,
preferences, qualifications, limitations, and restrictions thereof, as shall be determined in the resolution or resolutions providing for
the issue of such preferred stock adopted by our board of directors. The issuance of preferred stock could impede the completion of a
merger, tender offer or other takeover attempt.
These provisions of Delaware law, our certificate of incorporation and our bylaws may have the effect of deterring hostile takeovers
or delaying changes in our control or in our management. These provisions are intended to enhance the likelihood of continued
stability in the composition of our board of directors and in the policies they implement, and to discourage certain types of
transactions that may involve an actual or threatened change of our control. These provisions are designed to reduce our
vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in
proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as
a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover
attempts.
Delaware Business Combination Statute. 	We are subject to Section 203 of the DGCL (“Section 203”), which prohibits a Delaware
corporation from engaging in business combinations with an interested stockholder. An interested stockholder is generally defined as
an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation or any entity or person
affiliated with or controlling or controlled by such entity or person (“interested stockholder”). Section 203 provides that an interested
stockholder may not engage in business combinations with the corporation for a period of three years after the date that such
stockholder became an interested stockholder, with the following exceptions:
• 	before such date, the board of directors of the corporation approved either the business combination or the transaction that
resulted in the stockholder becoming an interested stockholder;
• 	upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began,
excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the
interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in
which employee participants do not
th
th
3

-- 96 of 180 --

Exhibit 4.17
have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange
offer; or
• 	on or after such date, the business combination is approved by the board of directors and authorized at an annual or special
meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
stock that is not owned by the interested stockholder.
In general, Section 203 defines business combinations to include the following:
• 	any merger or consolidation involving the corporation and the interested stockholder;
• 	any sale, lease, transfer, pledge or other disposition of 10% or more of the assets of the corporation to or with the interested
stockholder;
• 	subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder;
• 	any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or
series of the corporation beneficially owned by the interested stockholder; or
• 	the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits
by or through the corporation.
4

-- 97 of 180 --

Exhibit 4.17
DEBT SECURITIES
This description of our registered debt securities is based upon, and qualified by reference to the 2009 Base Indenture, the Eighth
Supplemental Indenture, the Thirteenth Supplemental Indenture, the Fifteenth Supplemental Indenture, the Sixteenth Supplemental
Indenture, the Eighteenth Supplemental Indenture, and the Twenty-First Supplemental Indenture (each as hereinafter defined). You
should read the 2009 Base Indenture, the Eighth Supplemental Indenture, the Thirteenth Supplemental Indenture, the Fifteenth
Supplemental Indenture, the Sixteenth Supplemental Indenture, the Eighteenth Supplemental Indenture, and the Twenty-First
Supplemental Indenture, which are incorporated by reference as Exhibits 4.1, 4.3, 4.5, 4.6, 4.7, 4.9, and 4.11, respectively, to the
Annual Report on Form 10-K of which this Exhibit 4.17 is a part, for the provisions that are important to you.
As used in this description of registered debt securities, the term “Issuer” refers to Thermo Fisher, the term “Fixed Rate Notes”
refers collectively to the 2024 Notes, the March 2025 Notes, the April 2025 Notes, the 2026 Notes, the March 2027 Notes, the April
2027 Notes, the March 2028 Notes, the September 2028 Notes, the 2029 Notes, the 2031 Notes, the 2032 Notes, the 2037 Notes, the
2039 Notes, and the 2049 Notes (each as hereinafter defined), and the term “indenture” means the 2009 Base Indenture as
supplemented by the applicable supplemental indenture for the particular series of Fixed Rate Notes being described.
General
We currently have the following series of senior notes issued and outstanding under an Indenture (the “2009 Base Indenture”), dated
as of November 20, 2009, by and between Thermo Fisher, as issuer, and The Bank of New York Mellon Trust Company, N.A. (the
“Trustee”), as trustee, as supplemented by the Eighth Supplemental Indenture (the “Eighth Supplemental Indenture”), dated as of
November 24, 2014, by and among Thermo Fisher, as issuer, the Trustee, as trustee, and The Bank of New York Mellon, London
Branch (“BNY London Branch”), as London paying agent: 2.000% Senior Notes due 2025 (the “April 2025 Notes”).
We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by
the Thirteenth Supplemental Indenture (the “Thirteenth Supplemental Indenture”), dated as of September 12, 2016, by and between
Thermo Fisher, as issuer, and the Trustee, as trustee: 0.750% Senior Notes due 2024 (the “2024 Notes”) and 1.375% Senior Notes
due 2028 (the “September 2028 Notes”).
We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by
the Fifteenth Supplemental Indenture (the “Fifteenth Supplemental Indenture”), dated as of March 16, 2017, by and between Thermo
Fisher, as issuer, and the Trustee, as trustee: 1.450% Senior Notes due 2027 (the “March 	2027 Notes”).
We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by
the Sixteenth Supplemental Indenture (the “Sixteenth Supplemental Indenture”), dated as of July 24, 2017, by and between Thermo
Fisher, as issuer, and the Trustee, as trustee: 1.400% Senior Notes due 2026 (the “2026 Notes”), 1.950% Senior Notes due 2029 (the
“2029 Notes”), and 2.875% Senior Notes due 2037 (the “2037 Notes”).
We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by
the Eighteenth Supplemental Indenture (the “Eighteenth Supplemental Indenture”), dated as of September 30, 2019, by and between
Thermo Fisher, as issuer, and the Trustee, as trustee: 0.125% Senior Notes due 2025 (the “March 2025 Notes”), 0.500% Senior
Notes due 2028 (the “March 2028 Notes”), 0.875% Senior
5

-- 98 of 180 --

Exhibit 4.17
Notes due 2031 (the “2031 Notes”), 1.500% Senior Notes due 2039 (the “2039 Notes”), and 1.875% Senior Notes due 2049 (the
“2049 Notes”).
We currently have the following series of senior notes issued and outstanding under the 2009 Base Indenture, as supplemented by
the Twenty-First Supplemental Indenture (the “Twenty-First Supplemental Indenture”), dated as of April 2, 2020, by and between
Thermo Fisher, as issuer, and the Trustee, as trustee: 1.750% Senior Notes due 2027 (the “April 2027 Notes”) and 2.375% Senior
Notes due 2032 (the “2032 Notes”).
The Fixed Rate Notes are general unsecured obligations of the Issuer. Each series of Fixed Rate Notes ranks equally in right of
payment with existing and any future unsecured indebtedness of Thermo Fisher, and is junior in right of payment to the Issuer’s
senior indebtedness (including senior debt securities). Each series of Fixed Rate Notes is also effectively subordinated to any
existing and future secured indebtedness of Thermo Fisher to the extent of the assets securing such indebtedness, and will be
structurally subordinated to all existing and any future indebtedness and any other liabilities of their respective subsidiaries. Each
series of Fixed Rate Notes is senior in right of payment to any of our existing and future indebtedness that is subordinated to such
Fixed Rate Notes.
Aside from the restrictions set forth under “Certain Covenants” below, neither the Fixed Rate Notes nor the indentures restrict our
ability or the ability of our subsidiaries to incur additional debt, repurchase securities, recapitalize, or pay dividends or make
distributions to shareholders, or require us to maintain interest coverage or other current ratios. We may from time to time, without
notice to or the consent of the holders of any series of Fixed Rate Notes, create and issue further notes of any such series ranking
equally with the Fixed Rate Notes of such series, and having the same terms as such series (or the same terms other than (1) the
payment of interest accruing prior to the issue date of such further notes or (2) the first payment of interest following the issue date
of such further notes). Such further notes may be consolidated and form a single series with the notes of such series and have the
same terms as to status, redemption, or otherwise as the notes of such series.
Maturity
Each series of Fixed Rate Notes will mature and bear interest as provided in the following table:
Series 	Maturity 	Interest Rate 	Interest Payment Dates 	Record Dates Aggregate Principal Amount
Issued/ Authorized/
Outstanding
2024 Notes 	September 12,
2024 0.750% 	Annually in arrears on
September 12 of each
year, commencing on
September 12, 2017
August 28 	€ 1,000,000,000
March 2025
Notes March 1, 2025 	0.125% 	Annually in arrears on
March 1 of each year,
commencing on March 1,
2020
Fifteenth calendar
day prior to the
applicable interest
payment date
€ 800,000,000
April 2025
Notes April 15, 2025 	2.000% 	Annually in arrears on
April 15 of each year,
commencing on April 15,
2015
April 1 	€ 640,000,000
6

-- 99 of 180 --

Exhibit 4.17
Series 	Maturity 	Interest Rate 	Interest Payment Dates 	Record Dates Aggregate Principal Amount
Issued/ Authorized/
Outstanding
2026 Notes 	January 23, 2026 	1.400% 	Annually in arrears on
January 23 of each year,
commencing on January
23, 2018
January 8 	€ 700,000,000
March 2027 Notes 	March 16, 2027 	1.450% 	Annually in arrears on
March 16 of each year,
commencing on March
16, 2018
March 1 	€ 500,000,000
April 2027 Notes 	April 15, 2027 	1.750% 	Annually in arrears on
April 15 of each year,
commencing on April
15, 2020
Fifteenth calendar
day prior to the
applicable interest
payment date
€ 600,000,000
March 2028 Notes 	March 1, 2028 	0.500% 	Annually in arrears on
March 1 of each year,
commencing on March
1, 2020
Fifteenth calendar
day prior to the
applicable interest
payment date
€ 800,000,000
September 2028
Notes September 12,
2028 1.375% 	Annually in arrears on
September 12 of each
year, commencing on
September 12, 2017
August 28 	€ 600,000,000
2029 Notes 	July 24, 2029 	1.950% 	Annually in arrears on
July 24 of each year,
commencing on July 24,
2018
July 9 	€ 700,000,000
2031 Notes 	October 1, 2031 	0.875% 	Annually in arrears on
October 1 of each year,
commencing on October
1, 2020
Fifteenth calendar
day prior to the
applicable interest
payment date
€ 900,000,000
2032 Notes 	April 15, 2032 	2.375% 	Annually in arrears on
April 15 of each year,
commencing on April
15, 2020
Fifteenth calendar
day prior to the
applicable interest
payment date
€ 600,000,000
2037 Notes 	July 24, 2037 	2.875% 	Annually in arrears on
July 24 of each year,
commencing on July 24,
2018
July 9 	€ 700,000,000
2039 Notes 	October 1, 2039 	1.500% 	Annually in arrears on
October 1 of each year,
commencing on October
1, 2020
Fifteenth calendar
day prior to the
applicable interest
payment date
€ 900,000,000
2049 Notes 	October 1, 2049 	1.875% 	Annually in arrears on
October 1 of each year,
commencing on October
1, 2020
Fifteenth calendar
day prior to the
applicable interest
payment date
€ 1,000,000,000
The Fixed Rate Notes are not subject to any sinking fund.
7

-- 100 of 180 --

Exhibit 4.17
Interest
The Fixed Rate Notes bear interest, which is paid annually in arrears, at the rates and from the respective dates set forth in the table
above.
Interest on an interest payment date is paid to the persons, or “holders” in whose names the Fixed Rate Notes are registered in the
security register on the immediately preceding record date noted in the table above, whether or not a business day, as the case may
be (each such date being a “regular record date”). Interest on the Fixed Rate Notes will be computed on the basis of an
ACTUAL/ACTUAL (ICMA) (as defined in the rulebook of the International Capital Markets Association) day count convention.
If any interest payment date, maturity date, or earlier date of redemption falls on a day that is not a business day, the required
payment on the Fixed Rate Notes shall be made on the next business day as if it were made on the date the payment was due and no
interest shall accrue on the amount so payable for the period from and after that interest payment date, that maturity date, or that date
of redemption, as the case may be, until the next business day.
For purposes of the Fixed Rate Notes, “business day” means any day, other than a Saturday or Sunday, (1) which is not a day on
which banking institutions in The City of New York or London are authorized or required by law, regulation, or executive order to
close and (2) on which the Trans-European Automated Real-Time Gross Settlement Express Transfer system (the TARGET2
system), or any successor thereto, is open.
Optional Redemption
We have the option to redeem the Fixed Rate Notes of any series, in whole at any time or in part from time to time, on at least 15
days but no more than 60 days prior written notice transmitted to the registered holders of the Fixed Rate Notes to be redeemed.
With respect to the March 2025 Notes, the April 2027 Notes, the March 2028 Notes, the 2031 Notes, the 2032 Notes, the 2039
Notes, and the 2049 Notes, any notice may, at our discretion, be subject to the satisfaction or waiver of one or more conditions
precedent. In such case, the notice shall state the nature of such condition precedent.
Prior to the applicable Par Call Date, upon redemption of the Fixed Rate Notes of any series, we will pay a redemption price equal to
the greater of:
(1) 	100% of the principal amount of the Fixed Rate Notes to be redeemed, and
(2) 	the sum of the present values of the Remaining Scheduled Payments (as defined below) of the Fixed Rate Notes to be
redeemed, discounted to the date of redemption on an annual basis (ACTUAL/ACTUAL (ICMA)) using a discount
rate equal to the Comparable Bond Rate (as defined below) plus 19 basis points in the case of the April 2025 Notes,
20 basis points in the case of the 2024 Notes, the March 2025 Notes, the 2026 Notes, the March 2027 Notes, and the
March 2028 Notes, 25 basis points in the case of the September 2028 Notes, the 2029 Notes, and the 2031 Notes, 30
basis points in the case of the 2037 Notes and the 2039 Notes, 35 basis points in the case of the 2049 Notes, 40 basis
points in the case of the April 2027 Notes, and 45 basis points in the case of the 2032 Notes,
plus, in each case, accrued and unpaid interest thereon, if any, to, but excluding, the redemption date.
8

-- 101 of 180 --

Exhibit 4.17
On and after the applicable Par Call Date, upon redemption of the Fixed Rate Notes of any series, we will pay a redemption price
equal to 100% of the principal amount of the Fixed Rate Notes to be redeemed, plus, in each case, accrued and unpaid interest
thereon, if any, to, but excluding, the redemption date.
Notwithstanding the foregoing, installments of interest on the Fixed Rate Notes that are due and payable on an interest payment date
falling on or prior to a redemption date will be payable on the interest payment date to the registered holders as of the close of
business on the relevant record date in accordance with the Fixed Rate Notes and the applicable indenture.
If less than all of the March 2025 Notes, the April 2027 Notes, the March 2028 Notes, the 2031 Notes, the 2032 Notes, the 2039
Notes, or the 2049 Notes are to be redeemed, the Fixed Rate Notes of such series to be redeemed, shall be selected, in the case of
global securities, in accordance with applicable depositary procedures and, in the case of definitive securities, in a manner the
Trustee deems to be fair and appropriate, unless otherwise required by law or applicable stock exchange requirements. If less than all
of the 2024 Notes, the April 2025 Notes, the 2026 Notes, the March 2027 Notes, the 2029 Notes, the September 2028 Notes, or the
2037 Notes are to be redeemed, the Fixed Rate Notes of such series to be redeemed shall be selected by the Trustee, in a manner that
it deems fair and appropriate in accordance with applicable depositary procedures, unless otherwise required by law or applicable
stock exchange requirements. Fixed Rate Notes may be redeemed in part in the minimum authorized denomination for Fixed Rate
Notes or in any integral multiple of such amount. Unless we default in payment of the redemption price, on and after the redemption
date, interest will cease to accrue on the Fixed Rate Notes or portions thereof called for redemption.
“Comparable Bond Rate” means, for any redemption date, the rate per annum equal to the annual equivalent yield to maturity or
interpolated yield to maturity (on a day count basis), computed as of the third business day immediately preceding that redemption
date, of the Comparable Government Issue, assuming a price for the Comparable Government Issue (expressed as a percentage of its
principal amount) equal to the Comparable Price for that redemption date.
“Comparable Government Issue” means the euro-denominated security issued by the German government selected by an
Independent Investment Banker (as defined below) as having an actual or interpolated maturity comparable to the remaining term of
the Fixed Rate Notes to be redeemed (assuming in the case of the 2024 Notes, the March 2025 Notes, the 2026 Notes, the March
2027 Notes, the April 2027 Notes, the March 2028 Notes, the September 2028 Notes, the 2029 Notes, the 2031 Notes, the 2032
Notes, the 2037 Notes, the 2039 Notes, or the 2049 Notes to be redeemed matured on their applicable Par Call Date) that would be
utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt
securities of comparable maturity to the remaining term of the Fixed Rate Notes to be redeemed.
“Comparable Price” means, with respect to any redemption date, (a) the average of the Reference Dealer Quotations (as defined
below) for such redemption date, after excluding the highest and lowest of the Reference Dealer Quotations, (b) if we obtain fewer
than four Reference Dealer Quotations, the arithmetic average of those quotations, or (c) if we obtain only one Reference Dealer
Quotation, such Reference Dealer Quotation.
“Independent Investment Banker” means
(a) 	with respect to the 2024 Notes, the April 2027 Notes, the September 2028 Notes, and the 2032 Notes, each Reference
Dealer appointed by us as Independent Investment Banker (initially, J.P. Morgan Securities plc);
9

-- 102 of 180 --

Exhibit 4.17
(b) 	with respect to the March 2025 Notes, the March 2028 Notes, the 2031 Notes, the 2039 Notes, and the 2049 Notes, any
Reference Dealer appointed by us as Independent Investment Banker (initially, Merrill Lynch International);
(c) 	with respect to the April 2025 Notes, each Reference Dealer appointed by us as Independent Investment Banker (initially,
HSBC Bank plc, Deutsche Bank AG, London Branch and The Royal Bank of Scotland plc);
(d) 	with respect to the 2026 Notes, the 2029 Notes, and the 2037 Notes, each Reference Dealer appointed by us as
Independent Investment Banker (initially, Goldman Sachs & Co. LLC); and
(e) 	with respect to the March 2027 Notes, each Reference Dealer appointed by us as Independent Investment Banker
(initially, HSBC Bank plc).
“Par Call Date” means June 12, 2024 in the case of the 2024 Notes; January 15, 2025 in the case of the April 2025 Notes; February
1, 2025 in the case of the March 2025 Notes; November 23, 2025 in the case of the 2026 Notes; December 16, 2026 in the case of
the March 2027 Notes; February 15, 2027 in the case of the April 2027 Notes; December 1, 2027 in the case of the March 2028
Notes; June 12, 2028 in the case of the September 2028 Notes; April 24, 2029 in the case of the 2029 Notes; July 1, 2031 in the case
of the 2031 Notes; January 15, 2032 in the case of the 2032 Notes; April 24, 2037 in the case of the 2037 Notes; April 1, 2039 in the
case of the 2039 Notes; and April 1, 2049, in the case of the 2049 Notes.
“Reference Dealer” means
(a) 	with respect to the 2024 Notes and the September 2028 Notes, each of (i) J.P. Morgan Securities plc, Barclays Bank PLC,
Mizuho International plc, and Morgan Stanley & Co. International plc and their respective affiliates or successors and (ii)
one other nationally recognized investment banking firm (or its respective affiliates) that is a broker or dealer of, and/or a
market maker in, German government bonds (each, for purposes of this clause “a”, a “Primary Bond Dealer”) that we
select in connection with the particular redemption, and their respective successors;
(b) 	with respect to the March 2025 Notes, the March 2028 Notes, the 2031 Notes, the 2039 Notes, and the 2049 Notes, each
of (i) Merrill Lynch International, Goldman Sachs & Co. LLC, Citigroup Global Markets Limited, and J.P. Morgan
Securities plc and their respective affiliates or successors and (ii) one other nationally recognized investment banking
firm (or its affiliate) that is a broker or dealer of, and/or market maker in, German government bonds (each, for purposes
of this clause “b”, a “Primary Bond Dealer”) that we select in connection with the particular redemption, and its
successors;
(c) 	with respect to the April 2025 Notes, each of (i) HSBC Bank plc, Deutsche Bank AG, London Branch and The Royal
Bank of Scotland plc, and their respective affiliates or successors and (ii) two other nationally recognized investment
banking firms (or their respective affiliates) that are brokers or dealers of, and/or market makers in, German government
bonds (each, for purposes of this clause “c”, a “Primary Bond Dealer”) that we select in connection with the particular
redemption, and their respective successors;
(d) 	With respect to the 2026 Notes, the 2029 Notes, and the 2037 Notes, each of (i) Goldman Sachs & Co. LLC, Merrill
Lynch International, Barclays Bank PLC, and HSBC Bank plc and their respective affiliates or successors and (ii) one
other nationally recognized investment banking firm (or its affiliate) that is a broker or dealer of, and/or a market maker
in, German government bonds (each, for purposes of this clause “d”, a “Primary Bond Dealer”) that we select in
connection with the particular redemption, and its successors;
10

-- 103 of 180 --

Exhibit 4.17
(e) 	With respect to the March 2027 Notes, each of (i) Credit Suisse Securities (Europe) Limited and HSBC Bank plc and
their respective affiliates or successors and (ii) three other nationally recognized investment banking firms (or their
respective affiliates) that are brokers or dealers of, and/or market makers in, German government bonds (each, for
purposes of this clause “e”, a “Primary Bond Dealer”) that we select in connection with the particular redemption, and
their respective successors; and
(f) 	With respect to the April 2027 Notes and the 2032 Notes, each of (i) J.P. Morgan Securities plc, Morgan Stanley & Co.
International plc, Merrill Lynch International, and Citigroup Global Markets Limited and their respective affiliates or
successors and (ii) one other nationally recognized investment banking firm (or its affiliate) that is a broker or dealer of,
and/or market maker in, German government bonds (each, for purposes of this clause “f”, a “Primary Bond Dealer”) that
we select in connection with the particular redemption, and its successors;
provided, 	in each case, that if at any time any of the above is not a Primary Bond Dealer, we will substitute that entity with
another nationally recognized investment banking firm that we select that is a Primary Bond Dealer.
“Reference Dealer Quotations” means, with respect to each Reference Dealer and any redemption date, the arithmetic average, as
determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Government Issue (expressed, in
each case, as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Dealer
at 11:00 a.m., London time, on the third business day preceding such redemption date.
“Remaining Scheduled Payments” means,
(a) 	with respect to each 2024 Note, March 2025 Note, 2026 Note, March 2027 Note, April 2027 Note, March 2028 Note,
September 2028 Note, 2029 Note, 2031 Note, 2032 Note, 2037 Note, 2039 Note, and 2049 Note to be redeemed, the
remaining scheduled payments of the principal thereof and interest thereon that would be due after the related redemption
date but for such redemption (assuming that such notes to be redeemed matured on their applicable Par Call Date); and
(b) 	with respect to each April 2025 Note to be redeemed, the remaining scheduled payments of the principal thereof and
interest thereon that would be due after the related redemption date for such redemption;
provided, however, that, if any such redemption date is not an interest payment date with respect to such note, the amount of
the next succeeding scheduled interest payment thereon will be reduced by the amount of interest accrued thereon to such
redemption date.
Redemption Upon Tax Event
We may redeem at our option any series of Fixed Rate Notes in whole, but not in part, on at least 15 days’ but not more than 60
days’ notice, at a redemption price equal to 100% of their principal amount (plus any accrued interest and additional amounts then
payable with respect to the Fixed Rate Notes to be redeemed), if we determine that (A) as a result of any change or amendment to
the laws, treaties, regulations or rulings of the United States or any political subdivision or taxing authority thereof, which change or
amendment is announced or becomes effective on or after the date of the applicable prospectus supplement pursuant to which the
Fixed Rate Notes of such series were issued, there is a material probability that we have or will become obligated to pay additional
amounts as described under “Payment of Additional Amounts” on any Fixed Rate Notes of such
11

-- 104 of 180 --

Exhibit 4.17
series or (B) on or after the date of the applicable prospectus supplement pursuant to which the Fixed Rate Notes of such series were
issued, any change in the official application, enforcement or interpretation of those laws, treaties, regulations or rulings, including a
holding by a court of competent jurisdiction in the United States or any other action, taken by any taxing authority or a court of
competent jurisdiction in the United States, whether or not such action was taken or made with respect to us, results in a material
probability that we have or will become obligated to pay additional amounts as described under “Payment of Additional Amounts”
on any Fixed Rate Notes of such series; 	provided 	that we determine, in our business judgment, that the obligation to pay such
additional amounts cannot be avoided by use of reasonable measures available to us, not including substitution of the obligor under
the Fixed Rate Notes. Prior to the mailing of any notice of such a redemption, we will deliver to the Trustee (1) an officer’s
certificate stating that we are entitled to effect such a redemption and setting forth a statement of facts showing that the conditions
precedent to the right of our company to so redeem have occurred and (2) an opinion of counsel to that effect based on that statement
of facts.
Payment of Additional Amounts
We will pay to a holder of Fixed Rate Notes who is not a United States person (as defined below) additional amounts as may be
necessary so that every net payment of the principal of and premium, if any, and interest on such holder’s Fixed Rate Notes, after
deduction or withholding for or on account of any present or future tax, assessment or other governmental charge imposed upon that
holder by the United States or any taxing authority thereof or therein, will not be less than the amount provided in such holder’s
Fixed Rate Notes to be then due and payable. We will not be required, however, to make any payment of additional amounts for or
on account of:
(a) 	any tax, assessment or other governmental charge that would not have been imposed but for (1) the existence of any
present or former connection (other than a connection arising solely from the ownership of those Fixed Rate Notes or the
receipt of payments in respect of those Fixed Rate Notes) between that holder (or the beneficial owner for whose benefit
such holder holds such Fixed Rate Notes), or between a fiduciary, settlor, beneficiary of, member or shareholder of, or
possessor of a power over, that holder or beneficial owner, if that holder or beneficial owner is an estate, trust, partnership
or corporation, and the United States, including that holder or beneficial owner, or that fiduciary, settlor, beneficiary,
member, shareholder or possessor, being or having been a citizen or resident or treated as a resident of the United States
or being or having been engaged in trade or business or present in the United States or having had a permanent
establishment in the United States or (2) the presentation of a debt security for payment on a date more than 30 days after
the later of the date on which that payment becomes due and payable and the date on which payment is duly provided for;
(b) 	any estate, inheritance, gift, sales, transfer, excise, personal property, wealth, capital gains, interest equalization or similar
tax, assessment or other governmental charge;
(c) 	any tax, assessment, or other governmental charge imposed on foreign personal holding company income or by reason of
a holder (or the beneficial owner for whose benefit such holder holds such Fixed Rate Notes), or a fiduciary, settlor,
beneficiary of, member or shareholder of, or possessor of a power over, the holder or beneficial owner, if that holder or
beneficial owner is an estate, trust, partnership, or corporation, being or having been a passive foreign investment
company, a controlled foreign corporation, a foreign tax exempt organization, or a personal holding company with
respect to the United States or a corporation that accumulates earnings to avoid U.S. federal income tax;
12

-- 105 of 180 --

Exhibit 4.17
(d) 	any tax, assessment or other governmental charge which is payable otherwise than by withholding from payment of
principal of or premium, if any, or interest on such holder’s Fixed Rate Notes;
(e) 	any tax, assessment, or other governmental charge required to be withheld by any paying agent from any payment of
principal of and premium, if any, or interest on any note if that payment can be made without withholding by any other
paying agent;
(f) 	any tax, assessment, or other governmental charge which would not have been imposed but for the failure of a holder (or
the beneficial owner for whose benefit such holder holds the Fixed Rate Notes), or a fiduciary, settlor, beneficiary of,
member or shareholder of, or possessor of power over, the holder or beneficial owner, if that holder or beneficial owner is
an estate, trust, partnership or corporation, or any intermediary through which a beneficial owner holds Fixed Rate Notes
to comply with our request to comply with certification, information, documentation or other reporting requirements
concerning the nationality, residence, identity, or connections with the United States of the beneficial owner or any holder
of the Fixed Rate Notes (including, but not limited to, the requirement to provide Internal Revenue Service Forms W-
8BEN, Forms W-8BEN-E, Forms W-8ECI, or any subsequent versions thereof or successor thereto, and including,
without limitation, any documentation requirement under an applicable income tax treaty);
(g) 	any tax, assessment, or other governmental charge imposed as a result of a holder (or the beneficial owner for whose
benefit such holder holds such Fixed Rate Notes), or a fiduciary, settlor, beneficiary of, member or shareholder of, or
possessor of a power over, the holder or beneficial owner, if that holder or beneficial owner is an estate, trust, partnership
or corporation, being or having been (1) a 10% shareholder (as defined in Section 871(h)(3)(B) of the U.S. Internal
Revenue Code of 1986, as amended (the “Code”), and the regulations that may be promulgated thereunder) of our
company or (2) a controlled foreign corporation that is related to us within the meaning of Section 864(d)(4) of the Code,
or (3) a bank receiving interest described in Section 881(c)(3)(A) of the Code;
(h) 	any tax, assessment, or other governmental charge that would not have been imposed but for a change in law, regulation,
or administrative or judicial interpretation that becomes effective more than 15 days after the payment becomes due or is
duly provided for, whichever occurs later;
(i) 	any taxes payable under Sections 1471 through 1474 of the Code (or any amended or successor version of such Sections),
any current or future regulations or other guidance thereunder, or any agreement (including any intergovernmental
agreement) entered into in connection therewith;
(j) 	any combination of items (a), (b), (c), (d), (e), (f), (g), (h), and (i); or
(k) 	with respect to the April 2025 Notes, any withholding or deduction that is imposed on a payment to an individual and is
required to be made pursuant to European Council Directive 2003/48/EC relating to the taxation of savings or any law
implementing or complying with, or introduced in order to conform to, such Directive (or any successor version that is
substantively comparable) or any combination of items (a), (b), (c), (d), (e), (f), (g), (h), (i), and this item (k);
nor will we pay any additional amounts to any holder that is not the sole beneficial owner of the Fixed Rate Notes, or a portion of the
Fixed Rate Notes, or that is a fiduciary, partnership, or limited liability company to the extent that a beneficial owner with respect to
the holder, a beneficiary, or settlor with respect to the fiduciary or a member of that partnership, limited liability company, or a
beneficial owner thereof would not have been entitled to the payment of those additional amounts had that beneficiary, settlor,
member, or beneficial owner received directly its beneficial or distributive share of the payment.
As used in the preceding paragraph, the term “United States person” means any individual who is a citizen or resident of the United
States for U.S. federal income tax purposes, a corporation, partnership, or other entity
13

-- 106 of 180 --

Exhibit 4.17
created or organized in or under the laws of the United States, any state of the United States, or the District of Columbia (other than
a partnership that is not treated as a United States person under any applicable Treasury Regulations), or any estate or trust the
income of which is subject to United States federal income taxation regardless of its source. As used under this heading “Payment of
Additional Amounts” and under the heading “Redemption Upon Tax Event”, the term “United States” means the United States of
America, the states of the United States, and the District of Columbia.
The Fixed Rate Notes are subject in all cases to any tax, fiscal, or other law or regulation or administrative or judicial interpretation
applicable to the Fixed Rate Notes. Except as specifically provided under this heading “Payment of Additional Amounts,” we will
not be required to make any payment for any tax, assessment, or other governmental charge imposed by any government or a
political subdivision or taxing authority of or in any government or political subdivision.
Repurchase Upon a Change of Control
If a Change of Control Triggering Event occurs with respect to any series of Fixed Rate Notes, unless the Issuer has redeemed such
series of Fixed Rate Notes in full, as described above, has defeased such series of Fixed Rate Notes, or has satisfied and discharged
such series of Fixed Rate Notes as described below, the Issuer will make an offer to each holder of the applicable series of Fixed
Rate Notes (the “Change of Control Offer”) to repurchase any and all of such holder’s Fixed Rate Notes of such series at a
repurchase price in cash equal to 101% of the aggregate principal amount of such Fixed Rate Notes (such principal amount to be
equal to €100,000 or an integral multiple of €1,000 in excess thereof), plus accrued and unpaid interest, if any, thereon, to, but
excluding, the date of repurchase (the “Change of Control Payment”). Within 30 days following any Change of Control Triggering
Event, notice shall be delivered to holders of Fixed Rate Notes of such series describing the transaction or transactions that constitute
the Change of Control Triggering Event and offering to repurchase such Fixed Rate Notes on the date specified in the notice, which
date will be no earlier than 15 days and no later than 60 days from the date such notice is delivered (the “Change of Control Payment
Date”), pursuant to the procedures required by the Fixed Rate Notes and described in such notice. Notwithstanding the foregoing,
installments of interest on any series of Fixed Rate Notes that are due and payable on interest payment dates falling on or prior to the
Change of Control Payment Date will be payable on such interest payment dates to the registered holders as of the close of business
on the relevant record dates in accordance with such series of Fixed Rate Notes and the applicable indenture. The Issuer must
comply in all material respects with the requirements of Rule 14e-1 under the Exchange Act, and any other securities laws and
regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Fixed Rate
Notes as a result of a Change of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations
conflict with the Change of Control repurchase provisions of the Fixed Rate Notes, the Issuer will be required to comply with the
applicable securities laws and regulations and will not be deemed to have breached its obligations under the Change of Control
repurchase provisions of the Fixed Rate Notes by virtue of such conflicts.
On the Change of Control Payment Date, the Issuer will be required, to the extent lawful, to:
• 	accept for payment all Fixed Rate Notes or portions of Fixed Rate Notes of the applicable series properly tendered pursuant
to the Change of Control Offer;
• 	deposit with the Trustee or a paying agent an amount equal to the Change of Control Payment in respect of all Fixed Rate
Notes or portions of Fixed Rate Notes of the applicable series properly tendered; and
14

-- 107 of 180 --

Exhibit 4.17
• 	deliver or cause to be delivered to the Trustee the Fixed Rate Notes properly accepted, together with an officer’s certificate
stating the principal amount of Fixed Rate Notes or portions of Fixed Rate Notes of such series being repurchased.
“Below Investment Grade Rating Event” means, with respect to a series of Fixed Rate Notes, such Fixed Rate Notes are downgraded
below Investment Grade Rating (as defined below) by any two of the Rating Agencies (as defined below) on any date during the
period (the “Trigger Period”) commencing 60 days prior to the first public announcement by Thermo Fisher of the occurrence of a
Change of Control (or pending Change of Control) and ending 60 days following consummation of such Change of Control (which
Trigger Period shall be extended so long as the rating of such Fixed Rate Notes is under publicly announced consideration for
possible downgrade by at least two of such Rating Agencies on such 60 	day, such extension to last with respect to each such Rating
Agency until the date on which such Rating Agency considering such possible downgrade either (x) rates such Fixed Rate Notes
below Investment Grade or (y) publicly announces that it is no longer considering such Fixed Rate Notes for possible downgrade,
provided 	that no such extension will occur if on such 60 	day such Fixed Rate Notes are rated Investment Grade by at least two of
such Rating Agencies in question and are not subject to review for possible downgrade by such Rating Agencies).
“Change of Control” means the occurrence of any of the following:
(1) 	the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one
or a series of related transactions, of all or substantially all of the properties or assets of Thermo Fisher and its
subsidiaries taken as a whole to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) other than
Thermo Fisher or one of its direct or indirect wholly-owned subsidiaries;
(2) 	the consummation of any transaction (including, without limitation, any merger or consolidation) as a result of which any
“person” (as that term is used in Section 13(d)(3) of the Exchange Act) becomes the “beneficial owner” (as defined in
Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of more than 50% of Thermo Fisher’s outstanding
voting stock or other voting stock into which Thermo Fisher’s voting stock is reclassified, consolidated, exchanged, or
changed, measured by voting power rather than number of shares;
(3) 	Thermo Fisher consolidates with, or merges with or into, any “person” or “group” (as that term is used in Section 13(d)
(3) of the Exchange Act), or any “person” or “group” consolidates with, or merges with or into, Thermo Fisher, in any
such event pursuant to a transaction in which any of Thermo Fisher’s voting stock or the voting stock of such other
person is converted into or exchanged for cash, securities, or other property, other than any such transaction where the
shares of Thermo Fisher’s voting stock outstanding immediately prior to such transaction constitute, or are converted into
or exchanged for, a majority of the voting stock of the surviving person or any direct or indirect parent company of the
surviving person immediately after giving effect to such transaction;
(4) 	with respect to the April 2025 Notes, the first day on which a majority of the members of Thermo Fisher’s board of
directors are not Continuing Directors (as defined below); or
(5) 	the adoption of a plan relating to Thermo Fisher’s liquidation or dissolution.
Notwithstanding the foregoing, a transaction will not be deemed to involve a Change of Control if (a) Thermo Fisher becomes a
direct or indirect wholly-owned subsidiary of a holding company (which shall include a parent company) and (b)(i) the holders of
the voting stock of such holding company immediately following that transaction are substantially the same as the holders of
Thermo Fisher’s voting stock immediately prior to that transaction or (ii) no “person” (as that term is used in Section 13(d)(3) of the
Exchange Act) (other than a
th
th
15

-- 108 of 180 --

Exhibit 4.17
holding company satisfying the requirements of this sentence) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5
under the Exchange Act), directly or indirectly, of more than 50% of the voting power of the voting stock of such holding company
immediately following such transaction.
For purposes of this definition, “voting stock” means with respect to any specified person (as that term is used in Section 13(d)(3) of
the Exchange Act) capital stock of any class or kind the holders of which are ordinarily, in the absence of contingencies, entitled to
vote for the election of directors (or persons performing similar functions) of such person, even if the right to vote has been
suspended by the happening of such a contingency.
The definition of Change of Control includes a phrase relating to the direct or indirect sale, lease, transfer, conveyance, or other
disposition of “all or substantially all” of the properties or assets of Thermo Fisher and its subsidiaries taken as a whole. Although
there is a limited body of case law interpreting the phrase “substantially all,” there is no precise established definition of the phrase
under applicable law. Accordingly, the applicability of the requirement that Thermo Fisher offer to repurchase the Fixed Rate Notes
as a result of a sale, lease, transfer, conveyance, or other disposition of less than all of the assets of Thermo Fisher and its
subsidiaries taken as a whole to another person or group may be uncertain.
“Change of Control Triggering Event” means, with respect to any series of Fixed Rate Notes, the occurrence of both a Change of
Control and a Below Investment Grade Rating Event.
“Continuing Directors” means, as of any date of determination, any member of the board of directors of Thermo Fisher who (1) was
a member of the board of directors of Thermo Fisher on the date of the issuance of the April 2025 Notes; or (2) was nominated for
election or elected to the board of directors of Thermo Fisher with the approval of a majority of the Continuing Directors who were
members of such board of directors of Thermo Fisher at the time of such nomination or election (either by specific vote or by
approval of Thermo Fisher’s proxy statement in which such member was named as a nominee for election as a director, without
objection to such nomination).
“Fitch” means Fitch Ratings Limited, and any successor to its rating agency business.
“Investment Grade Rating” means a rating by Moody’s equal to or higher than Baa3 (or the equivalent under a successor rating
category of Moody’s) or a rating by S&P equal to or higher than BBB- (or the equivalent under any successor rating category of
S&P) or a rating by Fitch equal to or higher than BBB- (or the equivalent under any successor rating category of Fitch).
“Moody’s” means Moody’s Investors Service, Inc., and any successor to its rating agency business.
“Rating Agencies” means (1) Moody’s, S&P and Fitch; and (2) if any of Moody’s, S&P or Fitch ceases to rate the applicable series
of Fixed Rate Notes or fails to make a rating of such Fixed Rate Notes publicly available for any reason, a “nationally recognized
statistical rating organization” within the meaning of Section 3(a)(62) of the Exchange Act, selected by Thermo Fisher (as certified
by a resolution of its board of directors) as a replacement agency for any of Moody’s, S&P or Fitch, or all of them, as the case may
be.
“S&P” means S&P Global Ratings, a division of S&P Global, Inc., and any successor to its rating agency business.
16

-- 109 of 180 --

Exhibit 4.17
Certain Covenants
Limitations on Liens. 	The Issuer will not, and will not permit any of its subsidiaries to, create, incur, assume, or otherwise cause to
become effective any Lien (as defined below) (other than permitted Liens) on any Principal Property (as defined below) or upon
shares of stock of any Principal Subsidiary (as defined below) (whether such Principal Property or shares are now existing or owned
or hereafter created or acquired), to secure any indebtedness of the Issuer, any of its subsidiaries or any indebtedness of any other
Person (as defined below), unless the Issuer or such subsidiary also secures all payments due under the Fixed Rate Notes and all
senior debt securities of any series having the benefit of this covenant (together with, if the Issuer shall so determine, any other
indebtedness of the Issuer or any subsidiary of the Issuer then existing or thereafter created ranking equally with the Fixed Rate
Notes), on an equal and ratable basis with such other indebtedness so secured (or, in the case of indebtedness subordinated to the
Fixed Rate Notes, prior or senior thereto, with the same relative priority as the Fixed Rate Notes will have with respect to such
subordinated indebtedness) for so long as such other indebtedness shall be so secured. The indentures contain the following
exceptions to the foregoing prohibition:
(a) 	Liens existing on the date when the Issuer first issued the applicable series of Fixed Rate Notes pursuant to the applicable
indenture;
(b) 	Liens on property owned or leased by a Person existing at the time such Person is merged with or into or consolidated
with the Issuer or any subsidiary of the Issuer or the Issuer or one or more of its subsidiaries acquires directly or
indirectly all or substantially all of the stock or assets of such Person; 	provided 	that such Liens were in existence prior to
the contemplation of such merger, consolidation or acquisition and do not extend to any assets other than those of the
Person merged into, consolidated with, or acquired by the Issuer or such subsidiary;
(c) 	Liens on property existing at the time of acquisition thereof by the Issuer or any subsidiary of the Issuer, 	provided 	that
such Liens were in existence prior to the contemplation of such acquisition and do not extend to any property other than
the property so acquired by the Issuer or such subsidiary;
(d) 	Liens to secure indebtedness incurred prior to, at the time of or within 18 months after the later of the acquisition of any
property and the completion of the construction, alteration, repair, or improvement of any property, as the case may be,
for the purpose of financing all or a part of the purchase price thereof or cost of the construction, alteration, repair, or
improvement thereof and Liens to the extent they secure indebtedness in excess of such purchase price or cost and for the
payment of which recourse may be had only against such property;
(e) 	Liens in favor of the United States or any state, territory, or possession thereof (or the District of Columbia), or any
department, agency, instrumentality, or political subdivision of the United States or any state, territory, or possession
thereof (or the District of Columbia), to secure partial, progress, advance or other payments pursuant to any contract or
statute or to secure any indebtedness incurred for the purpose of financing all or any part of the purchase price or the cost
of constructing or improving the property subject to such Liens;
(f) 	any Lien securing indebtedness of a subsidiary owing to the Issuer or to one or more of its subsidiaries;
(g) 	Liens incurred or assumed in connection with the issuance of revenue bonds the interest on which is exempt from federal
taxation pursuant to Section 103 of the Code;
(h) 	Liens created, incurred or assumed in connection with an industrial revenue bond, pollution control bond, or similar
financing between the Issuer or any subsidiary of the Issuer and any federal, state, or municipal government or other
government body or quasi-governmental agency;
17

-- 110 of 180 --

Exhibit 4.17
(i) 	any extension, renewal, or replacement (or successive extensions, renewals, or replacements) in whole or in part of any
Lien referred to in clauses (a) through (h) above, inclusive, so long as (1) the principal amount of the indebtedness
secured thereby does not exceed the principal amount of indebtedness so secured at the time of the extension, renewal, or
replacement (except that, where an additional principal amount of indebtedness is incurred to provide funds for the
completion of a specific project, the additional principal amount, and any related financing costs, may be secured by the
Lien as well) and (2) the Lien is limited to the same property subject to the Lien so extended, renewed or replaced (and
improvements on the property); and
(j) 	any Lien on a Principal Property or the shares of stock of a Principal Subsidiary that would not otherwise be permitted by
clauses (a) through (i) above, inclusive, securing indebtedness which, together with:
• 	the aggregate outstanding principal amount of all other indebtedness of the Issuer and its subsidiaries secured by
Liens on a Principal Property or the shares of stock of a Principal Subsidiary that is permitted solely pursuant to this
clause (j), and
• 	the aggregate Value (as defined below) of existing Sale and Leaseback Transactions (as defined below) that are
permitted solely pursuant to clause (c) of “Limitation on Sale and Leaseback Transactions” and are still in existence,
does not exceed 10% of Consolidated Net Assets (as defined below).
Limitation on Sale and Leaseback Transactions. 	The Issuer will not, and will not permit any of its subsidiaries to, enter into any Sale
and Leaseback Transaction with respect to any Principal Property unless:
(a) 	the Issuer or such subsidiary could incur indebtedness, in a principal amount at least equal to the Value of such Sale and
Leaseback Transaction, secured by a Lien on the Principal Property to be leased (without equally and ratably securing
debt securities of any series having the benefit of this covenant) pursuant to clauses (a) through (i) under “Limitations on
Liens” above;
(b) 	the Issuer applies, during the six months following the effective date of the Sale and Leaseback Transaction, an amount
equal to the Value of the Sale and Leaseback Transaction to either (or a combination of) the voluntary retirement of
Funded Debt (as defined below) or to the acquisition of property; or
(c) 	the aggregate Value of such Sale and Leaseback Transaction plus the Value of all other Sale and Leaseback Transactions
of Principal Properties entered into after the date of the issuance of the Fixed Rate Notes permitted solely by this clause
(c) and still in existence, plus the aggregate amount of all indebtedness secured by Liens permitted solely by clause (j) of
“Limitations on Liens” does not exceed 10% of Consolidated Net Assets.
Certain Other Covenants. 	The indentures contain certain other covenants regarding, among other matters, corporate existence and
reports to holders of Fixed Rate Notes. The Fixed Rate Notes do not contain any additional financial or restrictive covenants,
including covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions
to shareholders or current ratios. The provisions of the indentures do not afford holders of Fixed Rate Notes issued thereunder
protection in the event of a sudden or significant decline in the Issuer’s credit quality or in the event of a takeover, recapitalization or
highly leveraged or similar transaction involving the Issuer or any of its affiliates that may adversely affect such holders.
Consolidation, Merger and Sale of Assets. 	The Issuer will not consolidate with, merge with or into, or sell, convey, transfer, lease or
otherwise dispose of all or substantially all of its and its subsidiaries property and
18

-- 111 of 180 --

Exhibit 4.17
assets taken as a whole (in one transaction or a series of related transactions) to any Person, or permit any Person to merge with or
into the Issuer, unless:
• 	the Issuer shall be the continuing Person, or the Person (if other than the Issuer) formed by such consolidation or into which
the Issuer is merged or that acquired or leased such property and assets (the “Surviving Person”), shall be a Person organized
and validly existing under the laws of the United States of America or any jurisdiction thereof, or, subject to certain
conditions (including an obligation to pay additional amounts in respect of withholding taxes), a jurisdiction outside the
United States, and shall expressly assume, by a supplemental indenture, executed and delivered to the Trustee, all of the
Issuer’s obligations under each applicable indenture and the Fixed Rate Notes;
• 	immediately after giving effect to such transaction, no default or event of default (each as defined in each applicable
indenture) shall have occurred and be continuing; and
• 	the Issuer delivers to the Trustee an officer’s certificate and opinion of counsel, in each case stating that such consolidation,
merger, or transfer and such supplemental indenture complies with this provision and that all conditions precedent provided
for herein relating to such transaction have been complied with.
The Surviving Person will succeed to, and be substituted for, the Issuer under each applicable indenture and the Fixed Rate Notes
and, except in the case of a lease, the Issuer shall be released of all obligations under the indenture and the Fixed Rate Notes.
Definition of Certain Terms. 	The following are the meanings of terms that are important in understanding the covenants described
above with respect to the Fixed Rate Notes.
“Capital Lease Obligation” means, at the time any determination thereof is to be made, the amount of the liability in respect of a
capital lease that would at that time be required to be capitalized on a balance sheet in accordance with U.S. GAAP (as defined
below) as in effect on the date of the applicable indenture.
“Consolidated Net Assets” means the consolidated total assets of the Issuer and its subsidiaries as reflected in its most recent balance
sheet prepared in accordance with U.S. GAAP as in effect at the time of such determination, less (a) all current liabilities (excluding
any notes and loans payable, current maturities of long-term debt, the current portion of deferred revenue and obligations under
capital leases) and (b) acquisition-related intangible assets in accordance with U.S. GAAP in effect at the time of such determination.
Consolidated Net Assets includes goodwill of the Issuer and its subsidiaries.
“Funded Debt” means, as of any date of determination, the Issuer’s indebtedness or the indebtedness of a subsidiary maturing by its
terms more than one year after its creation and indebtedness classified as long-term debt under U.S. GAAP as in effect on the date of
the applicable indenture, and in each case ranking at least 	pari passu 	with the senior debt securities.
“indebtedness” means, with respect to any specified Person, any indebtedness of such Person, whether or not contingent:
(1) 	in respect of borrowed money;
(2) 	evidenced by bonds, notes, debentures, or similar instruments or letters of credit (or reimbursement agreements in respect
thereof); and
19

-- 112 of 180 --

Exhibit 4.17
(3) 	in respect of Capital Lease Obligations.
In addition, the term “indebtedness” includes (x) all indebtedness (as defined above) of others secured by a Lien on any asset of the
specified Person (whether or not such indebtedness is assumed by the specified Person), 	provided 	that the amount of such
indebtedness will be the lesser of (A) the fair market value of such asset at such date of determination and (B) the amount of such
indebtedness, and (y) to the extent not otherwise included, the guarantee by the specified Person of any indebtedness (as defined
above) of any other Person.
“Lien” means, with respect to any asset, any mortgage, lien, pledge, charge, security interest, or encumbrance of any kind in respect
of such asset, whether or not filed, recorded, or otherwise perfected under applicable law, including any conditional sale or other title
retention agreement.
“Original Issue Discount Security” means any debt security which provides for an amount less than the principal amount thereof to
be due and payable upon a declaration of acceleration of maturity thereof pursuant to the applicable indenture.
“Person” means any individual, corporation, partnership, limited liability company, joint venture, joint-stock company, association,
trust, unincorporated organization, or government or any agency or political subdivision of a government or governmental agency.
“Principal Property” means any single parcel of real property or any permanent improvement thereon (i) owned by the Issuer or any
of its subsidiaries located in the United States, including the Issuer’s principal corporate office, any manufacturing facility or plant,
or any portion thereof and (ii) having a book value, as of the date of determination, in excess of 3% the Issuer’s Consolidated Net
Assets, as calculated most recently prior to the applicable issue due of the applicable series of Fixed Rate Notes. Principal Property
does not include any property that the Issuer’s board of directors has determined not to be of material importance to the business
conducted by the Issuer and its subsidiaries, taken as a whole.
“Principal Subsidiary” means any direct or indirect subsidiary of the Issuer that owns a Principal Property.
“Sale and Leaseback Transaction” means any arrangement with any Person providing for the leasing by the Issuer or any subsidiary
of any Principal Property which has been or is to be sold or transferred by the Issuer or such subsidiary to such Person, excluding (1)
temporary leases for a term, including renewals at the option of the lessee, of not more than three years, (2) leases between the Issuer
and a subsidiary or between subsidiaries of the Issuer, (3) leases of a Principal Property executed by the time of, or within 12 months
after the latest of, the acquisition, the completion of construction or improvement, or the commencement of commercial operation of
the property, and (4) arrangements pursuant to any provision of law with an effect similar to the former Section 168(f)(8) of the
Internal Revenue Code of 1954, as amended.
“U.S. GAAP” means generally accepted accounting principles set forth in the FASB Accounting Standards Codification or in such
other statements by such other entity as have been approved by a significant segment of the accounting profession, which are in
effect from time to time.
“Value” means, with respect to a Sale and Leaseback Transaction, an amount equal to the net present value of the lease payments
(other than amounts required to be paid on account of property taxes, maintenance, repairs, insurance, water rates and other items
that do not constitute payments for property rights) with respect to the term of the lease remaining on the date as of which the
amount is being determined, without regard to any renewal or extension options contained in the lease, discounted at the weighted
average interest rate on the debt
20

-- 113 of 180 --

Exhibit 4.17
securities of all series (including the yield to maturity on any Original Issue Discount Securities) which are outstanding on the
effective date of such Sale and Leaseback Transaction.
Events of Default
Each indenture defines an Event of Default with respect to any series of Fixed Rate Notes issued pursuant to the applicable
indenture. Events of Default on the Fixed Rate Notes are any of the following:
• 	Default in the payment of the principal or any premium on Fixed Rate Notes when due (whether at maturity, upon
acceleration, redemption or otherwise);
• 	Default for 30 days in the payment of interest on Fixed Rate Notes when due;
• 	Failure to comply with the provisions described under the caption “—Repurchase Upon a Change of Control” with respect to
any series of Fixed Rate Notes.
• 	Failure by Thermo Fisher to observe or perform any other term of the applicable indenture for a period of 90 days after it
receives a notice of default stating that it is in breach. The notice must be sent by either the Trustee or holders of 25% of the
principal amount of the Fixed Rate Notes of the affected series;
• 	(1) Failure by Thermo Fisher to pay indebtedness for money it borrowed or guaranteed the payment of in an aggregate
principal amount of at least $100 million, in the case of the 2024 Notes, the April 2025 Notes, the 2026 Notes, the March
2027 Notes, the September 2028 Notes, the 2029 Notes, or the 2037 Notes, or $150 million, in the case of the March 2025
Notes, the April 2027 Notes, the March 2028 Notes, the 2031 Notes, the 2032 Notes, the 2039 Notes, or the 2049 Notes, at
the later of final maturity and the expiration of any related applicable grace period and such defaulted payment shall not have
been made, waived or extended within 30 days or (2) acceleration of the maturity of any indebtedness for money that the
Issuer borrowed or guaranteed the payment of in an aggregate principal amount of at least $100 million, in the case of the
2024 Notes, the April 2025 Notes, the 2026 Notes, the March 2027 Notes, the September 2028 Notes, the 2029 Notes, or the
2037 Notes, or $150 million, in the case of the March 2025 Notes, the April 2027 Notes, the March 2028 Notes, the 2031
Notes, the 2032 Notes, the 2039 Notes, or the 2049 Notes, if such indebtedness has not been discharged in full or such
acceleration has not been rescinded or annulled within 30 days; 	provided, however, that, if the default under the instrument is
cured by the Issuer, or waived by the holders of the indebtedness, in each case as permitted by the governing instrument, then
the Event of Default under the applicable indenture governing the Fixed Rate Notes caused by such default will be deemed
likewise to be cured or waived; and
• 	Certain events in bankruptcy, insolvency or reorganization with respect to Thermo Fisher.
Each indenture provides that the Trustee may withhold notice to the holders of any series of debt securities issued thereunder of any
default if the Trustee’s board of directors, executive committee, or a trust committee of directors or trustees and/or certain officers of
the Trustee in good faith determine it in the interest of such holders to do so.
Remedies if an Event of Default Occurs. 	Each indenture provides that if an Event of Default has occurred with respect to the
applicable series of Fixed Rate Notes and has not been cured, the Trustee or the holders of not less than 25% in principal amount of
the Fixed Rate Notes of that series then outstanding may declare the entire
21

-- 114 of 180 --

Exhibit 4.17
principal amount of all the Fixed Rate Notes of that series, and accrued interest, if any, to be due and immediately payable. This is
called a declaration of acceleration of maturity. If an Event of Default occurs because of certain events in bankruptcy, insolvency, or
reorganization with respect to the Issuer, the principal amount of all the Fixed Rate Notes will be automatically accelerated, without
any action by the Trustee or any holder. The holders of a majority in aggregate principal amount of the Fixed Rate Notes of the
affected series may by written notice to the Issuer and the Trustee, on behalf of the holders of the Fixed Rate Notes of the affected
series, rescind an acceleration or waive any existing Default or Event of Default and its consequences under the applicable indenture,
if the rescission would not conflict with any judgment or decree, except a continuing Default or Event of Default in the payment of
principal of, premium on, if any, or interest, if any, on, such Fixed Rate Notes.
Except as may otherwise be provided in the applicable indenture in cases of default, where the Trustee has some special duties, the
Trustee is not required to take any action under such indenture at the request of any holders unless the holders offer the Trustee
protection from expenses and liability (called an “indemnity”). If indemnity satisfactory to the Trustee is provided, the holders of a
majority in principal amount of the outstanding Fixed Rate Notes of the affected series may direct the time, method and place of
conducting any lawsuit or other formal legal action seeking any remedy available to the Trustee. Subject to certain exceptions
contained in the applicable indenture, these majority holders may also direct the Trustee in performing any other action under the
applicable indenture.
Before a holder of Fixed Rate Notes bypasses the Trustee and brings its own lawsuit or other formal legal action or takes other steps
to enforce its rights or protect its interests relating to the applicable series of Fixed Rate Notes, the following must occur:
• 	The holder must give the Trustee written notice that an Event of Default has occurred and remains uncured.
• 	The holders of 25% in principal amount of all outstanding Fixed Rate Notes of the affected series must make a written
request that the Trustee take action because of the Event of Default and must offer reasonable indemnity to the Trustee
against the cost and other liabilities of taking that action.
• 	The Trustee must have failed to take action for 60 days after receipt of the above notice and offer of indemnity and, during
such 60-day period, the Trustee has not received a contrary instruction from holders of a majority in principal amount of all
outstanding Fixed Rate Notes of such series.
However, a holder of Fixed Rate Notes is entitled at any time to bring a lawsuit for the payment of money due on its Fixed Rate
Notes on or after the due date of that payment.
The Issuer will furnish to the Trustee every year a written statement of one to two of its officers certifying that to their knowledge
the Issuer is in compliance with the applicable indenture and the Fixed Rate Notes, or else specifying any default.
Satisfaction and Discharge
The applicable indenture will cease to be of further effect with respect to a series of Fixed Rate Notes and the Trustee, upon the
Issuer’s demand and at its expense, will execute appropriate instruments acknowledging the satisfaction and discharge of the
applicable indenture upon compliance with certain conditions, including:
22

-- 115 of 180 --

Exhibit 4.17
• 	the Issuer having paid all sums payable by it under such indenture, as and when the same shall be due and payable;
• 	the Issuer having delivered to the Trustee for cancellation all Fixed Rate Notes theretofore authenticated under such
indenture;
• 	all Fixed Rate Notes of any series outstanding under such indenture not theretofore delivered to the Trustee for cancellation
shall have become due and payable or are by their terms to become due and payable within one year and the Issuer shall have
deposited with the Trustee sufficient cash or U.S. government or U.S. government agency notes or bonds that will generate
enough cash to pay, at maturity or upon redemption, all such Fixed Rate Notes of any series outstanding under such
indenture; or
• 	the Issuer having delivered to the Trustee an officer’s certificate and an opinion of counsel, each stating that these conditions
have been satisfied
Defeasance
Full Defeasance. 	The Issuer can legally release itself from any payment or other obligations on the Fixed Rate Notes of any series
(called “full defeasance”) if the following conditions are met:
• 	The Issuer deposits in trust for the benefit of holders of Fixed Rate Notes of the same series a combination of money and
U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal, any
premium and any other payments on the Fixed Rate Notes of that series on their various due dates.
• 	There is a change in current U.S. federal tax law or an Internal Revenue Service ruling that lets the Issuer make the above
deposit without causing holders of Fixed Rate Notes to be taxed on the Fixed Rate Notes any differently than if the Issuer did
not make the deposit and instead repaid the Fixed Rate Notes itself when due. Under current U.S. federal tax law, the deposit
and the Issuer’s legal release from the Fixed Rate Notes would be treated as though the Issuer took back a holder’s Fixed
Rate Notes and gave such holder its share of the cash and debt securities or bonds deposited in trust. In that event, a holder of
Fixed Rate Notes could recognize gain or loss on the Fixed Rate Notes it give back to the Issuer.
• 	The Issuer delivers to the Trustee a legal opinion of its counsel confirming the tax law change or ruling described above.
If the Issuer ever did accomplish full defeasance, as described above, a holder of Fixed Rate Notes would have to rely solely on the
trust deposit for repayment of the Fixed Rate Notes. Such holders could not look to the Issuer for repayment in the event of any
shortfall.
However, even if the Issuer makes the deposit in trust and opinion delivery arrangements discussed above, a number of its
obligations relating to the Fixed Rate Notes will remain. These include the Issuer’s obligations:
• 	to register the transfer and exchange of Fixed Rate Notes;
• 	to replace mutilated, destroyed, lost or stolen Fixed Rate Notes;
• 	to maintain paying agencies; and
• 	to hold money for payment in trust.
23

-- 116 of 180 --

Exhibit 4.17
Covenant Defeasance. 	Without any change of current U.S. federal tax law, the Issuer can make the same type of deposit described
above and be released from some of the covenants on the Fixed Rate Notes of any series. This is called “covenant defeasance.” In
that event, holders of Fixed Rate Notes would lose the protection of those covenants but would gain the protection of having money
and securities set aside in trust to repay the Fixed Rate Notes. In order to achieve covenant defeasance, the Issuer must do the
following:
• 	The Issuer must deposit in trust for the benefit of holders of Fixed Rate Notes of the same series a combination of money and
U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal, any
premium and any other payments on the Fixed Rate Notes of that series on their various due dates.
• 	The Issuer must deliver to the Trustee a legal opinion of its counsel confirming that under current U.S. federal income tax
law the Issuer may make the above deposit without causing holders of such series of Fixed Rate Notes to be taxed on the
Fixed Rate Notes any differently than if it did not make the deposit and instead repaid the Fixed Rate Notes itself when due.
If the Issuer accomplishes covenant defeasance, a holder of such Fixed Rate Notes can still look to it for repayment of the Fixed Rate
Notes if there were a shortfall in the trust deposit. In fact, if one of the Events of Default occurred (such as the Issuer’s bankruptcy)
and the Fixed Rate Notes become immediately due and payable, there may be such a shortfall. Depending on the event causing the
default, a holder of such Fixed Rate Notes may not be able to obtain payment of the shortfall.
Modification and Waiver
There are three types of changes the Issuer can make to the indentures and the Fixed Rate Notes.
Changes Requiring Approval of the Holder. 	First, there are changes that cannot be made to a series of Fixed Rate Notes without
specific approval of each holder of Fixed Rate Notes of such series. The following is a list of those types of changes:
• 	change the stated maturity of the principal or interest on Fixed Rate Notes of any series;
• 	reduce any amounts due on any Fixed Rate Notes of such series;
• 	reduce the amount of principal payable upon acceleration of the maturity of the Fixed Rate Notes following an Event of
Default;
• 	change the place or currency of payment for such series of Fixed Rate Notes;
• 	impair the holder’s right to sue for the enforcement of any payment on or with respect to the Fixed Rate Notes;
• 	reduce the percentage in principal amount of the Fixed Rate Notes, the approval of whose holders is needed to modify or
amend the applicable indenture or the Fixed Rate Notes;
• 	reduce the percentage in principal amount of the Fixed Rate Notes, the approval of whose holders is needed to waive
compliance with certain provisions of the applicable indenture or to waive certain defaults; and
• 	modify any other aspect of the provisions dealing with modification and waiver of the applicable indenture, except to
increase the percentage required for any modification or to provide that other provisions of such indenture may not be
modified or waived without consent of the holder of each Fixed Rate Note of such series affected by the modification.
24

-- 117 of 180 --

Exhibit 4.17
Changes Not Requiring Approval. 	The second type of change does not require any vote by holders of the Fixed Rate Notes. The
following is a list of those types of changes:
• 	cure any ambiguity, defect, or inconsistency;
• 	evidence the succession of another entity to the Issuer’s obligations under the indentures;
• 	provide for uncertificated Fixed Rate Notes in addition to or in place of certificated Fixed Rate Notes;
• 	add to the covenants for the benefit of holders of outstanding Fixed Rate Notes or to surrender any right or power the Issuer
has under the applicable indenture;
• 	add additional events of default;
• 	secure Fixed Rate Notes of any series;
• 	make any change that does not adversely affect the rights of any holder of Fixed Rate Notes in any material respect;
• 	issue additional Fixed Rate Notes of any series;
• 	evidence and provide for a successor Trustee and add to or change the provisions of an indenture to provide for or facilitate
the administration of the trusts under the applicable indenture; or
• 	comply with requirements of the SEC in order to effect or maintain the qualification of the applicable indenture under the
Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”).
Changes Requiring a Majority Vote. 	Any other change to an indenture and the Fixed Rate Notes would require the following
approval:
• 	If the change affects only Fixed Rate Notes of one series, it must be approved by the holders of a majority in principal
amount of the Fixed Rate Notes of that series.
• 	If the change affects a series of Fixed Rate Notes as well as the senior debt securities of one or more other series issued under
the indentures, it must be approved by the holders of a majority in principal amount of the Fixed Rate Notes of such series
and each other series of senior debt securities affected by the change.
• 	In each case, the required approval must be given by written consent.
The same vote would be required for the Issuer to obtain a waiver of a past default. However, the Issuer cannot obtain a waiver of a
payment default or a waiver with respect to any other aspect of the applicable indenture and the Fixed Rate Notes listed in the first
category described previously under “Changes Requiring Approval of the Holder” unless the Issuer obtains a holder’s individual
consent to the waiver.
Further Details Concerning Voting
Any series of Fixed Rate Notes will not be considered outstanding, and therefore not eligible to vote, if the Issuer has deposited or
set aside in trust for holders of such series of Fixed Rate Notes money for their payment or redemption. The Fixed Rate Notes of any
series will also not be eligible to vote if they have been fully defeased as described above under “Full Defeasance.”
The Issuer generally is entitled to set any day as a record date for the purpose of determining the holders of outstanding Fixed Rate
Notes that are entitled to vote or take other action under the applicable indenture. In certain limited circumstances, the Trustee is
entitled to set a record date for action by holders. If the Issuer or the Trustee sets a record date for a vote or other action to be taken
by holders of Fixed Rate Notes, that vote or action may be taken only by persons who are holders of outstanding Fixed Rate Notes
on the record date and must be taken within 180 days following the record date or another period that the Issuer may specify (or as
the
25

-- 118 of 180 --

Exhibit 4.17
Trustee may specify, if it set the record date). The Issuer may shorten or lengthen (but not beyond 180 days) this period from time to
time.
No Personal Liability of Incorporators, Stockholders, Officers, Directors
The indentures provide that no recourse shall be had under any obligation, covenant, or agreement of the Issuer in the indentures or
in any of the Fixed Rate Notes or because of the creation of any indebtedness represented thereby, against any of its incorporators,
stockholders, officers, or directors, past, present, or future, or of any predecessor or successor entity thereof under any law, statute,
or constitutional provision or by the enforcement of any assessment or by any legal or equitable proceeding or otherwise. Each
holder, by accepting the Fixed Rate Notes, waived and released all such liability.
Concerning the Trustee
The Bank of New York Mellon Trust Company, N.A. is the trustee under the indentures. The Bank of New York Mellon, London
Branch, has been appointed as paying agent with respect to the April 2025 Notes. The Trustee or its affiliates may from time to time
in the future provide banking and other services to the Issuer in the ordinary course of its business.
The indentures provide that, prior to the occurrence of an Event of Default with respect to the Fixed Rate Notes of a series and after
the curing or waiving of all such Events of Default with respect to that series, the Trustee will not be liable except for the
performance of such duties as are specifically set forth in the applicable indenture. If an Event of Default has occurred and has not
been cured or waived, the Trustee will exercise such rights and powers vested in it under the applicable indenture and will use the
same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of such
person’s own affairs.
The indentures and the provisions of the Trust Indenture Act incorporated by reference therein contain limitations on the rights of the
Trustee thereunder, should it become a creditor of the Issuer or any of its subsidiaries, to obtain payment of claims in certain cases or
to realize on certain property received by the Trustee in respect of any such claims, as security or otherwise. The Trustee is permitted
to engage in other transactions, 	provided 	that if it acquires any conflicting interest (as defined in the Trust Indenture Act), it must
eliminate such conflict or resign.
Unclaimed Funds
All funds deposited with the Trustee or any paying agent for the payment of principal, interest, premium, or additional amounts in
respect of Fixed Rate Notes that remain unclaimed for one year after the date upon which the principal of, premium, if any, or
interest on such Fixed Rate Notes shall have become due and payable will be repaid to the Issuer. Thereafter, any right of any holder
of Fixed Rate Notes to such funds shall be enforceable only against the Issuer, and the Trustee and paying agents will have no
liability therefor.
Book-Entry; Delivery and Form
The Fixed Rate Notes are issued in the form of one or more global notes in fully registered form, without coupons, and have been
deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and
in respect of interests held through, Euroclear Bank SA/NV (“Euroclear”) and Clearstream Banking, S.A. (“Clearstream”). Except
as described herein, certificates will not
26

-- 119 of 180 --

Exhibit 4.17
be issued in exchange for beneficial interests in the global notes. Except as set forth below, the global notes may be transferred, in
whole and not in part, only to Euroclear or Clearstream or their respective nominees.
Beneficial interests in the global notes are represented, and transfers of such beneficial interests are effected, through accounts of
financial institutions acting on behalf of beneficial owners as direct or indirect participants in Euroclear or Clearstream. Those
beneficial interests must be in denominations of €100,000 and integral multiples of €1,000 in excess thereof. Investors may hold
Fixed Rate Notes directly through Euroclear or Clearstream, if they are participants in such systems, or indirectly through
organizations that are participants in such systems.
For so long as the Fixed Rate Notes are represented by global notes deposited with, and registered in the name of a nominee for, a
common depositary for Euroclear and/or Clearstream, each person (other than Euroclear or Clearstream) who is for the time being
shown in the records of Euroclear or of Clearstream as the holder of a particular nominal amount of the Fixed Rate Notes (in which
regard any certificate or other document issued by Euroclear or Clearstream as to the nominal amount of the Fixed Rate Notes
standing to the account of any person shall be conclusive and binding for all purposes save in the case of manifest error) shall upon
their receipt of a certificate or other document be treated by Thermo Fisher and the Trustee as the holder of such nominal amount of
the Fixed Rate Notes and the registered holder of the global notes shall be deemed not to be the holder for all purposes other than
with respect to the payment of principal or interest on such nominal amount of the Fixed Rate Notes, for which purpose the
registered holder of the relevant global note shall be treated by Thermo Fisher and the Trustee as the holder of such nominal amount
of the Fixed Rate Notes in accordance with and subject to the terms of the global notes and the expressions “noteholder” and “holder
of notes” and related expressions shall be construed accordingly.
Certificated Notes
If the depositary for any of the securities represented by a global security is at any time unwilling or unable to continue as depositary
or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency
under the Exchange Act is not appointed by us within 90 days, we will issue securities in definitive form in exchange for the global
security that had been held by the depositary. Any securities issued in definitive form in exchange for a global security will be
registered in the name or names that the depositary gives to the Trustee or other relevant agent of ours or theirs. It is expected that
the depositary’s instructions will be based upon directions received by the depositary from participants with respect to ownership of
beneficial interests in the global security that had been held by the depositary.
Governing Law
The indentures and the Fixed Rate Notes are governed by, and construed in accordance with, the laws of the State of New York.

-- 120 of 180 --

Exhibit 10.5
SUMMARY OF 2021 ANNUAL CASH INCENTIVE PLAN
In February 2021, the Compensation Committee of the Board of Directors (the "Compensation Committee") of Thermo
Fisher Scientific Inc. (the "Company") established a target cash bonus amount for 2021 for each of the Company’s executive
officers, as well as performance metrics and goals for the Company under the Company’s annual cash incentive program. The target
cash bonus amount for each executive, which is expressed as a percentage of base salary (ranging from 80% to 200%), was
determined by the Compensation Committee based on the salary level and position of such executive within the Company. The total
target opportunity under the annual cash incentive plan for 2021 is 0-200% of target cash bonus (other than in exceptional
circumstances).
The performance metrics and goals for the annual cash incentive plan for 2021 are based on (a) (70%) financial measures for
the Company, comprised of (i) growth in revenue (adjusted for the impact of acquisitions and divestitures and for foreign currency
changes) (35%), (ii) net income (adjusted for restructuring charges and certain other items of income or expense) (30%) and (iii)
operating cash flow (adjusted for capital expenditures) (5%) and (b) (30%) non-financial measures of such executives’ contributions
to the achievement of certain business objectives of the Company.
For each of the financial measures included in the Company’s annual incentive plan, the Company’s actual performance will
be measured relative to the Company’s internal operating plan for 2021, and the Compensation Committee will have the option of
considering the impact of macro-economic factors, including foreign exchange. In exceptional circumstances, the Committee has the
discretion to fund at a higher level than 200%.
27

-- 121 of 180 --

Exhibit 10.49
CONSULTING AGREEMENT
THIS AGREEMENT, made this 24th day of February, 2022, by and between Thermo Fisher Scientific Inc. (“Company”),
with its principal place of business located at 168 Third Avenue, Waltham, MA 02451, and Mark Stevenson (“Consultant”), with his
principal place of business at an address on file with the Company (collectively referred to as “the Parties”).
The Parties agree as follows:
1. 	CONSULTING PERIOD
The term of this Agreement shall commence on March 19, 2022, and shall continue until March 1, 2023, unless
terminated earlier or extended by mutual agreement as provided below (the “Consulting Period”).
2. 	CONSULTING SERVICES
Company engages Consultant to perform, and Consultant shall perform, the following advisory and consulting
services: (1) serve as a member of 	the Company’s Scientific Advisory Board during the Consulting Period, (2)
consulting on Covid-19 testing including assisting externally as needed, and (3) other duties and responsibilities as
mutually defined by the Parties. 	Consultant agrees to devote a sufficient number of hours per week in order to
complete the assignments given by Company in a timely manner.
3. 	CONSIDERATION
In full consideration of the services performed by Consultant under this Agreement and for the
noncompetition provision outlined in Section 7 and Schedule B to this Agreement, and for so long as Consultant
provides the Consulting Services to the Company pursuant to this Agreement, any and all outstanding and unvested
equity awards granted to Consultant by the Company will continue to vest and be exercisable in accordance with the
applicable equity plans and award agreements; provided, however, that if Consultant continues to provide the
Consulting Services through March 1, 2023, Consultant shall for purposes of the equity awards identified on
Schedule A hereto be vested in such awards on March 1, 2023 to the same extent as if Consultant had “retired” from
the Company (as provided in such awards) on March 1, 2023 and shall, in the case of the Nonstatutory Stock Option
Award, be eligible to exercise such award through its “Final Exercise Date”. For avoidance of doubt, if this
Agreement is terminated for any reason 	prior to March 1, 2023, (i) Consultant will, as of such termination date, no
longer enjoy continued vesting in any outstanding equity award or the special vesting and other rights under the
awards identified on Schedule, (ii) all unvested equity awards as of the termination date shall be forfeited,
and (iii) vested equity awards shall be exercisable or paid in accordance

-- 122 of 180 --

with the terms of the original award agreement. Consultant specifically acknowledges and agrees that such
continuation of vesting is fair, reasonable, and mutually agreed-upon consideration for the services outlined in
Section 2 and for agreeing to the non-competition restriction in Section 7 below and Schedule B to this Agreement.
4. 	REIMBURSEMENT OF CONSULTANT EXPENSES
Company shall reimburse Consultant for all expenses reasonably incurred by Consultant on behalf of
Company to the extent that same have been duly authorized in advance by Company. 	Expenses will be reimbursed
within thirty (30) days after submission to Company.
5. 	INDEPENDENT CONTRACTOR STATUS
Consultant shall perform all services under this Agreement as an “independent contractor” and not as an
employee or agent of the Company. 	The Consultant is not authorized to assume or create any obligation or
responsibility, express or implied, on behalf of, or in the name of, the Company or to bind the Company in any
manner. 	Consultant shall not be entitled to any benefits, coverages or privileges, including, without limitation,
workers compensation, social security, unemployment, medical or pension payments, made available to employees of
the Company with respect to the services performed under this Agreement.
6. 	TAX REPORTING AND FILING; 409A COMPLIANCE
Company will report and withhold on the amount it pays Consultant in accordance with applicable Internal
Revenue Code provisions and/or state or local law. 	Consultant acknowledges and agrees to file all tax returns, tax
declarations, and tax schedules and to pay all taxes required, when due, with respect to any and all compensation
earned by Consultant under this Agreement.
Compensation earned by Consultant under this Agreement is intended to either be exempt from or comply
with the requirements of Internal Revenue Code Section 409A (“Section 409A”), 	and Company shall interpret and
administer such payments and benefits in accordance with this intention. 	Each payment subject to Section 409A made
to Consultant shall be considered a separate payment on a fixed payment date and not one of series of payments for
purposes of Section 409A. 	Consultant shall not have the right to designate the taxable year of payment.
2

-- 123 of 180 --

7. 	PERFORMING SERVICES FOR OTHERS; NO CONFLICTING WORK
Company agrees that Consultant may perform services for others, so long as the performance of these services
does not interfere with the performance of the Services to be provided pursuant to this Agreement. 	Notwithstanding
the foregoing, Consultant agrees that at all times during the Consulting Period, and for a 12-month period
commencing on the termination of this Agreement, Consultant shall refrain from, alone as a consultant, or as a
partner, member, employee or agent of any partnership, or as an officer, employee, agent, director, stockholder or
investor of any corporation, or in any other individual or representative capacity, directly or indirectly (through an
affiliate or otherwise) working for or providing consulting or any other services to, or permitting the use of
Consultant’s name by, any business, person or activity, which is or which becomes during the Consulting Period,
directly or indirectly, competitive with Company’s business as conducted or proposed to be conducted. If any
restriction set forth in this paragraph is found by the applicable judicial authority of competent jurisdiction to be
unenforceable because it extends for too long a period of time or over too great a range of activities or over too broad
a geographic area, the parties agree it shall be interpreted to extend over a maximum period of time, range of
activities or geographic area as to which it may be enforceable.
8. 	NON-SOLICITATION OF COMPANY EMPLOYEES AND CUSTOMERS
Consultant shall not, directly or indirectly, during the Consulting Period, and for a 18-month period commencing
on the termination of this Agreement, solicit, interfere with, or induce any person, who is or was an employee or
consultant of Company, to (i) discontinue his, her or its relationship with Company, or (ii) accept employment by, or
enter into a business relationship with Consultant, or any other entity or person unless Company has approved of such
business or employment relationship beforehand in writing. 	Additionally, Consultant shall not, directly or indirectly,
during the Consulting Period, and for a 18-month period commencing on the termination of this Agreement solicit,
aid in or encourage the solicitation of, contract with, aid in or encourage the contracting with, service, or contact any
person or entity which is or was, a customer or client of Company, for purposes of marketing, offering or selling a
product or service competitive with Company. 	Consultant acknowledges that this paragraph is reasonable and
necessary for the protection of the business of Company and its affiliates, and that part of the compensation paid
under this Agreement is in consideration for the provisions contained in this paragraph. 	If any restriction set forth in
this paragraph is found by the applicable judicial authority of competent jurisdiction to be unenforceable because it
extends for too long a period of time or over too great a range of activities or over too broad a geographic area, the
parties agree it shall be interpreted to extend over a maximum period of time, range of activities or geographic area as
to which it may be enforceable.
3

-- 124 of 180 --

9. 	CONFIDENTIAL DATA
Consultant agrees to keep secret and retain in the strictest confidence all Confidential Information of
Company and its affiliates, and not to disclose any such Confidential Information to anyone outside of Company
unless authorized by Company on a “need to know” basis, or except as may be required in the good faith performance
of the Services, or as may be required by law. 	Consultant further agrees to take all other reasonable precautions to
prevent any unauthorized disclosure of such Confidential Information. 	For purposes of this Agreement,
“Confidential Information” means any proprietary information including, without limitation, all information in
whatever form provided relating to the past, present or future business affairs of Company or its affiliates, or another
party whose information Company has in its possession under obligation of confidentiality, which is disclosed by
Company or its affiliates to Consultant, or which Consultant learns from inspection of drawings, parts or equipment
including, without limitation, trade secrets, computer programs, computer code graphics, algorithms, engineering,
product and service planning, client or customer lists, hardware configuration information, and information, research,
and development, business plans, pricing and fee policies, information relating to operations, systems, security,
merchandising, marketing, affiliate relations, products and product development, financial and personnel data, and
specialized knowledge, data or property concerning any idea, invention, discovery, process, program, services or
products provided, used, developed, investigated, manufactured or considered by Company or its affiliates during the
Consulting Period, whether commercial, experimental or patented, patentable or not. 	Consultant also agrees that all
such Confidential Information, as well as all records, files and other memoranda made or kept by Consultant in
connection with the Services, shall be the exclusive property of Company. 	Upon termination of this Agreement, for
whatever reason, Consultant will promptly deliver to Company all materials, notebooks, records, data, lists,
information, memoranda, documents (including all copies) and all other property belonging to Company or
containing Confidential Information, including, among other things, Confidential Information which relates to the
Services, including Confidential Information that was created or obtained by Consultant while performing the
Services or by virtue of Consultant’s relationship with Company. 	Under the Defend Trade Secrets Act of 2016
(“DTSA”), Consultant shall not be held criminally or civilly liable under any federal or state trade secret law for the
disclosure of a trade secret that: 	(a) is made (i) in confidence to a federal, state, or local government official, either
directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected
violation of law; or (b) is made to Consultant’s attorney in relation to a retaliation lawsuit brought by Consultant for
reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other
proceeding, if such filing is made under seal.
4

-- 125 of 180 --

10. 	INVENTIONS
All inventions, ideas, data, technology, devices, software in whatever form, processes, innovations and
improvements, whether or not patentable and whether or not copyrightable, hereafter made, conceived, reduced to
practice, created, written, designed or developed by the Consultant solely or jointly with others during the Consulting
Period (or thereafter if resulting or directly derived from Proprietary Information, as defined below) and which relate
in any manner to the business of the Company, or to its actual or planned research or development, or are suggested
or result from any task assigned to the Consultant under this Agreement or work performed by the Consultant for or
on behalf of the Company, shall be the sole property of the Company (collectively, “Inventions”). 	The Consultant
hereby assigns to the Company all Inventions and any and all related patent, copyrights, trademarks, trade names and
other intellectual property rights and applications therefor, in the United States and elsewhere, and appoints any
officer of the Company as his duly authorized attorney to execute, file, prosecute and protect the same before any
government agency, court or authority. 	Upon the request of the Company, and without further compensation except
as expressly provided below, the Consultant shall execute such further assignments, documents and other instruments
as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the
Company in applying for, obtaining and enforcing patents, copyrights or other rights in the United States and in any
foreign country with respect to any Invention. 	The Consultant shall promptly disclose to the Company all Inventions
and the Consultant further agrees that all papers and records of every kind relating to any Inventions which shall at
any time come into the Consultant's possession shall be the sole and exclusive property of the Company and shall be
surrendered to the Company upon the termination of the Consulting Period or upon request at any other time either
during or after the termination of the Consulting Period. 	The Consultant agrees that the obligations and undertakings
stated in this Section shall continue beyond the termination of the Consulting Period.
11. 	CONFLICTING OBLIGATIONS
Consultant certifies that Consultant has no outstanding agreement or obligation that is in conflict with any of
the provisions of this Agreement or that would preclude Consultant from complying with the provisions of this
Agreement. 	Consultant will not enter into any such conflicting agreement during the term of this Agreement.
Consultant’s violation of this paragraph will be considered a material breach of this Agreement.
12. 	NOTICES
All notices required or permitted under this Agreement shall be in writing and shall be addressed to the other
party at the address first above shown. 	All
5

-- 126 of 180 --

notices shall be sent by registered or certified mail, return receipt requested, or by Federal Express or other
comparable courier providing proof of delivery, and shall be deemed duly given and received (i) if mailed, on the
third business day following the mailing thereof, or (ii) if sent by courier, the date of its receipt (or, if such day is not
a business day, the next succeeding business day).
13. 	EARLY TERMINATION
Notwithstanding anything to the contrary in this Agreement, the Consulting Period shall terminate
automatically and immediately upon the occurrence of any one of the following events: (i) the death of Consultant;
(ii) the breach of any material term of this Agreement; or (iii) the termination of this Agreement by either Party for
any reason or no reason upon 30 days written notice to the other Party. 	Any such termination shall not, however,
affect or otherwise modify the obligation of Company to pay accrued sums owed to the Consultant pursuant to the
terms of this Agreement. 	Termination of this Agreement for any reason shall not affect Consultant’s continuing
obligations under Sections 7, 8, 9, and 10, except that the non-competition restrictions in Section 7 shall not be
applicable in the event the Consulting Period is ended by the Company without cause.
14. 	ASSIGNMENT
Should Company at any time be merged or consolidated into or with any other entity, or if substantially all of
the assets of Company are transferred to another entity, this Agreement may be assigned to such entity. 	Consultant
shall not assign any rights under this Agreement to any other person or entity.
15. 	INDEMNIFICATION
Company agrees to indemnify, hold harmless and defend Consultant from any liability or financial loss
(including, without limitation, attorneys’ fees and costs) arising from its intentional, reckless, negligent or otherwise
wrongful acts, errors or omissions in the performance of this Agreement. 	Consultant agrees to indemnify, hold
harmless and defend Company and its related and affiliated entities from any liability or financial loss (including,
without limitation, attorneys’ fees and costs) arising from intentional, reckless, negligent or otherwise wrongful acts,
errors or omissions committed by Consultant or Consultant's assistants in the performance of this Agreement by
Consultant or Consultant’s assistants.
6

-- 127 of 180 --

16. 	INTEGRATION
This Agreement is intended to be the final, complete and exhaustive statement of the terms of Consultant’s
engagement by Company. 	This Agreement supercedes all prior and contemporaneous agreements and statements,
whether written or oral, express or implied, pertaining in any manner to the engagement of Consultant and it may not
be contradicted by evidence of any prior or contemporaneous statements or agreements. 	To the extent that practices,
policies, or procedures of Company, now or in the future, apply to Consultant and are inconsistent with the terms of
this Agreement, the provisions of this Agreement shall prevail. 	Notwithstanding the foregoing, nothing in this
Agreement changes or alters Consultant’s continuing legal obligations (including but not limited to Consultant’s
Noncompetition Agreement with the Company) incurred while Consultant was employed by the Company.
17. 	SEVERABILITY
If a Court or Arbitrator holds any provision of this Agreement to be invalid, unenforceable or void, the
remainder of this Agreement, shall remain in full force and effect.
18. 	GOVERNING LAW
This 	Agreement 	shall 	be 	construed, 	interpreted 	and 	enforced 	in 	accordance 	with 	the 	laws 	of 	the
Commonwealth of Massachusetts without reference to its choice of law provisions. 	Each party hereby irrevocably
consents to the exclusive jurisdiction of the state and federal courts located in Suffolk County, MA, in any action
arising out of or relating to this Agreement and waives any other venue to which it may be entitled by domicile or
otherwise (but without prejudice to rights of action and enforcement which may arise in the courts of England &
Wales under the Restrictive Covenant Agreement appended as Schedule B to this Agreement, which are expressly
reserved). 	In the event of any legal proceeding between the Company and Consultant relating to this Agreement,
neither party may claim the right to a trial by jury, and both parties waive any right they may have under applicable
law or otherwise to a right to a trial by jury.
19. 	ADVICE OF COUNSEL
Consultant acknowledges that, in executing this Agreement, Consultant has had the opportunity to seek the advice
of independent legal counsel, and has 	read and understood all of the terms and provisions of this Agreement. 	This
Agreement shall not be construed against any party by reason of the drafting or preparation hereof.
7

-- 128 of 180 --

20. 	NOTICE
Consultant acknowledges that he was provided this Agreement ten (10) business days before commencement
of the consultancy relationship with the Company.
IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the above date.
THERMO FISHER SCIENTIFIC INC.
/s/ Lisa Britt
CONSULTANT
/s/ Mark Stevenson
Lisa Britt 	Mark Stevenson
SVP, Chief Human Resources Officer
8

-- 129 of 180 --

Schedule A
Grant Type 	Grant Date 	Grant Expiration
Date Grant Price 	Amount
Granted
Unvested Amount
Stock Options 	02/23/2021 	02/23/2028 	$458.81 	17,875 	13,407
RSUs 	02/23/2021 	N/A 	N/A 	4,000 	3,400
PRSUs 	02/23/2021 	N/A 	N/A 	4,000 	2,667
Total: 25,875 	Total: 19,474
Non-Statutory Stock Option Agreement dated February 23, 2021 between Company and Mark Stevenson. 	If the vesting conditions of the Non-Statutory Stock Option Agreement and the
Consulting Agreement are satisfied, the remaining unvested option shall vest as follows: 	4,469 Stock Options – February 23, 2023; 8,938 Stock Options – March 1, 2023
Restricted Stock Unit Agreement dated February 23, 2021 between Company and Mark Stevenson. 	If the vesting conditions of the Restricted Stock Unit Agreement and the Consulting
Agreement are satisfied, the remaining outstanding RSUs shall be settled as follows: 1,000 RSUs – August 23, 2022; 2,400 RSUs – March 1, 2023. 	Shares shall be delivered within 5 business
days of the settlement date.
Performance Restricted Stock Unit Agreement 	dated February 23, 2021 between Company and Mark Stevenson. 	If the vesting conditions of the Performance Restricted Stock Unit Agreement
and the Consulting Agreement are satisfied, the shares that become issuable pursuant to a PRSU based on the provisions of Schedule A of the Performance Restricted Stock Unit Agreement , to
the extent not previously delivered, shall be delivered within the sixty (60) day period following the date such PRSUs would have vested had the Consultant remained employed with the
Company.
1
2
3
1
2
3

-- 130 of 180 --

Schedule B
Restrictive Covenant Agreement
This Agreement 	is made on 	February 24, 2022
Between
(1) 	LIFE TECHNOLOGIES LIMITED 	(Registered Company Number SC083107), whose registered address is 3 Fountain Drive, Inchinnan
Business Park, Paisley PA4 9RF (hereinafter referred to as “the Company”) part of the Thermo Fisher Scientific group of companies; 	and
(2) 	MARK STEVENSON, 	currently residing at an address on file with the Company (“Consultant”).
Whereas
(A) 	The Consultant has been engaged by the Company’s parent company, Thermo Fisher Scientific Inc., to provide certain consultancy
services for valuable consideration in accordance with a Consulting Agreement dated February 24, 2022 (“Consulting Agreement”) and the
Consultant has agreed to enter into this supplementary Restrictive Covenant Agreement (“RC Agreement”) as Schedule B to and a
condition of the terms of the Consulting Agreement; and
(B) 	Prior to his retirement from Thermo Fisher Scientific Inc., the Consultant was employed as the Executive Vice President and Chief
Operating Officer for the Group, a role which had global responsibility across the Company and in which role the Consultant had deep
insight to and/or leadership responsibility for key Confidential Information, strategic decisions, objectives and commercial relationships
across the Group’s business; and
(C) 	The Consultant will continue to have access to key Confidential Information in the performance of the services under the Consulting
Agreement; and
(D) 	The Parties have agreed that the restrictions contained in this RC Agreement are necessary to secure the legitimate business interests of
Thermo Fisher Scientific Inc. and the Group;
It is agreed
1 	Definitions and interpretation
1.1 	In this RC Agreement unless the context otherwise requires the following expressions have the following meanings:
Confidential Information 	has the same meaning as in the Consulting Agreement
General Counsel 	means the Senior Vice President & General Counsel of the Group
Group 	means the Company and the Group Companies
Group Company 	means any company which is for the time being a subsidiary or holding company of the Group and any subsidiary of any
such holding company (including, for the

-- 131 of 180 --

avoidance of doubt and without limitation, Thermo Fisher Scientific Inc., whose registered office is at 168 Third Avenue, Waltham,
Massachusetts 02451, USA, and any company which is for the time being a subsidiary or holding company of Thermo Fisher Scientific Inc.),
and for the purposes of this RC Agreement the terms subsidiary and holding company shall have the meanings ascribed to them by section
1159 Companies Act 2006 or in any subordinate legislation made under the Companies Act 2006 (and Group Companies shall be
interpreted accordingly)
Restricted Businesses 	shall mean the business and activities of Thermo Fisher Scientific Inc. and its Group Companies
Restricted Territory 	shall mean the United States of America, the United Kingdom, Switzerland, and all other countries in the European
Economic Area and the rest of the World that the Consultant has had oversight or responsibility for in his role in the 24 months immediately
preceding the Termination Date
Termination Date 	means the date of the termination of the Consulting Agreement
1.2 	Any reference in this RC Agreement to a statutory provision shall be deemed to include a reference to any statutory amendment,
modification or re-enactment of it.
1.3 	The headings to the clauses are for convenience only and shall not affect the construction or interpretation of this RC Agreement.
2 	Restrictive covenants
2.1 	The Consultant covenants that he will not (without the previous consent in writing of the General Counsel) whether as principal or agent,
and whether alone or jointly with, or as a director, manager, partner, shareholder, employee or consultant of any other person, directly or
indirectly either during the term of the Consulting Agreement or:
(a) 	for the period of 12 months immediately after the Termination Date carry on, or be engaged, concerned or interested in any
business in the Restricted Territory, which competes with the Restricted Businesses and/or any business being carried on by the
Company or by any other Group Company which the Consultant has had oversight or responsibility for in the 36 month period
immediately preceding the Termination Date;
(b) 	for the period of 18 months immediately after the Termination Date negotiate with, solicit business from or endeavour to entice away
from the Company, or any other Group Company the business of any person, firm, company or organisation who or which is and
has been a customer, client or agent of or supplier to (or who had regular business dealings with) the Company or any Group
Company during the period of 36 months immediately preceding the Termination Date;
(c) 	for the period of 18 months immediately after the Termination Date undertake to provide in competition with the Company or any
other Group Company any service or manufacture or supply any product similar to those with which he was concerned during the
period of 36 months immediately preceding the Termination Date to or for any person who is or was a customer, client or agent of
(or who had regular business dealings with)

-- 132 of 180 --

the Company or any other Group Company during the period of 36 months immediately preceding the Termination Date;
(d) 	for the period of 18 months immediately after the Termination Date employ or engage for the provision of work or services, solicit or
endeavour to entice away from the Company or any other Group Company, any person who is an employee of or otherwise works
for the Company or any Group Company and who is either:
(i) 	part of the Group’s senior management (Band 9 and above) within the Restricted Businesses; or
(ii) 	who by reason of their knowledge of trade secrets or confidential information of the Restricted Businesses or knowledge or
influence over the clients, customers or suppliers of the Restricted Businesses is likely to be able to assist or benefit a
business which competes or proposes to compete with the Company or any other Group Company.
2.2 	For the avoidance of doubt, none of the restrictions contained in this RC Agreement shall prohibit any activities by the Consultant which are
not in direct or indirect competition with any business being carried on by the Company or any other Group Company at the Termination
Date.
2.3 	Nothing in clause 2.1 shall preclude the Consultant from acquiring or holding (directly or through nominees) publicly traded stock or other
publicly traded securities of a business, so long as Consultant’s ownership does not exceed 1% percent of the outstanding securities of
such company of the same class as those held by the Consultant.
2.4 	The Consultant agrees that, having regard to all the circumstances, the restrictions contained in this RC Agreement are reasonable and
necessary for the protection of the Company or any other Group Company and that they do not bear harshly upon him and the parties agree
that:
(a) 	each restriction shall be read and construed independently of the other restrictions so that if one or more are found to be void or
unenforceable as an unreasonable restraint of trade or for any other reason the remaining restrictions shall not be affected; and
(b) 	if any restriction is found to be void but would be valid and enforceable if some part of it were deleted, that restriction shall apply
with such deletion as may be necessary to make it valid and enforceable.
2.5 	The Consultant shall not, during or after the term of the Consulting Agreement, assist or advise or give any information to any person for the
purpose of that person doing an act which, if done by the Consultant himself, would be in breach of any of the provisions of this RC
Agreement.
2.6 	If the Consultant applies for or is offered a new employment, appointment or engagement, before entering into any related contract the
Consultant will bring the terms of this RC Agreement to the attention of a third party proposing to directly or indirectly employ, appoint or
engage him.
2.7 	The Consultant will at the request and cost of the Company enter into direct undertakings with the Company and/or any Group Company
which correspond to the restrictions in the Consulting

-- 133 of 180 --

Agreement and this RC Agreement, or which are less onerous only to the extent necessary (in the opinion of the Group or its legal advisors)
to ensure that such undertakings are valid and enforceable.
3 	Third party rights
The benefit of each agreement and obligation of the Consultant under this RC Agreement may be assigned to and enforced by all
successors and assigns for the time being of the Company and any Group Company and such agreements and obligations shall operate
and remain binding notwithstanding the termination of this RC Agreement.
4 	Choice of law and submission to jurisdiction
4.1 	This RC Agreement shall be governed by and interpreted in accordance with the laws of England & Wales.
4.2 	The parties submit to the exclusive jurisdiction of the English courts, but this RC Agreement may be enforced by the Group in any court of
competent jurisdiction.

-- 134 of 180 --

Executed as a deed by Life Technologies Limited (the
Company) acting by two directors or by a director
and its secretary
) 	..........................................................................
) 	Director
)
) 	..........................................................................
) 	Director/Secretary
Executed as a deed by the Consultant
in the presence of
)
)
) 	..........................................................................
..........................................................................
Signature of witness
Name ................................................................
Address .............................................................
..........................................................................

-- 135 of 180 --

Exhibit 21
THERMO FISHER SCIENTIFIC INC.
NAME
STATE OR
JURISDICTION OF
ORGANIZATION
PERCENT OF
OWNERSHIP
Thermo Fisher Scientific Operating Company LLC 	Delaware 	100
Thermo Fisher Scientific Senior Financing LLC 	Delaware 	100
Thermo Fisher Scientific (DE) Holding S.a.r.l. 	Luxembourg 	100
Laboratory Management Systems, Inc. 	Delaware 	100
Thermo Fisher Scientific Peru S.R.L.
[1% by Fisher Clinical Services (Peru) LLC] Peru 	99
Thermo Fisher Scientific Malaysia Sdn. Bhd. 	Malaysia 	100
Thermo Fisher Scientific (Barbados) Holding, Limited 	Barbados 	100
Fisher Clinical Logistics LLC 	Delaware 	100
Fisher Clinical Services (Suzhou) Co., Ltd. 	China 	100
Fisher Clinical Services Limited Liability Company
[1% by Thermo Fisher Scientific Inc.] Russia 	99
Fisher Clinical Services Japan K.K. 	Japan 	100
Fisher Clinical Services (Korea) Co., Ltd 	Korea 	100
Cohesive Technologies Inc. 	Delaware 	100
Cohesive Technologies (UK) Limited 	England 	100
Thermo Hypersil-Keystone LLC 	Delaware 	100
Thermo Electron A/S 	Denmark 	100
Phitonex, Inc. 	North Carolina 	100
TWX, LLC
[22.5% by 	Thermo Scientific Portable Analytical Instruments Inc.] Massachusetts 	77.5
Thermo Fisher GP LLC 	Delaware 	100
Thermo Fisher Scientific C.V.
[1% by TFLP LLC] Netherlands 	99
Phadia GmbH 	Germany 	100
Thermo Dutch Holdings Limited Partnership
[1% by Thermo Finland Holdings LLC] England 	99
Fisher Clinical Services Mexico, S. de R.L. de C.V.
[1% by Fisher Clinical Services (Mexico) LLC] Mexico 	99
Fisher Clinical Services (Mexico) LLC 	Delaware 	100
D-finitive Technologies, Inc. 	South Carolina 	100
Thermo Fisher Scientific Africa Proprietary Ltd 	South Africa 	100
Thermo Fisher Scientific Middle East Holdings Inc. 	Delaware 	100
Thermo Portable Holdings LLC 	Delaware 	100
TSP Holdings I LLC 	Delaware 	100
1

-- 136 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Thermo Scientific Portable Analytical Instruments Inc. 	Delaware 	100
Thermo Fisher Germany B.V. 	Netherlands 	100
NovaWave Technologies, Inc. 	California 	100
Thermo Fisher RE I Corporation
[20% by Thermo Fisher Insurance Holdings Inc.] Delaware 	80
Thermo Fisher RE II Corporation 	Delaware 	100
Thermo Fisher Scientific Re Ltd. 	Bermuda 	100
Thermo Finland Holdings LLC 	Delaware 	100
Pelican Acquisition Corporation 	Delaware 	100
Priority Air Holdings Corp 	Delaware 	100
Priority Air Express, LLC 	Delaware 	100
Priority Air Express UK Limited 	England 	100
Priority Air Express Pte. Ltd. 	Singapore 	100
PAX – DSI Acquisition LLC 	Delaware 	100
Distribution Solutions International, Inc. 	Michigan 	100
Thermo EGS Gauging LLC 	Delaware 	100
EGS Gauging Technical Services Company 	Delaware 	100
EGS Gauging Ltd. 	England 	100
Thermo Asset Management Services Inc. 	Delaware 	100
Thermo CRS Holdings Ltd. 	Canada 	100
Thermo CRS Ltd.
[Series 1 Preferred Shares held by Oxoid Company, Diagnostix Ltd. and Thermo Fisher Scientific
(Mississauga) Inc.]
Canada 	100
Robocon Labor- und Industrieroboter Gesellschaft m.b.H 	Austria 	100
Thermo Fisher Scientific West Palm Holdings LLC 	Delaware 	100
Thermo Electron North America LLC 	Delaware 	100
picoSpin, LLC 	Colorado 	100
Loftus Furnace Company 	Pennsylvania 	100
NAPCO, Inc. 	Connecticut 	100
Fisher Clinical Services (Colombia) LLC 	Delaware 	100
Fisher Clinical Services Colombia S.A.S. 	Colombia 	100
Fisher Servicios Clinicos (Chile) LLC 	Delaware 	100
Fisher Servicios Clinicos Chile Ltda
[1% by Thermo Fisher Scientific Inc.] Chile 	99
Staten Island Cogeneration Corporation 	New York 	100
Doe & Ingalls Investors, Inc. 	Delaware 	100
2

-- 137 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Doe & Ingalls Management, LLC
[47% by Thermo Fisher Scientific Inc.] Delaware 	53
Doe & Ingalls of California Operating LLC 	North Carolina 	100
Doe & Ingalls of Florida Operating LLC 	Florida 	100
Doe & Ingalls of Maryland Operating LLC 	North Carolina 	100
Doe & Ingalls of Massachusetts Operating LLC 	North Carolina 	100
Doe & Ingalls of North Carolina Operating LLC 	North Carolina 	100
Doe & Ingalls Properties II, LLC 	North Carolina 	100
Doe & Ingalls Properties, LLC 	North Carolina 	100
Thermo Electron Export Inc. 	Barbados 	100
Thermo Fisher Scientific (Mexico City) LLC 	Delaware 	100
Odyssey Luxembourg Holdings S.C.S.
[1% by Odyssey Holdings LLC] Luxembourg 	99
Fisher Worldwide Gene Distribution SPV 	Cayman Islands 	100
Thermo Fisher Scientific Odyssey Financing (Barbados) SRL 	Barbados 	100
Thermo Fisher Scientific Odyssey Holdings Limited 	England 	100
Odyssey Venture Corporation 	Delaware 	100
Odyssey Holdings Corporation 	Delaware 	100
One Lambda, Inc 	California 	100
SystemLink, Inc. 	Virginia 	100
Linkage Biosciences, Inc. 	California 	100
Thermo Fisher Scientific TDI S.a.r.l
[.26% by Applied Biosystems International, Inc., .06% by Thermo Fisher Scientific (Finance
II) S.a.r.l., and 16.81% by Thermo Fisher Scientific (Finance III) S.a.r.l.] Luxembourg 	82.87
Thermo Fisher (CN) Malta Holdings Limited
[.0000001% by Thermo Fisher Scientific (Finance III) LLC Malta 	99.9999999
Thermo Fisher Scientific (Finance III) LLC 	Delaware 	100
Thermo Fisher Scientific TDI 2 S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific Remel Luxembourg S.a.r.l. 	Luxembourg 	100
ABII 2 Limited 	England 	100
Remel Europe Limited 	England 	100
Odyssey Luxembourg IP Holdings 1 S.à r.l. 	Luxembourg 	100
Odyssey Luxembourg IP Holdings 2 S.à r.l. 	Luxembourg 	100
Thermo Foundation, Inc. 	Massachusetts 	100
Thermo Fisher Financial Services Inc. 	Delaware 	100
Thermo Fisher Scientific Chemicals Inc. 	Delaware 	100
3

-- 138 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Russell pH Limited 	Scotland 	100
Thermo Keytek LLC 	Delaware 	100
Thermo Finland Holdings MT2 B.V.
[10% by Thermo Finland Holdings LLC] Netherlands 	90
Thermo Cayman Holdings Ltd.
[21.27% by Thermo Cambridge Limited] Cayman Islands 	78.73
European Laboratory Holdings Limited 	Ireland 	100
Thermo Fisher Investments (Cayman) Ltd. 	Cayman Islands 	100
Thermo Fisher Scientific Investments (Luxembourg) II S.a.r.l. 	Luxembourg 	100
Thermo Suomi Holding B.V.
[33.33% 	by Life Sciences International Holdings BV] Netherlands 	66.67
Thermo Fisher (Finland Holdings 2) LLC 	Delaware 	100
Thermo Fisher (Finland Holdings) Limited Partnership
[.5% by Thermo Fisher (Finland Holdings 2) LLC] England 	99.5
Thermo Finland Holdings MT1 B.V.
[.5% by Thermo Fisher (Finland Holdings 2) LLC] Netherlands 	99.5
Thermo Fisher Scientific Oy 	Finland 	100
Life technologies Finland Oy 	Finland 	100
Thermo Electron Manufacturing Limited 	England 	100
Thermo Finnigan Limited 	England 	100
Thermo Hypersil Ltd 	England 	100
G V Instruments Limited 	England 	100
GV Instruments Inc 	Delaware 	100
GV Instruments Canada Ltd. 	Canada 	100
Thermo Fisher India Holding B.V.
[6.13% by Thermo Fisher Scientific Inc., .68% by Thermo Gamma-Metrics LLC and 30.74% by
Thermo Fisher Scientific (Asheville) LLC] Netherlands 	62.45
Thermo Fisher Scientific India Pvt Ltd
[.00161 % by Thermo Fisher Scientific Inc., .00320% by Thermo Electron LED GmbH,
2.66891% by Phadia Holding AB, .00001% by Phadia AB, and 22.23825% by Dionex
Corporation]
India 	75.08802
JSC “Thermo Fisher Scientific” 	Russia 	100
Thermedics Detection de Argentina S.R.L
[10% by Thermo Ramsey LLC] Argentina 	90
Fisher Clinical Services Latin America S.R.L.
[10% by Thermo Ramsey LLC] Argentina 	90
Thermo Detection de Mexico S. de R.L. de C.V.
[.00815586% by Thermo Environmental Instruments LLC and .02975898% by Thermo Fisher Scientific (Mexico
City) LLC] Mexico 	99.96208516
Thermo Fisher Scientific eCommerce Solutions, LLC 	Delaware 	100
Goring Kerr Detection Limited 	England 	100
4

-- 139 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Thermo Sentron Canada Inc.
[10% by Thermo Fisher Scientific Inc.] Canada 	90
Thermo Ramsey S.A. 	Spain 	100
Thermo Ramsey LLC 	Massachusetts 	100
Thermo Fisher Project Cyprus LLC 	Delaware 	100
Thermo Fisher Scientific Brasil Instrumentos de Processo Ltda.
[.01% by Thermo Ramsey LLC] Brazil 	99.99
IntegenX, Inc. 	California 	100
IntegenX Ltd 	England 	100
Thermo Re, Ltd. 	Bermuda 	100
Thermo Electron (Proprietary) Limited 	South Africa 	100
Odyssey Holdings LLC 	Delaware 	100
TFS Group Holding I LLC
[12.51% by Thermo Luxembourg Holding LLC, 4.70% by Molecular BioProducts, Inc., 20.48% by Fisher Scientific
Worldwide Inc., .37% by Fisher Clinical Services Inc., .70% by Liberty Lane Investment LLC, .15% by Fisher
Scientific International LLC, 7.40% by Thermo Fisher Scientific Life Investments US Financing II LLC, 13.37% by
Erie LP Holding LLC, preferred shares held by Thermo Fisher Scientific Life Investments US Financing I LLC, Fisher
Scientific Worldwide Holdings I C.V., and Thermo Fisher Scientific Investments (Sweden) S.a.r.l.]
Delaware 	40.32
Thermo Fisher Scientific Luxembourg Sweden Holdings I S.à r.l 	Luxembourg 	100
TFS Group Holdings IV LLC
[12.39% by Thermo Fisher Scientific Life Holdings III C.V. LLC and 0% by TFS Group Holdings III LLC] Delaware 	87.61
Thermo Fisher Scientific AU LLC 	Delaware 	100
Thermo Fisher Scientific AU C.V.
[1% by Thermo Fisher Scientific AU LLC] Netherlands 	99
Thermo Fisher Scientific Life Technologies Investment I LLC 	Delaware 	100
Thermo Fisher Scientific Life Technologies Investment II LLC 	Delaware 	100
Thermo Fisher Scientific Life Technologies Investments Holding LP
[.10% by Thermo Fisher Scientific Life Technologies Investment I LLC] England 	99.90
Thermo Electron Australia Pty Limited 	Australia 	100
Thermo Trace Pty Ltd. 	Australia 	100
Thermo Fisher Scientific Australia Pty Ltd 	Australia 	100
Dionex Pty Limited 	Australia 	100
Life Technologies Australia PTY Ltd. 	Australia 	100
Microgenics Diagnostics Pty Limited 	Australia 	100
Lomb Scientific (Aust) Pty Limited 	Australia 	100
Technology Design Solutions Pty Ltd 	Australia 	100
App-Tek International Pty Ltd 	Australia 	100
5

-- 140 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Thermo Fisher Scientific New Zealand Holdings 	New Zealand 	100
Thermo Fisher Scientific New Zealand Limited 	New Zealand 	100
Thermo Gamma-Metrics Holdings Pty Ltd. 	Australia 	100
Thermo Gamma-Metrics Pty Ltd 	Australia 	100
Thermo Electron (Chile) S.p.A. 	Chile 	100
Thermo Fisher Scientific Life Financing (Cayman) 	Cayman Islands 	100
Thermo Fisher Scientific Life Financing (Barbados) SRL 	Barbados 	100
Thermo Fisher Scientific Life Technologies Investment UK II Limited 	England 	100
Thermo Fisher Scientific Life Holdings Limited 	England 	100
Thermo Fisher Scientific Life Financing Limited 	England 	100
Thermo Fisher Scientific AU Limited 	England 	100
Life Technologies Limited 	Scotland 	100
Matrix MicroScience Ltd. 	England 	100
TFS Group Holding II LLC 	Delaware 	100
TFS Life Holding LLC
[6.19% by Thermo Fisher Scientific Life Technologies Investment UK I Limited, .01% by Thermo Fisher
Scientific Life Investments US Financing II LLC, preferred shares held by Thermo Fisher Scientific
Investments (Sweden) S.a.r.l. , Thermo Fisher Scientific Sweden Holdings LLC, and TFS Group Holding
II LLC]
Delaware 	93.80
FSWH II LLC 	Delaware 	100
Thermo Patheon Holdings LLC 	Delaware 	100
FSWH I LLC 	Delaware 	100
Thermo CIDTEC Inc.
[2.01% by Thermo Fisher Scientific Inc. and 1.44% by FSWH II LLC] New York 	96.55
Thermo Fisher Scientific Canada Holdings LLC 	Delaware 	100
Thermo Fisher Scientific Canada Financing 1 ULC 	Canada 	100
Thermo Fisher Scientific Senior Holdings US LP
[.01% by Thermo Fisher Scientific Canada Financing 3 ULC] Delaware 	99.99
Thermo Fisher Scientific Canada Financing 2 ULC 	Canada 	100
Thermo Fisher Scientific Senior Holdings LP
[.01% held by Thermo Fisher Scientific Canada Financing 2 ULC] Canada 	99.99
Life Technologies Inc.
[109,472 Class B by Thermo Fisher Scientific Life Canada Holding ULC
and 690,000 Class A by Fisher Scientific Company] Canada 	100
Thermo Fisher Scientific Canada Financing 3 ULC 	Canada 	100
Thermo Fisher (CN) Luxembourg Holding S.a.r.l.
[19% by TFS Life Holding LLC]
[Domesticated in the State of Delaware under the name of Thermo Fisher (CN)
Luxembourg Holding S.a.r.l. LLC]
Luxembourg 	81
6

-- 141 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
TFS Venture Holdings I LLC 	Delaware 	100
Thermo Fisher Scientific Luxembourg Venture Holdings I S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific Panama I Cayman Ltd 	Cayman Islands 	100
Thermo Fisher Senior Canada Holdings LLC 	Delaware 	100
Thermo Fisher (CN-I) Luxembourg LLC 	Delaware 	100
Thermo Fisher (CN-II) Luxembourg LLC 	Delaware 	100
Thermo Fisher Scientific (PN-II) SRL 	Barbados 	100
Thermo Fisher (CN) Luxembourg S.a.r.l. 	Luxembourg 	100
TFS Venture Holdings III S.C.S.
[.01 % by Thermo Fisher Scientific Luxembourg Venture Holdings I
S.a.r.l.] Luxembourg 	99.99
Thermo Fisher Scientific PN2 C.V
[1% by Thermo Fisher Scientific PN2 LLC] Netherlands 	99
Thermo Fisher Scientific PN2 LLC 	Delaware 	100
Thermo Fisher Scientific PN2 (Malta) Limited
[.04% by Thermo CN Luxembourg LLC] Malta 	99.96
DPI Newco LLC 	Delaware 	100
Thermo Fisher Scientific FLC LLC
[36.68% by Thermo Fisher Scientific Inc.] Delaware 	63.32
Patheon Manufacturing Services LLC 	Delaware 	100
Patheon Development Services Inc. 	Delaware 	100
REP GBP I-B Blocker, Inc. 	Delaware 	100
Patheon Biologics LLC
[24% by REP GBP I-B Blocker, Inc.] Delaware 	76
Patheon Biologics (NJ) LLC 	Delaware 	100
Patheon API Inc. 	South Carolina 	100
Patheon API Services Inc. 	South Carolina 	100
Patheon API Manufacturing Inc. 	South Carolina 	100
DSM Pharmaceutical Products, Inc. 	Delaware 	100
Percivia LLC
[50% 	held privately] Delaware 	50
Thermo Fisher Scientific (Finance I) S.a.r.l.
[1.26% by Thermo Luxembourg Holding S.a.r.l.] Luxembourg 	98.74
Thermo Fisher Insurance Holdings Inc. 	Delaware 	100
Thermo Fisher Insurance Holdings LLC
[45.62% by Thermo Fisher Scientific Re Ltd.] Delaware 	54.38
Thermo Scientific Microbiology Sdn Bhd 	Malaysia 	100
Thermo Scientific Microbiology Pte Ltd. 	Singapore 	100
7

-- 142 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
TFS FEI Holding LLC
[12.08% by Thermo Fisher Scientific (Finance I) S.a.r.l., 5.09% by Thermo Fisher (CN) Luxembourg S.a.r.l.,
and 21.22% Thermo Fisher (CN) Luxembourg Holding S.a.r.l] Delaware 	61.61
Thermo CN Luxembourg LLC 	Delaware 	100
Thermo Fisher Scientific Luxembourg Venture Holdings II S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific (DPI) Limited Partnership
[.00000001% by Thermo CN Luxembourg LLC] Canada 	99.99999999
Thermo Fisher Scientific (CP1) Limited 	England 	100
Thermo Fisher Scientific PN2 (Luxembourg) S.à.r.l 	Luxembourg 	100
Fisher Canada Holding ULC 1 	Canada 	100
Fisher Canada Holding ULC 2 	Canada 	100
Fisher CLP Holding Limited Partnership
[2.65574447% by Fisher Canada Holding ULC 2] Canada 	97.34425553
Fisher Canada Holding ULC 3 	Canada 	100
Fisher Scientific Company 	Canada 	100
Thermo Fisher Scientific (CP2) Limited 	England 	100
Patheon Inc. 	Canada 	100
Patheon KK 	Japan 	100
Patheon U.S. Holdings LLC 	Delaware 	100
Thermo Fisher Scientific PNM Limited Liability Partnership
[50% by Patheon Inc.] England 	50
Thermo Fisher Scientific (PN-I) SRL 	Barbados 	100
Thermo Fisher Scientific PNM S.a.r.l 	Luxembourg 	100
Patheon I B.V. 	Netherlands 	100
Patheon Cooperatief U.A.
[1% by Patheon Finance LLC] Netherlands 	99
Patheon Softgels B.V. 	Netherlands 	100
Patheon Finance LLC 	Delaware 	100
Patheon Holdings SAS 	France 	100
Patheon France SAS 	France 	100
Patheon Italia S.p.A. 	Italy 	100
Thermo Fisher Scientific (PN1) UK Ltd 	England 	100
Patheon UK Limited 	England 	100
Patheon Calculus Merger LLC 	Delaware 	100
Patheon Puerto Rico, Inc. 	Puerto Rico 	100
Patheon Puerto Rico
Acquisitions Corporation Puerto Rico 	100
8

-- 143 of 180 --

NAME
STATE OR
JURISDICTION
OF
ORGANIZATION
PERCENT OF
OWNERSHIP
CEPH International
Corporation Puerto Rico 	100
Patheon U.S. Holdings Inc. 	Delaware 	100
Patheon Pharmaceuticals
Services Inc. Delaware 	100
Patheon Pharmaceuticals Inc. 	Delaware 	100
Patheon Banner U.S. Holdings
Inc. Delaware 	100
Patheon Softgels Inc. 	Delaware 	100
Pharmacaps Mexicana
S.A. de C.V.
[.2% by Patheon
Banner U.S. Holdings
Inc.]
Mexico 	99.8
Thermo Fisher Scientific (PN) UK LLC 	Delaware 	100
Patheon UK Pension Trustees Limited 	England 	100
Thermo Fisher Scientific (PN) UK
Limited Partnership
[1% by Thermo Fisher Scientific (PN)
UK LLC]
England 	99
Thermo Fisher Scientific FSUKHCO Financing (Barbados) SRL 	Barbados 	100
Diagnostix Ltd. 	Canada 	100
Fisher Scientific Oxoid Holdings Ltd. 	England 	100
Oxoid Company 	Canada 	100
Fisher Scientific Luxembourg S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific UK Holding Company Financing Limited 	England 	100
Perbio Science (Canada) Company 	Canada 	100
Fisher Scientific UK Holding Company Limited 	England 	100
Fisher Scientific Oy 	Finland 	100
Fisher Scientific Norway AS 	Norway 	100
Fisher Scientific A/S 	Norway 	100
Doublecape Holding Limited 	England 	100
I.Q. (BIO) Limited 	England 	100
Oxoid (ELY) Limited 	England 	100
Doublecape Limited 	England 	100
Fisher Scientific Ireland Limited 	Ireland 	100
Doe & Ingalls Limited 	Ireland 	100
Fisher Scientific Holding U.K., Limited 	England 	100
Fisher Scientific U.K., Limited 	England 	100
FSUK Holdings Limited 	England 	100
Sterilin Limited 	England 	100
Fisher Scientific UK Holding Company 2 	England 	100
9

-- 144 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Fisher Clinical Services U.K. Limited 	England 	100
Fisher Clinical Services Pte Ltd. 	Singapore 	100
Fisher Clinical Services (Beijing) Co., Ltd. 	China 	100
Fisher Scientific Europe Holdings B.V. 	Netherlands 	100
Perbio Science International Netherlands B.V. 	Netherlands 	100
Fisher Scientific The Hague III B.V.
[35.00095% by Fisher Scientific Europe Holdings B.V.] Netherlands 	64.99905
Fisher Scientific The Hague IV B.V.
[4.545% 	by Fisher Scientific The Hague I B.V.] Netherlands 	95.455
Acros Organics BV
[.3333 by Fisher Scientific The Hague II B.V.] Belgium 	99.6667
Fisher Scientific AG
[17.55% by Fisher Scientific S.A.S.] Switzerland 	82.45
Fisher Scientific The Hague V B.V. 	Netherlands 	100
Fisher Clinical Services GmbH 	Switzerland 	100
Fisher BioPharma Services (India) Private
Limited
[.315% by Fisher Clinical Services U.K.
Limited]
India 	99.685
Fisher Scientific Ireland Investments Unlimited
[.10% by Fisher Scientific Europe Holdings B.V.] Ireland 	99.90
Fisher Emergo B.V. 	Netherlands 	100
Fisher Scientific The Hague II B.V. 	Netherlands 	100
Fisher Scientific The Hague I B.V. 	Netherlands 	100
Fisher Scientific Jersey Island Limited 	Jersey 	100
Fisher Maybridge Holdings Limited 	England 	100
Maybridge Chemical Holdings Limited 	England 	100
Maybridge Limited 	England 	100
Fisher Bioblock Holding II SNC
[.99% by Fisher Scientific The Hague II BV] France 	99.01
Thermo Electron Holdings SAS
[22.12% by Fisher Scientific Company] France 	77.88
Inel SAS 	France 	100
Inel Inc. 	Delaware 	100
Thermo Electron SAS 	France 	100
Thermo Electron LED S.A.S. 	France 	100
Jouan Limited 	England 	100
Thermo Electron Industries 	France 	100
10

-- 145 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
S.C.I. du 10 rue Dugay Trouin
[2% by Thermo Electron Industries] France 	98
Thermo Fisher Scientific Milano Srl
[.05% by Thermo Electron Industries] Italy 	99.95
Fisher Scientific S.A.S. 	France 	100
Fisher Scientific SRL
[.1% by Fisher Bioblock Holding II SNC] Belgium 	99.9
SCI Inno 92
[.0004% 	by Fisher Bioblock Holding II SNC] France 	99.9996
Fisher Scientific S.L. 	Spain 	100
Fisher Scientific, Unipessoal, Lda. 	Portugal 	100
Oxoid Holding SAS 	France 	100
Thermo Fisher Diagnostics SAS 	France 	100
Oxoid Senior Holdings Limited 	England 	100
Oxoid UKH LLC 	Delaware 	100
Oxoid 2000 Limited 	England 	100
Oxoid Holdings Limited 	England 	100
Oxoid International Limited 	England 	100
Oxoid Australia Pty. Limited 	Australia 	100
OXOID CZ s.r.o.
[1% by Oxoid Limited] Czech Republic 	99
Thermo Fisher Diagnostics AS 	Norway 	100
Thermo Fisher Diagnostics AB 	Sweden 	100
ILS Laboratories Scandinavia, AB 	Sweden 	100
Perbio Science Invest AB 	Sweden 	100
Perbio Science Projekt AB 	Sweden 	100
Fermentas Sweden AB 	Sweden 	100
Life Technologies BPD AB 	Sweden 	100
Power Sweden Holdings III
Aktiebolag Sweden 	100
Thermo Fisher Diagnostics AG 	Switzerland 	100
Thermo Fisher Diagnostics B.V. 	Netherlands 	100
Oxoid Inc. 	Delaware 	100
Oxoid NV
[.01% by Oxoid Holdings Limited] Belgium 	99.99
Thermo Fisher Diagnostics S.p.A. 	Italy 	100
Panomics S.r.l. 	Italy 	100
11

-- 146 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Prionics Italia S.r.l. 	Italy 	100
Oxoid Limited 	England 	100
Thermo Fisher (Heysham) Limited 	England 	100
Avocado Research Chemicals
Limited England 	100
Thermo Fisher (Kandel) GmbH 	Germany 	100
G & M Procter Limited 	Scotland 	100
Oxoid Limited 	Ireland 	100
Oxoid Pension Trustees Limited 	England 	100
Thermo Fisher Scientific Beteiligungsverwaltungs GmbH 	Germany 	100
Thermo Fisher Diagnostics Aps 	Denmark 	100
Phadia s.r.o.
[1% by Phadia AB] Czech Republic 	99
Phadia Taiwan Inc. 	Taiwan 	100
Thermo Fisher Diagnostics Limited 	England 	100
Thermo Fisher Diagnostics K.K. 	Japan 	100
Thermo Fisher Diagnostics Austria GmbH 	Austria 	100
Thermo Fisher Diagnostics NV
[.0016% by Thermo Fisher Diagnostics Limited] Belgium 	99.9984
Thermo Fisher Diagnostics, Sociedade Unipessoal Lda 	Portugal 	100
Thermo Fisher Diagnostics, S.L.U. 	Spain 	100
Thermo Fisher Diagnostics Oy 	Finland 	100
Fiberlite Centrifuge LLC 	Delaware 	100
Thermo MF Physics LLC
[3.02% by Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg II S.à r.l.] Delaware 	96.98
Thermo Fisher Investments (Cayman) LLC
[4.37% by Thermo Fisher Scientific Investments (Luxembourg) II S.a.r.l.] Delaware 	95.63
Thermo Fisher Scientific CMN LLC
[5.61% by Thermo Fisher Scientific Investments (Luxembourg) S.a.r.l.] Delaware 	94.39
Thermo Fisher Scientific Worldwide Investments LLC
[10.10% by Thermo Fisher Scientific Worldwide Investments (Luxembourg) S.a.r.l.] Delaware 	89.90
Thermo USC I LLC
[5.68% by Thermo Fisher Scientific Inc. and 2.66% by Thermo Fisher Scientific
(IVGN) Limited]
Delaware 	91.66
Phadia International LLC
[15.28% by Phadia International Holdings C.V.] Delaware 	84.72
Thermo Fisher Scientific Investments (Sweden) II LLC
[13.19% by Thermo Fisher Scientific Investments (Sweden) S.a.r.l.] Delaware 	86.81
Thermo Fisher Scientific (Cayman) LLC
[14.12% by Thermo Fisher Scientific (Luxembourg) II S.a.r.l.] Delaware 	85.88
12

-- 147 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Thermo Fisher Scientific Sweden Holdings S.a.r.l
[1% by Thermo Fisher Scientific Sweden Holdings LLC] Luxembourg 	99
FSII Sweden Holdings I AB 	Sweden 	100
FSII Sweden Holdings II AB 	Sweden 	100
CB Diagnostics I AB 	Sweden 	100
Power Sweden Holdings I AB 	Sweden 	100
FSII Sweden Holdings AB 	Sweden 	100
Thermo Fisher Scientific Life Canada Holding ULC 	Canada 	100
Life Technologies Japan Ltd. 	Japan 	100
Pasteur U.S. Corporation 	Delaware 	100
Phadia US Market Holdings LLC 	Delaware 	100
Life Technologies GmbH 	Germany 	100
Thermo Fisher Scientific GENEART GmbH 	Germany 	100
LTC Tech South Africa PTY Ltd. 	South Africa 	100
Power Sweden Holdings II AB 	Sweden 	100
Perbio Science AB 	Sweden 	100
Thermo Fisher Scientific PRB S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific Investments (Luxembourg) S.a.r.l.
[1% by FSII Sweden Holdings AB] Luxembourg 	99
Thermo Fisher Scientific Life Investments II S.à r.l. 	Luxembourg 	100
Thermo Fisher Scientific Life Investments US Financing II LLC
[1% by Perbio Science Sweden Holdings AB] Delaware 	99
Perbio Science Sweden Holdings AB 	Sweden 	100
Phadia Luxembourg Holdings S.a.r.l. 	Luxembourg 	100
Fisher Scientific GTF AB 	Sweden 	100
Fisher Scientific Biotech Line ApS 	Denmark 	100
CB Diagnostics Holding AB 	Sweden 	100
CB Diagnostics AB 	Sweden 	100
Sweden DIA (Sweden) AB 	Sweden 	100
Phadia Sweden AB 	Sweden 	100
Phadia Holding AB 	Sweden 	100
Phadia Diagnosticos Ltda
[1% 	by Phadia AB] Brazil 	99
Beijing Phadia Diagnostics Co Ltd 	China 	100
Allergon AB 	Sweden 	100
13

-- 148 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Nanjing WeiKangLe Trading Industrial Co
Ltd China 	100
Laboratory Specialties Proprietary Ltd. 	South Africa 	100
Phadia AB 	Sweden 	100
Phadia Real Property AB 	Sweden 	100
Phadia US Inc. 	Delaware 	100
Life Technologies BPD UK Limited 	England 	100
Perbio Science UK Limited 	England 	100
Perbio Science Nederland B.V. 	Netherlands 	100
Thermo Fisher Scientific (Finance III) S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific (Finance II) S.a.r.l. 	Luxembourg 	100
Thermo Fisher CM II LLC 	Delaware 	100
Thermo Fisher Scientific Falcon Senior Holdings Inc. 	Delaware 	100
FEI Company 	Oregon 	100
ASPEX Corporation 	Pennsylvania 	100
FEI Korea Ltd. 	Korea 	100
FEI Houston, Inc. 	Delaware 	100
FEI Melbourne Pty Ltd. 	Australia 	100
FEI Saudi Arabia LLC
[10% by FEI Europe B.V.] Saudi Arabia 	90
FEI Technologies, Inc. 	Oregon 	100
FEI EFA, Inc. 	Delaware 	100
Thermo Fisher Scientific FLC Hong Kong Limited 	Hong Kong 	100
Thermo Fisher Scientific Dutch Senior Holdings B.V. 	Netherlands 	100
Thermo Fisher Scientific FLC B.V. 	Netherlands 	100
Thermo Fisher Scientific B.V. 	Netherlands 	100
Eutech Instruments Europe B.V. 	Netherlands 	100
Thermo Optek S.A. 	Spain 	100
Thermo Fisher Financial Services B.V. 	Netherlands 	100
Thermo Quest S.A. 	Spain 	100
Thermo Fisher Scientific FLC II B.V.
[Domesticated in the State of Delaware under the name of Thermo Fisher
Scientific FLC II B.V.] Netherlands 	100
Thermo Fisher Scientific (Panama) B.V. 	Netherlands 	100
Thermo Fisher Scientific (Panama) II B.V. 	Netherlands 	100
Thermo Fisher Scientific (Panama) Dutch LLC 	Delaware 	100
14

-- 149 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Patheon B.V. 	Netherlands 	100
Patheon Holdings B.V. 	Netherlands 	100
Patheon Holdings I B.V. 	Netherlands 	100
Patheon Holdings II B.V. 	Netherlands 	100
Fisher Bioservices Netherlands B.V. 	Netherlands 	100
Patheon Biologics Australia Pty Ltd 	Australia 	100
Patheon Biologics B.V. 	Netherlands 	100
Patheon Regensburg GmbH 	Germany 	100
Patheon Life Science Products International
GmbH Austria 	100
Patheon I Holding GmbH 	Austria 	100
Patheon Austria GmbH & Co. KG
[0% by Patheon I Holding GmbH] Austria 	100
Thermo Fisher Scientific Dutch Holdings B.V. 	Netherlands 	100
FEI Electron Optics International B.V. 	Netherlands 	100
Thermo Fisher (FEI) Ireland Ltd 	Ireland 	100
FEI Microscopy Solutions Ltd 	Israel 	100
FEI CPD B.V. 	Netherlands 	100
FEI EFA International Pte. Ltd. 	Singapore 	100
DCG Systems G.K. 	Japan 	100
DCG Systems Korea Ltd. 	Korea 	100
FEI Company of USA (S.E.A.) Pte Ltd. 	Singapore 	100
FEI Europe B.V. 	Netherlands 	100
FEI Electron Optics B.V. 	Netherlands 	100
FEI Hong Kong Company Limited 	Hong Kong 	100
Thermo Fisher Electronic Technology Research
and Development (Shanghai) Co., Ltd China 	100
FEI Trading (Shanghai) Co., Ltd. 	China 	100
Thermo Fisher Scientific Brno s.r.o. 	Czech Republic 	100
FEI Asia Pacific Co., Ltd. 	China 	100
FEI Technology de Mexico S.A. de C.V.
[2% by FEI Company] Mexico 	98
FEI UK Ltd. 	England 	100
FEI France SAS 	France 	100
FEI Italia Srl 	Italy 	100
FEI SAS 	France 	100
15

-- 150 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
FEI Company Japan Ltd. 	Japan 	100
FEI Norway Holding AS 	Norway 	100
FEI Australia Pty Ltd 	Australia 	100
FEI Trondheim AS 	Norway 	100
Thermo Fisher Scientific Dutch Holdings II B.V. 	Netherlands 	100
Thermo Fisher Scientific Luxembourg Sweden Holdings II S.à
r.l. Luxembourg 	100
TFS Breda B.V.
[.25% by Thermo Fisher Scientific C.V.] Netherlands 	99.75
Thermo Fisher Scientific Switzerland B.V. 	Netherlands 	100
SwissAnalytic Group GmbH 	Switzerland 	100
Thermo Fisher Scientific (Ecublens) SARL 	Switzerland 	100
Thermo Fisher Scientific Holdings Europe Limited 	England 	100
Thermo Fisher Scientific SpA 	Italy 	100
Fisher Luxembourg Danish Holdings SARL 	Luxembourg 	100
Nunc A/S 	Denmark 	100
Proxeon Biosystems ApS 	Denmark 	100
Kendro Laboratory Products Ltd 	England 	100
Kendro Containment & Services Limited 	England 	100
Thermo Fisher Scientific (Johannesburg)
(Proprietary) Limited South Africa 	100
Thermo Fisher Scientific (Schweiz) AG 	Switzerland 	100
Thermo Fisher Scientific Wissenschaftliche Geräte
GmbH Austria 	100
Thermo Fisher Scientific (Praha) s.r.o. 	Czech Republic 	100
Thermo Electron Sweden Forvaltning AB
[10.08% by Dionex Corporation] Sweden 	89.92
Spectra-Physics AB 	Sweden 	100
Thermo Fisher Scientific Spectra S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific Spectra-Physics
Holdings Luxembourg II S.à r.l. Luxembourg 	100
Thermo Fisher Scientific Spectra-Physics
Holdings Luxembourg I S.à r.l. Luxembourg 	100
Spectra-Physics Holdings Limited 	England 	100
Thermo Fisher Scientific Japan Holdings III B.V. 	Netherlands 	100
Thermo Fisher Scientific K.K.
[0% by TFS Breda B.V. – preferred shares] Japan 	100
Saroph Sweden AB 	Sweden 	100
Thermo Electron Sweden AB 	Sweden 	100
16

-- 151 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Thermo Life Sciences AB 	Sweden 	100
Thermo Fisher Scientific Norway US Investments LLC 	Delaware 	100
Thermo Fisher Scientific Norway Holdings AS 	Norway 	100
Thermo Fisher Scientific Life Senior Holdings, Inc.
[15.37% by Thermo Fisher Scientific Norway Holdings AS] Delaware 	84.63
Erie UK 1 LLC 	Delaware 	100
Thermo Fisher Scientific Invitrogen Financing (Barbados) SRL 	Barbados 	100
Invitrogen Holdings Ltd. 	Scotland 	100
Invitrogen Europe Limited 	Scotland 	100
Erie N2 LLC 	Delaware 	100
Thermo Fisher Scientific Powder UK Holdings Limited 	England 	100
Erie N10 LLC 	Delaware 	100
Erie UK 4 Limited 	England 	100
Thermo Fisher Scientific AU II Limited 	England 	100
Erie Finance LLC 	Delaware 	100
Applied Biosystems International Inc. 	Delaware 	100
Erie N2 UK Limited 	England 	100
Thermo Fisher Scientific Powder Financing 2 LLC 	Delaware 	100
Thermo Fisher Scientific Powder Finance LLC 	Delaware 	100
Life Technologies Corporation 	Delaware 	100
Combinati Incorporated 	Delaware 	100
Affymetrix, Inc 	Delaware 	100
Affymetrix Japan K.K. 	Japan 	100
Bender MedSystems GmbH 	Austria 	100
eBioscience, Ltd 	England 	100
Panomics, L.L.C. 	California 	100
USB Corporation 	Ohio 	100
Thermo Fisher Scientific Life Technologies Israel Investment I Limited 	England 	100
Thermo Fisher Scientific Life Technologies Israel Investment II Limited 	England 	100
Thermo Fisher Israel Ltd. 	Israel 	100
STC Bio Manufacturing, Inc. 	Illinois 	100
Thermo Fisher Scientific Colombia S.A.S. 	Colombia 	100
HyClone International Trade (Tianjin) Co., Ltd 	China 	100
Invitrogen Argentina SA 	Argentina 	100
17

-- 152 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Invitrogen BioServices India Private Limited
[1% by Invitrogen Holdings LLC] India 	99
Invitrogen IP Holdings, Inc. 	Delaware 	100
Ion Torrent Systems, Inc. 	Delaware 	100
Molecular Probes, Inc. 	Oregon 	100
Acoustic Cytometry Systems, Inc. 	Delaware 	100
Matrix MicroScience Inc. 	Delaware 	100
Gold Cattle Standard Testing Labs, Inc. 	Texas 	100
Westover Scientific, Inc. 	Washington 	100
Kettlebrook Insurance Co. ltd.
[32.5% by Invitrogen Europe Limited] Hawaii 	67.5
Invitrogen Finance Corporation 	Delaware 	100
CellzDirect, Inc. 	Delaware 	100
Applied Biosystems, LLC 	Delaware 	100
NewcoGen PE, LLC 	Delaware 	100
BioTrove Corporation 	Delaware 	100
BioTrove International, Inc. 	Delaware 	100
Life Technologies Clinical Services Lab, Inc. 	Delaware 	100
Compendia Bioscience, Inc. 	Michigan 	100
Ambion, Inc. 	Delaware 	100
CHK Holdings Inc. 	Delaware 	100
Thermo Fisher Scientific Norway Senior Holding AS 	Norway 	100
Applied Biosystems de Mexico S. de R.L. de C.V.
[.002% by Applied Biosystems, LLC] Mexico 	99.998
Thermo Fisher Scientific (IVGN) Limited
[.84% by Ambion, Inc.] Hong Kong 	99.16
Applied Biosystems B.V. 	Netherlands 	100
Invitrogen Hong Kong Limited 	Hong Kong 	100
Life Technologies Limited
[23.5% by Applied Biosystems BV] Hong Kong 	76.5
Life Technologies Holdings PTE Ltd. 	Singapore 	100
Affymetrix Biotech Shanghai Ltd 	China 	100
Affymetrix UK Ltd 	England 	100
Life Technologies Magyarorszag Kft 	Hungary 	100
Life Technologies Czech Republic 	s.r.o. 	Czech Republic 	100
18

-- 153 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Life Technologies Polska Sp z.o.o.
[.08% by Invitrogen Holdings LLC] Poland 	99.92
Life Technologies Europe B.V. 	Netherlands 	100
Bio-Sciences Ltd 	Ireland 	100
Prionics USA Inc. 	Delaware 	100
Prionics Lelystad B.V. 	Netherlands 	100
Prionics France SAS 	France 	100
Life Technologies SA 	Spain 	100
Stokes Bio Ltd. 	Ireland 	100
Life Technologies s.r.o
[2.1% by Applied Biosystems BV] Slovakia 	97.9
Life Technologies AS 	Norway 	100
Life Technologies Norway Investments US LLC 	Delaware 	100
Nihon Dynal K.K.
[40% held privately] Japan 	60
Dynal Biotech Beijing Limited 	China 	100
Life Technologies SAS 	France 	100
Perbio Science France SAS 	France 	100
eBioscience SAS 	France 	100
Laboratoire Service International - L.S.I 	France 	100
BAC BV 	Netherlands 	100
BAC IP BV 	Netherlands 	100
Thermo Fisher Scientific (IVGN) B.V. 	Netherlands 	100
Thermo Fisher Scientific Life Tech Korea Holdings LLC 	Delaware 	100
Life Technologies Brasil Comercio e Industria de Produtos para
Biotecnologia Ltda
[3.45% by Thermo Fisher CHK Holding LLC]
Brazil 	96.55
Thermo Fisher CHK Holding LLC 	Delaware 	100
Invitrogen Holdings LLC 	Delaware 	100
Thermo Fisher Bioprocessing Research and Development
(Shanghai) Co., Ltd. China 	100
Invitrogen (Shanghai) Investment Co., Ltd. 	China 	100
Thermo Fisher Scientific (Guangzhou) Co., Ltd 	China 	100
Thermo Fisher Scientific Life Technologies Luxembourg
Holding LLC Delaware 	100
Thermo Fisher Scientific Luxembourg Life
Technologies UK Holding S.à r.l Luxembourg 	100
Thermo Fisher Scientific Life Technologies
Enterprise Holding Limited England 	100
19

-- 154 of 180 --

NAME
STATE OR
JURISDICTION
OF
ORGANIZATION
PERCENT OF
OWNERSHIP
Thermo Fisher Scientific Luxembourg Enterprise
Holdings S.à r.l. Luxembourg 	100
Thermo Fisher Scientific Life CV GP
Holdings II LLC Delaware 	100
Thermo Fisher Scientific One Limited 	England 	100
Thermo Fisher Scientific Life International
Holdings II LP
[.00000004% by Thermo Fisher Scientific
One Limited and .55383943% by Thermo
Fisher Scientific Life Investments IV S.a.r.l.]
England 	99.44616054
Thermo Fisher Scientific Life
Technologies Investment UK I Limited England 	100
Thermo Fisher Scientific Holdings
(Cayman) I
[37.88% by Thermo Fisher
Scientific Life Technologies
Investment I LLC and 23.42% by
Thermo Fisher Scientific Life
Technologies Investments Holding
LP]
Cayman Islands 	38.70
Thermo Fisher Scientific
Holdings (Cayman) II Cayman Islands 	100
Thermo Fisher Scientific
Cayman Investments LLC Delaware 	100
Thermo Fisher Scientific
(Luxembourg) II S.a.r.l. Luxembourg 	100
Invitrogen Trading (Shanghai) Co., Ltd. 	China 	100
Life Technologies DaAn Diagnostic (Guangzhou) Co., Ltd.
[42.5% 	held privately] China 	57.5
Life Technologies Finance Ltd. 	Scotland 	100
Thermo Fisher Scientific (Thailand) Co., Ltd. 	Thailand 	100
Thermo Fisher Scientific Solutions LLC
[20% by Thermo Fisher Scientific Life Tech Korea Holdings
LLC]
Korea 	80
Applied Biosystems Trading (Shanghai) Company Ltd. 	China 	100
Shanghai Life Technologies Biotechnology Co. Limited 	China 	100
Applied Biosystems Taiwan LLC 	Delaware 	100
Life Technologies Co., Ltd.
[42.6% by Applied Biosystems BV] Taiwan 	57.4
Life Technologies Chile SpA 	Chile 	100
Thermo Fisher Scientific Sweden Holdings LLC
[.2936% by Thermo Fisher Scientific Investments (Sweden) S.a.r.l.] Delaware 	99.7064
Princeton Gamma-Tech Instruments LLC 	Delaware 	100
TPI Real Estate Holdings LLC 	Delaware 	100
Comtest Limited 	England 	100
Thermo Electron Metallurgical Services, Inc. 	Texas 	100
20

-- 155 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
ONIX Systems Inc. 	Delaware 	100
Thermo Process Instruments GP, LLC 	Delaware 	100
Thermo Process Instruments, 	L.P.
[.10% by Thermo Process Instruments GP, LLC] Texas 	99.90
Thermo Measuretech Canada Inc. 	Canada 	100
Onix Holdings Limited 	England 	100
CAC Limited 	England 	100
Thermo Measurement Ltd 	England 	100
Thermo Onix Limited 	England 	100
Thermo Electron Scientific Instruments LLC 	Delaware 	100
Thermo Fisher Scientific Japan Holdings I LLC 	Delaware 	100
Thermo Fisher Scientific Japan Holdings I B.V. 	Netherlands 	100
Thermo Fisher Scientific Japan Holdings I LP
[10% by Thermo Fisher Scientific Japan 1 LLC] Delaware 	90
Thermo Fisher Scientific Japan 1 LLC 	Delaware 	100
Fuji Partnership
[17.8184% by Thermo Fisher Scientific Japan Holdings II B.V. and 10.1634% by Thermo Fisher Scientific
Japan Holdings III B.V.] Japan 	72.0182
TK Partnership (aka Silent Partnership)
[44.66% by Thermo Fisher Scientific K.K.] Japan 	55.34
Thermo Fisher Scientific (NK) LLC 	Delaware 	100
Thermo Fisher Eurobonds Ltd. 	Cayman Islands 	100
Thermo Fisher Scientific LSI Financing (Barbados) SRL 	Barbados 	100
Thermo Fisher Scientific (Mississauga) Inc.
[Thermo Finnigan LLC owns 100 Series A Preferred shares] Canada 	100
Life Sciences International Limited 	England 	100
Hybaid Limited 	England 	100
Thermo Optek Limited 	England 	100
Thermo Cambridge Limited 	England 	100
VG Systems Limited 	England 	100
Thermo Radiometrie Limited 	England 	100
Thermo Electron Limited 	England 	100
Thermo Electron Weighing & Inspection Limited 	England 	100
Thermo Electron (Management Services) Limited 	England 	100
Life Sciences International Holdings BV 	Netherlands 	100
Bioanalysis Labsystems, S.A.
[10% by Thermo Fisher Scientific B.V.] Spain 	90
21

-- 156 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Thermo Ramsey Italia S.r.l. 	Italy 	100
Helmet Securities Limited 	England 	100
Life Sciences International LLC 	Delaware 	100
Thermo Fisher Scientific (Asheville) LLC 	Delaware 	100
Thermo Fisher Scientific Japan Holdings II LLC 	Delaware 	100
Thermo Neslab LLC 	New Hampshire 	100
Thermo Fisher Scientific Japan Holdings II B.V. 	Netherlands 	100
Thermo Fisher Scientific Japan Holdings II LP
[10% by Thermo Fisher Scientific Japan 2 LLC] Delaware 	90
Thermo Fisher Scientific Japan 2 LLC 	Delaware 	100
Lab-Line Instruments, Inc. 	Delaware 	100
Thermo Scientific Services, Inc. 	California 	100
Thermo Fisher Scientific (Fuji) LLC 	Delaware 	100
Jouan LLC 	Delaware 	100
Thermo Kevex X-Ray LLC 	Delaware 	100
Thermo Gamma-Metrics LLC 	Delaware 	100
ThermoSpectra Limited 	England 	100
Thermo Fisher Scientific Cork Ltd 	Ireland 	100
Laser Analytical Systems, Inc. 	California 	100
Thermo Finnigan LLC 	Delaware 	100
TMOI Inc. 	Delaware 	100
Thermo Fisher Scientific (China) Holding Limited 	England 	100
TFS Singapore HK Limited 	Hong Kong 	100
Thermo Fisher Scientific NHK Limited 	Hong Kong 	100
Thermo Fisher Scientific TR Limited 	Hong Kong 	100
Thermo Fisher Scientific Baltics UAB
[18.24% by Thermo Fisher Scientific (IVGN) Limited and 3.86% by Oxoid Investments GmbH] Lithuania 	77.90
Fermentas China Co., Ltd 	China 	100
Thermo Fisher Scientific BHK (I) Limited 	Hong Kong 	100
Thermo Fisher China Business Trust II
[1% by Thermo Fisher Scientific BHK (II) Limited] China 	99
Thermo Fisher Scientific BHK (II) Limited 	Hong Kong 	100
Thermo Fisher Scientific (China-HK) Holding Limited 	Hong Kong 	100
Thermo Fisher Scientific (Suzhou) Research and Development Co., Ltd. 	China 	100
Alfa Aesar (Hong Kong) Limited 	Hong Kong 	100
22

-- 157 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Alfa Aesar (China) Chemical Co. Ltd. 	China 	100
Thermo Fisher Scientific (Shanghai) Instruments Co., Ltd. 	China 	100
Thermo Fisher Scientific (Suzhou) Instruments Co., Ltd 	China 	100
Thermo Fisher Scientific (China) Co., Ltd. 	China 	100
Thermo Fisher Biopharma Services (Hangzhou) Ltd.
[49 % held privately] China 	51
Thermo Fisher Scientific (Shanghai) Management Co., Ltd. 	China 	100
Thermo Fisher Scientific (Hong Kong) Limited 	Hong Kong 	100
Thermo Life Science International Trading (Tianjin) Co., Ltd. 	China 	100
Thermo Fisher Scientific SL 	Spain 	100
Thermo Fisher (Cayman) Holdings I Ltd. 	Cayman Islands 	100
Thermo Fisher (Gibraltar) Limited
[50% by Thermo Fisher (Cayman) Holdings II Ltd.] Gibraltar 	50
Thermo Fisher (Gibraltar) II Limited 	Gibraltar 	100
Navaho Acquisition Corp. 	Delaware 	100
NanoDrop Technologies LLC 	Delaware 	100
Thermo Fisher (Cayman) Holdings II Ltd. 	Cayman Islands 	100
Thermo BioAnalysis LLC
[5.1% by Life Sciences International Limited and 9.4% by Life Sciences International LLC] Delaware 	85.5
Thermo Fisher Scientific Senior Holdings Australia LLC 	Delaware 	100
Thermo LabSystems S.A. 	Spain 	100
Thermo Fisher German Holdings LLC 	Delaware 	100
Thermo Holding European Operations LLC 	Delaware 	100
Thermo DMA Inc. 	Texas 	100
Thermo BioAnalysis Limited 	England 	100
Thermo Fast U.K. Limited 	England 	100
Thermo Projects Limited 	England 	100
Thermo LabSystems Inc. 	Massachusetts 	100
InnaPhase Limited 	England 	100
Core Informatics, LLC 	Connecticut 	100
Core Informatics UK Ltd. 	England 	100
Thermo Environmental Instruments LLC 	California 	100
27 Forge Parkway LLC 	Delaware 	100
Thermo Electron (Calgary) Limited 	Canada 	100
Thermo Orion Inc. 	Massachusetts 	100
23

-- 158 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Thermo Fisher Scientific Aquasensors LLC 	Delaware 	100
Thermo Electron Puerto Rico, Inc. 	Puerto Rico 	100
Thermo Power Corporation 	Massachusetts 	100
ACI Holdings Inc. 	New York 	100
Thermo Securities Corporation 	Delaware 	100
Thermo Eberline Holdings I LLC
[49% by Thermo Fisher Scientific Inc.] Delaware 	51
Thermo Eberline Holdings II LLC 	Delaware 	100
Thermo Eberline LLC 	Delaware 	100
Thermo Instrument Controls de Mexico, S.A. de C.V.
[2% by Thermo Fisher Scientific Inc.] Mexico 	98
ThermoLase LLC 	Delaware 	100
Trex Medical Corporation 	Delaware 	100
Fermentas Inc. 	Maryland 	100
TFS LLC 	Massachusetts 	100
Thermo Corporation 	Delaware 	100
Fisher Scientific GmbH 	Germany 	100
Fisher Scientific Germany Beteiligungs GmbH 	Germany 	100
Fisher Scientific, spol. S.r.o 	Czech Republic 	100
Fisher Scientific (Austria) GmbH 	Austria 	100
Thermo Fisher Scientific Germany BV & Co. KG
[0% by Thermo Fisher Germany B.V.] Germany 	100
Thermo Fisher Scientific C.F. GmbH 	Germany 	100
Fisher Clinical Services GmbH 	Germany 	100
Fisher Clinical Services Rheinfelden GmbH 	Germany 	100
Thermo Fisher Scientific (Holding II) B.V. & Co. KG
[0% by Thermo Fisher Germany B.V.] Germany 	100
FEI Deutschland GmbH 	Germany 	100
Thermo Fisher Diagnostics GmbH 	Germany 	100
Microgenics Corporation
[0% by Thermo Fisher Scientific Vector Holdings 2 LLC] Delaware 	100
AcroMetrix LLC 	California 	100
Consolidated Technologies, Inc. 	Wisconsin 	100
Remel Inc. 	Wisconsin 	100
Trek Diagnostic Systems LLC 	Delaware 	100
Trek Holding Company Ltd. 	England 	100
24

-- 159 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Trek Holding Company II Ltd. 	England 	100
Trek Diagnostic Systems Ltd. 	England 	100
Thermo Luxembourg Holding S.a.r.l.
[Domesticated in the State of Delaware under the name of Thermo Luxembourg Holding LLC] Luxembourg 	100
Thermo MT II Limited
[.0000003% by Thermo MT II LLC] Malta 	99.9999997
Thermo MT II LLC 	Delaware 	100
Thermo Luxembourg U.S. S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific Asset Management 1 GmbH 	Germany 	100
Thermo Fisher Scientific Asset Management 2 GmbH 	Germany 	100
Thermo Fisher Scientific Vector Senior Holdings II UAB 	Lithuania 	100
Thermo Fisher Scientific Vector Senior Holdings I UAB 	Lithuania 	100
Thermo Fisher Scientific Vector Holdings UAB 	Lithuania 	100
Thermo Fisher Scientific Vector Holdings LLC 	Delaware 	100
Thermo Fisher Scientific Vector Holdings 2 LLC 	Delaware 	100
FB2 Blocker, LLC 	Delaware 	100
TFS Brammer Holding Corporation
[43.18% by Thermo Fisher Scientific Vector Holdings LLC] Delaware 	56.82
Brammer Bio Holding Company, LLC 	Delaware 	100
Brammer Bio, LLC 	Delaware 	100
Brammer Bio MA, LLC 	Delaware 	100
Thermo Fisher Scientific Biosciences Corp. 	Canada 	100
Oxoid Investments GmbH 	Germany 	100
B.R.A.H.M.S. GmbH
[5.025% by Phadia GmbH] Germany 	94.975
B.R.A.H.M.S. Biotech GmbH
[6% held privately] Germany 	94
Cezanne S.A.S. 	France 	100
B.R.A.H.M.S. UK Ltd 	England 	100
Thermo Fisher Scientific Luxembourg German Holdings S.a.r.l. 	Luxembourg 	100
Dionex (UK) Limited
[.10% by Dionex Corporation] England 	99.90
Thermo Fisher Scientific Chromatography Holdings S.à r.l.
[5.28% by Oxoid Investments GmbH] Luxembourg 	94.72
Thermo Fisher Scientific Chromatography Holdings Aps 	Denmark 	100
Dionex Corporation 	Delaware 	100
25

-- 160 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Thermo Fisher Scientific Pte. Ltd. 	Singapore 	100
Dionex Sweden AB 	Sweden 	100
Dionex I, LLC 	Delaware 	100
Dionex (Switzerland) AG 	Switzerland 	100
Dionex Canada Ltd. 	Canada 	100
Dionex Austria GmbH 	Austria 	100
Dionex Benelux B.V. 	Netherlands 	100
Dionex Holding GmbH 	Germany 	100
Dionex Softron GmbH 	Germany 	100
Dionex Singapore Pte Ltd. 	Singapore 	100
Thermo Fisher Scientific Korea Ltd. 	Korea 	100
Dionex S.A. 	France 	100
Thermo Fisher Diagnostics (Ireland) Limited 	Ireland 	100
Dionex S.p.A.
[.08% held privately] Italy 	99.92
Dionex China Limited 	Hong Kong 	100
Thermo Fisher (China) Analytical Ltd. 	China 	100
Thermo Fisher Scientific Taiwan Co., Ltd. 	Taiwan 	100
Dionex Denmark A/S 	Denmark 	100
Thermo Fisher Scientific (Breda) Holding BV 	Netherlands 	100
Thermo Luxembourg S.a.r.l. 	Luxembourg 	100
Thermo TLH L.P.
[.01% 	by Thermo TLH (U.K.) Limited] Delaware 	99.99
Thermo TLH (UK) Limited 	England 	100
Thermo TLH (MT) Limited
[.000003% by Thermo TLH L.P.] Malta 	99.999997
Thermo TLH Luxembourg S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific IT Services GmbH 	Germany 	100
Thermo Fisher Scientific GmbH 	Germany 	100
BmT GmbH Laborprodukte 	Germany 	100
Thermo Fisher Scientific (Real Estate 1) S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific Messtechnik 	GmbH
[10.04% by Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG] Germany 	89.96
Thermo Electron (Karlsruhe) GmbH
[10% by Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG] Germany 	90
Thermo Electron Pension Trust GmbH 	Germany 	100
26

-- 161 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG
[0% by Fisher Scientific Germany Beteiligungs GmbH as the General Partner] Germany 	100
Thermo Fisher Scientific (Bremen) GmbH
[10% by Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG] Germany 	90
La-Pha-Pack GmbH 	Germany 	100
Thermo Electron LED GmbH
[10% by Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG] Germany 	90
Oxoid Deutschland GmbH 	Germany 	100
Microgenics B.V. & Co. KG
[.01% by Thermo Fisher Germany B.V.] Germany 	99.9
Advanced Scientifics International, Inc. 	Pennsylvania 	100
Advanced Scientifics, Inc. 	Pennsylvania 	100
Avances Cientificos de Mexico, S. de R.L. de C.V.
[1.005% by Advanced Scientifics International, Inc.] Mexico 	98.995
Barnstead Thermolyne LLC 	Delaware 	100
Thermo Fisher Scientific China Holdings I B.V. 	Netherlands 	100
Thermo Fisher Scientific China Holdings II B.V. 	Netherlands 	100
Thermo Fisher Scientific China Holdings III B.V. 	Netherlands 	100
Thermo Fisher China Business Trust
[1% by Thermo Fisher Scientific China Holdings IV B.V.] China 	99
Thermo Fisher Scientific China Holdings IV B.V. 	Netherlands 	100
Fisher Scientific International LLC 	Delaware 	100
Thermo Fisher Scientific Powder Holdings III 	Cayman Islands 	100
Thermo Fisher Scientific Powder Holdings IV 	Cayman Islands 	100
NERL Diagnostics LLC 	Wisconsin 	100
FHP LLC 	Delaware 	100
Alchematrix, Inc. 	Delaware 	100
Fisher Internet Minority Holdings L.L.C. 	Delaware 	100
Alchematrix LLC 	Delaware 	100
Apogent Technologies Inc. 	Wisconsin 	100
Apogent Holding Company 	Delaware 	100
Niton Asia Limited 	Hong Kong 	100
Matrix Technologies LLC 	Delaware 	100
Molecular BioProducts, Inc. 	California 	100
Intrinsic BioProbes, Inc. 	Arizona 	100
27

-- 162 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Labomex MBP, S. de R. L. De C.V.
[.04% by Apogent Technologies Inc.] Mexico 	99.96
National Scientific Company 	Wisconsin 	100
Lab-Chrom-Pack LLC 	New York 	100
Robbins Scientific LLC 	California 	100
Apogent Transition Corp. 	Delaware 	100
Erie Scientific LLC 	Delaware 	100
Thermo Fisher TDI Holding LLC 	Delaware 	100
Microm Laborgerate S.L. 	Spain 	100
TFLP LLC
[.061140% by Thermo Fisher Scientific Inc., .000001% by Apogent Technologies Inc., .000060% by
Fisher Scientific Worldwide Inc., and 9.993898% by Fisher WWD Holding L.L.C.]
Delaware 	89.944901
Thermo Fisher Scientific AL-1 LLC 	Delaware 	100
Thermo Fisher Scientific Life Holdings III C.V. LLC
[33.19378799% by Erie Scientific LLC, 22.31855864% by Thermo Fisher Scientific Inc., and
.00000002% by Thermo Fisher Scientific AL-1 LLC] Delaware 	44.48765335
TFS Group Holdings III LLC 	Delaware 	100
Metavac LLC 	Delaware 	100
Abgene Inc. 	Delaware 	100
Apogent Finance Company 	Delaware 	100
Capitol Vial, Inc. 	Alabama 	100
Capitol Scientific Products, Inc. 	New York 	100
Chase Scientific Glass, Inc.
[50% 	by Apogent Holding Company] Wisconsin 	50
EP Scientific Products LLC 	Delaware 	100
Erie Scientific Company of Puerto Rico 	Delaware 	100
Erie Scientific Hungary Ipari és Szolgáltató Kft 	Hungary 	100
Erie UK Holding Company 	Delaware 	100
Erie LP Holding LLC 	Delaware 	100
Fisher Scientific Investments (Cayman), Ltd. 	Cayman Islands 	100
Thermo Fisher Scientific Erie Financing (Barbados) SRL 	Barbados 	100
Erie U.K. Limited 	England 	100
Lab Vision (UK) Limited 	England 	100
Nalge Nunc International Corporation 	Delaware 	100
Epsom Glass Industries Limited 	England 	100
28

-- 163 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Thermo Fisher Scientific (Monterrey), S. De R.L. De C.V.
[1% by Nalge Nunc International (Monterrey) LLC] Mexico 	99
236 Perinton Parkway, LLC 	New York 	100
ARG Services LLC 	Delaware 	100
Owl Separation Systems LLC 	Wisconsin 	100
Nalge Nunc International (Monterrey) LLC 	Delaware 	100
Erie UK Senior Holding Limited
[1.01% by Erie LP Holding LLC] England 	98.99
LambTrack Limited 	England 	100
Erie UK 2 Limited 	England 	100
Thermo BioSciences Holdings LLC 	Delaware 	100
Pierce Biotechnology, Inc. 	Delaware 	100
Perbio Science, Inc. 	Delaware 	100
Pierce Milwaukee, Inc. 	Delaware 	100
Pierce Milwaukee Holding Corp. 	Delaware 	100
Thermo Fisher Scientific (Milwaukee) LLC
[1% by Pierce Milwaukee, Inc.] Delaware 	99
Advanced Biotechnologies Limited 	England 	100
Abgene Limited 	England 	100
Apogent U.K. Limited 	England 	100
Matrix Technologies Corporation Limited 	England 	100
Nalge (Europe) Limited 	England 	100
Chromacol Limited 	England 	100
Ever Ready Thermometer Co., Inc. 	Wisconsin 	100
Samco Scientific LLC 	Delaware 	100
Samco Scientific (Monterrey) LLC 	Delaware 	100
Seradyn Inc. 	Delaware 	100
Applied Scientific Corporation 	California 	100
Cellomics, Inc. 	Delaware 	100
Fisher BioSciences Japan G.K. 	Japan 	100
CTPS LLC 	Delaware 	100
Clintrak Pharmaceutical Services, LLC 	Delaware 	100
Fisher Clinical Services (Bristol), LLC 	Delaware 	100
Clintrak Clinical Labeling Services, LLC 	Delaware 	100
Columbia Diagnostics, Inc. 	Delaware 	100
29

-- 164 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Drakeside Real Estate Holding Company LLC 	Delaware 	100
Duke Scientific Corporation 	California 	100
Fisher Clinical Services Inc. 	Pennsylvania 	100
Eutech Instruments Pte Ltd. 	Singapore 	100
Thermo Fisher Scientific Brasil Serviços de Logística Ltda
[.001% by Fisher BioServices Inc.] Brazil 	99.999
Fisher BioServices Inc. 	Virginia 	100
Southern Trials (Pty) Ltd. 	South Africa 	100
Schantz Road LLC 	Pennsylvania 	100
Specialty (SMI) Inc. 	California 	100
Fisher Hamilton China Inc. 	Delaware 	100
Fisher Scientific Brazil Inc. 	Delaware 	100
Systems Manufacturing Corporation 	Delaware 	100
Fisher Scientific Central America Inc. 	Delaware 	100
Fisher Scientific Chile Inc. 	Delaware 	100
Consultores Fisher Scientific Chile Ltd
[50% by Fisher Scientific Worldwide Inc.] Chile 	50
Fisher Scientific Colombia Inc. 	Delaware 	100
Fisher Scientific Company L.L.C. 	Delaware 	100
Fisher Scientific Costa Rica Sociedad de Responsabilidad Limitada 	Costa Rica 	100
Thermo Fisher Scientific Brahms LLC 	Delaware 	100
Biochemical Sciences LLC 	Delaware 	100
Fisher Scientific de Mexico S.A. 	Mexico 	100
Medical Analysis Systems, Inc. 	Delaware 	100
Medical Analysis Systems International, Inc. 	California 	100
Medical Diagnostics Systems, Inc. 	California 	100
United Diagnostics, Inc. 	Delaware 	100
Fisher Scientific Latin America Inc. 	Delaware 	100
Fisher Scientific Mexico Inc. 	Delaware 	100
FS Mexicana Holdings LLC
[.01% by Fisher Scientific Mexicana, S. de R.L. de C.V] Delaware 	99.99
Fisher Alder S. de R.L. de C.V.
[.0020% by Fisher Scientific International LLC] Mexico 	99.9980
Fisher Hamilton Mexico LLC 	Delaware 	100
Fisher Scientific Mexicana, S. de R.L. de C.V.
[.01% by Fisher Scientific Worldwide Inc.] Mexico 	99.99
30

-- 165 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
FS Casa Rocas Holdings LLC
[1% by Fisher Mexico, S. de R.L. de C.V] Delaware 	99
Fisher Mexico, S. de R.L. de C.V.
[.0000269% by FS Casa Rocas Holdings LLC] Mexico 	99.9999731
Fisher Scientific Middle East and Africa Inc. 	Delaware 	100
Fisher Scientific Operating Company 	Delaware 	100
Fisher Scientific Venezuela Inc. 	Delaware 	100
Fisher Scientific Worldwide (Shanghai) Co., Ltd. 	China 	100
FRC Holding Inc., V 	Delaware 	100
Golden West Indemnity Company Limited 	Bermuda 	100
Liberty Lane Real Estate Holding Company LLC 	Delaware 	100
New FS Holdings Inc. 	Delaware 	100
Hangar 215, Inc. 	Delaware 	100
Fisher Scientific Worldwide Inc. 	Delaware 	100
Spectra-Physics Holdings USA, LLC 	Delaware 	100
Thermo Fisher Scientific Powder Holdings I 	Cayman Islands 	100
Thermo Fisher Scientific Powder Holdings II
[11.76% by Thermo Fisher Scientific Powder Holdings IV] Cayman Islands 	88.24
Thermo Fisher Scientific Powder SRL 	Barbados 	100
Thermo Fisher Scientific Powder US Holdings Limited 	England 	100
Thermo Fisher Scientific Powder US Holdings Corp. 	Delaware 	100
PPD, Inc. 	Delaware 	100
Eagle Holding Company II, LLC 	Delaware 	100
Jaguar Holding Company I, LLC 	Delaware 	100
Jaguar Holding Company II 	Delaware 	100
Jaguar (Barbados) Finance SRL 	Barbados 	100
Wildcat Acquisition Holdings (UK) Limited 	United Kingdom 	100
Pharmaceutical Product Development, LLC 	Delaware 	100
Synexus Clinical Research Topco Limited 	United Kingdom 	100
PPD Vaccines and Biologics, LLC 	Pennsylvania 	100
Synexus Compass, Inc. (fmr. Synarc Inc.) 	Delaware 	100
MediciGroup, Inc. 	Pennsylvania 	100
Compass Research, LLC 	Florida 	100
The Compass Clinic, LLC 	Florida 	100
Compass NeuroHealth, LLC 	Florida 	100
31

-- 166 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
NeuroHealth, Inc. 	Florida 	100
Center for Health and Medical Research -CCBR Hong Kong
Limited Hong Kong 	100
Center for Clinical and Basic Research A/S 	Denmark 	100
UAB Center for Clinical and Basic Research 	Lithuania 	100
UAB DDF Properties LT 	Lithuania 	100
CCBR (Beijing) Company Limited 	China 	100
CCBR Asia Ltd. 	Hong Kong 	100
PPD Services, Inc. 	North Carolina 	100
PPD Investigator Services, LLC 	Delaware 	100
Synexus Clinical Research US, Inc. 	Arizona 	100
Optimal Research, LLC 	Maryland 	100
PPD Global Central Labs, LLC 	Kentucky 	100
PPD Corporate Foundation 	Delaware 	100
Applied Bioscience International, LLC 	Delaware 	100
PPD GP, LLC 	Delaware 	100
PPD Holdings, LLC 	Delaware 	100
PPD Development, L.P.
[.1% by PPD GP, LLC] Delaware 	99.9
River Ventures, LLC 	North Carolina 	100
PPD Aeronautics, LLC 	North Carolina 	100
Pharmaco Investments, Inc. 	Delaware 	100
Acurian, Inc. 	Delaware 	100
Panoply Health Limited 	United Kingdom 	100
APBI Finance Corporation 	Delaware 	100
PPD CT Investments LLP
[20% by PPD International Holdings, LLC] United Kingdom 	80
ATP, LLC 	North Carolina 	100
Evidera, Inc. 	Delaware 	100
0972792 B.C. LTD 	Canada 	100
Evidera Holdings Ltd 	United Kingdom 	100
Evidera Access Consulting Ltd 	United Kingdom 	100
Evidera Ltd 	United Kingdom 	100
PPD International Holdings, LLC 	Delaware 	100
PPD Scandinavia AB 	Sweden 	100
PPD Pharmaceutical Development Japan K.K. 	Japan 	100
32

-- 167 of 180 --

NAME
STATE OR
JURISDICTION
OF
ORGANIZATION
PERCENT OF
OWNERSHIP
PPD-SNBL K.K.
[40% by Shin Nippon Biomedical Laboratories,
Ltd.] Japan 	60
PPD Peru S.A.C.
[.01% by Applied Bioscience International, LLC] Peru 	99.99
PPD Mexico S.A. de C.V.
[.002% by PPD Development, L.P.] Mexico 	99.998
PPD Italy S.r.l 	Italy 	100
PPD International Holdings, Inc. y Compania
Limitada
[1 % Applied Bioscience International, LLC] Chile 	99
PPD International Holdings (UK) Ltd 	United Kingdom 	100
PPD Switzerland GmbH 	Switzerland 	100
PPD International Investments Limited
[.4% by AbC.R.O., Inc.] United Kingdom 	99.6
Synexus Clinical Research Midco No1
Limited United Kingdom 	100
Synexus Clinical Research Midco
No2 Limited United Kingdom 	100
Synexus Clinical Research
Midco No3 Limited United Kingdom 	100
Synexus Clinical Research
Midco No4 Limited United Kingdom 	100
Synexus Clinical
Research Finance
Limited United Kingdom 	100
Synexus Clinical
Research
Acquisitions
Limited
United Kingdom 	100
Synexus Clinical Research Limited 	United Kingdom 	100
Synexus Clinical Research South
Africa (Pty) Limited South Africa 	100
Synexus Clinical Research
GmbH Germany 	100
Synexus Czech s.r.o. 	Czech Republic 	100
Synexus Limited 	United Kingdom 	100
Synexus Magyarorszg Egszsggyi
Szolgltat Korltolt Felelssg Trsasg Hungary 	100
Synexus Polska Sp. Z o.o 	Poland 	100
Synexus Ukraine Limited
Liability Company
[1% by Synexus Clinical
Research Acquisitions Limited]
Ukraine 	99
Synexus Bulgaria EOOD 	Bulgaria 	100
Medical Centre Synexus
Sofia EOOD Bulgaria 	100
PPD UK Holdings Limited 	United Kingdom 	100
33

-- 168 of 180 --

NAME
STATE OR
JURISDICTION
OF
ORGANIZATION
PERCENT OF
OWNERSHIP
PPD Slovak Republic s.r.o.
[15% by PPD Global Ltd] Slovak Republic 	85
PPD Pharmaceutical Development
Vietnam Company Limited Vietnam 	100
PPD Pharmaceutical Development
India Private Limited
[.01% by PPD Global Ltd.]
India 	99.99
PPD Serbia D.O.O. Beograd 	Serbia 	100
PPD Latvia SIA 	Latvia 	100
PPD Global Ltd. 	United Kingdom 	100
Clinical Technology Centre
(International) Limited
[1% by PPD UK Holdings
Limited]
United Kingdom 	99
PPD Global Central Labs BVBA
[.1% by PPD Global Ltd] Belgium 	99.9
PPD Laboratories (Suzhou)
Co., Ltd. China 	100
PPD Global Central Labs (S) Pte.
Ltd. Singapore 	100
PPD Development Ireland Limited 	Ireland 	100
PPD Development (S) Pte. Ltd. 	Singapore 	100
PPD Pharmaceutical
Development (Beijing) Co.,
Ltd.
China 	100
PPD Development (HK)
Limited.
[50% by Applied Bioscience
International, LLC]
Hong Kong 	50
PPD Colombia S.A.S 	Colombia 	100
PPD Bulgaria EOOD 	Bulgaria 	100
PPD (Netherlands) B.V. 	Netherlands 	100
PPD Pharmaceutical
Development Philippines Corp.
[.0001% held privately]
Philippines 	99.9999
Shorecloud Corporation
[.0001% held privately] Philippines 	99.9999
PPD International Holdings
GmbH Germany 	100
PPD Poland Sp.Z o.o. 	Poland 	100
PPD Hungary Research
and Development Ltd.
[3.33% by PPD
International Holdings,
LLC]
Hungary 	96.67
PPD Germany GmbH &
Co. KG
[28% by PPD Germany
GmbH]
Germany 	72
34

-- 169 of 180 --

NAME
STATE OR
JURISDICTION
OF
ORGANIZATION
PERCENT OF
OWNERSHIP
PPD Germany GmbH 	Germany 	100
PPD Czech Republic
S.R.O.
[2.22% by PPD
International Holdings,
LLC]
Czech Republic 	97.78
PPD France SAS 	France 	100
Greenbird Limited 	Cyprus 	100
Limited Liability Company
PPD Development (Smolensk) Russia 	100
Limited Liability
Company Contract
Research Organisation
Innopharm
Ukraine 	100
Excel PharmaStudies Inc. 	Cayman Islands 	100
Clinical Technology Centre
(Ireland) Limited Ireland 	100
PPD Guatemala, S.A.
[1.0% by Applied Biosciences International,
LLC] Guatemala 	99
PPD do Brasil- Suporte a Pesquisa Clinica Ltd
[.00002% by Pharmaceutical Product
Development, LLC]
Brazil 	99.99998
Medimix Latam Pesquisa de Mercado Ltda 	Brazil 	100
PPD Development (Thailand) Co., Ltd.
[.0025% by PPD Development (S) Pte. Ltd. and
.0025% by PPD UK Holdings Limited]
Thailand 	99.995
PPD Canada 	Canada 	100
PPD Australia Pty Limited 	Australia 	100
PPD Argentina S.A.
[5% by Applied Bioscience International, LLC] Argentina 	95
Pharmaceutical Product Development Spain SL
[.763% by PPD Development, L.P.] Spain 	99.237
Pharmaceutical Product Development South
Africa (Proprietary) Ltd South Africa 	100
AbC.R.O., Inc. 	Virginia 	100
PPD Romania SRL
[.67% by PPD Bulgaria EOOD] Romania 	99.33
PPD Hrvatska d.o.o. 	Croatia 	100
FSIR Holdings (US) Inc.
[1.265% by Fisher Clinical Services Inc.] Delaware 	98.735
Liberty Lane Investment LLC 	Delaware 	100
Fisher Scientific Holding Company LLC 	Delaware 	100
Fisher Manufacturing (Malaysia) Sdn Bhd 	Malaysia 	100
Bumi-Sans Sendirian Berhad 	Malaysia 	100
35

-- 170 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Fisher Scientific (M) Sdn Bhd 	Malaysia 	100
General Scientific Company Sdn Bhd (M) 	Malaysia 	100
Fisher Scientific Holdings (S) Pte Ltd 	Singapore 	100
Fisher Scientific Pte. Ltd.
[16.57% by Fisher Scientific International LLC] Singapore 	83.43
Fisher Scientific (SEA) Pte. Ltd. 	Singapore 	100
Fisher Scientific Australia Pty Limited 	Australia 	100
FSIR Holdings (UK) Limited 	England 	100
FSWH Company LLC 	Delaware 	100
FSI Receivables Company LLC 	Delaware 	100
Fisher Bermuda Holdings Limited 	Bermuda 	100
Thermo Fisher Scientific FSIR Financing (Barbados) SRL 	Barbados 	100
Thermo Fisher Scientific FSIR Financing S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific FSIR Holdings (UK) Financing Limited 	England 	100
Fisher Scientific Worldwide Holdings I C.V.
[12% by Fisher Scientific Worldwide Inc.] Netherlands 	88
Finesse Solutions, Inc. 	Delaware 	100
Finesse Scientific Equipment (Shanghai) Co., Ltd. 	China 	100
FSWH International Holdings LLC 	Delaware 	100
Phadia International Holdings LP
[.01% by FSIR Holdings (UK) Limited and 9.99% by FSIR Holdings (US) Inc.] England 	90
Thermo Fisher Scientific Life Investments US Financing I LLC
[1% by FSIR Holdings (US) Inc.] Delaware 	99
Phadia International Holdings C.V.
[10% by FSIR Holdings (US) Inc.] Netherlands 	90
Thermo Fisher Scientific BV 	Belgium 	100
PharmaFluidics NV 	Belgium 	100
Thermo Fisher Scientific Worldwide Investments (Cayman) 	Cayman Islands 	100
Thermo Fisher Scientific Worldwide Investments (Luxembourg) S.a.r.l. 	Luxembourg 	100
Thermo Fisher Scientific Investments (Sweden) S.a.r.l.
[16.086% by CHK Holdings Inc.] Luxembourg 	83.914
Thermo Fisher Scientific Denmark Senior Holdings ApS 	Denmark 	100
Fisher Scientific Holding HK Limited
[.01% by Fisher Scientific Holding Company LLC] Hong Kong 	99.99
Fisher Scientific (Hong Kong) Limited
[.022% Fisher Scientific Holding Company LLC] Hong Kong 	99.978
Fisher Scientific Japan, Ltd. 	Japan 	100
36

-- 171 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Fisher Scientific Korea Ltd 	Korea 	100
Fisher WWD Holding L.L.C. 	Delaware 	100
Kyle Jordan Investments LLC 	Delaware 	100
Pacific Rim Far East Industries LLC 	Delaware 	100
Pacific Rim Investment, LLC 	Delaware 	100
Marketbase International Limited 	Hong Kong 	100
Thermo-Fisher Biochemical Product (Beijing) Co., Ltd. 	China 	100
HighChem s.r.o. 	Slovakia 	100
Thermo Fisher Scientific HR Services Mexico, S. de R.L. de C.V.
[1% by Fisher Clinical Services (Mexico) LLC] Mexico 	99
Thermo Fisher Scientific China (C-I) LLC 	Delaware 	100
Shanghai Thermo Fisher (C-I) Trading Co. Ltd 	China 	100
Pasteur Acquisition SRL 	Barbados 	100
Thermo Fisher Scientific China (S) LLC 	Delaware 	100
Shanghai Thermo Fisher (S) Trading Co. Ltd 	China 	100
Molecular Transfer, Inc. 	Delaware 	100
Thermo Fisher Scientific Cyprus I Ltd 	Cayman Islands 	100
Thermo Fisher Scientific Cyprus II Ltd 	Cayman Islands 	100
Thermo Fisher Scientific India Holding LLC 	Delaware 	100
Thermo Fisher Scientific Cyprus III Ltd 	Cayman Islands 	100
Thermo Fisher Scientific PSG Corporation 	Delaware 	100
Thermo Fisher Detection Mexico LLC 	Delaware 	100
Thermo Fisher Costa Rica Sociedad de Responsabilidad Limitada
[1% by Fisher Scientific Company L.L.C.] Costa Rica 	99
Thermo Fisher Scientific South Africa Proprietary Ltd 	South Africa 	100
TFS (Barbados) I Srl 	Barbados 	100
Thermo Fisher Biopharma Services Pte. Ltd. 	Singapore 	100
Thermo Services (Hungary) Kft 	Hungary 	100
Erie UK 1 Limited 	England 	100
Erie UK 5 Limited 	England 	100
Erie US II LLC 	Delaware 	100
Erie Finance Holding Limited 	England 	100
Erie Finance Limited 	England 	100
Erie Finance 2 Limited 	England 	100
Erie Finance 1 Limited 	England 	100
37

-- 172 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Erie (GC) Holding Limited
[1% by Erie US III LLC] England 	99
Erie UK 3 Limited 	England 	100
Erie GC Holding LLC 	Delaware 	100
Erie GC Limited 	England 	100
Erie US III LLC 	Delaware 	100
Quebec Court B.V.
[5.71% by Erie Finance Limited] Netherlands 	94.29
Quebec B.V. 	Netherlands 	100
Thermo Fisher Scientific Powder LLC 	Delaware 	100
Thermo Fisher Scientific (Finance I) B.V. 	Netherlands 	100
Thermo Fisher Scientific Erie Financing S.a r.l 	Luxembourg 	100
Erie Luxembourg LLC 	Delaware 	100
Thermo Fisher Scientific Erie 1 Financing (Barbados) SRL 	Barbados 	100
Thermo Fisher Scientific EMEA Limited 	Ireland 	100
Oncomine Molecular Inc. 	Delaware 	100
Oncomine LLC 	Delaware 	100
Oncomine India Private Limited
[.01% by Oncomine Molecular Inc. India 	99.99
Oncomine 	France 	100
Oncomine Limited 	England 	100
Oncomine ULC 	Canada 	100
Oncomine Pte. Ltd 	Singapore 	100
Oncomine Molecular, S.L 	Spain 	100
Oncomine S.r.l 	Italy 	100
Oncomine K.K. 	Japan 	100
Thermo FLC LP
[42.78% By Thermo Fisher Scientific FLC LLC] Delaware 	57.22
Mesa Biotech, Inc. 	Delaware 	100
Fisher Clinical Services (Peru) LLC 	Delaware 	100
Fisher Clinical Services Peru S.R.L
[1% by Thermo Fisher Scientific Inc.] Peru 	99
Henogen SA 	Belgium 	100
Ginko Park SA 	Belgium 	100
Thermo USC II LLC 	Delaware 	100
Thermo Fisher Scientific Life Sciences COE Corporation 	Delaware 	100
38

-- 173 of 180 --

NAME
STATE OR
JURISDICTION OF
ORGANIZATION PERCENT OF
OWNERSHIP
Phadia Malta Holdings Limited 	Malta 	100
Thermo Fisher Scientific Life Investments IV S.a.r.l 	Luxembourg 	100
Thermo Fisher Scientific Life Investments Malta II Limited
[.00001% by Thermo Fisher Scientific Life Investments Malta Holding I LLC] Malta 	99.99999
Thermo Fisher Scientific Life Investments Malta Holding I LLC 	Delaware 	100
Thermo Fisher Scientific Investments (Malta) Limited
[.00000066% by Thermo Fisher Scientific Malta Holdings LLC] Malta 	99.99999934
Thermo Fisher Scientific Malta Holdings LLC 	Delaware 	100
Thermo Fisher Scientific PRB Malta Limited
[.03997% by Thermo Fisher Scientific PRB LLC] Malta 	99.96003
Thermo Fisher Scientific PRB LLC 	Delaware 	100
Thermo Fisher Scientific Spectra Malta Limited
[.03997% by Thermo Fisher Scientific Spectra LLC] Malta 	99.96003
Thermo Fisher Scientific Spectra LLC 	Delaware 	100
Thermo Fisher Scientific Spectra-Physics Investments Malta Limited
[.0000011% by Spectra-Physics Holdings USA, LLC] Malta 	99.9999989
Thermo Fisher Scientific Investments Malta (Sweden Financing) Limited
[.00000002% by Thermo Fisher Scientific Investments (Sweden) LLC and 26.76040344% by Thermo Fisher
Scientific Life Investments I S.a.r.l] Malta 	73.23959654
Thermo Fisher Scientific Investments (Sweden) LLC 	Delaware 	100
PeproTech, Inc. 	New Jersey 	100
PeproTech EC Ltd. 	England 	100
PeproTech France 	France 	100
PeproTech GmbH 	Germany 	100
PeproTech Asia Ltd 	Israel 	100
PeproTech BioTech (Suzhou) Co., Ltd. 	China 	100
PeproTech Korea 	Korea 	100
39

-- 174 of 180 --

Exhibit 22
Subsidiary Issuer of Guaranteed Securities
Thermo Fisher Scientific Inc. (the “Registrant”) is the guarantor of the senior secured registered notes listed below issued by Thermo Fisher Scientific
(Finance I) B.V., a wholly-owned finance subsidiary of the Registrant.
Thermo Fisher Scientific (Finance I) B.V.
0.800% Senior Notes due 2030
1.125% Senior Notes due 2033
1.625% Senior Notes due 2041
2.000% Senior Notes due 2051
Floating Rate Senior Notes due 2023
0.000% Senior Notes due 2023
0.000% Senior Notes due 2025

-- 175 of 180 --

Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-229951) and Form S-8 (Nos. 33-51189, 33-54347, 333-
146068, 333-152344, 333-161939, 333-188846, 333-220231 and 333-261548) of Thermo Fisher Scientific Inc. of our report dated February 24, 2022 relating to
the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 24, 2022

-- 176 of 180 --

Exhibit 31.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Marc N. Casper, certify that:
1. 	I have reviewed this Annual Report on Form 10-K of Thermo Fisher Scientific Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
a) 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) 	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) 	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s
auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) 	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: 	February 24, 2022
/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer

-- 177 of 180 --

Exhibit 31.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen Williamson, certify that:
1. 	I have reviewed this Annual Report on Form 10-K of Thermo Fisher Scientific Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
a) 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) 	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) 	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s
auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) 	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: 	February 24, 2022
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer

-- 178 of 180 --

Exhibit 32.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the “Company”) for the period ended December 31, 2021 as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, Chairman, President and Chief Executive Officer of
the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) 	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 24, 2022
/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will
be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

-- 179 of 180 --

Exhibit 32.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the “Company”) for the period ended December 31, 2021 as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Stephen Williamson, Senior Vice President and Chief Financial
Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) 	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 24, 2022
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will
be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

-- 180 of 180 --